Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 135398513 |
| CHEMBL ID | 184 |
| CHEBI ID | 2453 |
| SCHEMBL ID | 3175 |
| SCHEMBL ID | 9828560 |
| MeSH ID | M0000326 |
| Synonym |
|---|
| BIDD:GT0646 |
| HMS3269M15 |
| MLS000069633 , |
| KBIO1_000185 |
| DIVK1C_000185 |
| acyclofoam |
| viropump |
| genvir |
| acyclovir lauriad |
| maynar |
| sitavig |
| sitavir |
| bw-248-u |
| 2-amino-9-{[(2-hydroxyethyl)oxy]methyl}-1,9-dihydro-6h-purin-6-one |
| nsc-645011 |
| EU-0100037 |
| acycloguanosine, >=99% (hplc), powder |
| einecs 261-685-1 |
| aciclovirum [inn-latin] |
| 2-amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)-6h-purin-6-one |
| acyclovir [usan] |
| c8h11n5o3 |
| bw-248u |
| nsc 645011 |
| SPECTRUM_001739 |
| 6h-purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)- |
| aciclovirum [latin] |
| ccris 1953 |
| hsdb 6511 |
| drg-0008 |
| 6h-purin-6-one, 1,9-dihydro-2-amino-9-((2-hydroxyethoxy)methyl)- |
| wellcome-248u |
| 9-((2-hydroxyethoxy)methyl)guanine |
| w-248-u |
| IDI1_000185 |
| PRESTWICK_6 |
| cas-59277-89-3 |
| NCGC00015061-01 |
| NCGC00015061-02 |
| lopac-a-4669 |
| SPECTRUM5_001093 |
| virorax |
| 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6h-purin-6-one |
| nsc645011 |
| 2-amino-9-(2-hydroxyethoxymethyl)-1h-purin-6-one |
| acycloguanosine |
| 9-[(2-hydroxyethoxy)-methyl]guanine |
| vipral |
| zovirax |
| PRESTWICK3_000086 |
| PRESTWICK2_000086 |
| SMP1_000007 |
| BSPBIO_003348 |
| LOPAC0_000037 |
| 6h-purin-6-one, 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]- |
| 2-amino-9-[(2-hydroxyethoxy)methyl]-1,9-dihydro-6h-purin-6-one |
| inchi=1/c8h11n5o3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14h,1-2,4h2,(h3,9,11,12,15 |
| acyclovir & pluronic f-68 |
| acv & pluronic f-68 |
| 9-hyroxyethoxymethylguanine |
| AC2 , |
| aciclovir |
| C06810 |
| 59277-89-3 |
| acyclovir |
| 1PWY |
| DB00787 |
| acyclovir (usp) |
| aciclovir (jp17/inn) |
| D00222 |
| sitavig (tn) |
| NCGC00093555-03 |
| 9-(2-hydroxyethoxy)methylguanine |
| NCGC00093555-02 |
| smr000058225 |
| KBIO2_004787 |
| KBIO2_002219 |
| KBIOSS_002219 |
| KBIO3_002850 |
| KBIO2_007355 |
| KBIOGR_000889 |
| SPECTRUM2_001563 |
| SPECTRUM3_001874 |
| SPECTRUM4_000225 |
| SPBIO_001466 |
| PRESTWICK1_000086 |
| SPBIO_001951 |
| PRESTWICK0_000086 |
| NINDS_000185 |
| SPECTRUM1503603 |
| BPBIO1_000014 |
| BSPBIO_000012 |
| NCGC00022426-03 |
| NCGC00093555-04 |
| NCGC00093555-01 |
| NCGC00015061-03 |
| NCGC00167756-01 |
| aciclovirum |
| zyclir |
| zovir |
| activir |
| CHEBI:2453 , |
| acic |
| acyclo-v |
| NCGC00015061-04 |
| A 4669 , |
| HMS2090G09 |
| 9-[(2-hydroxyethoxy)methyl]guanine |
| NCGC00015061-10 |
| CHEMBL184 |
| nsc-758477 |
| novirus |
| gerpevir |
| HMS500J07 |
| FT-0657847 |
| AKOS000656213 |
| HMS1922E08 |
| HMS1568A14 |
| 2-amino-9-(2-hydroxyethoxymethyl)-3h-purin-6-one |
| bdbm50021776 |
| 2-amino-9-(2-hydroxy-ethoxymethyl)-5,9-dihydro-purin-6-one |
| 2-amino-9-(2-hydroxy-ethoxymethyl)-5,9-dihydro-purin-6-one (acv) |
| A832236 |
| 2-azanyl-9-(2-hydroxyethyloxymethyl)-3h-purin-6-one |
| NCGC00167756-02 |
| HMS2095A14 |
| HMS3260G15 |
| HMS3259N10 |
| pharmakon1600-01503603 |
| nsc758477 |
| dtxsid1022556 , |
| tox21_110075 |
| dtxcid102556 |
| HMS2234K21 |
| AKOS015995680 |
| CCG-39909 |
| NCGC00015061-06 |
| NCGC00015061-07 |
| NCGC00015061-08 |
| NCGC00015061-05 |
| NCGC00015061-09 |
| 2-amino-9-[(2-hydroxyethoxy)methyl]hydropurin-6-one |
| aciclovier |
| HY-17422 |
| CS-1353 |
| aciclovir [inn] |
| x4hes1o11f , |
| hascovir |
| unii-x4hes1o11f |
| acyclovir [usan:usp] |
| 2-amino-9-((2-hydroxyethoxy)methyl)-1h-purin-6(9h)-one |
| acicloftal |
| cargosil |
| FT-0621607 |
| NCGC00015061-12 |
| AM20100442 |
| LP00037 |
| 88713-38-6 |
| aciclovir [who-ip] |
| aciclovir [jan] |
| aciclovir [who-dd] |
| avaclyr |
| acyclovir [hsdb] |
| acyclovir [mi] |
| acyclovir [vandf] |
| valaciclovir hydrochloride impurity b [ep impurity] |
| aciclovir [mart.] |
| acyclovir [orange book] |
| acyclovir [usp-rs] |
| acyclovir [usp monograph] |
| aciclovirum [who-ip] |
| aciclovir [ep monograph] |
| valaciclovir hydrochloride hydrate impurity b [ep impurity] |
| aciclovir [iarc] |
| S1807 |
| gtpl4829 |
| HMS3372K02 |
| AKOS022135433 |
| NC00717 |
| SCHEMBL3175 |
| NCGC00015061-13 |
| tox21_110075_1 |
| KS-1027 |
| SCHEMBL9828560 |
| NCGC00260722-01 |
| 2-amino-9-((2-hydroxyethoxy)methyl)-3h-purin-6(9h)-one |
| tox21_500037 |
| 9-(2-hydroxyethoxymethyl)guanine |
| 9-(2-hydroxyethoxy methyl) guanine |
| 9(2-hydroxyethoxymethyl)guanine |
| 2-amino-9-((2-hydroxyethoxy)methyl)-1,9-dihydro-6h-purin-6-one |
| acyclovir-sidechain-2-3h |
| 141294-79-3 |
| poviral |
| 2-amino-9-[(2-hydroxyethoxy)methyl]-1,9-dihydro-6h-purin-6-one # |
| Q-200591 |
| OPERA_ID_1674 |
| acyclovir-side chain-2-3h |
| mfcd00057880 |
| 2-amino-9-[(2-hydroxyethoxy)methyl]-6,9-dihydro-3h-purin-6-one |
| F2173-0946 |
| aciclovir, european pharmacopoeia (ep) reference standard |
| AC-8068 |
| sr-01000075540 |
| SR-01000075540-1 |
| acyclovir, united states pharmacopeia (usp) reference standard |
| HMS3655C14 |
| bdbm50103518 |
| cyclovir |
| aciclovir for peak identification 2, european pharmacopoeia (ep) reference standard |
| aciclovir for system suitability, european pharmacopoeia (ep) reference standard |
| aciclovir for peak identification 1, european pharmacopoeia (ep) reference standard |
| acyclovir, pharmaceutical secondary standard; certified reference material |
| aciclovir 1.0 mg/ml in dimethyl sulfoxide |
| SR-01000075540-5 |
| SR-01000075540-3 |
| HMS3712A14 |
| acyclovir (aciclovir) |
| 2-amino-9-((2-hydroxyethoxy)methyl)-3,9-dihydro-6h-purin-6-one |
| aciclovir, british pharmacopoeia (bp) reference standard |
| SW196324-3 |
| EN300-123010 |
| HMS3677D21 |
| acv; acycloguanosine; acyclovir; nsc 645011; nsc-645011; nsc645011 |
| BCP11036 |
| HMS3413D21 |
| Q147101 |
| BRD-K32318651-001-17-9 |
| SDCCGSBI-0050026.P003 |
| NCGC00015061-28 |
| NCGC00381719-03 |
| SY051130 |
| A935190 |
| NCGC00015061-29 |
| 2-amino-9-(2-hydroxyethoxymethyl)purin-6-ol |
| nsc-780378 |
| nsc780378 |
| Z1546610471 |
| aciclovir (mart.) |
| acyclovir (usp-rs) |
| aclovir |
| d06bb03 |
| s01ad03 |
| acyclovir (usan:usp) |
| nsc335752 |
| aciclovir (ep monograph) |
| valaciclovir hydrochloride hydrate impurity b (ep impurity) |
| aciclovir (iarc) |
| aciclovirum (inn-latin) |
| valaciclovir hydrochloride impurity b (ep impurity) |
| aciclovirum (latin) |
| j05ab01 |
| acyclovir (usp monograph) |
Acyclovir (ACY) is an antiviral class of drugs used to treat herpes simplex virus infections. It is only absorbed in the upper part of the gastrointestinal tract. Oral acyclovir prophylaxis is a safe and an effe.
Acyclovir (ACV) has a novel, highly selective biological activity which results in the inhibition of herpesvirus replication at concentrations 300-3000-fold lower than those that will inhibit mammalian cellular functions. Valacyclovir has an acceptable safety profile in patients with herpes simplex and herpes zoster.
Acyclovir has been used in the treatment of herpes simplex and varicella zoster viral infections for over 30 years. The effectiveness of prophylaxis is controversial. AcyclovIR has been reported as a potential therapy for pityriasis rosea (PR) in several clinical trials.
| Excerpt | Reference |
|---|---|
| "Valacyclovir has an acceptable safety profile in patients with herpes simplex and herpes zoster." | ( Valacyclovir for the treatment of genital herpes. Brantley, JS; Hicks, L; Sra, K; Tyring, SK, 2006) |
| "Oral acyclovir also has a potential role in suppressing reactivations of HSV infections in immunocompromised patients or patients experiencing greater than 10-12 recurrences of genital herpes per year." | ( Update on acyclovir: oral therapy for herpesvirus infections. Carter, BL; True, BL, ) |
| "Acyclovir (ACV) has an ED50 of 0.3 microM against EBV replication in vitro. " | ( Acyclovir and Epstein-Barr virus infection. Lin, JC; Pagano, JS; Sixbey, JW, 1983) |
| "Acyclovir (ACV) has a novel, highly selective biological activity which results in the inhibition of herpesvirus replication at concentrations 300-3000-fold lower than those that will inhibit mammalian cellular functions. " | ( The mechanism of action, pharmacokinetics and toxicity of acyclovir--a review. Brigden, D; Whiteman, P, 1983) |
| "Acyclovir has a relatively low oral bioavailability." | ( Acyclovir--and beyond. Darby, G, 1994) |
| "Acyclovir prophylaxis has an impact on fever development, but not on the duration of fever or the need for antibiotics. " | ( Acyclovir prophylaxis and fever during remission-induction therapy of patients with acute myeloid leukemia: a randomized, double-blind, placebo-controlled trial. Bergmann, OJ; Ellegaard, J; Ellermann-Eriksen, S; Mogensen, SC, 1997) |
| "Oral acyclovir has an average plasma half-life of three hours and is eliminated primarily by renal mechanisms." | ( Evaluation of oral acyclovir therapy. Bean, B; Fletcher, C, ) |
| "Acyclovir has an excellent safety profile, its major adverse effect being transient serum creatinine elevations during high-dose intravenous use." | ( Drugs five years later: acyclovir. Crumpacker, CS; Dorsky, DI, 1987) |
| "Acyclovir cream has a similar effect with external lesions in mild attacks." | ( Management of genital herpes simplex infections. Thin, RN, 1988) |
| "Acyclovir has been used in the treatment of herpes simplex and varicella zoster viral infections for over 30 years. " | ( Acyclovir-induced thrombocytopaenia in a patient with SLE. Missouris, C; Psarellis, S; Tsappa, I, 2018) |
| "Acyclovir has been used for the prophylaxis of VZV disease after HCT, but the effectiveness of prophylaxis is controversial." | ( Effectiveness of acyclovir prophylaxis against varicella zoster virus disease after allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis. Hiratoko, K; Ito, S; Shiba, N; Takeuchi, M; Tanoshima, R; Tsujimoto, SI; Wada-Shimosato, Y; Yamanaka, T, 2019) |
| "Acyclovir has been widely used to treat infections caused by herpes simplex virus (HSV) and varicella zoster virus (VZV). " | ( A rare case report of acyclovir-induced immune thrombocytopenia with tongue hematomas as the first sign, and a literature review. Hong, X; Wang, X; Wang, Z, 2017) |
| "Acyclovir has been conjugated to the acyclic isoprenoid chain of squalene to form the squalenoyl-acyclovir prodrug. " | ( Interaction of acyclovir and its squalenoyl-acyclovir prodrug with DMPC in monolayers at the air/water interface. Castelli, F; Ceruti, M; Micieli, D; Ottimo, S; Rocco, F; Sarpietro, MG, 2010) |
| "Acyclovir prophylaxis has been considered as mandatory for patients receiving bortezomib because herpes zoster is a common adverse event associated with the use of bortezomib. " | ( Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study. Bae, SH; Do, YR; Kim, K; Kim, SJ; Lee, JJ; Yang, DH, 2011) |
| "Acyclovir (ACV) has been commonly used as an antiviral for decades. " | ( Polymorphs and hydrates of acyclovir. Lutker, KM; Matzger, AJ; Quiñones, R; Ramamoorthy, A; Xu, J, 2011) |
| "Oral acyclovir has been successful in suppression of the disease." | ( Arthritis associated with recurrent erythema multiforme responding to oral acyclovir. Matulis, M; Molnar, I, 2002) |
| "Oral acyclovir has been demonstrated to prevent reactivation of herpes simplex virus (HSV) infections when administered prophylactically to autologous bone marrow transplant (BMT) recipients or patients undergoing stem cell rescue therapy. " | ( Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy. Broun, ER; DeVoe, M; Eisen, D; Essell, J; Sigmund, D, 2003) |
| "Acyclovir (ACV) has been used for over two decades to treat herpes virus infections. " | ( High serum concentrations of the acyclovir main metabolite 9-carboxymethoxymethylguanine in renal failure patients with acyclovir-related neuropsychiatric side effects: an observational study. Barkholt, L; Diener, P; Helldén, A; Medin, C; Odar-Cederlöf, I; Säwe, J; Ståhle, L; Svensson, JO, 2003) |
| "Acyclovir has been shown to be effective in preventing recurrent herpes simplex virus lesions of the genitalia and oral labia. " | ( Effect of acyclovir on thermal stress-induced herpesvirus reactivation. Gebhardt, BM; Hill, JM; Kaufman, HE, ) |
| "Acyclovir tolerance has been explored in a broad range of human populations and dosage regimens with intravenous, topical, and oral formulations. " | ( Acyclovir tolerance in humans. Bridgen, D; Keeney, RE; Kirk, LE, 1982) |
| "Acyclovir (ACV) has been shown to inhibit the replication of herpes simplex virus (HSV) in vitro. " | ( Herpes simplex virus variants restraint to high concentrations of acyclovir exist in clinical isolates. Harrington, JE; Parris, DS, 1982) |
| "Acyclovir has shown clinical activity against herpes simplex virus (HSV) types 1 and 2 and varicella zoster virus (VZV), but its usefulness in cytomegalovirus, Epstein-Barr virus, and chronic hepatitis B infections requires further study." | ( The clinical use of intravenous acyclovir. Hopefl, AW, 1983) |
| "Acyclovir sodium has been approved as a topical agent in the treatment of limited mucocutaneous herpes simplex viral infections in immunosuppressed patients and of initial episodes of genital herpes simplex infections in patients with normal immunity." | ( Antiviral agents. Cockerill, FR; Hermans, PE, 1983) |
| "Acyclovir ointment has been reported to have an antiviral effect but no clinical benefit and a newer formulation, acyclovir cream, has been developed in an attempt to enhance skin penetration." | ( Treatment of herpes labialis. Clark, AE; Fiddian, AP; Yeo, JM, 1983) |
| "Acyclovir (ACV) has been found to diminish virus shedding and clinical symptoms in patients with first episode genital HSV when given topically or intravenously." | ( Current status and prospects for oral acyclovir treatment of first episode and recurrent genital herpes simplex virus. Bryson, YJ, 1983) |
| "Acyclovir has been shown to be effective in treating established infections with HSV and VZV, and in the prophylaxis against HSV, severe CMV infections, and VZV.(ABSTRACT TRUNCATED AT 250 WORDS)" | ( Acyclovir influence on graft versus host disease. Saral, R, 1993) |
| "Acyclovir has been approved in the United States and elsewhere as antiviral therapy for otherwise healthy children and adolescents with varicella. " | ( Acyclovir therapy for varicella in otherwise healthy children and adolescents. Feldman, S, 1993) |
| "Acyclovir resistance has been increasingly described and is caused by mutations in either the thymidine kinase or the DNA polymerase genes." | ( Herpes simplex virus resistance to acyclovir: clinical relevance. Kessler, HA; Pottage, JC, 1995) |
| "Acyclovir has been used with success rates of 55% in treating these episodes." | ( Recurrent Stevens-Johnson syndrome secondary to herpes simplex: a follow up on a successful management program. Cheriyan, S; Patterson, R, ) |
| "Acyclovir has been associated with enhanced survival in AIDS but not with CMV disease prevention." | ( A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study G Coakley, D; Cooper, D; Feinberg, JE; Fry, J; Gill, MJ; Griffiths, PD; Holland, FJ; Holland, GN; Hurwitz, S; Jacobson, MA; MacGregor, RR; Owens, S; Pollard, RB; Powderly, W; Power, ME; Sattler, FR; Youle, M, 1998) |
| "Acyclovir (ACV) has been used for more than 15 years in the management of herpes simplex virus (HSV) and varicella-zoster virus (VZV) disease. " | ( Survey of resistance of herpes simplex virus to acyclovir in northwest England. Christophers, J; Clayton, J; Collins, P; Craske, J; Darby, G; Trowbridge, M; Ward, R, 1998) |
| "Acyclovir (ACV) has shown efficacy in the prophylactic suppression of human cytomegalovirus (HCMV) reactivation in immunocompromised renal transplant patients without the toxicity associated with ganciclovir (GCV). " | ( Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein. Biron, KK; Burnette, TC; Coen, DM; Davis, MG; He, Z; Miller, WH; Ng, TI; Roizman, B; Smith, SL; Stanat, SC; Talarico, CL, 1999) |
| "Acyclovir cream has been available for the treatment of herpes labialis in numerous countries outside the United States for over a decade. " | ( Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials. Johnson, J; Marbury, T; Nett, R; Spaulding, T; Spruance, SL; Wolff, R, 2002) |
| "Acyclovir resistance has been reported in patients with profound and prolonged immune deficiency, but remains rare in patients treated for cancer." | ( Herpes simplex virus infection in cancer patients: prevention and treatment. Shepp, DH; Tang, IT, 1992) |
| "Acyclovir has been reported to potentiate the effect of zidovudine on HIV in vitro." | ( A pilot study of low-dose zidovudine in human immunodeficiency virus infection. Bozzette, S; Causey, DM; Collier, AC; Coombs, RW; Davies, G; Leedom, JM; Pettinelli, CB; Richman, DD; Schoenfeld, DA; Spector, SA, 1990) |
| "Oral acyclovir has been used successfully to treat and prevent symptomatic episodes of genital herpes simplex virus infection. " | ( Treatment of genital herpes. Stone, KM; Whittington, WL, ) |
| "Acyclovir has been extensively studied in the treatment of a a variety of HSV infections in immunocompromised patients and in otherwise healthy patients." | ( Treatment of oro-facial herpes simplex infections with acyclovir: a review. Eskinazi, DP; Perna, JJ, 1988) |
| "Acyclovir has been found to be superior to vidarabine for treatment of both chickenpox and herpes zoster." | ( Varicella zoster virus infections in immunocompromised hosts. A review of the natural history and management. Balfour, HH, 1988) |
| "Acyclovir has been prescribed with the intent to decrease the impact of the infection." | ( Varicella pneumonia during pregnancy. Treatment of two cases with acyclovir. Apuzzio, JJ; Eder, SE; Weiss, G, 1988) |
| "Acyclovir has been widely used against the various manifestations of eye disease due to herpes simplex since it first became generally available in the UK nearly five years ago. " | ( Rational acyclovir therapy in herpetic eye disease. Falcon, MG, 1987) |
| Excerpt | Reference |
|---|---|
| "Acyclovir was shown to inhibit viral shedding rapidly, to be well tolerated, and to permit the complete healing of lesions." | ( Acyclovir for chronic mucocutaneous herpes simplex virus infection in immunosuppressed patients. Brickman, C; de Miranda, P; Keeney, RE; McLaren, C; Smith, HA; Straus, SE, 1982) |
Acyclovir treatment was given orally (20 mg/kg, three times daily), starting on day 0 (D0), 2 (D2) or 4 (D4) after infection and continuing until day 10. Valacyclovir completely abrogated EBV replication in vivo.
Valacyclovir was not associated with infant or maternal toxicities or adverse events, and no congenital malformations were observed. The neurotoxicity induced by acy Clovir is a poorly known and rare adverse effect.
Ayyclovir can be particularly complicated in pediatric patients with evolving renal impairment, because of intraindividual pharmacokinetic variability linked to the patient's clinical condition. This study aimed to establish a new in vitro-in vivo correlation (IVIVC) platform for drugs with site-dependent absorption.
The sensitivity of varicella zoster virus (VZV) strain Ellen to acyclovir in combination with other antiherpetic agents in vitro has been examined. Study aimed to explore the safety and clinical efficacy of light emitting diode (LED) golden light combined with acy Clovir.
| Excerpt | Reference |
|---|---|
| "The antiviral effects of selected combinations between acemannan (ACE-M), a long-chained, polydispersed, beta-(1,4)-acetylated mannan, were tested in combination with azidothymidine (AZT) and acyclovir (ACY) in vitro." | ( In vitro evaluation of the synergistic antiviral effects of acemannan in combination with azidothymidine and acyclovir. Carpenter, RH; Kahlon, JB; Kemp, MC; McAnalley, BH; Shannon, WM; Yawei, N, 1991) |
| "We studied the effect of cytomegalovirus immunoglobulin alone, or combined with ganciclovir, on the outcome of biopsy proven cytomegalovirus pneumonia after bone marrow transplantation." | ( Treatment of cytomegalovirus pneumonia after bone marrow transplantation with cytomegalovirus immunoglobulin combined with ganciclovir. de Gast, GC; de Weger, RA; Dekker, AW; Rozenberg-Arska, M; Schuurman, HJ; Verdonck, LF, 1989) |
| "25 mg/kg when given in combination with an ineffective dose of 4MuIFN-gamma (10(3) units per mouse)." | ( Enhanced efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine in combination with gamma interferon against herpes simplex virus type 2 in mice. Eppstein, DA; Fraser-Smith, EB; Marsh, YV; Matthews, TR, 1985) |
| "A double-blind comparative trial of acyclovir (ACV) and adenine arabinoside (ARA-A) in combination with dilute betamethasone was carried out in 30 patients with herpetic disciform keratitis." | ( A double-blind comparative trial of acyclovir and adenine arabinoside in combination with dilute betamethasone in the management of herpetic disciform keratitis. Collum, LM; Grant, DM, 1987) |
| " A second course of intravenous acyclovir (15 mg/kg twice daily for 2 weeks) was given to 5 patients in combination with intramuscular lymphoblastoid alpha-interferon treatment (2." | ( Acyclovir, oral, intravenous and combined with interferon for chronic HBeAg-positive hepatitis. De Man, RA; Heytink, RA; Schalm, SW; Van Buuren, HR, 1986) |
| " The antiCMV activity of acyclovir in combination with human fibroblast interferon (IFN-beta), phosphonoformic acid (PFA), or trifluorothymidine (TFT) was therefore evaluated." | ( Effects of acyclovir combined with other antiviral agents on human cytomegalovirus. Kelley, E; Spector, SA; Tyndall, M, 1982) |
| "The sensitivity of varicella zoster virus (VZV) strain Ellen to acyclovir in combination with other antiherpetic agents in vitro has been examined by the plaque-reduction and infectious center assay methods." | ( Effect of acyclovir combined with other antiherpetic agents on varicella zoster virus in vitro. Biron, KK; Elion, GB, 1982) |
| " The effective dose at which 50% of the mice survived was lowered approximately 10-fold for DHPG when it was given in combination with a marginally effective dose of alpha-interferon and greater than 10-fold for alpha-interferon when it was given in combination with a nontherapeutic dose of DHPG." | ( Enhanced efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine in combination with alpha-interferon against herpes simplex virus type 2 in mice. Eppstein, DA; Fraser-Smith, EB; Marsh, YV; Matthews, TR, 1984) |
| " When combined with dilute steroid, acyclovir heals herpetic disciform keratitis and preliminary results of a double-blind clinical trial suggest that it may be more effective and less toxic than adenine arabinoside in the treatment of this condition." | ( Comparison of the efficacy and toxicity of acyclovir and of adenine arabinoside when combined with dilute betamethasone in herpetic disciform keratitis: preliminary results of a double-blind trial. Collum, LM; Logan, P; O'Connor, M, 1983) |
| " et Perry, or Terminalia chebula Retzus showed a stronger anti-HSV-1 activity in combination with acyclovir than the other herbal extracts in vitro." | ( Efficacy of traditional herbal medicines in combination with acyclovir against herpes simplex virus type 1 infection in vitro and in vivo. Hirabayashi, T; Hozumi, T; Kadota, S; Kageyama, T; Kurokawa, M; Nagasaka, K; Namba, T; Ohyama, H; Sato, H; Uyama, S, 1995) |
| " They must be administered with caution during pregnancy, because some are known teratogens (e." | ( Adverse effects and drug interactions of clinical importance with antiviral drugs. Morris, DJ, 1994) |
| " We treated 10 human immunodeficiency virus-infected patients with acyclovir-resistant anogenital herpes simplex virus infection with a topical preparation of 348U87 (3%) in combination with acyclovir (5%) in an open-labelled study." | ( Topical treatment of infection with acyclovir-resistant mucocutaneous herpes simplex virus with the ribonucleotide reductase inhibitor 348U87 in combination with acyclovir. Corey, L; Delehanty, J; Hill, E; Safrin, S; Schacker, T, 1993) |
| " 3TC and PCV are deoxycytidine and deoxyguanosine analogs, respectively, and their modes of action and how they interact are matters of both theoretical and practical interest." | ( Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Colledge, D; Locarnini, S; Shaw, T, 1997) |
| " We choose low dose MTX with the intent of determining whether chemosensitization of the osteosarcoma may be possible in combination with gene therapy with an overall reduced toxicity profile and enhanced therapeutic efficacy when compared to a single agent alone." | ( Chemogene therapy: osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model. Cheon, J; Chung, LW; Gardner, TA; Gotoh, A; Kao, C; Ko, SC; Shirakawa, T, ) |
| " The ability of BILD 1351 SE to inhibit the replication of HSV-1 when used in combination with acyclovir (ACV) for the treatment of HSV infections was investigated in baby hamster kidney cells using a 96-well enzyme-linked immunosorbent assay." | ( The antiviral activity of the ribonucleotide reductase inhibitor BILD 1351 SE in combination with acyclovir against HSV type-1 in cell culture. Lawetz, C; Liuzzi, M, 1998) |
| "Adenovirus expressing herpes simplex virus-thymidine kinase (HSV-TK) sensitizes internal rat glioma cells to radiation in combination with acyclovir (ACV)." | ( Improved radiosensitization of rat glioma cells with adenovirus-expressed mutant herpes simplex virus-thymidine kinase in combination with acyclovir. Amir, C; Brust, D; Farnsworth, J; Feden, J; Hershey, C; Taher, MM; Valerie, K, 2000) |
| " We compared survival in users of acyclovir alone, zidovudine alone, and acyclovir and zidovudine in combination with the survival of those using neither drug." | ( Acyclovir in combination with zidovudine does not prolong survival in advanced HIV disease. Chaisson, RE; Erbelding, EJ; Gallant, JE; Moore, RD, 1997) |
| " Survival was comparable to that of patients of other studies with secondary cytoreductive surgery in combination with chemotherapy." | ( Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up. Aguilar-Cordova, E; Fischer, DC; Hasenburg, A; Kaplan, AL; Kaufman, RH; Kieback, DG; Nyberg-Hoffman, C; Ramzy, I; Rojas-Martinez, A; Tong, XW, 2001) |
| " Synergy was observed between both LF or Lfcin in combination with ACV against the HSV laboratory strains." | ( Lactoferrin and lactoferricin inhibit Herpes simplex 1 and 2 infection and exhibit synergy when combined with acyclovir. Andersen, JH; Gutteberg, TJ; Jenssen, H, 2003) |
| "Two methods are presented for the determination of 'respectively' the plasma protein unbound and total concentration of acyclovir in horse plasma and body fluids: first, a liquid-liquid extraction was performed on plasma, combined with HPLC-fluorescence detection for the total plasma concentration; second a more sensitive method using high-performance liquid chromatography combined with heated electrospray ionization tandem mass spectrometry (LC-HESI-MS/MS) was described for plasma and for body fluids analysis." | ( Determination of acyclovir in horse plasma and body fluids by high-performance liquid chromatography combined with fluorescence detection and heated electrospray ionization tandem mass spectrometry. Croubels, S; De Backer, P; Desmet, N; Garré, B; Maes, A; Nauwynck, H; van der Meulen, K, 2009) |
| " These mt-QSARs offer also a good opportunity to construct drug-drug Complex Networks (CNs) that can be used to explore large and complex drug-viral species databases." | ( Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E, 2009) |
| "To evaluate clinical therapeutic effect and the safety of pricking blood therapy combined with ultraviolet irradiation for treatment of acute herpes zoster." | ( [Pricking blood therapy combined with ultraviolet irradiation for treatment of acute herpes zoster]. Hou, YL; Ouyang, Q; Wei, ZJ, 2009) |
| " The observation group was treated with pricking blood therapy combined with ultraviolet irradiation." | ( [Pricking blood therapy combined with ultraviolet irradiation for treatment of acute herpes zoster]. Hou, YL; Ouyang, Q; Wei, ZJ, 2009) |
| "The pricking blood therapy combined with ultraviolet irradiation has rapid therapeutic effect, effectively shortens duration of illness, decreases the incidence rate of post herpetic neuralgia and it is a safe remedy for treatment of herpes zoster." | ( [Pricking blood therapy combined with ultraviolet irradiation for treatment of acute herpes zoster]. Hou, YL; Ouyang, Q; Wei, ZJ, 2009) |
| "We report a case of a potential drug-drug interaction in a woman treated by a first injection of high-dose methotrexate for a T-lymphoblastic lymphoma." | ( Suspicion of drug-drug interaction between high-dose methotrexate and proton pump inhibitors: a case report - should the practice be changed? Bouafia, F; Franchon, E; Gouraud, A; Pham, BN; Ranchon, F; Rioufol, C; Salles, G; Schwiertz, V; Vantard, N; Vial, T; You, B, 2011) |
| "The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions." | ( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012) |
| "In vitro activity of interferon-alpha-2b in combination with various antioxidants against the influenza virus and Herpes simplex was studied." | ( [Antiviral activity of recombinant interferon-alpha-2b in combination with certain antioxidant]. Deriabin, PG; Galegov, GA; Vasil'ev, AN, 2011) |
| " The drug-drug interactions (DDIs) between simotinib and other drugs in combination and the underlying mechanism of its gastrointestinal toxicity remain unclear." | ( Drug interaction studies reveal that simotinib upregulates intestinal absorption by increasing the paracellular permeability of intestinal epithelial cells. Cheng, Z; Li, P; Liu, Z; Zhu, Q, 2014) |
| "Little is known about the effects of drug-drug interactions between valacyclovir and non-steroidal anti-inflammatory drugs (NSAIDs)." | ( Acute kidney injury during concomitant use of valacyclovir and loxoprofen: detecting drug-drug interactions in a spontaneous reporting system. Jiang, P; Shi, J; Sun, H; Yue, Z, 2014) |
| "To observe the effect of electroacupuncture (EA) combined with ultraviolet therapy on herpes zoster at the acute stage and the impacts on serum interleukin 2 (IL-2), interleukin 6 (IL-6) and interleukin 10 (IL-10) in the patients." | ( [Impacts of electroacupuncture combined with ultraviolet therapy on cytokines of herpes zoster at the acute stage in patients]. Jiang, Y; Xu, X; Yang, J; Zhang, H, 2015) |
| "EA combined with ultraviolet irradiation more rapidly and effectively relief the symptoms of herpes zoster, significantly relief pain, shorten the duration of sickness, improve the body immunity and reduce nerve injury." | ( [Impacts of electroacupuncture combined with ultraviolet therapy on cytokines of herpes zoster at the acute stage in patients]. Jiang, Y; Xu, X; Yang, J; Zhang, H, 2015) |
| "05) were reduced in mice treated with VACV combined with ART versus VACV alone." | ( Valacyclovir combined with artesunate or rapamycin improves the outcome of herpes simplex virus encephalitis in mice compared to antiviral therapy alone. Boivin, G; Canivet, C; Menasria, R; Piret, J; Rhéaume, C, 2015) |
| " This study not only illuminates the effect of GSH on BoHV-1 infection but also provides evidence that pharmacological modulation of GSH-mediated ROS production in combination with specific antiviral drugs is a viable therapeutic approach to fighting virus infection." | ( The synergistic antiviral effects of GSH in combination with acyclovir against BoHV-1 infection in vitro. Ding, X; Fu, X; Huang, L; Ma, Y; Yuan, Ch; Zhu, G; Zhu, L, ) |
| "Despite peptide transporter 1 (PEPT1) being responsible for the bioavailability for a variety of drugs, there has been little study of its potential involvement in drug-drug interactions." | ( In Vitro and Clinical Evaluations of the Drug-Drug Interaction Potential of a Metabotropic Glutamate 2/3 Receptor Agonist Prodrug with Intestinal Peptide Transporter 1. Annes, WF; Ayan-Oshodi, MA; Hillgren, KM; Knadler, MP; Leese, P; Long, AJ; Mitchell, MI; Pak, YA; Witcher, JW, 2017) |
| " This mechanistic static approach was further applied to quantitatively predict renal drug-drug interactions (AFE ∼1." | ( Quantitative Prediction of Human Renal Clearance and Drug-Drug Interactions of Organic Anion Transporter Substrates Using In Vitro Transport Data: A Relative Activity Factor Approach. Feng, B; Litchfield, J; Mathialagan, S; Piotrowski, MA; Tess, DA; Varma, MV, 2017) |
| "Our results demonstrate that apigenin regulates OAT1, and can cause TDI or herb-drug interaction (HDI) when used in combination with acyclovir or adefovir." | ( Apigenin, a novel candidate involving herb-drug interaction (HDI), interacts with organic anion transporter 1 (OAT1). Cao, Y; Chen, J; Fu, W; Li, H; Pang, J; Wu, T; Zhou, P, 2017) |
| "To analyze the clinical efficacy of naloxone combined with acyclovir in the treatment of children viral encephalitis and the impacts on inflammatory factors IL-1 and IL-6." | ( Observation of the efficacy of naloxone combined with acyclovir in the treatment of children viral encephalitis and its impacts on IL-1 and IL-6. Li, XY; Liu, CX; Niu, L; Yang, G; Yu, M; Zhao, XZ, 2020) |
| " They were divided into control group (45 cases treated with acyclovir) and observation group (51 cases treated with acyclovir combined with naloxone)." | ( Observation of the efficacy of naloxone combined with acyclovir in the treatment of children viral encephalitis and its impacts on IL-1 and IL-6. Li, XY; Liu, CX; Niu, L; Yang, G; Yu, M; Zhao, XZ, 2020) |
| "In the treatment of children, viral encephalitis has naloxone combined with ganciclovir had a more significant effect on the decrease of levels of serum IL-1 and IL-6; naloxone combined with acyclovir in the treatment of children viral encephalitis had better effects, lower adverse reactions and lower prevalence of sequelae compared with sole medication, which is worth clinical promotion." | ( Observation of the efficacy of naloxone combined with acyclovir in the treatment of children viral encephalitis and its impacts on IL-1 and IL-6. Li, XY; Liu, CX; Niu, L; Yang, G; Yu, M; Zhao, XZ, 2020) |
| "The aim of this study was to systematically evaluate the efficacy and prognosis of acyclovir combined with naloxone in the treatment of patients with viral encephalitis (VE)." | ( Acyclovir Combined with Naloxone in the Treatment of Viral Encephalitis: A Meta-Analysis. Wang, W; Zhang, Q; Zhao, Q, 2022) |
| " The treatment group was treated with acyclovir combined with naloxone, and the control group was treated with acyclovir alone." | ( Acyclovir Combined with Naloxone in the Treatment of Viral Encephalitis: A Meta-Analysis. Wang, W; Zhang, Q; Zhao, Q, 2022) |
| " Nevertheless, to date few studies have focused on the eco-genotoxic effects on freshwater organisms caused by polystyrene microplastic particles (PS-MPs) in combination with other pollutants such as pharmaceuticals and pesticides." | ( Polystyrene microplastic particles in combination with pesticides and antiviral drugs: Toxicity and genotoxicity in Ceriodaphnia dubia. Isidori, M; Kundi, M; Lavorgna, M; Nugnes, R; Orlo, E; Russo, C, 2022) |
| " A drug-drug interaction study was conducted in healthy participants (N = 16) to assess the effect of letermovir on acyclovir pharmacokinetics." | ( A drug-drug interaction study with letermovir and acyclovir in healthy participants. Fancourt, C; Iwamoto, M; McCrea, JB; Menzel, K; Stoch, SA; Witter, R; Zhao, T, 2023) |
| "This study aimed to explore the safety and clinical efficacy of light emitting diode (LED) golden light combined with acyclovir in treating herpes zoster (HZ)." | ( Clinical efficacy of LED golden light combined with acyclovir in the treatment of herpes zoster: a single-center prospective study. Cao, X; Fei, W; Gong, Y; Guo, Z; Li, S; Tong, J; Wang, D; Wang, G; Xiao, Z; Yang, K; Zhang, Z, 2023) |
An in situ gelling system was used to increase the residence time and thus the bioavailability of acyclovir in oral mucosa. In view of the high oral bioavailability, the risk of neurotoxicity becomes more prominent.
| Excerpt | Reference |
|---|---|
| "71 h and a bioavailability of 90." | ( Acyclovir (Zovirax) pharmacokinetics in Quaker parakeets, Myiopsitta monachus. Clark, CH; Coniglario, J; Gaskin, J; Kollias, GV; Norton, TM; Wilson, RC, 1992) |
| " In vitro and in vivo human skin model systems were used in the present study to quantitate ACV disposition and absorption in skin and blood following two routes of administration and to investigate whether bioavailability differences were the result of insufficient drug delivery." | ( Acyclovir bioavailability in human skin. Dunn, P; Parry, GE; Pershing, LK; Shah, VP, 1992) |
| " The median bioavailability of oral zidovudine was 67% (42 to 120%) and did not vary with dosage." | ( Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection. Benedetti, J; Collier, AC; Corey, L; Gianola, FG; Opheim, K; Tartaglione, TA, 1991) |
| " After rectal administration in the absence of absorption-promoter, the bioavailability of acyclovir was 37%." | ( The effect of fatty acids on the rectal absorption of acyclovir in rats. Itoh, S; Kobayashi, M; Komatsu, T; Sawanoi, M; Suzuki, S; Tanabe, K; Yamazaki, M, 1990) |
| "The mechanism of transport of desciclovir (DCV)--a structural analogue and prodrug of acyclovir (ACV) which provides an improved oral bioavailability of ACV--was investigated in human erythrocytes with a "papaverine-stop" assay." | ( Desciclovir permeation of the human erythrocyte membrane by nonfacilitated diffusion. Domin, BA; Mahony, WB; Zimmerman, TP, 1991) |
| " Although without significant antiviral activity in cell cultures, the 2-aminopurines (13, 14-16, 26-29) and 2-amino-6-alkoxypurines (12, 23-25) are well absorbed after oral administration to mice and are converted efficiently to the antiviral guanine derivatives (8, 21) in vivo." | ( Synthesis and antiviral activity of 9-alkoxypurines. 1. 9-(3-Hydroxypropoxy)- and 9-[3-hydroxymethyl)propoxy]purines. Boyd, MR; Harnden, MR; Sutton, D; Wyatt, PG, 1990) |
| " The bioavailability of ganciclovir after oral administration of HOE 602 or ganciclovir was similar in mice, while in rhesus monkeys much higher serum levels of ganciclovir were reached with HOE 602." | ( Antiviral activity and pharmacokinetics of HOE 602, an acyclic nucleoside, in animal models. Helsberg, M; Jähne, G; Rösner, M; Scholl, T; Winkelmann, E; Winkler, I, 1990) |
| " Intraperitoneal dosing in subjects receiving CAPD resulted in a bioavailability of 61 +/- 10% and drug levels sufficient to inhibit herpes simplex virus (HSV) and varicella zoster virus (VZV)." | ( Intraperitoneal administration of acyclovir in patients receiving continuous ambulatory peritoneal dialysis. Burgess, ED; Gill, MJ, 1990) |
| " The resultant decreased bioavailability of cyclosporine may precipitate graft rejection." | ( Interactions of cyclosporine with antimicrobial agents. Brown, RB; Sands, M, ) |
| "Potential oral prodrugs of the antiherpesvirus acyclonucleoside 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine (1, BRL 39123) have been synthesized and evaluated for bioavailability of 1 in the blood of mice." | ( Prodrugs of the selective antiherpesvirus agent 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine (BRL 39123) with improved gastrointestinal absorption properties. Boyd, MR; Harnden, MR; Jarvest, RL; Sutton, D; Vere Hodge, RA, 1989) |
| " An important direction for future clinical research is the development of more effective and less toxic therapy, as well as orally bioavailable drugs for maintenance therapy." | ( Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment. Jacobson, MA; Mills, J, 1988) |
| "5 hours after administration and the oral bioavailability is 15 to 30 percent." | ( Evaluation of oral acyclovir therapy. Bean, B; Fletcher, C, ) |
| " Acyclovir is well absorbed and distributed, with cerebrospinal fluid levels 50% that of plasma." | ( Drugs five years later: acyclovir. Crumpacker, CS; Dorsky, DI, 1987) |
| " 6-Deoxyacyclovir, an analog of acyclovir, is well absorbed when given orally, and is converted to acyclovir by xanthine oxidase which is present in the gut and liver." | ( The disposition of 6-deoxyacyclovir, a xanthine oxidase-activated prodrug of acyclovir, in the isolated perfused rat liver. Hoofnagle, JH; Jones, DB; Jones, EA; Kornhauser, DM; Quinn, R; Rustgi, VK; Woods, A, ) |
| " In all cases the bioavailability of acyclovir following oral administration of A515U was substantially increased over that achieved in the same subjects with oral acyclovir itself." | ( A515U: a prodrug of acyclovir with increased oral bioavailability. Grant, DM; Prentice, HG; Rees, PJ; Selby, P; Whiteman, PD, 1986) |
| " After oral administration, the bioavailability of acyclovir was approximately 20%." | ( Pharmacokinetics of acyclovir after intravenous and oral administration. Blum, MR; de Miranda, P, 1983) |
| "A515U (6-deoxyacyclovir) is an analogue of acyclovir devoid of antiviral activity in vitro but which is well absorbed and undergoes conversion to acyclovir after oral administration to rats." | ( Tolerance and pharmacokinetics of A515U, an acyclovir analogue, in healthy volunteers. Bye, A; Fowle, AS; Jeal, S; Land, G; Posner, J; Whiteman, PD, 1984) |
| " Good oral bioavailability (91 and 80%) was observed after the administration of a capsule at the lower doses (5 and 20 mg/kg, respectively) but bioavailability declined (52%) at the 50 mg/kg dose, indicating the possibility that the gastrointestinal absorption of acyclovir is a saturable process." | ( Pharmacokinetics and bioavailability of acyclovir in the dog. Blum, MR; de Miranda, P; Elion, GB; Krasny, HC, 1981) |
| " The limited oral bioavailability of acyclovir necessitates frequent dosing." | ( Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Andersen, PL; Beutner, KR; Forszpaniak, C; Friedman, DJ; Wood, MJ, 1995) |
| " We suggest that the interaction occurs at gastrointestinal level with a reduction of PHT and VPA oral bioavailability during antiviral treatment." | ( Possible interaction between acyclovir and antiepileptic treatment. Parmeggiani, A; Posar, A; Riva, R; Rossi, PG, 1995) |
| "The pharmacokinetics and bioavailability of aciclovir (CAS 59277-89-3) were examined after administration of newly developed 200 mg and 400 mg tablets." | ( Pharmacokinetics and bioavailability of different formulations of aciclovir. Kikuta, C; Mascher, H; Metz, R; Vergin, H, 1995) |
| " A-73209 was orally bioavailable in mice, with maximal serum concentrations well in excess of in vitro inhibitory concentrations." | ( Efficacy of A-73209, a potent orally active agent against VZV and HSV infections. Alder, J; Clement, J; Kern, ER; Marsh, K; Mitten, M; Norbeck, D, 1994) |
| " The oral bioavailability of acyclovir derived from valaciclovir in cynomolgus monkey was 67 +/- 13%, representing a significant improvement over the limited bioavailability after acyclovir administration to primates." | ( Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys. Burnette, TC; de Miranda, P, ) |
| " The apparent nasal absorption rate constants of acyclovir and its butyrate, valerate, pivalate, and hexanoate ester prodrugs in mixed micellar solutions containing an esterase inhibitor (1 mM phenylmethylsulfonyl fluoride) were individually calculated." | ( Bile salt-fatty acid mixed micelles as nasal absorption promoters. III. Effects on nasal transport and enzymatic degradation of acyclovir prodrugs. Mitra, AK; Shao, Z, 1994) |
| " The first approach was directed towards improving the bioavailability of acyclovir by examining the potential of a variety of prodrugs, leading to the new compound valaciclovir hydrochloride." | ( Review of research leading to new anti-herpesvirus agents in clinical development: valaciclovir hydrochloride (256U, the L-valyl ester of acyclovir) and 882C, a specific agent for varicella zoster virus. Beauchamp, LM; Darby, G; de Miranda, P; Ertl, P; Krenitsky, TA; Lacey, S; Powell, KL; Purifoy, DJ; Rahim, SG; Roberts, G, 1993) |
| " Valaciclovir is well absorbed and is rapidly converted to acyclovir, resulting in three- to fourfold higher acyclovir levels than can be achieved with oral acyclovir, even in patients with advanced HIV disease." | ( Valaciclovir (BW256U87): the L-valyl ester of acyclovir. Jacobson, MA, 1993) |
| " Valaciclovir was rapidly and extensively converted to acyclovir, resulting in significantly greater acyclovir bioavailability (approximately threefold to fivefold) compared with that historically observed with high-dose (800 mg) oral acyclovir." | ( Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Blum, MR; Burnette, T; Cederberg, DM; de Miranda, P; Doucette, M; Smiley, ML; Weller, S, 1993) |
| " Current work includes the development of increased bioavailability prodrugs (BW 256, famciclovir), which are converted to active drug once absorbed, enabling rapid high serum levels, and hence may turn out to have increased efficacy in HSV- and VZV-induced diseases, for which oral acyclovir currently is the treatment of choice." | ( Systemic antivirals in herpesvirus infections. Sacks, SL; Sasadeusz, JJ, 1993) |
| " PCV and ACV reduced virus replication to a similar extent when given ad libitum in drinking water, even though ACV had better oral bioavailability and greater potency in murine cells." | ( Comparative activity of penciclovir and acyclovir in mice infected intraperitoneally with herpes simplex virus type 1 SC16. Boyd, MR; Sutton, D, 1993) |
| " The absolute bioavailability of acyclovir from valaciclovir and the metabolic disposition of valaciclovir were investigated with healthy volunteers in two separate studies." | ( Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. On, N; Posner, J; Rolan, P; Seaber, E; Soul-Lawton, J; Wootton, R, 1995) |
| "Oral administration of the prodrug valacyclovir results in enhanced bioavailability and significantly greater plasma concentrations of acyclovir than can be achieved with oral doses of acyclovir itself." | ( Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Beutner, KR, 1995) |
| "Valaciclovir, the 1-valyl ester of acyclovir, has provided a peroral acyclovir bioavailability 3 to 5 times that of acyclovir itself and is rapidly and completely converted to acyclovir by the liver." | ( A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. Beutner, K; DeGregorio, B; Miller, C; Spruance, SL; Tyring, SK, ) |
| "Famciclovir is the well-absorbed oral form of penciclovir, a potent and selective antiviral agent, with activity against members of the herpesvirus family, including varicella-zoster virus (VZV), and herpes simplex virus-1 (HSV-1) and HSV-2." | ( The pharmacological profile of famciclovir. Crumpacker, C, 1996) |
| " The bioavailability of valacyclovir is 54% compared to approximately 20% for oral acyclovir." | ( Valacyclovir. Acosta, EP; Fletcher, CV, 1997) |
| "Valacyclovir has improved bioavailability over acyclovir and is at least as efficacious." | ( Valacyclovir. Acosta, EP; Fletcher, CV, 1997) |
| " Much of the current antiviral research focuses on providing drugs with (i) improved oral bioavailability and pharmacokinetics which permit less frequent oral or topical dosing for suppressive treatment of herpes simplex virus (HSV) infections, (ii) different mechanisms of action for synergic effects in treating resistant HSV infections in the immunocompromised host and (iii) improved efficacy." | ( New therapeutic approaches to the alphaherpesvirus infections. Cassady, KA; Whitley, RJ, 1997) |
| " The bioavailability of aciclovir from oral valaciclovir is considerably greater than that achieved after oral aciclovir administration." | ( Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Faulds, D; Perry, CM, 1996) |
| " ODG-P-[3H]ACV was well absorbed orally." | ( Enhanced oral absorption and antiviral activity of 1-O-octadecyl-sn-glycero-3-phospho-acyclovir and related compounds in hepatitis B virus infection, in vitro. Beadle, JR; Gardner, MF; Hostetler, KY; Kini, GD; Korba, BA; Wright, KN; Wu, TH, 1997) |
| "To determine whether the improved bioavailability of valaciclovir and a more convenient, less frequent dose regimen can maintain the clinical efficacy previously demonstrated for acyclovir." | ( Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. The Valaciclovir International Herpes Simplex Virus Study Group. Barbarash, RA; Degregorio, B; Fife, KH; Roth, R; Rudolph, T, 1997) |
| "The bioavailability of acyclovir to the ophthalmic epithelium is low and when the drug is administered in ophthalmic ointment it must be applied every four hours." | ( Bioadhesive microspheres for ophthalmic administration of acyclovir. Conti, B; Genta, I; Pavanetto, F; Perugini, P; Puglisi, G; Spadaro, A, 1997) |
| "This investigation was carried out to evaluate the bioavailability of a new tablet formulation of acyclovir (400 mg), Clovir, relative to reference product, Zovirax (400 mg) tablets." | ( Comparative bioavailability of two tablet formulations of acyclovir in healthy volunteers. Al-Khamis, KI; Al-Rashood, KA; Al-Yamani, MJ; Bawazir, SA; El-Sayed, YM; Gouda, MW, 1998) |
| " VACV demonstrates an oral bioavailability that is three to five time greater than acyclovir, concentration dependent, and saturable in humans." | ( Carrier-mediated intestinal absorption of valacyclovir, the L-valyl ester prodrug of acyclovir: 1. Interactions with peptides, organic anions and organic cations in rats. Balimane, PV; Sinko, PJ, 1998) |
| " These results suggest that the gastrointestinal maturation of CyA-treated neonates is suppressed, resulting in increased bioavailability of acyclovir, while the gastrointestinal absorption of acyclovir does not differ between adult CyA-treated and control rats." | ( Effect of cyclosporine A on the gastrointestinal absorption of acyclovir in neonatal and adult rats. Mizuno, N; Takagi, C; Takahashi, K; Yamamoto, N, 1998) |
| " Valacyclovir, a water soluble amino acid ester prodrug of acyclovir has been reported to increase the oral bioavailability of acyclovir but its absorption mechanism is unknown." | ( 5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Amidon, GL; Covitz, KM; de Vrueh, RL; Han, H; Lee, CP; Oh, DM; Rhie, JK; Sadée, W; Smith, PL, 1998) |
| "A series of 2-amino-9-(3-hydroxymethyl-4-alkoxycarbonyloxybut-1-yl)purines (4-10) and 2-amino-9-(2-(2-oxo-1,3-dioxan-5-yl)ethyl)purine (1) were synthesized as potential prodrugs of penciclovir and evaluated for their oral penciclovir bioavailability in mice and rats." | ( Synthesis and evaluation of 2-amino-9-(3-hydroxymethyl-4-alkoxycarbonyloxybut-1-yl)purines as potential prodrugs of penciclovir. Chang, K; Cho, YB; Choi, WS; Hwang, YY; Im, GJ; Jung, I; Kim, DK; Kim, JS; Kim, KH; Kim, TS; Kim, YW; Lee, N; Min, DS; Um, KA, 1998) |
| "2-Amino-6-fluoro-9-(2-hydroxyethoxymethyl)purine (2) and its ester derivatives 4a-d were synthesized as potential prodrugs of acyclovir, and were evaluated for their oral acyclovir bioavailability in rats and in vivo antiviral efficacy in HSV-1-infected mice." | ( Synthesis and evaluation of 2-amino-6-fluoro-9-(2-hydroxyethoxymethyl)purine esters as potential prodrugs of acyclovir. Im, GJ; Kim, DK; Kim, HT; Kim, KH; Lee, N, 1998) |
| "The amino acid ester derivatives of 6-deoxypenciclovir, 11-20, were synthesized as potential prodrugs of penciclovir, and were evaluated for their oral penciclovir bioavailability in mice and rats." | ( Synthesis and evaluation of amino acid esters of 6-deoxypenciclovir as potential prodrugs of penciclovir. Chang, K; Choi, WS; Im, GJ; Kim, DK; Kim, KH; Kim, YW; Lee, N, 1999) |
| " New antiviral drugs with improved oral bioavailability (famciclovir and valaciclovir) allow a better efficacy." | ( [Drug clinics. How I treat zona]. Nikkels, AF; Piérard, GE, 1999) |
| " The determination of the detailed pharmacokinetic parameters and the relative bioavailability was carried out on 24 healthy male volunteers in a two way, open, randomised, cross-over design study after single dose administration." | ( [Comparative pharmacokinetics of 800 mg of acyclovir-containing Telviran and Zovirax tablets in healthy volunteers]. Baloghné, NK; Csörgó, M; Dalmadiné, KB; Grézal, G; Klebovich, I; Mózsik, G; Nagy, L; Patai, V; Szentpéteri, I; Tömló, J, 1999) |
| " Our results suggest that L-valine is a desirable L-amino acid for the esterification of poorly permeable drugs to enhance their oral bioavailability targeting intestinal PEPT1." | ( Recognition of L-amino acid ester compounds by rat peptide transporters PEPT1 and PEPT2. Hashimoto, Y; Inui, KI; Saito, H; Sawada, K; Terada, T, 1999) |
| "(1) Valaciclovir, a metabolic precursor of aciclovir, improves the bioavailability of the active compound." | ( Valaciclovir in herpes zoster ophthalmicus: new indication. An empty clinical assessment file. , 1999) |
| " The interindividual variations of the bioavailability were 48." | ( Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy. Eksborg, S; Grimfors, G; Gruber, A; Kalin, M; Palm, C; Steingrimsdottir, H, 2000) |
| " It showed good oral bioavailability in rats (68." | ( Synthesis and antiviral activity of novel anti-VZV 5-substituted uracil nucleosides with a cyclopropane sugar moiety. Aoki, M; Iwayama, S; Mukai, C; Nakagawa, R; Nakazawa, H; Ohmura, Y; Okunishi, M; Onishi, T; Ono, N; Sekiyama, T; Suzuki, K; Tsuji, T, 2000) |
| " Famciclovir and valacyclovir offer improved oral bioavailability and convenient oral dosing schedules but are more expensive than acyclovir." | ( Treatment of common cutaneous herpes simplex virus infections. Emmert, DH, 2000) |
| "A rapid, simple and sensitive reversed-phase high-performance liquid chromatographic (HPLC) method has been developed for the measurement of acyclovir concentrations in human plasma and its use in bioavailability studies is evaluated." | ( Rapid, simple and sensitive high-performance liquid chromatographic method for detection and determination of acyclovir in human plasma and its use in bioavailability studies. Bangaru, RA; Bansal, YK; Gandhi, TP; Rao, AR, 2000) |
| "We synthesized, 1-O-hexadecylpropanediol-3-P-acyclovir, an orally bioavailable lipid prodrug of acyclovir and evaluated it for in vitro and in vivo activity against herpes simplex virus infections." | ( Synthesis and antiviral evaluation of 1-O-hexadecylpropanediol-3-P-acyclovir: efficacy against HSV-1 infection in mice. Aldern, KA; Beadle, JR; Gardner, MF; Hostetler, KY; Kern, ER; Kini, GD; Rybak, RJ; Wright, KN, ) |
| " The higher oral bioavailability of newer antiviral agents allows part of the extended treatment period of patients with herpes simplex encephalitis to be carried out as an ambulatory oral regimen." | ( Use of oral valaciclovir in a 12-year-old boy with herpes simplex encephalitis. Chan, PK; Chow, PC; Huen, KF; Mak, AW; Peiris, JS, 2000) |
| " Oral valaciclovir provides significantly better oral bioavailability than oral aciclovir itself, contributing to the need for less frequent administration." | ( Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections. Ormrod, D; Perry, CM; Scott, LJ, 2000) |
| " However, the low oral bioavailability of aciclovir has to some extent limited its efficacy in the treatment of herpes zoster and has prompted the development of the more readily absorbed oral prodrug valaciclovir." | ( Valaciclovir: a review of its use in the management of herpes zoster. Goa, K; Ormrod, D, 2000) |
| " The use of oral acyclovir preparations with higher bioavailability (valacyclovir) or intravenous acyclovir early on may prevent the considerable morbidity associated with disseminated zoster infection." | ( Varicella zoster meningoencephalitis following treatment for dermatomal zoster in an alloBMT patient. Mahendra, P; Osman, H; Tauro, S; Toh, V, 2000) |
| " The reported great similarity in apparent first-order absorption rate constants (k) of seven structurally diverse compounds between the two species were obtained." | ( Similarity in the linear and non-linear oral absorption of drugs between human and rat. Chiou, WL; Chung, SM; Jeong, HY; Ma, C; Wu, TC, 2000) |
| " In vivo ocular bioavailability was evaluated by instilling 50 microL of the acyclovir-loaded nanospheres only once in the conjunctival sac of rabbit eyes." | ( Ocular tolerability and in vivo bioavailability of poly(ethylene glycol) (PEG)-coated polyethyl-2-cyanoacrylate nanosphere-encapsulated acyclovir. Bucolo, C; Cavallaro, G; Fontana, G; Fresta, M; Giammona, G; Puglisi, G, 2001) |
| " Thus, the therapeutic efficacy of oral administration at the various doses of eugeniin was similar to that of intraperitoneal administration, suggesting that the oral bioavailability of eugeniin was high with respect to absorption." | ( Biological characterization of eugeniin as an anti-herpes simplex virus type 1 compound in vitro and in vivo. Hozumi, T; Kadota, S; Kurokawa, M; Namba, T; Shiraki, K; Tsurita, M, 2001) |
| " The bioavailability of valacyclovir is 54% compared to approximately 20% for oral acyclovir and may account for unexpected overdoses, which may lead to serious neurological toxicity." | ( [Neurologic toxicity caused by zelitrex (valaciclovir) in 3 patients with renal failure. Is overdose associated with improvement of product bioavailability improvement?]. Bengler, C; Blayac, JP; Branger, B; Hillaire-Buys, D; Peyrière, H; Pinzani, V; Vécina, F, 2001) |
| " The mean absolute bioavailability of aciclovir from oral valaciclovir was 60 +/- 21%." | ( Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients. Höglund, M; Ljungman, P; Weller, S, 2001) |
| " These data indicate that introduction of an isopropoxy carbonate group into one of the two hydroxyl groups of M4 did not significantly alter the oral bioavailability of penciclovir compared with famciclovir." | ( Pharmacokinetic studies of 2-amino-9-(3-acetoxymethyl-4-isopropoxycarbonyl-oxybut-1-yl)purine, an oral prodrug for the antiviral agent penciclovir. Chang, K; Choi, WS; Im, GJ; Jung, I; Kim, DK; Kim, JS; Kim, TK; Kim, TS; Kim, YW; Lee, N; Lee, SJ, 2001) |
| " Its limited oral bioavailability and short half-life, however, necessitates frequent dosing." | ( Comparative study of the efficacy and safety of valaciclovir versus acyclovir in the treatment of herpes zoster. Chen, YS; Chiang, SC; Huang, CK; Lee, SS; Lin, HH; Lin, WR; Liu, YC; Tsai, HC; Wann, SR; Yen, MY, 2001) |
| "The pharmacokinetics and relative bioavailability of a new sustained release formulation (200mg) of acyclovir (ACV) in comparison with a 100mg reference was investigated." | ( Pharmacokinetics and bioavailability of sustained release and conventional formulation of acyclovir. Chen, XJ; Cheng, K; Gang, YY; Wu, ZH; Xu, XY; Zhang, JH; Zhao, R; Zhu, JB, ) |
| " There was no effect of sex on acyclovir bioavailability with either drug." | ( Comparative bioavailability of acyclovir from oral valacyclovir and acyclovir in patients treated for recurrent genital herpes simplex virus infection. Aoki, FY; Bras, AP; Sitar, DS, 2001) |
| " The treatment of these conditions has been advanced over the past two decades by the introduction of guanosine nucleoside antivirals such as valacyclovir (Valtrex), Glaxo Wellcome), the highly bioavailable prodrug of acyclovir (Zovirax), Glaxo Wellcome)." | ( Valacyclovir in the treatment of genital herpes and herpes zoster. Baker, DA, 2002) |
| "Acyclovir is a widely used agent in the treatment of herpes virus infections of the skin, but owing to its poor physicochemical properties in terms of bioavailability and suboptimal formulations, the treatment is far from optimal." | ( Release kinetics of acyclovir from a suspension of acyclovir incorporated in a cubic phase delivery system. Helledi, LS; Schubert, L, 2001) |
| " Valacyclovir has good bioavailability and has not been studied for prophylaxis of HSV among PCT patients." | ( Valacyclovir prophylaxis for the prevention of Herpes simplex virus reactivation in recipients of progenitor cells transplantation. Desmery, P; Dignani, MC; Intile, D; Mammana, L; Michelet, M; Milone, G; Mykietiuk, A; Pavlovsky, S, 2002) |
| " The bioavailability of acyclovir after oral administration of valacyclovir was 45% (median value; 95% CI: 37-55%)." | ( Pharmacokinetics of acyclovir in immunocompromized children with leukopenia and mucositis after chemotherapy: can intravenous acyclovir be substituted by oral valacyclovir? Eksborg, S; Kalin, M; Pal, N; Palm, C; Söderhäll, S, 2002) |
| " In view of the high oral bioavailability of valaciclovir (the L-valyl ester of acyclovir) the risk of neurotoxicity becomes more prominent." | ( Evaluation of valaciclovir dosage reduction in continuous ambulatory peritoneal dialysis patients. Dhillon, S; Stathakis, C; Stathoulopoulou, F; Thodis, H; Vargemezis, V, 2002) |
| " The mean absolute bioavailability of aciclovir is of 54." | ( [Valaciclovir]. Lebrun-Vignes, B, 2002) |
| " Various prodrugs have been successful in achieving the goals of enhanced bioavailability and are, therefore, considered to be an important tool in biopharmaceutics." | ( Current prodrug strategies via membrane transporters/receptors. Anand, BS; Dey, S; Mitra, AK, 2002) |
| " The peptide transporter on the corneal epithelium may be targeted to improve the ocular bioavailability of poorly absorbed drugs." | ( Mechanism of corneal permeation of L-valyl ester of acyclovir: targeting the oligopeptide transporter on the rabbit cornea. Anand, BS; Mitra, AK, 2002) |
| " Valacyclovir has greater oral bioavailability and requires less frequent dosing." | ( Valacyclovir versus acyclovir for HSV prophylaxisin neutropenic patients. Barnett, MJ; Campbell, LM; Cox, VC; Epstein, JB; Marra, F; Ransier, A; Warkentin, DI; Yip, JG, 2002) |
| " Valacyclovir enhances acyclovir bioavailability compared with orally administered acyclovir." | ( Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir. Baker, D; Snowden, W; Tyring, SK, 2002) |
| " By using historical data for intravenous acyclovir as reference, the overall estimate of acyclovir bioavailability from valacyclovir was 48%, 2- to 4-fold greater than for oral acyclovir." | ( An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised children. Floret, D; Leibundgut, K; Leverger, G; Nadal, D; Perel, Y; Sokal, EM; Weller, S, 2002) |
| " The oral bioavailability of acyclovir is thereby affected and reaches only 15-30%." | ( Preliminary pharmacokinetic study of different preparations of acyclovir with beta-cyclodextrin. Aránguiz, T; Hernández, L; Luengo, J; Sepúlveda, J; Von Plessing, C, 2002) |
| " Afterwards other drugs have been developed either with a better bioavailability or with an activity against aciclovir-resistant strains." | ( [Antiretroviral drugs for the treatment and prevention of herpes infections in the year 2000]. Malkin, JE, 2002) |
| " The relative bioavailability of the valaciclovir tablets compared with the suspension was 115 +/- 32%." | ( Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness. Deeter, RG; Fish, DN; Simon, MW, 2002) |
| "Oral valacyclovir is better absorbed than oral acyclovir, increasing acyclovir bioavailability three- to fivefold." | ( High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Barber, J; Blatter, MM; Goldstein, D; Hill, J; Jones, TM; Schultz, M; Spruance, SL; Vargas-Cortes, M, 2003) |
| " Oral valacyclovir, which is converted in the body to acyclovir, has greater oral bioavailability than oral acyclovir and compared with oral acyclovir yields similar acyclovir plasma concentrations with less frequent (twice-daily) dosing." | ( Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy. Broun, ER; DeVoe, M; Eisen, D; Essell, J; Sigmund, D, 2003) |
| " Valacyclovir, a prodrug of acyclovir with a higher level of bioavailability than acyclovir, has also been shown to be effective in preventing CMV disease when given as prophylactic treatment." | ( Comparative study of prophylactic oral ganciclovir and valacyclovir in high-risk kidney transplant recipients. Beaulieu, J; Dworkin, L; Gohh, R; Monaco, A; Morrissey, P; Shemin, D; Yango, A; Zanabli, A, 2003) |
| "Hydrophilic drugs are poorly absorbed when applied topically, due to low partitioning through the lipid matrix of the stratum corneum." | ( The role of stratum corneum and dermal microvascular perfusion in penetration and tissue levels of water-soluble drugs investigated by microdialysis. Friedmann, PS; Morgan, CJ; Renwick, AG, 2003) |
| "The plasma bioavailability for acyclovir, valacyclovir and val-valacyclovir were similar with area under curve values being 896." | ( Ocular penetration of acyclovir and its peptide prodrugs valacyclovir and val-valacyclovir following systemic administration in rabbits: An evaluation using ocular microdialysis and LC-MS. Atluri, H; Dias, C; Mitra, A; Nashed, Y, 2002) |
| " The increased bioavailability of valacyclovir is attributed to carrier-mediated intestinal absorption, via the hPEPT1 peptide transporter, followed by the rapid and complete conversion to acyclovir." | ( Identification of a human valacyclovirase: biphenyl hydrolase-like protein as valacyclovir hydrolase. Amidon, GL; Chu, XY; Kim, I; Kim, S; Lee, KD; Provoda, CJ, 2003) |
| " The aqueous humor acyclovir levels were monitored for 6 h to determine the drug's ocular bioavailability for the various formulations." | ( Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability. Bucolo, C; Fresta, M; Giannavola, C; Lee, VH; Maltese, A; Paolino, D; Puglisi, G; Vandelli, MA, 2003) |
| "This study investigated the oral bioavailability and efficacy of BILS 45 BS, a selective herpes simplex virus (HSV) helicase-primase inhibitor, against acyclovir (ACV)-resistant (ACV(r)) infections mediated by the HSV type 1 (HSV-1) dlsptk and PAA(r)5 mutant strains." | ( Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1. Browne, A; Cordingley, MG; Dansereau, N; Duan, J; Faucher, AM; Liard, F; Liuzzi, M; Paris, W; Simoneau, B, 2003) |
| " This method was developed and validated for use in bioavailability and bioequivalence studies." | ( Technique validation by liquid chromatography for the determination of acyclovir in plasma. Aránguiz, T; Fernández, M; Sepúlveda, J; von Plessing, C, 2003) |
| "A series of dipeptide prodrugs of antiviral nucleoside acyclovir (ACV) were designed to target the oligopeptide transporter on the cornea with an aim of improving the ocular bioavailability and therapeutic activity of ACV." | ( Novel dipeptide prodrugs of acyclovir for ocular herpes infections: Bioreversion, antiviral activity and transport across rabbit cornea. Anand, B; Mitra, A; Nashed, Y, ) |
| "Variability in valacyclovir bioavailability and the potential for cephalexin-valacyclovir interaction were evaluated." | ( Intra- and interindividual variabilities of valacyclovir oral bioavailability and effect of coadministration of an hPEPT1 inhibitor. Anderle, P; Chin-Hong, P; Guglielmo, BJ; Lin, ET; Phan, DD; Sadee, W, 2003) |
| " We conclude that the improved bioavailability previously reported for valacyclovir in plasma results in higher concentrations in CSF, while the CSF/serum AUC ratio remains constant." | ( Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir. Lycke, J; Malmeström, C; Ståhle, L, 2003) |
| " The results of this study suggest that PS could be regarded as a potential corneal enhancer to increase the intraocular bioavailability of AC and TM." | ( Enhancer effects on in vitro corneal permeation of timolol and acyclovir. Bucolo, C; Montenegro, L; Puglisi, G, 2003) |
| " Over the past two decades, the treatment of these conditions has been transformed by guanosine nucleoside antivirals such as valacyclovir (Valtrex, a highly bioavailable prodrug of acyclovir (Zovirax, and famciclovir (Famvir), a highly bioavailable prodrug of penciclovir (Denavir)." | ( Valacyclovir in the treatment of herpes simplex, herpes zoster, and other viral infections. Brentjens, MH; Lee, P; Torres, G; Tyring, SK; Wu, JJ; Yeung-Yue, K, ) |
| "Famciclovir, the well absorbed oral pro-drug of penciclovir, is effective in the treatment of herpes zoster when given three times daily." | ( Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. Ashton, R; Candaele, D; Decroix, J; Forszpaniak, C; Paulet, C; Shafran, SD; Tyring, SK; Wade, A, 2004) |
| "tert-Azido or amino substituted penciclovir analogs, 1-3 were synthesized for the purpose of improving the efficacy and bioavailability of penciclovir and searching for novel antiviral agents." | ( Synthesis and biological evaluation of novel tert-azido or tert-amino substituted penciclovir analogs. Baek, HW; Chun, MW; Jeong, LS; Kim, DK; Kim, HO; Moon, HR, 2004) |
| " Initial absorption rate constants were determined by the plot of log% remaining amount of drug in perfusate vs time." | ( The influence of absorption enhancers on nasal absorption of acyclovir. Chavanpatil, MD; Vavia, PR, 2004) |
| " Enhanced bioavailability of VACV has been attributed to its carrier-mediated intestinal absorption via hPEPT1 peptide transporter followed by rapid and complete conversion to ACV." | ( Pharmacokinetics of novel dipeptide ester prodrugs of acyclovir after oral administration: intestinal absorption and liver metabolism. Anand, BS; Katragadda, S; Mitra, AK, 2004) |
| "Low oral bioavailability continues to drive research toward identifying novel approaches to enhance drug delivery." | ( The impact of DeltaG on the oral bioavailability of low bioavailable therapeutic agents. Eddington, ND; Fasano, A; Salama, NN; Thakar, M, 2005) |
| " This drug's short serum half-life and low oral bioavailability make frequent dosing necessary, however, and we therefore sought to determine if the pro-drug valacyclovir, which has improved bioavailability, could be successfully substituted for this indication." | ( Oral valacyclovir as prophylaxis against herpes simplex virus reactivation during high dose chemotherapy for leukemia. Ambinder, RF; Gore, SD; Hartley, EE; Miller, CB; Mills, SR; Orlowski, RZ; Piantadosi, S; Ye, X, 2004) |
| "The aim of this study was to explore the feasibility of improvement of ocular bioavailability of the antiviral agent acyclovir by designing amino acid prodrugs targeted to the amino acid transporters on the rabbit cornea." | ( Amino acid prodrugs of acyclovir as possible antiviral agents against ocular HSV-1 infections: interactions with the neutral and cationic amino acid transporter on the corneal epithelium. Anand, BS; Katragadda, S; Mitra, AK; Nashed, YE, ) |
| " Subsequently, the orally bioavailable prodrugs valaciclovir and famciclovir have been introduced." | ( Recent clinical experience with famciclovir--a "third generation" nucleoside prodrug. Beutner, K; Chakrabarty, A; Rauser, M; Tyring, SK, 2004) |
| "Two studies were performed to assess the relative bioavailability of Lovrak (Julphar, UAE) compared with Zovirax (Glaxo Wellcome, UK) at the International Pharmaceutical Research Center (IPRC), Amman, Jordan." | ( Bioequivalence assessment of Lovrak (Julphar, UAE) compared with Zovirax (Glaxo Wellcome, UK)--Two brands of Acyclovir--in healthy human volunteers. Admour, I; Alam, SM; Beshtawi, M; Dham, R; Idkaidek, N; Mohammed, B; Najib, NM, 2005) |
| "The bioavailability of a generic preparation of acyclovir (Avorax) was compared with the innovator product, Zovirax." | ( Bioavailability and pharmacokinetics of acyclovir tablet preparation. Billa, N; Chan, KL; Peh, KK; Toh, WT; Yuen, KH, 1998) |
| " Oral administration of acyclovir valylchenodeoxycholate to rats resulted in a 2-fold increase in the bioavailability of acyclovir, compared to the bioavailability after administration of acyclovir alone." | ( Increased acyclovir oral bioavailability via a bile acid conjugate. Coop, A; Lentz, KA; Maeda, DY; Polli, JE; Tolle-Sander, S, 2004) |
| "Design of a liposome delivery system for vaginal administration of acyclovir, able to provide sustained release and improved bioavailability of the encapsulated drug for the local treatment of genital herpes was investigated." | ( Development and in vitro evaluation of a liposomal vaginal delivery system for acyclovir. Filipović-Grcić, J; Jalsenjak, I; Martinac, A; Pavelić, Z; Skalko-Basnet, N, 2005) |
| "The pharmacokinetics and bioavailability of acyclovir sustained-release tablets in dogs were investigated." | ( Pharmacokinetics and bioavailability of acyclovir sustained-release tablets in dogs. Hu, Q; Yang, Q, ) |
| "The purpose of the study reported here was to describe the bioavailability and pharmacokinetics of acyclovir after intravenous and oral administration to horses." | ( Pharmacokinetics of acyclovir after single intravenous and oral administration to adult horses. Bentz, BG; Clarke, CR; Davis, MS; Erkert, RS; MacAllister, CG; Maxwell, LK; Royer, CM, ) |
| "The absolute bioavailability of the prodrug valacyclovir, the l-valyl ester of acyclovir, after oral administration is approximately 54." | ( Stability of valacyclovir: implications for its oral bioavailability. Amidon, GL; Granero, GE, 2006) |
| " While there is no cure for these conditions, treatment to alleviate symptoms, suppress recurrences and reduce transmission has been drastically improved over the past 20 years with the use of guanine nucleoside antivirals, such as valacyclovir hydrochloride (Valtrex), GlaxoSmithKline) the highly bioavailable prodrug of acyclovir (Zovirax((R)), GlaxoSmithKline), and famciclovir (Famvir, Novartis), a highly bioavailable prodrug of penciclovir (Denavir, Novartis)." | ( Valacyclovir for the treatment of genital herpes. Brantley, JS; Hicks, L; Sra, K; Tyring, SK, 2006) |
| " Absorption rate constants of all the compounds were found to be lower than the elimination rate constants." | ( In vivo ocular pharmacokinetics of acyclovir dipeptide ester prodrugs by microdialysis in rabbits. Anand, BS; Gunda, S; Katragadda, S; Mitra, AK, ) |
| "The main purpose of this work was to develop an oral microemulsion formulation for enhancing the bioavailability of acyclovir." | ( Design and development of microemulsion drug delivery system of acyclovir for improvement of oral bioavailability. Ghosh, PK; Majithiya, RJ; Murthy, RS; Umrethia, ML, 2006) |
| " Patients who have no response to acyclovir may have a response to valacyclovir or famcilovir, which have greater oral bioavailability and more convenient dosing." | ( Erythema multiforme. Hsu, WT; Lamoreux, MR; Sternbach, MR, 2006) |
| " The shape of the curve between F(NC) and P(Caco-2) was similar with the one observed in the case of oral bioavailability except the curve shifted right." | ( Evaluation of the contribution of the nasal cavity and gastrointestinal tract to drug absorption following nasal application to rats. Furubayashi, T; Higashi, Y; Kamaguchi, A; Kataoka, M; Kawaharada, K; Masaoka, Y; Sakane, T; Yamashita, S, 2007) |
| "The effect of colitis induced with dextran sodium sulfate (DSS) in rats on the bioavailability of drugs transported by the oligopeptide transporter PepT-1 was analyzed by studying the pharmacokinetics of PepT-1 substrates: cephalexin and valacyclovir, the prodrug of antiviral acyclovir." | ( Regulation of the oligopeptide transporter, PEPT-1, in DSS-induced rat colitis. Bado, A; Beaufils, B; Buyse, M; Farinotti, R; Hindlet, P; Radeva, G; Walker, F, 2007) |
| " Six oral generic formulations of acyclovir are available in Mexico; however, a literature search failed to identify data information concerning the bioavailability of these formulations in the Mexican population." | ( Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects. Absalón-Reyes, JA; Burke-Fraga, V; de Lago, A; González-de la Parra, M; Namur, S; Novoa-Heckel, G; Oliva, I; Palma-Aguirre, JA; Rodríguez, Z, 2007) |
| "The aim of these 2 studies was to compare the bioavailability of 4 oral formulations of acyclovir 400 mg--2 tablet formulations and 2 suspension formulations--with their corresponding listed drug references in Mexico (a list issued by Mexican Health Authorities)." | ( Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects. Absalón-Reyes, JA; Burke-Fraga, V; de Lago, A; González-de la Parra, M; Namur, S; Novoa-Heckel, G; Oliva, I; Palma-Aguirre, JA; Rodríguez, Z, 2007) |
| " The first aim was to evaluate the oral bioavailability and pharmacokinetics (PKs) of acyclovir in horses after intravenous (i." | ( Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. Baert, K; Croubels, S; De Backer, P; Deprez, P; Garré, B; Gryspeerdt, A; Nauwynck, H; Shebany, K; van der Meulen, K, 2007) |
| " For atenolol (highly soluble drug), GInf resulted in a prolonged Tmax and reduced Cmax in comparison to PO, whereas bioavailability was similar." | ( Selection of drug candidates for gastroretentive dosage forms: pharmacokinetics following continuous intragastric mode of administration in a rat model. Hoffman, A; Kagan, L, 2008) |
| "This study aimed to compare the systemic bioavailability of two aciclovir tablets, Rouz-Aciclovir (test) and Zovirax (reference), in 12 healthy volunteers." | ( Lack of bioequivalence between two aciclovir tablets in healthy subjects. Ahmadiani, A; Amini, H; Gazerani, P; Ghaffari, A; Javan, M, 2008) |
| " The main purpose of this work was to develop self-microemulsifying drug delivery system (SMEDDS) for oral bioavailability enhancement of acyclovir." | ( Oral bioavailability enhancement of acyclovir by self-microemulsifying drug delivery systems (SMEDDS). Patel, D; Sawant, KK, 2007) |
| " The in vivo study revealed that the niosomal dispersion significantly improved the oral bioavailability of acyclovir in rabbits after a single oral dose of 40 mg kg(-1)." | ( Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits. Attia, IA; Donia, AM; El-Gizawy, SA; Fouda, MA, 2007) |
| " Significantly improved permeation of acyclovir in the presence of selected combinations of absorption enhancers may be used as a viable approach in overcoming the problem of limited oral bioavailability of acyclovir." | ( In vitro assessment of acyclovir permeation across cell monolayers in the presence of absorption enhancers. Bagchi, T; Jogani, V; Mishra, AK; Mishra, P; Misra, A; Shah, P, 2008) |
| " In vivo ocular bioavailability of these compounds was also evaluated with a combination of topical well infusion and aqueous humor microdialysis techniques." | ( Ocular pharmacokinetics of acyclovir amino acid ester prodrugs in the anterior chamber: evaluation of their utility in treating ocular HSV infections. Gunda, S; Hariharan, S; Katragadda, S; Mitra, AK, 2008) |
| " Absorption rate constants of all the compounds were found to be lower than the elimination rate constants." | ( Ocular pharmacokinetics of acyclovir amino acid ester prodrugs in the anterior chamber: evaluation of their utility in treating ocular HSV infections. Gunda, S; Hariharan, S; Katragadda, S; Mitra, AK, 2008) |
| " The poor bioavailability of acyclovir is attributed to short retention of its dosage form at the absorption sites (in upper gastrointestinal tract to duodenum and jejunum)." | ( Mucoadhesive microspheres for gastroretentive delivery of acyclovir: in vitro and in vivo evaluation. Dhaliwal, S; Jain, S; Singh, HP; Tiwary, AK, 2008) |
| "A rapid, simple and sensitive reversed-phase high-performance liquid chromatographic (HPLC) method has been developed for the measurement of acyclovir (CAS 59277-89-3) concentrations in human plasma and its use in bioavailability studies is evaluated." | ( A simple high-performance liquid chromatographic method for the determination of acyclovir in human plasma and application to a pharmacokinetic study. Xiang, B; Yu, L; Zhan, Y, 2008) |
| " The mean bioavailability of acyclovir from valacyclovir was 64%." | ( Valacyclovir and acyclovir pharmacokinetics in immunocompromised children. Aleksic, A; Berg, S; Blaney, S; Bomgaars, L; Serabe, B; Thompson, P, 2008) |
| " In vivo systemic bioavailability of these prodrugs upon oral administration was evaluated in jugular vein cannulated rats." | ( Pharmacokinetics of amino acid ester prodrugs of acyclovir after oral administration: interaction with the transporters on Caco-2 cells. Hariharan, S; Jain, R; Katragadda, S; Kwatra, D; Mitra, AK, 2008) |
| " The bioavailability of acyclovir from nasal mucoadhesive gel was 60." | ( Acyclovir liposomes for intranasal systemic delivery: development and pharmacokinetics evaluation. Alanazi, FK; Alsarra, IA; Hamed, AY, 2008) |
| "Acyclovir, a selective antiherpes virus agent, was loaded in the hollow microspheres to improve bioavailability and patient compliance by prolonging the residence time in the gastrointestinal tract." | ( Floating properties and release characteristics of hollow microspheres of acyclovir. Junyaprasert, VB; Pornsuwannapha, S, 2008) |
| " In rat, chitosan glutamate doubled oral bioavailability of acyclovir and tripled the amount of acyclovir excreted unchanged into urine." | ( Effect of chitosan glutamate, carbomer 974P, and EDTA on the in vitro Caco-2 permeability and oral pharmacokinetic profile of acyclovir in rats. Christoffersen, C; El-Kattan, A; Merzlikine, A; Poe, J; Rago, B; Rotter, C; Thomas, VH; Troutman, M, 2009) |
| " These findings may be valuable in developing formulation strategies to optimize ocular bioavailability of topically administered ocular agents." | ( Expression of multidrug resistance associated protein 5 (MRP5) on cornea and its role in drug efflux. Herndon, BL; Karla, PK; Mitra, A; Pal, D; Quinn, TL; Thomas, P, 2009) |
| " However, its limited solubility in water and limited oral bioavailability represent the main limitations of this drug." | ( A new homodimer of aciclovir as a prodrug with increased solubility and antiviral activity. Brandi, G; Magnani, M; Millo, E; Rossi, L; Schiavano, GF, 2009) |
| "Acyclovir-loaded mucoadhesive microspheres (ACV-ad-ms) using Ethylcellulose as matrix and Carbopol 974P NF as mucoadhesive polymer were prepared for the purpose of improving the oral bioavailability of acyclovir." | ( Development of mucoadhesive microspheres of acyclovir with enhanced bioavailability. Gu, B; Lu, W; Lu, Y; Pan, J; Sun, Y; Tao, Y, 2009) |
| " The efficacy of newer antiviral agents with better bioavailability (e." | ( Antiviral agents for treatment of herpes simplex virus infection in neonates. Badawi, N; Jones, CA; Walker, KS, 2009) |
| " These "in combo" PAMPA data were used to predict the human absolute bioavailability of the ampholytes." | ( The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. Avdeef, A; Sun, N; Tam, KY; Tsinman, O, 2010) |
| "Valacyclovir provides enhanced acyclovir bioavailability in adults, but limited data are available in children." | ( Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month through 11 years of age. Bradley, JS; Heitman, CK; Jacobs, RF; Kimberlin, DW; Man, CY; van der Walt, JS; Weller, S, 2010) |
| "Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)." | ( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010) |
| "The aim of the present study was to compare the bioavailability of valacyclovir (CAS 124832-26-4; INN: valaciclovir) from two valacyclovir hydrochloride (CAS 214832-27-5) capsules (150 mg/capsule as test preparation and 150 mg/capsule commercially available original capsule of the drug as reference preparation) in 20 Chinese healthy male volunteers, aged between 20 and 27." | ( Pharmacokinetics and bioequivalence study of valacyclovir hydrochloride capsules after single dose administration in healthy Chinese male volunteers. Lin, H; Mao, GG; Tian, JX; Tian, Y; Zhang, ZJ, 2010) |
| " GI transit test of the prepared microspheres was carried out in rats and beagle dogs, followed by the in vivo bioavailability evaluation of the microspheres in beagle dogs." | ( Preparation and evaluation of a novel gastric mucoadhesive sustained-release acyclovir microsphere. Dong, Y; Ji, L; Ke, P; Liu, H; Pan, W, 2010) |
| " Meanwhile, the relative bioavailability of AV microspheres was 145%." | ( Preparation and evaluation of a novel gastric mucoadhesive sustained-release acyclovir microsphere. Dong, Y; Ji, L; Ke, P; Liu, H; Pan, W, 2010) |
| " To increase bioavailability of these compounds, synthesis of their structurally diverse ester prodrugs was carried out: alkoxyalkyl (hexadecyloxypropyl, octadecyloxyethyl, hexadecyloxyethyl), pivaloyloxymethyl (POM), 2,2,2-trifluoroethyl, butylsalicylyl, and prodrugs based on peptidomimetics." | ( Synthesis of ester prodrugs of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) as anti-poxvirus agents. Andrei, G; Balzarini, J; Brehová, P; Cihlar, T; De Clercq, E; Dracínský, M; Holý, A; Hui, H; Krecmerová, M; Laflamme, G; Masojídková, M; Naesens, L; Neyts, J; Pohl, R; Pomeisl, K; Snoeck, R; Tichý, T, 2010) |
| "In the current study, the influence of chitosan on the dissolution rate and bioavailability of acyclovir has been illustrated through the preparation of co-crystals by simple solvent change method." | ( Formulation and physicochemical characterization of chitosan/acyclovir co-crystals. Allam, AN; El Gamal, SS; Naggar, VF, ) |
| " CMX001 is an orally bioavailable lipid conjugate of cidofovir that is substantially less nephrotoxic than the parent drug and has excellent antiviral activity against all the human herpesviruses." | ( CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections. Hartline, CB; Kern, ER; Lanier, ER; Prichard, MN; Quenelle, DC, 2011) |
| " (l)-Tyr-NH-i-Bu cHPMPA (11) was converted in rat or mouse plasma solely to two active metabolites and had significantly enhanced oral bioavailability vs parent drug 1 in a mouse model (39% vs <5%)." | ( Tyrosine-based 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine and -adenine ((S)-HPMPC and (S)-HPMPA) prodrugs: synthesis, stability, antiviral activity, and in vivo transport studies. Borysko, KZ; Breitenbach, JM; Collins, M; Drach, JC; Hilfinger, JM; Kashemirov, BA; Krylov, IS; McKenna, CE; Peterson, LW; Serpi, M; Zakharova, VM, 2011) |
| "The aim of this study was to increase bioavailability of the antiviral drug acyclovir (ACV) when administered by the ocular route." | ( Nonpolymeric nanoassemblies for ocular administration of acyclovir: pharmacokinetic evaluation in rabbits. Arpicco, S; Burgalassi, S; Cattel, L; Chetoni, P; Nicosia, N; Rocco, F; Stella, B; Tampucci, S, 2012) |
| "Honey can significantly increase the ACV concentration and bioavailability in the eye, extend the action time of ACV in target cells and increase the retention capacity of ACV in the target tissue; thereby improving treatment success." | ( [Effects of honey to acyclovir in the rabbit eye transport kinetics]. He, Q; Jiang, Y; Wang, S; Xu, J; Zhang, J; Zhang, X, 2011) |
| " Absorption of orally administered ACV is variable and incomplete, with a bioavailability of ca." | ( Development and evaluation of a monolithic floating drug delivery system for acyclovir. Dorkoosh, F; Motaghi, S; Tamaddon, L; Tavakoli, N; Varshosaz, J, 2012) |
| "The objective of the present investigation was to improve the ocular bioavailability of acyclovir by incorporating it into solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs)." | ( Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir. Al-Kassas, R; Seyfoddin, A, 2013) |
| "A majority of studies involving prodrugs are directed to overcome low bioavailability of the parent drug." | ( Targeted lipid based drug conjugates: a novel strategy for drug delivery. Earla, R; Kwatra, D; Mitra, AK; Pal, D; Samanta, SK; Vadlapatla, RK; Vadlapudi, AD, 2012) |
| "4 hours, respectively; and penciclovir bioavailability was 12." | ( Pharmacokinetics of penciclovir in healthy cats following oral administration of famciclovir or intravenous infusion of penciclovir. Bales, JL; Ferrone, M; Maggs, DJ; Stanley, SD; Thomasy, SM; Whittem, T, 2012) |
| " In vivo studies in rats indicated prolonged release and better oral bioavailability as compared to drug solution." | ( Design and development of multiple emulsion for enhancement of oral bioavailability of acyclovir. Kumar, A; Paul, S; Sawant, K; Yedurkar, P, 2013) |
| " Here, we describe the synthesis, antiviral activities in infected cell cultures and decomposition study of bis(pivaloyloxymethoxy)-S-PMEA [Bis-POM-S-PMEA, 13] and bis(isopropyloxymethylcarbonyl)-S-PMPA [Bis-POC-S-PMPA, 14] as orally bioavailable prodrugs of the S-PMEA 8 and S-PMPA 9, in comparison to the equivalent "non-thio" derivatives [Bis-POM-PMEA, 11] and [Bis-POC-PMPA, 12]." | ( Ester prodrugs of acyclic nucleoside thiophosphonates compared to phosphonates: synthesis, antiviral activity and decomposition study. Alvarez, K; Balzarini, J; Canard, B; Fournier, M; Payrot, N; Priet, S; Roux, L; Weck, C; Zoulim, F, 2013) |
| "This study aimed at improving the oral bioavailability of acyclovir (ACV) through incorporating it into gastroretentive dosage form based on floating hollow chitosan beads." | ( Development of mucoadhesive floating hollow beads of acyclovir with gastroretentive properties. Al-Kassas, R; Chalabi, S; In Kim, JH; Langford, C; Painter, S; Seyfoddin, A; Svirskis, D, 2014) |
| "The objective of this work was to design polymeric nanoparticles of Acyclovir and then incorporate the drug-loaded nanoparticles within an in situ gelling system to provide dual sustained release effect, whereby the duration of action and bioavailability through different routes of administration could be improved." | ( Dual sustained release delivery system for multiple route therapy of an antiviral drug. Ramyadevi, D; Sandhya, P, 2014) |
| "The therapeutic potential of acyclovir is limited by the low oral bioavailability owing to its limited aqueous solubility and low permeability." | ( Enhanced oral bioavailability of acyclovir by inclusion complex using hydroxypropyl-β-cyclodextrin. Ahmed, M; Al-Dhubiab, BE; Attimarad, M; Harsha, S; Nair, AB; Wadhwa, J, 2014) |
| " The relative bioavailability of the GR formulation was 261% of the IR formulation." | ( Development and characterization of gastroretentive sustained-release formulation by combination of swelling and mucoadhesive approach: a mechanistic study. Jain, SK; Sankar, R, 2013) |
| "The GR formulation of acyclovir, based on swelling and mucoadhesive mechanisms, has prolonged retention in the upper gastrointestinal tract, sustained in vitro drug release, prolonged in vivo absorption, and better bioavailability than the IR formulation." | ( Development and characterization of gastroretentive sustained-release formulation by combination of swelling and mucoadhesive approach: a mechanistic study. Jain, SK; Sankar, R, 2013) |
| " Here, the use of engineered thin planar poly(methyl methacrylate) (PMMA) microdevices is tested to enhance oral bioavailability of acyclovir, a poorly permeable drug." | ( Planar microdevices for enhanced in vivo retention and oral bioavailability of poorly permeable drugs. Chirra, HD; Ciaccio, N; Desai, TA; Fox, CB; Ma, A; Shao, L; Wade, JM, 2014) |
| "In this present study the possibility to develop Eudragit RLPO(®) based nanoparticles of acyclovir was investigated in order to increase its efficacy because acyclovir has oral bioavailability of only 10-20% thus showing erratic absorption and bioavailability behaviour." | ( In-vitro release of acyclovir loaded Eudragit RLPO(®) nanoparticles for sustained drug delivery. Gandhi, A; Jana, S; Sen, KK, 2014) |
| " An in situ gelling system was used to increase the residence time and thus the bioavailability of acyclovir in oral mucosa." | ( Preparation and evaluation of novel in situ gels containing acyclovir for the treatment of oral herpes simplex virus infections. Chaudhary, B; Verma, S, 2014) |
| " The relative bioavailability of the optimized ACV nanoemulsion hydrogel improved to 535." | ( Utilization of nanotechnology to enhance percutaneous absorption of acyclovir in the treatment of herpes simplex viral infections. Ahmed, TA; Al-Subaie, MM; Aljaeid, BM; El-Say, KM; Hosny, KM, 2015) |
| "The aim of our study was to improve the bioavailability of acyclovir (ACV) by delivery of mucoadhesive nanoparticles (NPs) and controlled delivery of drug at its absorption window." | ( Development and optimisation of mucoadhesive nanoparticles of acyclovir using design of experiments approach. Kharia, AA; Singhai, AK, 2015) |
| "Attempts to formulate acyclovir to improve its bioavailability and reduce the frequency of dosing from the present q4h have not materialized." | ( The Interesting Case of Acyclovir Delivered Using Chitosan in Humans: Is it a Drug Issue or Formulation Issue? Srinivas, NR, 2016) |
| "Oral bioavailability of acyclovir is limited, primarily because of low permeability across the gastrointestinal membrane." | ( Formulation and evaluation of nano based drug delivery system for the buccal delivery of acyclovir. Al-Dhubiab, BE; Attimarad, M; Harsha, S; Kumria, R; Nair, AB, 2015) |
| " It may be treated by acyclovir (ACV), however this antiviral drug is poorly soluble with low ocular bioavailability requiring high and frequent dosing." | ( Ex vivo and In vivo Evaluation of Chitosan Coated Nanostructured Lipid Carriers for Ocular Delivery of Acyclovir. Al-Kassas, R; McGhee, CN; Patel, DV; Rupenthal, ID; Seyfoddin, A; Sherwin, T; Taylor, JA, 2016) |
| "NLCs enhanced the ocular bioavailability and antiviral properties of ACV through cell internalisation, sustained release, and increased corneal permeation." | ( Ex vivo and In vivo Evaluation of Chitosan Coated Nanostructured Lipid Carriers for Ocular Delivery of Acyclovir. Al-Kassas, R; McGhee, CN; Patel, DV; Rupenthal, ID; Seyfoddin, A; Sherwin, T; Taylor, JA, 2016) |
| "Acyclovir a BCS class III drug exhibits poor bioavailability due to limited permeability." | ( Improving oral bioavailability of acyclovir using nanoparticulates of thiolated xyloglucan. Bhalekar, MR; Dikpati, AA; Madgulkar, A, 2016) |
| " In the case of acyclovir, Cap-Na either alone or in combination with SLS or chitosan has the potential to improve its absorption and bioavailability and has yet to be explored." | ( Effect of permeability enhancers on paracellular permeability of acyclovir. Ates, M; Kaynak, MS; Sahin, S, 2016) |
| " The Herpetic Eye Disease Study has guided the management of herpetic eye disease for almost twenty years, but newer medications such as valacyclovir are now available and are considered to have better bioavailability than acyclovir." | ( Herpes simplex virus keratitis: an update of the pathogenesis and current treatment with oral and topical antiviral agents. Anderson, D; Athanasiadis, I; Hossain, P; MacGregor, C; Moschos, MM; Tsatsos, M, 2016) |
| " Acyclovir is a clinically successful antiviral molecule till date, in-spite of limitations as poor solubility, low half-life, reduced oral bioavailability and side effects at higher doses." | ( Heterogeneous polymer composite nanoparticles loaded in situ gel for controlled release intra-vaginal therapy of genital herpes. Rajan, KS; Ramyadevi, D; Ruckmani, K; Subramanian, N; Vedhahari, BN, 2016) |
| " A novel cutaneous pharmacokinetic approach, dermal open-flow microperfusion (dOFM), can continuously assess the rate and extent to which a topical drug becomes available in the dermis, to compare in vivo dermal bioavailability (BA) and support BE evaluations for topical products." | ( Open Flow Microperfusion as a Dermal Pharmacokinetic Approach to Evaluate Topical Bioequivalence. Augustin, T; Birngruber, T; Bodenlenz, M; Dragatin, C; Kanfer, I; Pieber, TR; Raml, R; Raney, SG; Schimek, D; Schwagerle, G; Sinner, F; Tiffner, KI, 2017) |
| " RM-5061 8a in rats showed 7-fold higher blood concentration compared to 1a: absolute bioavailability increased from 3 to 20%, with a good safety profile in animal safety pharmacology and toxicology." | ( Synthesis and pre-clinical studies of new amino-acid ester thiazolide prodrugs. Cooper, M; Norton, D; Reynolds, S; Rossignol, JF; Slonecker, SD; Stachulski, AV; Swift, K, 2017) |
| "In the recent decades, various controlled delivery systems have been introduced with the aim to improve solubility, stability and bioavailability of poorly absorbed drugs." | ( Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye - Part II - Ocular drug-loaded lipid nanoparticles. Doktorovova, S; Espina, M; García, ML; Sánchez-López, E; Souto, EB, 2017) |
| " Although it is known that valacyclovir has an improved bioavailability and steadier plasma concentration, it is currently unclear as to whether this leads to better treatment results and less ocular complications." | ( Valacyclovir versus acyclovir for the treatment of herpes zoster ophthalmicus in immunocompetent patients. Harder, BC; Jarczok, MN; Schlichtenbrede, FC; Schuster, AK; Tesarz, J, 2016) |
| "Despite peptide transporter 1 (PEPT1) being responsible for the bioavailability for a variety of drugs, there has been little study of its potential involvement in drug-drug interactions." | ( In Vitro and Clinical Evaluations of the Drug-Drug Interaction Potential of a Metabotropic Glutamate 2/3 Receptor Agonist Prodrug with Intestinal Peptide Transporter 1. Annes, WF; Ayan-Oshodi, MA; Hillgren, KM; Knadler, MP; Leese, P; Long, AJ; Mitchell, MI; Pak, YA; Witcher, JW, 2017) |
| "The dissolution and subsequent oral bioavailability of acyclovir (ACY) is limited by its poor aqueous solubility." | ( Acyclovir-Polyethylene Glycol 6000 Binary Dispersions: Mechanistic Insights. Gunasunderi, R; Kai, HW; Khoo, K; Nayak, MM; Parasuraman, S; Shah, SAA; Sureshkumar, K; Venkateskumar, K, 2017) |
| "Semi-synthetic biopolymer complex (SSBC) nanoparticles were investigated as a potential oral drug delivery system to enhance the bioavailability of a poorly water-soluble model drug acyclovir (ACV)." | ( Development of a Novel Polymeric Nanocomposite Complex for Drugs with Low Bioavailability. Choonara, YE; du Toit, LC; Kondiah, PPD; Kumar, P; Marimuthu, T; Pillay, V; Sithole, MN, 2018) |
| " The most widely utilized antiherpes drugs, acyclovir and its derivatives, have serious limitations, such as low bioavailability and severe side effects." | ( Inhibition of Herpes Simplex Viruses by Cationic Dextran Derivatives. Ciejka, J; Klysik, K; Nowakowska, M; Pachota, M; Pyrć, K; Synowiec, A; Szczubiałka, K, 2017) |
| " The analogues of acyclovir, especially their esters, characterized by significantly higher bioavailability and safety, may gradually replace acyclovir in selected applications." | ( Acyclovir in the Treatment of Herpes Viruses - A Review. Karewicz, A; Kłysik, K; Nowakowska, M; Pietraszek, A, 2020) |
| " A new potential approach for solubility, bioavailability and permeability enhancement of acyclovir and other BCS class IV drugs was successfully established." | ( FORMULATION AND IN VITRO EVALUATION OF ACYCLOVIR LOADED POLYMERIC MICROPARTICLES: A SOLUBILITY ENHANCEMENT STUDY. Ahmad, M; Mahmood, A; Minhas, MU; Sarfraz, RM; Yaqoob, A, 2016) |
| " Bioavailability was 40% after single oral administration." | ( Absorption, Distribution, Metabolism, and Excretion of the Novel Helicase-Primase Inhibitor, Amenamevir (ASP2151), in Rodents. Noguchi, K; Ohtsu, Y; Susaki, Y, 2018) |
| " However, chitosan was recently shown to reduce the oral bioavailability of acyclovir in humans." | ( The effect of chitosan on the bioaccessibility and intestinal permeability of acyclovir. Augustijns, P; García, MA; Heinen, C; Kubbinga, M; Langguth, P; Verwei, M; Wortelboer, HM, 2019) |
| "Gastroretentive (GR) systems are designed to prolong gastric residence time to allow sustained absorption and improve the oral bioavailability of drugs with a narrow absorption window in the upper part of the gastrointestinal tract." | ( Development of a gastroretentive delivery system for acyclovir by 3D printing technology and its in vivo pharmacokinetic evaluation in Beagle dogs. Chung, SE; Jeong, SW; Kim, DH; Kim, TH; Lee, DY; Shin, BS; Shin, S, 2019) |
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) |
| "To examine the potential of stratum corneum (SC) sampling via tape-stripping in humans to assess bioequivalence of topical acyclovir drug products, and to explore the potential value of alternative metrics of local skin bioavailability calculable from SC sampling experiments." | ( Stratum Corneum Sampling to Assess Bioequivalence between Topical Acyclovir Products. Bunge, AL; Chiu, WS; Cordery, SF; Delgado-Charro, MB; Guy, RH; Pensado, A; Rantou, E, 2019) |
| " Because the optimal dose of ACV varies among individuals depending on the bioavailability of ACV and metabolic enzyme activity, ACV encephalopathy can occur even when the acyclovir dose is modified according to the renal function of the affected patient." | ( [Acyclovir encephalopathy in a peritoneal dialysis patient despite adjusting the dose of oral acyclovir: a case report]. Ikuma, D; Kawabe Matsukawa, M; Sugimoto, I; Suwabe, T; Suzuki, Y; Uesaka, Y, 2019) |
| " The changes of absorption rate over time after oral administration were also successfully estimated." | ( Development of a Population Pharmacokinetics-Based in vitro-in vivo Correlation Model for Drugs with Site-Dependent Absorption: the Acyclovir Case Study. Chung, SE; Kim, DH; Kim, TH; Lee, DY; Lee, JB; Shin, BS; Shin, S, 2020) |
| " Obtained results show that tested modification do not improve bioavailability of nucleoside analogs in cells." | ( Modifications on the heterocyclic base of ganciclovir, penciclovir, acyclovir - syntheses and antiviral properties. Chayrov, R; Chuchkov, K; Hinkov, A; Shishkova, K; Stankova, IG; Todorov, D, 2020) |
| "It is a great challenge to improve the oral bioavailability for BCS class IV drugs because they have low solubility and poor permeability." | ( A novel cascade strategy using a nanonized targeted prodrug for enhanced oral delivery efficiency. Fu, Q; Guo, M; He, Z; Huang, Y; Li, M; Liu, D; Song, H; Yu, S, 2020) |
| " Many of these drugs suffer from polymorphic transformations with changes in the drug's safety and efficacy; many are poorly soluble, poorly bioavailable drugs." | ( Are Myths and Preconceptions Preventing us from Applying Ionic Liquid Forms of Antiviral Medicines to the Current Health Crisis? Rogers, RD; Shamshina, JL, 2020) |
| "The current study demonstrated that the IVPT method, with an appropriate statistical analysis of the results, is a sensitive and discriminating test that can detect differences in the rate and extent of acyclovir bioavailability in the skin from differently formulated cream products." | ( Cutaneous Pharmacokinetics of Acyclovir Cream 5% Products: Evaluating Bioequivalence with an In Vitro Permeation Test and an Adaptation of Scaled Average Bioequivalence. Ghosh, P; Hassan, H; Raney, SG; Rantou, E; Shin, SH; Stinchcomb, A, 2020) |
| "Acyclovir is an antiviral drug poorly absorbed in the gastrointestinal tract due to its hydrophilicity, with low oral bioavailability (~20%)." | ( Novel Insights to Enhance Therapeutics With Acyclovir in the Management of Herpes Simplex Encephalitis. Caldeira, TG; de Moraes, FS; de Souza, J; Fernandes Pedrosa, TC; Gurgel Assis, MS; Pereira, GR; Ruela, ALM, 2021) |
| " The currently available therapies of ACY suffer from limitations like poor oral bioavailability (10-15%) and high-dose requirement." | ( Pluronic F127-tailored lecithin organogel of acyclovir: preclinical evidence of antiviral activity using BALB/c murine model of cutaneous HSV-1 infection. Amarji, B; Katare, OP; Kaur, B; Mahajan, A; Sharma, G; Singh, MP; Thakur, K, 2022) |
| " The problem of the oral bioavailability of acyclovir is limited because of the low permeability across the gastrointestinal membrane." | ( Pseudoboehmite as a drug delivery system for acyclovir. Bernussi, A; de Lima, NB; de Oliveira, MO; de Oliveira, RR; Munhoz, AH; Peres, RM; Rossi, MV; Sarmento, B; Sousa, JML; Warzywoda, J, 2021) |
| " In this study, solid lipid nanoparticles were designed to improve the oral bioavailability of acyclovir." | ( Central Composite Design for Formulation and Optimization of Solid Lipid Nanoparticles to Enhance Oral Bioavailability of Acyclovir. Adam, SK; Alias, E; Basir, R; Hassan, H; Meor Mohd Affandi, MMR; Shamsuddin, AF, 2021) |
| " A complete cross-over bioavailability study of the selected acyclovir-loaded sustained release tablets and marketed immediate-release tablets were compared in six healthy male volunteers." | ( Effect of Hydrophilic Polymers on the Release Rate and Pharmacokinetics of Acyclovir Tablets Obtained by Wet Granulation: In Vitro and In Vivo Assays. Dobrowolska, A; Eder, P; Fonseca, J; Kovacevic, A; Meyyanathan, SN; Souto, EB; Venkatesh, DN; Zielińska, A, 2022) |
| "Topical treatments to modulate hair growth are generally limited by low drug bioavailability due to poor skin permeability." | ( Modulation of hair growth by topical drug delivery enhanced by STAR particles. Prausnitz, MR; Woo, MR, 2023) |
| "Acyclovir, an antiviral drug, has low bioavailability due to its low permeability." | ( An industrial procedure for the intestinal permeability enhancement of acyclovir: in-vitro and histological evidence. Abo Elnasr, SE; Hedaya, AA; Mady, OY; Thabit, SM, 2023) |
Acyclovir is used to treat herpes infections in preterm and term infants. The influence of maturation on drug disposition and dosing requirements is poorly characterized in this population. Study aimed at improving the oral bioavailability of acyclovir through incorporating it into gastroretentive dosage form based on floating hollow chitosan beads.
| Excerpt | Reference |
|---|---|
| "Data from human studies were extracted by the author and evaluated according to the patient population studied, sample size, dosage regimen, and therapeutic response." | ( Treatment of herpesvirus infections in HIV-infected individuals. Fletcher, CV, ) |
| " None of the novel ribonucleotide reductase inactivators was hematologically toxic to rats following oral dosing at 60 mg/kg/day for 30 days." | ( Inactivators of herpes simplex virus ribonucleotide reductase: hematological profiles and in vivo potentiation of the antiviral activity of acyclovir. Blumenkopf, TA; Ellis, MN; Lobe, DC; Spector, T; Szczech, GM, 1992) |
| "Acyclovir is very effective in suppressing recurrent genital herpes and is clearly superior to isoprinosine which is not clinically useful in the dosage studied." | ( Acyclovir vs isoprinosine (immunovir) for suppression of recurrent genital herpes simplex infection. De Maubeuge, J; Engst, R; Foidart, JM; Kinghorn, GR; Thin, RN; Woolley, PD, 1992) |
| " The dosage of acyclovir used by the author was 5mg/kg/12-24 hours." | ( [Acute herpes simplex encephalitis treated with acyclovir. Report of 5 cases]. Hou, X, 1992) |
| "Foscarnet is a potentially effective and tolerable antiviral agent for patients with acyclovir-resistant, varicella-zoster virus infection; however, the optimal dosage and duration of therapy require further study, as does the relation between clinical findings and in-vitro susceptibility results." | ( Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Berger, TG; Biron, KK; Gilson, I; Mills, J; Safrin, S; Wofsy, CB; Wolfe, PR, 1991) |
| " Concentrations of acyclovir in plasma were determined to verify the ability of the dosing strategy to achieve predicted values." | ( Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients. Balfour, HH; Dunn, DL; Edelman, CK; Englund, JA; Fletcher, CV; Gross, CR, 1991) |
| " One study compares a tapering dosage of topical prednisolone or placebo eye drops for HSV stromal keratitis (HEDS-SKN)." | ( Design and organization of the herpetic eye disease study (HEDS). Barron, BA; Dawson, CR; Hauck, WW; Jones, DB; Kaufman, HE; Wilhelmus, KR, 1991) |
| " The dosage administered was determined by the score of the ocular inflammation." | ( Double-masked trial of topical acyclovir and steroids in the treatment of herpes zoster ocular inflammation. Cooper, M; Marsh, RJ, 1991) |
| " In order to prevent renal involvement during treatment with acyclovir, the following precautions are recommended: acyclovir should be infused slowly, regular control of renal function should be undertaken and the dosage should be reduced if evidence of renal involvement is found." | ( [Renal involvement during intravenous treatment with acyclovir]. Bömers, K; Gedebjerg, K, 1991) |
| "Neonates with hepatic or renal dysfunction or young premature infants accumulate acyclovir when dosed without adjustment for organ dysfunction." | ( Acyclovir therapy in neonates. Balfour, HH; Englund, JA; Fletcher, CV, 1991) |
| " Cells infected with herpesvirus type 1 were used in an infectivity assay for acyclovir dose-response studies." | ( Effect of acyclovir on herpes simplex virus infected neuronal, glial, and neurohybridoma cells in vitro. Borcholte, T; Kliem, V; Verhagen, W; Wellhöner, HH, 1990) |
| " However it prevented symptoms and mortality in mice systemically infected with HSV-1, HSV-2 or MCMV when administered intraperitoneally or orally at a dosage of 100 mumol/kg twice per day." | ( Antiviral activity and pharmacokinetics of HOE 602, an acyclic nucleoside, in animal models. Helsberg, M; Jähne, G; Rösner, M; Scholl, T; Winkelmann, E; Winkler, I, 1990) |
| " Although acyclovir can effectively control symptomatology and speed the healing of lesions, it does not, with current dosage regimens, decrease the frequency of subsequent recurrences." | ( Genital herpes simplex infections. Dawkins, BJ, 1990) |
| " At present, if zidovudine therapy is required during pregnancy, the standard dosage of 200 mg every 4 hours should be used." | ( Antiviral therapy in pregnancy. Brown, ZA; Watts, DH, 1990) |
| " After the significant increase of HSV antibody titers in serum and cerebro-spinal fluid (CSF) established a definite diagnosis, acyclovir was intravenously given at a daily dosage of 30 mg/kg for a period of 6 days in order to prevent the recurrence of HSE." | ( [A case of herpes simplex encephalitis with cerebral white matter lesion after acyclovir administration]. Gotoh, T; Konno, K; Matsumoto, S; Tamura, T; Watanabe, K, 1990) |
| " Intraperitoneal dosing in subjects receiving CAPD resulted in a bioavailability of 61 +/- 10% and drug levels sufficient to inhibit herpes simplex virus (HSV) and varicella zoster virus (VZV)." | ( Intraperitoneal administration of acyclovir in patients receiving continuous ambulatory peritoneal dialysis. Burgess, ED; Gill, MJ, 1990) |
| " During the two years, there were 2940 users who received a total of 6182 prescriptions for acyclovir; 47 percent used oral acyclovir and 56 percent of prescriptions were for the oral dosage form." | ( Acyclovir use and its surveillance in a general population. Andrews, EB; Johnson, RE; Mullooly, JP; Tilson, HH; Valanis, BG, 1990) |
| " This allowed a total dosage not much less than might have been given by other routes, but with the advantage that it was evenly deposited over the surface of the infected respiratory tract beginning within seconds of the start of treatment and reached higher concentration in nasal secretions than in serum." | ( Chemotherapy of respiratory viruses. Gilbert, BE; Knight, V, 1986) |
| "Foscarnet, 60 mg/kg body weight intravenously every 8 hours (with reduced dosage for renal impairment), for 12 to 50 days." | ( Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial. Drennan, DP; Erlich, KS; Follansbee, SE; Gooze, L; Jacobson, MA; Koehler, JE; Mills, J; Safrin, S, 1989) |
| " nurse's monitoring specific drug therapy includes familiarity with a drug's action, with its performance in different clinical situations, with proper dosage and observations for adverse effects." | ( New drug therapies: esmolol HCL, aztreonam and ganciclovir. Pauley, SY, ) |
| " The directives for an optimal dosage are subject to further prospective randomized clinical studies." | ( [Experiences with DHPG (ganciclovir)--treatment of cytomegalovirus retinitis in AIDS]. Fabricius, EM; Holzer, E; Prantl, F, 1989) |
| " More pharmacokinetic data are needed to determine optimal dosing schemes." | ( Cytomegalovirus infection and renal transplantation. Metselaar, HJ; Weimar, W, 1989) |
| " However, when ACV was combined with 10 or 100 U of rHuIFN-alpha/ml, synergistic antiviral effects were associated with ACV dosage of 10 to 62." | ( Synergistic antiviral activities of acyclovir and recombinant human leukocyte (alpha) interferon on feline herpesvirus replication. Weiss, RC, 1989) |
| " These subsequent studies confirmed that, after oral dosing with famciclovir, more than half the dose was absorbed and rapidly converted to penciclovir." | ( Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]. Boyd, MR; Harnden, MR; Jarvest, RL; Sutton, D; Vere Hodge, RA, 1989) |
| " Total dosage of the radiation was 50-60 Grey for each case." | ( [A trial of ACNU and radiation therapy with sensitizing agents for malignant gliomas]. Hayashi, M; Ishii, H; Ishii, Y; Kawano, H; Nakatsugawa, S; Satoh, K, 1989) |
| " We review each of these potential uses and the pharmacokinetics of acyclovir in pregnancy while emphasizing that at the present time, safety, efficacy, and appropriate dosage of the drug have not been established for any use in pregnancy." | ( Acyclovir therapy during pregnancy. Baker, DA; Brown, ZA, 1989) |
| " In immunocompromised patients, intravenous, oral and topical acyclovir shorten the clinical course of herpes simplex infections while prophylaxis with oral or intravenous dosage forms suppresses reactivation of infection during the period of drug administration." | ( Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Campoli-Richards, DM; O'Brien, JJ, 1989) |
| " Both 5 and its esters (14-17, 21, 22) and also 18 were well absorbed after oral administration and converted efficiently to 1, the diacetyl (14) and dipropionyl (16) esters providing concentrations of 1 in the blood that were more than 15-fold higher than those observed after dosing either 1 or its esters (25-27)." | ( Prodrugs of the selective antiherpesvirus agent 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine (BRL 39123) with improved gastrointestinal absorption properties. Boyd, MR; Harnden, MR; Jarvest, RL; Sutton, D; Vere Hodge, RA, 1989) |
| " The usual dosage was 10 mg/kg/day over 2 weeks." | ( DHPG effectively treats CMV infection in heart and heart-lung transplant patients: a preliminary report. Copeland, JG; Icenogle, TB; Minnich, L; Peterson, E; Ray, G, ) |
| " Maintenance therapy with DHPG would appear to be necessary to prevent relapse, but the logistics of this are difficult, and the effective dosage of DHPG is as yet uncertain." | ( Treatment of CMV retinitis in an AIDS patient. Acheson, JF; Bradbeer, C; Shah, SM; Spalton, DJ; Thin, RN, 1987) |
| " The dosage adjustment scheme and pharmacokinetic model performed well, allowing us to safely administer high-dose oral acyclovir immediately after renal transplantation." | ( Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation. Balfour, HH; Chace, B; Chinnock, BJ; Fletcher, CV, 1988) |
| " For that reason, most patients have received continued therapy with the drug, most commonly at a dosage of 5-6 mg/(kg." | ( Treatment of cytomegalovirus retinitis in patients with AIDS. Cederberg, D; Holland, GN; Jacobson, MA; Mills, J; O'Donnell, JJ, ) |
| " Ganciclovir dosage was adjusted for renal function." | ( Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Bowden, RA; Dandliker, PS; Lilleby, KE; Meyers, JD; Reed, EC, 1988) |
| " The lower dosage had less toxicity." | ( Efficacy and safety of two different dose levels of ganciclovir for the treatment of cytomegalovirus chorioretinitis in AIDS patients. Faber, V; Gaub, J; Højgaard, K; Nielsen, JO; Pedersen, C; Poulsen, AG; Thomson, MH; Tinning, S, 1988) |
| " These questions concern appropriate routes of administration for antiviral compounds, optimal dosage regimens, risks of long-term prophylaxis, and the emergence of resistant organisms." | ( Antiviral chemotherapy and chemoprophylaxis. Dolin, R, 1985) |
| "Forty patients with serum antibody against herpes simplex virus (HSV) were enrolled in a randomized, placebo-controlled, double-blind investigation of acyclovir given orally in a low dosage as prophylaxis against recurrent HSV infection after renal transplantation." | ( Prevention of herpesvirus infections in renal allograft recipients by low-dose oral acyclovir. Jackson, GG; Jones, CJ; Kathpalia, S; Maddux, MS; Mozes, M; Packham, D; Seale, L, 1985) |
| " Dosage was adjusted according to renal function and clinical response in the remaining 10 cases." | ( [Experiences with acyclovir in herpes virus infections]. Baumgartner, G; Fortelny, A; Heinz, R; Lutz, D; Waldner, R, 1986) |
| " However, dosage reduction is necessary in renal insufficiency." | ( Human pharmacokinetics of the antiviral drug DHPG. Balfour, HH; Chinnock, B; de Miranda, P; Fletcher, C; Sawchuk, R, 1986) |
| " It is only by such a study that the influence of patient and therapeutic factors such as immune function, anatomical location of the infection and dosage regimens used can be understood." | ( Clinical and laboratory experience with acyclovir-resistant herpes viruses. Barry, DW; Ellis, MN; Lehrman, SN, 1986) |
| "A new dosage regimen of orally administered acyclovir, 800 mg twice daily for five days, for the treatment of recurrent genital herpes was compared with the standard dosage of 200 mg given five times per day." | ( Episodic twice-daily treatment for recurrent genital herpes. Allen, ML; Chapman, S; Conant, MA; Donohew, PS; Goldberg, LH; Illeman, M; Kaufman, R; Sperber, J, 1988) |
| " In a six-month follow-up of recipients in the higher dosage study, the acyclovir recipients experienced less post-zoster pain than placebo recipients; differences in the prevalence of pain were most significant for the presence of a persistent pain in the first three months of follow-up." | ( Therapy of herpes zoster with oral acyclovir. Balfour, HH; Bean, B; Bryson, YJ; Connor, JD; Corey, L; Huff, JC; Laskin, OL; McGuirt, P, 1988) |
| "A patient with chronic lymphocytic leukemia and severe and frequently recurring herpes labialis received oral acyclovir for more than 18 months, during most of this period at a low dosage (400 mg/d)." | ( Long-term suppression of recurrent herpes labialis by low-dose oral acyclovir in an immunocompromised patient. Dan, M; Michaeli, D; Siegman-Igra, Y; Weinberg, M, 1986) |
| " In milder and non-life-threatening first-episode infections, acyclovir may be given orally in a dosage of 200 mg five times a day for 10 days." | ( Treatment of mucocutaneous herpes simplex infections with acyclovir. Krusinski, PA, 1988) |
| " At these doses adequate hydration and urine flow must be maintained, the mental status of the patient must be monitored, and impaired renal function requires regulation of dosage downward." | ( Antiviral treatment in chickenpox and herpes zoster. Huff, JC, 1988) |
| " We treated an immunocompetent patient with a ten-day course of intravenous acyclovir sodium at the recommended dosage of 10 mg/kg every eight hours for clinically apparent herpes simplex encephalitis." | ( Relapse of herpes simplex encephalitis after conventional acyclovir therapy. Hayden, FG; Marsteller, HB; Ross, GW; VanLandingham, KE, 1988) |
| " The clinical effects were comparable to those obtained with oral and intravenous acyclovir, even with a dosage of only 125 mg thrice daily." | ( Open study of 2-amino-9-(hydroxyethoxymethyl)-9H-purine (desciclovir) in the treatment of herpes zoster. Esmann, V; Geil, JP; Mogensen, CE; Petersen, CM; Peterslund, NA, 1987) |
| " The model parameters predicted efficient transfer of acyclovir from the peritoneum to plasma, such that hypothetical peritoneal dosing might give 91% bioavailability." | ( Multiple dose pharmacokinetics of intravenous acyclovir in patients on continuous ambulatory peritoneal dialysis. Boelaert, J; Daneels, R; Schurgers, M; Van Landuyt, HW; Weatherley, BC, 1987) |
| " Further studies are needed to establish a dosing regimen for CAPD patients." | ( Acyclovir pharmacokinetics in a patient on continuous ambulatory peritoneal dialysis. Krasny, HC; Shah, GM; Winer, RL, 1986) |
| "This multicenter double-blind study of 157 patients was designed to evaluate the safety and efficacy of a new dosage regimen of oral acyclovir (800 mg twice a day for 5 days) for the treatment of recurrent genital herpes." | ( Oral acyclovir for episodic treatment of recurrent genital herpes. Efficacy and safety. Allen, ML; Chapman, S; Conant, MA; Goldberg, LH; Illeman, M; Kaufman, R; Sperber, J, 1986) |
| " At dosage regimens that were not toxic for the host, xylotubercidin proved efficacious in various HSV-2 animal model infections." | ( Xylotubercidin against herpes simplex virus type 2 in mice. De Clercq, E; Robins, MJ, 1986) |
| " Crystaluria can be avoided provided the patient is well hydrated and attention is paid to the dosing instructions especially in patients with renal failure." | ( The clinical pharmacology of acyclovir and its prodrugs. Brigden, D; Whiteman, P, 1985) |
| " Each patient received acyclovir by slow intravenous infusion in a dosage of 5 mg/kg every 8 hr for 10 days." | ( Treatment of chronic non-A, non-B hepatitis wih acyclovir: pilot study. Hoofnagle, JH; Jones, EA; Pappas, SC; Straus, SE; Young, N, 1985) |
| " A linear dose-response curve was observed with these cells, and their proliferation was inhibited 50% by 100 microM acyclovir." | ( Effect of acyclovir on the proliferation of human fibroblasts and peripheral blood mononuclear cells. Arbeit, RD; Leary, PL; Levin, MJ, 1980) |
| " In a comparative study with this 3-day dosage schedule, the efficacy of daily doses of 50 mg of FMAU per kg was greater than that of the same doses of FIAC and FIAU, in that order; all these were more effective than daily doses of 50, 100, or 200 mg of acyclovir or of 500 mg of phosphonoformic acid per kg." | ( Treatment of primary acute genital herpes in guinea pigs by intraperitoneal administration of fluoropyrimidines. Hsiung, GD; Mayo, DR, 1984) |
| "Acyclovir (9-(2-hydroxyethoxymethyl)guanine) administered as an intramuscular formulation twice daily at a dosage of 100 mg/kg per day prevented the development of disease in African green monkeys inoculated with simian varicella virus." | ( Acyclovir in the treatment of simian varicella virus infection of the African green monkey. Gerone, PJ; Soike, KF, 1982) |
| "Acyclovir tolerance has been explored in a broad range of human populations and dosage regimens with intravenous, topical, and oral formulations." | ( Acyclovir tolerance in humans. Bridgen, D; Keeney, RE; Kirk, LE, 1982) |
| " This occurred after intravenous bolus injection of high dosages of acyclovir but the risk was considerably reduced by slow intravenous infusion of the same dosage over one hour, with adequate hydration of the patient and adjustment of dosage in patients with preexisting impaired renal function." | ( Renal function after acyclovir intravenous injection. Brigden, D; Rosling, AE; Woods, NC, 1982) |
| " Acyclovir was administered intravenously in a dosage of 5 to 15 mg/kg every eight hours for five to 10 days." | ( Use of acyclovir in premature and term neonates. Yeager, AS, 1982) |
| " The mean percent urinary recovery of acyclovir (+/- SD) at each dosage level was similar, with an overall mean recovery of 65 percent." | ( Neonatal acyclovir pharmacokinetics in patients with herpes virus infections. Blum, MR; Connor, JD; Hintz, M; Keeney, RE; Spector, SA; Yeager, AS, 1982) |
| "2 mg/kg per day dosage to 36." | ( Treatment of herpes virus infections in immunocompromised patients with acyclovir by continuous intravenous infusion. Connor, JD; Hintz, M; Keeney, RE; Liao, S; Spector, SA; Wyborny, C, 1982) |
| " The drug was administered intravenously at 8-hourly intervals in a total daily dosage of 1500 mg/m2 for 5 days." | ( Acyclovir and Epstein-Barr virus infection. Lin, JC; Pagano, JS; Sixbey, JW, 1983) |
| " Levels of acyclovir effectively reducing viral replication by 50% when determined by estimation of reduction in replication of herpes simplex virus or derived from dose-response curves, were comparable for a number of herpes simplex virus isolates from genital sources." | ( Rapid method for determining the susceptibility of herpes simplex virus to acyclovir. Howell, CL; Miller, MJ, 1984) |
| " Drug dosage was 10 mg/kg every eight hours for 5 days as a one hour infusion." | ( [Acyclovir therapy in varicella/zoster diseases in immunocompromised children with cancer]. Kuhn, N; Landbeck, G, 1984) |
| " After intravenous dosing of patients with normal renal function, 8 to 14% of the dose is recovered in the urine as the metabolite 9-carboxymethoxymethylguanine." | ( Pharmacokinetics of acyclovir after intravenous and oral administration. Blum, MR; de Miranda, P, 1983) |
| " Dosage adjustment is required in patients with renal failure." | ( Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications. Barton, NH; Gnann, JW; Whitley, RJ, ) |
| " Thus, at the dosage of drug used, prophylaxis of CMV was unsuccessful suggesting that claims of therapeutic efficacy are unlikely to be supported in controlled trials." | ( Studies in the prophylaxis of herpes infections in severely immunocompromised patients using acyclovir. Hann, IM; Prentice, HG, 1983) |
| "The effect of intravenous acyclovir (at a dosage of 30 mg/kg per day for five days) on uncomplicated herpes zoster was investigated in 51 patients in a double-blind study." | ( Limited value of acyclovir in the treatment of uncomplicated herpes zoster: a placebo-controlled study. Mattie, H; Mulder, JD; van den Broek, PJ; van der Meer, JW; Versteeg, J, ) |
| "Forty-one patients with herpes zoster were treated with acyclovir or placebo at a dosage of 400 mg five times a day by mouth for five days in a double-blind randomized domiciliary study." | ( Oral acyclovir in herpes zoster. Burke, C; Care, C; Hickmott, E; McKendrick, GD; McKendrick, MW, 1984) |
| " In rats dosed orally with 6- deoxyacyclovir , absorption was extensive and the major urinary metabolite was acyclovir." | ( 6-Deoxyacyclovir: a xanthine oxidase-activated prodrug of acyclovir. Beauchamp, LM; de Miranda, P; Hall, WW; Krenitsky, TA; Schaeffer, HJ; Whiteman, PD, 1984) |
| " When dosing was started at 3 h postinfection, 33% of the animals did not develop any sign of primary or recrudescent infection throughout the 9-week test." | ( Efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine against primary and recrudescent genital herpes simplex virus type 2 infections in guinea pigs. Fraser-Smith, EB; Matthews, TR; Smee, DF, 1983) |
| " Oral dosing of dogs and rats with A134U resulted in peak plasma concentrations and total urinary recoveries of ACV greater than those observed after equivalent oral doses of ACV, suggesting that A134U might be an effective prodrug of ACV for use in the oral therapy of herpes simplex virus infections." | ( Disposition in the dog and the rat of 2, 6-diamino-9-(2-hydroxyethoxymethyl)purine (A134U), a potential prodrug of acyclovir. de Miranda, P; Elion, GB; Good, SS; Krasny, HC, 1983) |
| " Transient renal impairment was seen in two patients who received high dosage by the iv bolus mode of administration." | ( Acyclovir in hepatitis B antigen-positive chronic liver disease: inhibition of viral replication and transient renal impairment with iv bolus administration. Carreno, V; Fowler, MJ; Makinen, D; Monjardino, J; Sherlock, S; Sweny, P; Thomas, HC; Varghese, Z; Weller, IV, 1983) |
| " Dosage adjustment for various stages of renal impairment are proposed based on the observed relationship between Cltot and Clcr." | ( Overview of acyclovir pharmacokinetic disposition in adults and children. Blum, MR; de Miranda, P; Liao, SH, 1982) |
| " At the higher dosage of 100 mg/kg per day for four days, there was a slight reduction in the numbers of these cells." | ( Effect of acyclovir on various murine in vivo and in vitro immunologic assay systems. Elion, GB; Medzihradsky, J; Quinn, RP; Wolberg, G, 1982) |
| " Since ACV elimination is markedly reduced in end-stage renal failure and because ACV is readily hemodialyzible, dosage modification are needed to avoid cumulation and to replace dialyzed drug." | ( Acyclovir kinetics in end-stage renal disease. Keeney, RE; Krasny, HC; Laskin, OL; Lietman, PS; Longstreth, JA; Rocco, L; Whelton, A, 1982) |
| " A fall in DNA polymerase activity was seen with all courses of acyclovir but no dose-response relationship was evident." | ( Preliminary studies of acyclovir in chronic hepatitis B. Gregory, PB; Merigan, TC; Robinson, WS; Scullard, GH; Smith, CI, 1982) |
| " In a randomized, double-blind, multicenter study, the safety and efficacy of oral valaciclovir given at a dosage of 1,000 mg three times daily for 7 or 14 days and oral acyclovir given at a dosage of 800 mg five times daily for 7 days were compared in immunocompetent adults aged > or = 50 years with herpes zoster." | ( Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Andersen, PL; Beutner, KR; Forszpaniak, C; Friedman, DJ; Wood, MJ, 1995) |
| " The neutropenia did not recur when the dosage of oral acyclovir was reduced to 10 mg/(kg." | ( Acyclovir-induced neutropenia in an infant with herpes simplex encephalitis: case report. Feder, HM; Goyal, RK; Krause, PJ, 1995) |
| " When dosing was reduced to once per day, both compounds were less effective at controlling the infection." | ( Comparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunosuppression model. Field, HJ; Sutton, D; Tewari, D; Thackray, AM, 1995) |
| " In SCID (severe combined immune deficient) mice that had been infected with a thymidine kinase-deficient HSV-1 strain, S2242 (administered subcutaneously at a dosage of 50 mg/kg/day) completely protected against virus-induced mortality whereas foscarnet was less effective and acyclovir had no or little protective effect." | ( In vivo antiherpesvirus activity of N-7-substituted acyclic nucleoside analog 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine. Andrei, G; De Clercq, E; Jähne, G; Neyts, J; Snoeck, R; Winkler, I, 1995) |
| " Further investigations on the immunomodulatory potency, dosage and effects on postherpetic herpes neuralgia are, however, still required." | ( [Enzyme therapy--an alternative in treatment of herpes zoster. A controlled study of 192 patients]. Billigmann, P, 1995) |
| " On oral dosing of famciclovir to humans, only penciclovir and BRL 42359 can be detected consistently in the plasma; thus, attention was focused on the oxidation reaction." | ( Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver. Chenery, RJ; Clarke, SE; Harrell, AW, 1995) |
| " The ocular surface changes resolved within one to three months after dosage reduction or discontinuation of systemic ganciclovir and acyclovir." | ( Corneal lipidosis in patients with the acquired immunodeficiency syndrome. Font, RL; Jones, DB; Keener, MJ; Wilhelmus, KR, 1995) |
| " We conclude that ACV at a dosage of 4,800 mg/day does not suppress CMV excretion in urine of symptomatic HIV antibody positive patients taking concurrent ZDV." | ( Failure of high-dose oral acyclovir to suppress CMV viruria or induce ganciclovir-resistant CMV in HIV antibody positive patients. Anderson, R; Davis, G; Drew, WL; Lalezari, J; Lang, W; Miner, RC, 1995) |
| " Several questions remain in addition to these: What is the optimal dosage and duration of treatment with CMVIG for prophylaxis of CMV infection and disease in lung transplant recipients; Is this strategy cost-effective; Will it reduce the incidence of obliterative bronchiolitis following lung transplantation and enhance allograft survival? A prospective, random-assignment trial is warranted to answer these questions." | ( Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients. Badesch, DB; Campbell, DN; Diercks, MJ; Fisher, JH; Fullerton, DA; Grover, FL; Leone, S; Zamora, MR, 1994) |
| "4 micrograms/ml and 120 h micrograms/ml, respectively, after a dosage of 2,000 mg of valaciclovir four times daily." | ( Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease. Blum, MR; Coakley, D; Feinberg, J; Gallant, J; Gary, D; Jacobson, MA; Smiley, ML; Squires, L; Wang, LH; Weller, S, 1994) |
| " However the dosage and duration of the antiviral therapy for prevention of an infection in the second eye or treatment of an infection on an affected fellow eye is still not known." | ( [Bilateral acute retinal artery necrosis--healing of the second affected eye]. Bernasconi, E; Gloor, B; Kalman, A; Vogt, M, 1994) |
| " This dosage was reduced to 5 x 400 mg for another 12 weeks." | ( [Bilateral acute retinal artery necrosis--healing of the second affected eye]. Bernasconi, E; Gloor, B; Kalman, A; Vogt, M, 1994) |
| " This new drug produces enhanced plasma levels of acyclovir following oral dosing, which will not only allow more convenient dosing for the treatment of herpes simplex virus and varicella zoster virus (VZV) infections, but also mean that valaciclovir has the potential for superior clinical efficacy over acyclovir." | ( Acyclovir--and beyond. Darby, G, 1994) |
| "The maternal dosage of acyclovir was 800 mg five times daily for seven days." | ( Acyclovir excretion in human breast milk. Klein, J; Koren, G; Taddio, A, 1994) |
| " The optimum dosage for commencing acyclovir suppression is 200 mg four times daily, and the dose may subsequently be reduced." | ( Long-term clinical and psychological management of genital herpes. Mindel, A, 1993) |
| " In patients with renal failure the half-life of acyclovir is prolonged, this report indicates the importance of adhering to the dosage reductions in patients with renal failure." | ( [Severe central nervous system symptoms following oral administration of acyclovir in a patient with chronic renal failure: a case report]. Fujisawa, M; Matsuzaki, M; Niibori, D, 1993) |
| " We explored this strategy by quantitating the synergy produced by combinations of acyclovir and other drugs using three-dimensional dose-response surface methodology (MacSynergy II)." | ( Inhibitors of thymidylate synthase and dihydrofolate reductase potentiate the antiviral effect of acyclovir. Prichard, LE; Prichard, MN; Shipman, C, 1993) |
| " In mice dosed orally with 97, sustained plasma drug levels were evident that may account for the high efficacy observed." | ( 3-Quinolinecarboxamides. A series of novel orally-active antiherpetic agents. Bacon, ER; Bailey, TR; Brundage, RP; Carabateas, PM; Castaldi, MJ; Dorff, PH; Perni, RB; Wentland, MP; Woods, MG; Young, DC, 1993) |
| "Data from human studies were extracted by the authors and evaluated according to patient population, sample size, dosing regimen, efficacy, and safety." | ( Varicella in pediatric patients. Drwal-Klein, LA; O'Donovan, CA, ) |
| " The dosage of acyclovir was increased to 45 mg/kg, administered by continuous infusion, and the lesions subsequently resolved." | ( Acyclovir-resistant chronic cutaneous herpes simplex in Wiskott-Aldrich syndrome. Barbaud, A; Georges, JC; Gillet-Terver, MN; Modiano, P; Salloum, E; Schmutz, JL; Thouvenot, D; Weber, M, 1995) |
| " Dosage adjustment is required in the presence of renal impairment." | ( Pharmacokinetics of new antiherpetic agents. Rolan, P, 1995) |
| " For patients receiving acyclovir, the dosage was 2,000 mg (400 mg 5 times daily) for 10 days." | ( Bell's palsy treatment with acyclovir and prednisone compared with prednisone alone: a double-blind, randomized, controlled trial. Adour, KK; Byl, FM; Hitchcock, T; Quesenberry, CP; Ruboyianes, JM; Trent, CS; Von Doersten, PG, 1996) |
| " Because optimal levels of acyclovir are achieved with a simpler dosing regimen of valacyclovir, compliance may be improved in many patients, thus reducing the incidence of resistant virus." | ( Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Beutner, KR, 1995) |
| " The dose-response curve for GCV appeared more exponential, without a threshold, but with a no-effect dose of around 150 mumols/kg per day." | ( Comparative in-vivo genotoxicity of antiviral nucleoside analogues; penciclovir, acyclovir, ganciclovir and the xanthine analogue, caffeine, in the mouse bone marrow micronucleus assay. Haynes, P; Lambert, TR; Mitchell, ID, 1996) |
| " Increasing the oral acyclovir dosage resulted in resolution of herpes simplex virus-only ulcers in all but one case." | ( Herpesviridae-associated persistent mucocutaneous ulcers in acquired immunodeficiency syndrome. A clinicopathologic study. Flaitz, CM; Hicks, MJ; Nichols, CM, 1996) |
| " Therefore, there is no need for restriction of valaciclovir dosing in patients receiving antacid medication." | ( Lack of interaction between valaciclovir, the L-valyl ester of acyclovir, and Maalox antacid. Bidault, R; de Bony, F; Peck, R; Posner, J, 1996) |
| " Five different formulations (containing 5% ACV) were examined in a finite dose multiple dosing regimen (twice a day application) to simulate the clinical situation." | ( Correlation of in vivo topical efficacies with in vitro predictions using acyclovir formulations in the treatment of cutaneous HSV-1 infections in hairless mice: an evaluation of the predictive value of the C* concept. Ghanem, AH; Higuchi, WI; Kern, ER; Patel, PJ; Srinivasan, V, 1996) |
| " Further, it was shown that the compounds do not exhibit saturation kinetics over the dosage ranges used in the clinical setting." | ( Vitreous disposition of two acycloguanosine antivirals in the albino and pigmented rabbit models: a novel ocular microdialysis technique. Hughes, PM; Krishnamoorthy, R; Mitra, AK, 1996) |
| "micrograms/ml) following dosing of valaciclovir (500 and 1,000 mg) three times a day were two to three times greater than those expected after high-dose oral acyclovir treatment (800 mg, five times daily)." | ( Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy. Blum, MR; Schultz, M; Smiley, ML; Wang, LH; Weller, S, 1996) |
| " Despite acceptance that acyclovir sodium is the most effective drug for treatment, there is not a consensus on the dosage and duration of the antiviral therapy because some patients fail to respond and sometimes there is recurrence following therapy." | ( Failure of acyclovir sodium therapy in herpes simplex encephalitis. Gürses, N; Işlek, I; Kalayci, AG; Us, D, 1996) |
| " This dosage schedule is a cost-effective alternative to the long-term daily prophylactic dosing currently recommended." | ( "Stat." single dose of acyclovir for prevention of herpes simplex. Shelley, ED; Shelley, WB, 1996) |
| " Dosage adjustment is not required for famciclovir in elderly patients with normal or mildly impaired renal function, and the extent of penciclovir availability is not affected by food." | ( The pharmacological profile of famciclovir. Crumpacker, C, 1996) |
| " Computer modelling of various dosage simulations suggests that daily doses of 800 and 600 mg will achieve therapeutic levels (4-8 microM)." | ( Clinical pharmacokinetics of oral acyclovir in patients on continuous ambulatory peritoneal dialysis. Almond, MK; Dhillon, S; Raftery, MJ; Stathoulopoulou, F, 1996) |
| " An approximately normal level of core particles was present in the liver of this woodchuck after 26 days of the ACV protocol; excess drug-arrested nucleocapsids were steadily removed throughout the dosing period upon their envelopment and secretion as virion-like particles into the circulation." | ( Heterogeneous response for a mammalian hepadnavirus infection to acyclovir: drug-arrested intermediates of minus-strand viral DNA synthesis are enveloped and secreted from infected cells as virion-like particles. Newbold, JE; Tencza, MG, 1997) |
| " Much of the current antiviral research focuses on providing drugs with (i) improved oral bioavailability and pharmacokinetics which permit less frequent oral or topical dosing for suppressive treatment of herpes simplex virus (HSV) infections, (ii) different mechanisms of action for synergic effects in treating resistant HSV infections in the immunocompromised host and (iii) improved efficacy." | ( New therapeutic approaches to the alphaherpesvirus infections. Cassady, KA; Whitley, RJ, 1997) |
| " Our purpose was to study the therapeutic effect of oral acyclovir on selected patients, by observing the effect of acyclovir in a dosage of from 100 mg every six hours to 800 mg every four hours in fourteen patients with angioedema or chronic urticaria." | ( Acyclovir therapy for angioedema and chronic urticaria. Shelley, ED; Shelley, WB, 1997) |
| " Thus, valaciclovir delivers therapeutic aciclovir concentrations when administered in a less frequent oral dosage regimen than is required for aciclovir." | ( Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Faulds, D; Perry, CM, 1996) |
| " Famciclovir and valacyclovir demonstrate superior pharmacokinetics compared with acyclovir and allow for less frequent daily dosing with higher achievable serum drug concentrations." | ( Management of herpes simplex and varicella-zoster virus infections. Erlich, KS, 1997) |
| " With the completion of the first efficacy trials for each of these agents it has become apparent that, whilst less frequent dosing can he accomplished, it is not easy to significantly improve on the efficacy of aciclovir." | ( Antiviral drugs in development for herpes zoster. Fiddian, AP, 1996) |
| "In one case neurotoxicity resulted from the use of a dosage regimen that would be appropriate in patients with normal renal function." | ( Neurotoxicity associated with acyclovir in end stage renal failure. Fagg, D; Hatfield, PJ; Hay, NM; Kitching, AR; Macdonald, A, 1997) |
| " Once daily dosing with valaciclovir provides a more convenient dosing regimen than the more frequent aciclovir regimens." | ( Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group. Bodsworth, NJ; Gibb, A; Patel, R; Peters, B; Robinson, J; Saari, S; Vejlsgaard, G; Woolley, P, 1997) |
| " Valaciclovir maintains the established efficacy and safety of aciclovir but offers a much more convenient twice daily dosing regimen." | ( Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group. Bodsworth, NJ; Borelli, S; Crooks, RJ; Esmann, J; Gibb, A; Ingamells, AJ; Paavonen, J; Strand, A; Uexkull, N; Vejlsgaard, G; Worm, AM, 1997) |
| " Valaciclovir provides a useful alternative to acyclovir with the advantage of a more convenient dosing regimen and the potential for improved compliance." | ( Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. The Valaciclovir International Herpes Simplex Virus Study Group. Barbarash, RA; Degregorio, B; Fife, KH; Roth, R; Rudolph, T, 1997) |
| " Three patients were treated with intravenous acyclovir with concomitant reduction of steroid dosage and recovered completely." | ( Management of varicella infection during the course of inflammatory bowel disease. Balasubramanian, S; Giannadaki, E; Greenstein, AJ; Manousos, ON; Mouzas, IA; Sachar, DB, 1997) |
| " If varicella infection occurs, prompt diagnosis and treatment with acyclovir and concomitant reduction in immunosuppressive therapy (reduction in steroid dosage and discontinuation of azathioprine) should be initiated immediately to limit viremia and avoid fatal complications." | ( Management of varicella infection during the course of inflammatory bowel disease. Balasubramanian, S; Giannadaki, E; Greenstein, AJ; Manousos, ON; Mouzas, IA; Sachar, DB, 1997) |
| " Advantages of the intravenous formulation include weekly dosing and efficacy." | ( Cidofovir use in acyclovir-resistant herpes infection. Luks-Golger, DB; Martinez, CM, 1997) |
| " We conclude that acyclovir in children with end-stage renal failure may lead to severe and reversible neurotoxicity, despite acyclovir dosage adjustment based on renal impairment." | ( Acute acyclovir neurotoxicity in a hemodialyzed child. Hébert, D; Strong, DK, 1997) |
| " Discontinuation or dosage reduction of acyclovir and ganciclovir is necessary to manage neurologic toxicity that is directly attributed to either agent." | ( Acyclovir- and ganciclovir-induced neurotoxicity. Ernst, ME; Franey, RJ, 1998) |
| " Therefore, valacyclovir could prove a useful alternative to acyclovir when convenience of dosing or compliance issues are the prime considerations in treatment." | ( A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group. Corey, L; Douglas, JM; Esmann, J; Spruance, SL; Tyring, SK, 1998) |
| "No dosage adjustment is required when valaciclovir and digoxin are coadministered." | ( Lack of interaction between valaciclovir, the L-valyl ester of aciclovir, and digoxin. Layton, G; Peck, RW; Posner, J; Soul-Lawton, JH; Weatherley, BC, 1998) |
| " The acyclovir dosage was 2400 mg (800 mg three times a day) for 10 days, and prednisone was given as a single daily dose of 1 mg/kg of body weight for 10 days and tapered to 0 over the next 6 days." | ( Idiopathic facial paralysis: a randomized, prospective, and controlled study using single-dose prednisone versus acyclovir three times daily. De Diego, JI; De Sarriá, MJ; Gavilán, J; Madero, R; Prim, MP, 1998) |
| "Ducks congenitally infected with duck hepatitis B virus (DHBV) were treated with the antiviral guanine nucleoside analog penciclovir for 12 or 24 weeks at a dosage of 10 mg/kg of body weight per day." | ( Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo. Colledge, D; Lin, E; Locarnini, S; Luscombe, C; Wang, YY, 1998) |
| " There was a dose-response relationship (P < ." | ( Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group. Borelli, S; Chambers, LO; Corey, L; Lang, W; Reitano, M; Robinson, JM; Thoming, C; Tyring, S; Worm, AM, 1998) |
| " An extracorporal magnet was used to prolong the gastric residence times of the dosage forms and to influence the duration of absorption of acyclovir." | ( Acyclovir serum concentrations following peroral administration of magnetic depot tablets and the influence of extracorporal magnets to control gastrointestinal transit. Berntgen, M; Georgarakis, M; Gröning, R, 1998) |
| " Therefore, despite the drug's short terminal half-life (3 hours), acyclovir plasma concentrations obtained after oral administration of the prodrug offer a more convenient dosage regimen in patients with herpes zoster than that required after acyclovir administration." | ( Determination of acyclovir in plasma by solid-phase extraction and column liquid chromatography. Jaillon, P; Poirier, JM; Radembino, N, 1999) |
| " In conclusion, PCV q12h is a well-tolerated and effective therapy for mucocutaneous HSV infection in IC patients and offers a reduced frequency of dosing compared with ACV q8h." | ( Intravenous penciclovir for treatment of herpes simplex infections in immunocompromised patients: results of a multicenter, acyclovir-controlled trial. The Penciclovir Immunocompromised Study Group. Aoun, M; Belanger, R; Candoni, A; Jurewicz, R; Lazarus, HM; Marks, L, 1999) |
| " Further studies need to be performed to determine proper dosing regimen for suppression of outbreaks in patients with a disease duration of less than 2 years." | ( The effectiveness of valacyclovir in preventing reactivation of herpes gladiatorum in wrestlers. Anderson, BJ, 1999) |
| " We suggest the possibility that the optimum dose, dosing interval or preparation of MMF has not yet been established for pediatric patients." | ( A comparative analysis of the use of mycophenolate mofetil in pediatric vs. adult renal allograft recipients. Reisman, L; Roberti, I, 1999) |
| " Bayesian adaptive control of acyclovir dosage regimen was performed in a pediatric patient with bone marrow transplant who developed severe renal impairment." | ( Assessment of acyclovir intraindividual pharmacokinetic variability during continuous hemofiltration, continuous hemodiafiltration, and continuous hemodialysis. Aulagner, G; Barou, P; Berthier, JC; Bleyzac, N; Contamin, B; Maire, P; Massenavette, B, 1999) |
| " Current recommendations regarding the dosing of antivirals used prophylactically are based mostly on anecdotal experience." | ( Use of valacyclovir for herpes simplex virus-1 (HSV-1) prophylaxis after facial resurfacing: A randomized clinical trial of dosing regimens. Gilbert, S; McBurney, E, 2000) |
| " Three patients have been maintained on prophylactic dosage of oral acyclovir because of recurrent disease or because they have been chronically treated with topical corticosteroids for immune stromal keratitis." | ( Oral acyclovir for the management of herpes simplex virus keratitis in children. Holland, EJ; Schwartz, GS, 2000) |
| " Famciclovir and valacyclovir offer improved oral bioavailability and convenient oral dosing schedules but are more expensive than acyclovir." | ( Treatment of common cutaneous herpes simplex virus infections. Emmert, DH, 2000) |
| " At a dosage of 10 mg/kg of body weight twice a day, the test compound significantly inhibited viral replication in vivo, as indicated by a 95% reduction in serum woodchuck hepatitis virus DNA levels and by a 54% reduction in levels of woodchuck hepatitis virus replicative intermediates in the liver." | ( Antiviral activities of oral 1-O-hexadecylpropanediol-3-phosphoacyclovir and acyclovir in woodchucks with chronic woodchuck hepatitis virus infection. Beadle, JR; Bellezza, CA; Cote, PJ; Gerin, JL; Hornbuckle, WE; Hostetler, KY; Korba, BE; Tennant, BC; Tochkov, IA, 2000) |
| " Tolerability of the two drugs is similar, but the dosing schedule of valaciclovir is simpler." | ( Comparison of the efficacy and safety of valaciclovir and acyclovir for the treatment of herpes zoster ophthalmicus. Cochener, B; Colin, J; Hoang-Xuan, T; Lescale, O; Prisant, O; Rolland, B, 2000) |
| " The dose-response for both groups was linear." | ( Effect of acyclovir on the radiation-induced micronuclei and cell death. Aruna, R; Jagetia, GC, 2000) |
| " The objectives of the present study were to determine the typical pharmacokinetics of an oral suspension of acyclovir given to children younger than 2 years of age and the interindividual variabilities in the values of the pharmacokinetic parameters in order to support the proposed dosing regimen (24 mg/kg of body weight three times a day for patients younger than 1 month of age or four times a day otherwise)." | ( Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis. Aujard, Y; Bidault, R; De Bony, F; Lokiec, F; Petitjean, O; Tod, M, 2001) |
| " Prophylaxis with intraperitoneal valacyclovir decreases the recurrence rate in a dose-response fashion." | ( Valacyclovir for the prevention of recurrent herpes simplex virus eye disease after excimer laser photokeratectomy. Asbell, PA, 2000) |
| " The advantage observed with the valaciclovir is the dosing comfort and the facility of completing the treatment." | ( [Valaciclovir in the treatment of initial infection by genital herpes virus: comparative study]. García, A; García, I; García, S; Lanchares, JL; Sánchez, JA, 2001) |
| " She developed neurotoxicity with an adjustment dosage of valacyclovir for a cutaneous zoster infection." | ( Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study. Aymard, G; Deray, G; Issad, B; Izzedine, H; Launay-Vacher, V; Martinez, V; Mercadal, L, ) |
| " Acyclovir suppression prevents recurrent HSV, and a dosage of 600 mg/day is more effective than 400 mg/day." | ( Prevention of recurrent herpes simplex virus (HSV) infections in HIV-infected persons. Absar, N; Beall, G; Chang, E, 1995) |
| " The values of C(max), AUC, and urinary recovery of penciclovir after dosing with SK1899 to rats and dogs were similar or slightly higher than those from famciclovir." | ( Pharmacokinetic studies of 2-amino-9-(3-acetoxymethyl-4-isopropoxycarbonyl-oxybut-1-yl)purine, an oral prodrug for the antiviral agent penciclovir. Chang, K; Choi, WS; Im, GJ; Jung, I; Kim, DK; Kim, JS; Kim, TK; Kim, TS; Kim, YW; Lee, N; Lee, SJ, 2001) |
| " Valaciclovir allows less frequent dosing and maintains the safety profiles of the parent drug." | ( Comparative study of the efficacy and safety of valaciclovir versus acyclovir in the treatment of herpes zoster. Chen, YS; Chiang, SC; Huang, CK; Lee, SS; Lin, HH; Lin, WR; Liu, YC; Tsai, HC; Wann, SR; Yen, MY, 2001) |
| "The study was an open-label evaluation of intravenous acyclovir at dosages higher than the 30 mg/kg/d standard dosage approved by the US Food and Drug Administration." | ( Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Arvin, AM; Bradley, JS; Corey, L; de Sierra, TM; Diaz, PS; Gruber, WC; Gutierrez, K; Jacobs, RF; Kiell, J; Kimberlin, DW; Kumar, M; Lakeman, FD; Lin, CY; Powell, DA; Rathore, M; Shelton, M; Sleasman, JW; Soong, SJ; Weiner, LB; Weller, S; Whitley, RJ, 2001) |
| " In all 6 cases, the ANC recovered during continuation of acyclovir at the same dosage or after completion of acyclovir therapy, and there were no apparent adverse sequelae of the transient neutropenia." | ( Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Arvin, AM; Bradley, JS; Corey, L; de Sierra, TM; Diaz, PS; Gruber, WC; Gutierrez, K; Jacobs, RF; Kiell, J; Kimberlin, DW; Kumar, M; Lakeman, FD; Lin, CY; Powell, DA; Rathore, M; Shelton, M; Sleasman, JW; Soong, SJ; Weiner, LB; Weller, S; Whitley, RJ, 2001) |
| " Decreasing the acyclovir dosage or administering granulocyte colony-stimulating factor should be considered if the ANC remains below 500/mm(3) for a prolonged period." | ( Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Arvin, AM; Bradley, JS; Corey, L; de Sierra, TM; Diaz, PS; Gruber, WC; Gutierrez, K; Jacobs, RF; Kiell, J; Kimberlin, DW; Kumar, M; Lakeman, FD; Lin, CY; Powell, DA; Rathore, M; Shelton, M; Sleasman, JW; Soong, SJ; Weiner, LB; Weller, S; Whitley, RJ, 2001) |
| "The aim of this study was to demonstrate a sustained-release microparticulate dosage form for acyclovir via an in vitro study." | ( In vitro modified release of acyclovir from ethyl cellulose microspheres. Chen, PF; Chen, RR; Cheu, SJ; Lin, WJ, ) |
| " Intensive and sparse pharmacokinetic sampling occurred during both dosing phases of the study." | ( Acyclovir for treatment of postherpetic neuralgia: efficacy and pharmacokinetics. Acosta, EP; Balfour, HH, 2001) |
| " We hypothesised that a lower dosage of VACV would prevent CMV disease with fewer CNS side effects." | ( CMV disease in CMV-mismatched renal transplant recipients with prophylactic low dose valaciclovir. Eriksson, BM; Sund, F; Wahlberg, J, 2001) |
| " The bioavailability of sustained release tablets relative to conventional tablets following single and multiple dosing was 105." | ( Pharmacokinetics and bioavailability of sustained release and conventional formulation of acyclovir. Chen, XJ; Cheng, K; Gang, YY; Wu, ZH; Xu, XY; Zhang, JH; Zhao, R; Zhu, JB, ) |
| " Valacyclovir is the only antiviral shown to be effective with a short (3-day) course in the episodic treatment of recurrent genital herpes, as well as with once-daily dosing for daily suppressive therapy." | ( Valacyclovir in the treatment of genital herpes and herpes zoster. Baker, DA, 2002) |
| " However, the amount of acyclovir in breast milk after valaciclovir administration is considerably less (2%) than that used in therapeutic dosing of neonates." | ( Acyclovir concentrations in human breast milk after valaciclovir administration. Cadematori, S; Fish, DN; Hollier, LM; Nobles, BJ; Sheffield, JS; Wendel, GD, 2002) |
| " No significant differences were detected between the 2 dosing schedules for any of the end points measured." | ( Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. Leone, PA; Miller, JM; Trottier, S, 2002) |
| " However, dosage simulations confirmed supratherapeutic acyclovir concentrations for all participants when following the recommended dose of 1,000 mg valaciclovir/24 h for varicella zoster infections." | ( Evaluation of valaciclovir dosage reduction in continuous ambulatory peritoneal dialysis patients. Dhillon, S; Stathakis, C; Stathoulopoulou, F; Thodis, H; Vargemezis, V, 2002) |
| " Pharmacopeia (USP) apparatus 3 can be used as an alternative to USP apparatus 2 for dissolution testing of immediate-release (IR) dosage forms." | ( Evaluation of USP apparatus 3 for dissolution testing of immediate-release products. Hussain, AS; Wang, JT; Yu, LX, 2002) |
| " Curative treatment is acyclovir at high dosage - 60 mg/kg/d - during 14 days for localized forms and 21 days for neurological and disseminated diseases." | ( [Modalities of treatment local and general, medicamentous or not, controlling neonate suspected to be infected/contaminated by HSV1 or HSV2]. Aujard, Y, 2002) |
| " The prodrugs valacyclovir and famciclovir offer easier, less-frequent dosing than required for acyclovir." | ( Progress in meeting today's demands in genital herpes: an overview of current management. Patel, R, 2002) |
| " Dosage options for using valacyclovir in children are discussed." | ( An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised children. Floret, D; Leibundgut, K; Leverger, G; Nadal, D; Perel, Y; Sokal, EM; Weller, S, 2002) |
| " Until formal guidelines have been established, ganciclovir or acyclovir dosage should be adjusted according to the results of monitoring of plasma drug concentration." | ( Liquid chromatographic method for the determination of ganciclovir and/or acyclovir in human plasma using pulsed amperometric detection. Furukawa, H; Kishino, S; Miyazaki, K; Shimamura, T; Sugawara, M; Takekuma, Y; Todo, S, 2002) |
| " The proposed method was applied successfully to the determination of acyclovir in its dosage forms." | ( Spectrophotometric determination of acyclovir in some pharmaceutical formulations. Sultan, M, 2002) |
| " No studies to date have evaluated the efficacy, safety or proper dosing of valaciclovir in children for the treatment of EBV infection." | ( Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness. Deeter, RG; Fish, DN; Simon, MW, 2002) |
| " We concluded that the 16 CFS patients (included in both phases of this study) with EBV-persistent infection (EBV single-virus subset) are improved after 6 months of continuous pharmacokinetic dosing with valacyclovir." | ( A six-month trial of valacyclovir in the Epstein-Barr virus subset of chronic fatigue syndrome: improvement in left ventricular function. Beqaj, SH; Chang, CH; Deeter, RG; Dworkin, HJ; Fitzgerald, JT; Goldstein, J; Lerner, AM; O'Neill, W; Zervos, M, 2002) |
| " The 1-day valacyclovir regimen offers patients a unique and convenient dosing alternative compared to available topical therapies." | ( High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Barber, J; Blatter, MM; Goldstein, D; Hill, J; Jones, TM; Schultz, M; Spruance, SL; Vargas-Cortes, M, 2003) |
| " The less frequent dosing schedule with valacyclovir compared with acyclovir offers a potential advantage for patients undergoing BMT who frequently suffer with severe mucositis and have difficulty taking oral medications." | ( Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy. Broun, ER; DeVoe, M; Eisen, D; Essell, J; Sigmund, D, 2003) |
| " The dosage of foscarnet should be 40 milligrams per kilogram three times per day or 60 milligrams per kilogram twice daily." | ( Management of acyclovir-resistant herpes simplex virus. Chilukuri, S; Rosen, T, 2003) |
| " Inflammation was stabilized, and steroid dosage could be significantly reduced." | ( Nonnecrotizing herpetic retinopathies masquerading as severe posterior uveitis. Bodaghi, B; Cassoux, N; Fardeau, C; LeHoang, P; Rozenberg, F, 2003) |
| "Valacyclovir is the only oral antiviral agent approved for therapy of herpes labialis, the only antiviral drug approved for a 3-day course in the episodic treatment of recurrent genital herpes, as well as the only antiviral drug approved for once daily dosing for suppressive therapy." | ( Valacyclovir in the treatment of herpes simplex, herpes zoster, and other viral infections. Brentjens, MH; Lee, P; Torres, G; Tyring, SK; Wu, JJ; Yeung-Yue, K, ) |
| "Fourier transform (FT) Raman spectroscopy based on band intensity or band area measurements was used for the quantitative determination of acyclovir in pharmaceutical solid dosage forms through their poly(vinyl chloride) blister package." | ( Rapid, noninvasive quantitative determination of acyclovir in pharmaceutical solid dosage forms through their poly(vinyl chloride) blister package by solid-state Fourier transform Raman spectroscopy. Georgiou, CA; Skoulika, SG, 2003) |
| " However, the optimal duration and dosage of antiviral prevention have yet to be defined." | ( [The latest in herpes simplex keratitis therapy]. Labetoulle, M, 2004) |
| " Choice of therapy would then depend on convenience of dosing and cost." | ( Antiviral treatment of genital herpes. Apoola, A; Radcliffe, K, 2004) |
| " This drug's short serum half-life and low oral bioavailability make frequent dosing necessary, however, and we therefore sought to determine if the pro-drug valacyclovir, which has improved bioavailability, could be successfully substituted for this indication." | ( Oral valacyclovir as prophylaxis against herpes simplex virus reactivation during high dose chemotherapy for leukemia. Ambinder, RF; Gore, SD; Hartley, EE; Miller, CB; Mills, SR; Orlowski, RZ; Piantadosi, S; Ye, X, 2004) |
| " These compounds offer high oral bioavailabilty and deliver acyclovir and penciclovir, respectively, to the target cells by means of more convenient dosing schedules." | ( Recent clinical experience with famciclovir--a "third generation" nucleoside prodrug. Beutner, K; Chakrabarty, A; Rauser, M; Tyring, SK, 2004) |
| "In the SIN Mailing List a message published in May 2004 gave rise to an interesting debate as to the use and dosage of acyclovir in dialysis patients for the treatment of varicella-zoster infection, considering the side effects (mainly neurological) reported in patients affected by renal insufficiency." | ( [On the mailing list: use of acyclovir in patients on hemodialysis]. D'Amico, M; Fraticelli, M; Limido, A, ) |
| " No interference could be observed from the excipients commonly present in dosage forms." | ( Simple fluorimetric method for determination of certain antiviral drugs via their oxidation with cerium (IV). Askal, HF; Darwish, IA; Khedr, AS; Mahmoud, RM, ) |
| " Acyclovir was started at a dosage of 60mg/kg/day for 21 days and neurological symptoms improved." | ( Herpes simplex encephalitis: diagnostic problems and late relapse. Burlot, K; De Tiège, X; Gaudelus, J; Héron, B; Ponsot, G; Rozenberg, F, 2006) |
| "4g of aciclovir tablets 3 times per day for 5 days and 50 mg of prednisone daily for 5 days, and the patients in P group were treated with 50 mg of prednisone daily for 5 days, and then the dosage of prednisone was reduced by 20 mg per two days for the next 10 days." | ( [Outcome of treatment 46 patients with Bell's palsy with aciclovir and prednisone]. Chen, WL; Huang, ZQ; Yang, ZH, 2005) |
| " The factors influencing the choice of therapy, such as cost, ease of dosing and acyclovir resistance are also discussed." | ( Genital herpes: antiviral therapy for symptom relief and prevention of transmission. Gupta, R; Wald, A, 2006) |
| " Dosing and administration of topical agents in the treatment of primary herpetic gingivostomatitis in preschoolers were problematic." | ( Management of primary herpetic gingivostomatitis in young children. Faden, H, 2006) |
| "Intravenous acyclovir at a dosage of 10 mg/kg every 8 hours for 14 days followed by oral valacyclovir at a dosage of 1000 mg 3 times per day for 1 month." | ( Improvement of postherpetic neuralgia after treatment with intravenous acyclovir followed by oral valacyclovir. Gilden, DH; Hammack, BN; Kittelson, J; Quan, D, 2006) |
| " The less frequent dosing regimen makes it an attractive option in the treatment of genital herpes and other viral infections, and may contribute to increased patient adherence to therapy." | ( Valacyclovir for the treatment of genital herpes. Brantley, JS; Hicks, L; Sra, K; Tyring, SK, 2006) |
| " This higher dosage enhance the risk of acute renal failure." | ( [Acute renal failure with acyclovir in a 42-year-old patient without previous renal dysfunction]. Coquerel, A; Dargère, S; De Deyne, S; De la Gastine, B; Gras, G; Verdon, R, 2006) |
| " We point out the need to monitor renal function when high dosage of acyclovir is indicated." | ( [Acute renal failure with acyclovir in a 42-year-old patient without previous renal dysfunction]. Coquerel, A; Dargère, S; De Deyne, S; De la Gastine, B; Gras, G; Verdon, R, 2006) |
| "The objective of this study was to develop and evaluate new collagen gastroretentive dosage forms (GRDFs) which expand in the stomach after contact with gastric fluids." | ( Development and in vitro evaluation of expandable gastroretentive dosage forms based on compressed collagen sponges. Cloer, C; Gröning, R; Müller, RS, 2006) |
| " Satisfaction with treatment is important since daily dosing with suppressive therapy is necessary in the absence of symptoms." | ( Validation of the genital herpes treatment satisfaction questionnaire (GHerpTSQ) in status and change versions. Bradley, C; Taback, NA, 2006) |
| " This dosage of aciclovir did not change the activity of 7-ethoxyresorufin O-dealkylation, which is represented as CYP1A2 activity." | ( Lack of effect of aciclovir on metabolism of theophylline and expression of hepatic cytochrome P450 1A2 in rats. Hasegawa, T; Kato, M; Kimura, M; Nadai, M; Tsunekawa, Y; Ueyama, J; Yasui, K; Yoshizumi, H; Zhao, YL, 2007) |
| "Ready dosage form (eye drops) prepared on the basis of recombinant alpha2-IFN exhibits high activity towards herpes simplex type 1 virus in vitro." | ( Combined antiherpetic effect of complex preparation "Viferon-eye drops" and modified nucleosides. Andronova, VL; Galegov, GA; Malinovskaya, VV; Vyzhlova, EN, 2006) |
| " A questionnaire was applied to 31 physicians working in hospital- or community-based settings in Santiago, Chile in order to characterize their dosing and timing preferences for aciclovir or valaciclovir prescriptions." | ( [Erroneous prescriptions of aciclovir and valaciclovir in herpes zoster treatment]. Donaire R, L; Fica C, A; Jadue A, C, 2007) |
| " The dosing schedule of bid versus three times daily is desirable for enhancing patient compliance and to subsequently reduce the incidence of viral resistance." | ( Open-label study of valacyclovir 1.5 g twice daily for the treatment of uncomplicated herpes zoster in immunocompetent patients 18 years of age or older. Aboutlabeti, S; Arora, A; Babb-Tarbox, M; Madkan, VK; Tyring, S, ) |
| " The results showed that twice-daily dosing was as safe and effective as three times daily dosing for the reduction of ZAP and ZAAS." | ( Open-label study of valacyclovir 1.5 g twice daily for the treatment of uncomplicated herpes zoster in immunocompetent patients 18 years of age or older. Aboutlabeti, S; Arora, A; Babb-Tarbox, M; Madkan, VK; Tyring, S, ) |
| " Twice-daily dosing may help increase patient compliance and therefore increase the effectiveness of treatment of the acute herpes zoster rash and the prevention of ZAP." | ( Open-label study of valacyclovir 1.5 g twice daily for the treatment of uncomplicated herpes zoster in immunocompetent patients 18 years of age or older. Aboutlabeti, S; Arora, A; Babb-Tarbox, M; Madkan, VK; Tyring, S, ) |
| " The disappearance of FITC-labeled Dextran (FD, a marker of the dosing solution) applied with control solution followed monoexponential kinetics, while FD applied with Dex solution showed biexponential elimination." | ( Influence of formulation viscosity on drug absorption following nasal application in rats. Furubayashi, T; Higashi, Y; Inoue, D; Kamaguchi, A; Sakane, T, 2007) |
| " Newer trials are also reviewed, which are beginning to evaluate protocols of preemption or prophylaxis representative of current practice, as well as to explore alternative dosing strategies, the benefits of cytomegalovirus immune globulin, and the potential benefit of a longer course of prophylaxis." | ( Prophylaxis and treatment of cytomegalovirus disease in recipients of solid organ transplants: current approach and future challenges. Puius, YA; Snydman, DR, 2007) |
| " So far, there has been no demonstration of the superiority of prophylactic or preemptive regimens, nor has the exact nature and dosing of the oral antiviral agent of choice been established." | ( Prophylaxis and treatment of cytomegalovirus disease in recipients of solid organ transplants: current approach and future challenges. Puius, YA; Snydman, DR, 2007) |
| "Twenty-six subjects were enrolled in the study for the suspension dosage form and 25 completed it (13 men, 12 women; mean age, 22." | ( Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects. Absalón-Reyes, JA; Burke-Fraga, V; de Lago, A; González-de la Parra, M; Namur, S; Novoa-Heckel, G; Oliva, I; Palma-Aguirre, JA; Rodríguez, Z, 2007) |
| ", 50% effective concentrations (EC(50) values) from in vitro studies, to design an optimal dosage schedule." | ( Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. Baert, K; Croubels, S; De Backer, P; Deprez, P; Garré, B; Gryspeerdt, A; Nauwynck, H; Shebany, K; van der Meulen, K, 2007) |
| "Penciclovir pharmacokinetics following oral famciclovir administration in cats appeared complex within the dosage range studied." | ( Pharmacokinetics and safety of penciclovir following oral administration of famciclovir to cats. Maggs, DJ; Moulin, NK; Stanley, SD; Thomasy, SM, 2007) |
| "The purpose of the study was to evaluate the pharmacokinetic effects obtained by gastroretentive dosage form (GRDF) for drugs absorbed by passive paracellular diffusion (atenolol, acyclovir) or active transport (valacyclovir)." | ( Selection of drug candidates for gastroretentive dosage forms: pharmacokinetics following continuous intragastric mode of administration in a rat model. Hoffman, A; Kagan, L, 2008) |
| "Within the recommended age-dependent dosage schedule of aciclovir there was no effect of dose per kg, age, or sex on nephrotoxicity." | ( Determinants of aciclovir-induced nephrotoxicity in children. Koren, G; Schreiber, R; Wolpin, J, 2008) |
| "A dosage of 1 g of valacyclovir 3 times per day (TID) for 7 days has already been shown to be superior to an oral dosage of 800 mg acyclovir 5 times per day for 7 days in immunocompetent individuals." | ( Double-blind study comparing 2 dosages of valacyclovir hydrochloride for the treatment of uncomplicated herpes zoster in immunocompromised patients 18 years of age and older. Arora, A; Brantley, J; Dix, L; Mendoza, N; Tyring, S; Yates, B, 2008) |
| "Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing (biowaiver) for the approval of immediate release (IR) solid oral dosage forms containing aciclovir are reviewed." | ( Biowaiver monographs for immediate release solid oral dosage forms: aciclovir. Amidon, GL; Arnal, J; Barends, DM; Bermejo, M; Dressman, JB; Gonzalez-Alvarez, I; Junginger, HE; Kopp, S; Midha, KK; Shah, VP; Stavchansky, S, 2008) |
| " The poor bioavailability of acyclovir is attributed to short retention of its dosage form at the absorption sites (in upper gastrointestinal tract to duodenum and jejunum)." | ( Mucoadhesive microspheres for gastroretentive delivery of acyclovir: in vitro and in vivo evaluation. Dhaliwal, S; Jain, S; Singh, HP; Tiwary, AK, 2008) |
| " Whereas the diagnosis of this condition is often straightforward, choosing an appropriate drug (eg, acyclovir, valacyclovir hydrochloride, or famciclovir) and dosing regimen can be confusing in view of (1) competing clinical approaches to therapy; (2) evolving dosing schedules based on new research; (3) approved regimens of the Food and Drug Administration that may not match recommendations of the Centers for Disease Control and Prevention or of other experts; and (4) dissimilar regimens for oral and genital infections." | ( The treatment of herpes simplex infections: an evidence-based review. Brodell, RT; Cernik, C; Gallina, K, 2008) |
| " The tolerability of the two drugs is similar, but the dosing for VAL might be more comfortable for patients." | ( Comparison of oral antiviral therapy with valacyclovir or acyclovir after penetrating keratoplasty for herpetic keratitis. Bachmann, C; Frueh, BE; Garweg, J; Goldblum, D; Tappeiner, C, 2008) |
| " The methods were successfully used to perform pharmacokinetic and clinical studies in horses after intravenous and oral dosage of acyclovir and its prodrug valacyclovir." | ( Determination of acyclovir in horse plasma and body fluids by high-performance liquid chromatography combined with fluorescence detection and heated electrospray ionization tandem mass spectrometry. Croubels, S; De Backer, P; Desmet, N; Garré, B; Maes, A; Nauwynck, H; van der Meulen, K, 2009) |
| " Six patients (3F, mean age 62 years) with mild-moderate PD (mean disease duration 6 years, UPDRS-off 13, UPDRS-on 3, H&Y stage 2, daily levodopa dosage 450 mg) were studied off and on levodopa on separate days." | ( Spike-timing-related plasticity is preserved in Parkinson's disease and is enhanced by dopamine: evidence from transcranial magnetic stimulation. Mastaglia, FL; Rodrigues, JP; Stell, R; Thickbroom, GW; Walters, SE, 2008) |
| " Four ponies were treated with valacyclovir at a dosage of 40mg/kg bodyweight, 3 times daily, for 5 (n=2) or 7 (n=2) consecutive days, while the other four ponies served as untreated controls." | ( Evaluation of orally administered valacyclovir in experimentally EHV1-infected ponies. Croubels, S; De Backer, P; Garré, B; Gryspeerdt, A; Nauwynck, H, 2009) |
| " Persistence of HSV, detection of high viral load or detection of HSV by polymerase chain reaction, prior corticosteroid therapy, low total dosage of acyclovir (especially for children under 2 years of age) and short duration of therapy were suspected risk factors." | ( Relapsing Herpes simplex virus encephalitis despite high-dose acyclovir therapy: a case report. Devrim, I; Haliloğlu, G; Kara, A; Seçmeer, G; Tezer, H, ) |
| "1 million genome-copies/ml, and thereafter declined precipitously, coinciding with an increase in the dosage of valaciclovir given; HHV-8 DNA was detected most often in WMS compared with parotid saliva, and buccal and palatal exfoliates." | ( Extensive oral shedding of human herpesvirus 8 in a renal allograft recipient. Al-Otaibi, LM; Al-Sulaiman, MH; Porter, SR; Teo, CG, 2009) |
| " An eight-step weight-based dosing regimen was developed to optimize exposure in smaller children and was used in the 7-day multiple-dose safety phases of both studies, which enrolled 100 patients with confirmed/suspected viral infections." | ( Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection. Abrams, B; Arguedas, A; Bomgaars, L; De León Castrejón, T; Hamed, K; Kaiser, G; Looby, M; Roberts, M; Rodriguez, A; Sáez-Llorens, X; Spigarelli, MG; Yogev, R; Zhou, W, 2009) |
| " This validated population pharmacokinetic model for acyclovir may be used to develop dosing guidelines for safe and effective antiviral therapy in young people with malignancy." | ( Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. Blair, EY; Coakley, JC; Earl, JW; McLachlan, AJ; Nath, CE; Shaw, PJ; Stephen, K; Zeng, L, 2009) |
| "A simple and sensitive, stability-indicating polarographic method was developed for the determination of acyclovir (ACV) in raw materials and dosage forms." | ( Stability-indicating polarographic determination of acyclovir through chelation with nickel(II). El-Brashy, AM; El-Gamal, RM; Sheribah, ZA, ) |
| " acyclovir 1 g over 60 minutes every eight hours, with the dosage based on actual body weight." | ( Acyclovir-induced renal failure in an obese patient. Hernandez, JO; Norstrom, J; Wysock, G, 2009) |
| "The aim of the current study was to investigate whether multiple oral dosing of valacyclovir could result in plasma concentrations exceeding the EC(50)-value of acyclovir against equine herpesvirus 1 (EHV1) during the majority of the treatment period." | ( Multiple oral dosing of valacyclovir in horses and ponies. Baert, K; Croubels, S; De Backer, P; Deprez, P; Garré, B; Nauwynck, H, 2009) |
| " Developing optimal treatment regimens requires understanding how to best measure anti-HIV activity in vitro and how drug dose-response curves generated in vitro correlate with in-vivo efficacy." | ( New approaches for quantitating the inhibition of HIV-1 replication by antiviral drugs in vitro and in vivo. McMahon, MA; Shen, L; Siliciano, RF, 2009) |
| " Recent studies using a single-round infectivity assay have shown that a previously neglected parameter, the dose-response curve slope, is an extremely important determinant of antiviral activity." | ( New approaches for quantitating the inhibition of HIV-1 replication by antiviral drugs in vitro and in vivo. McMahon, MA; Shen, L; Siliciano, RF, 2009) |
| " Its normal plasma half-life is 2 - 3 hours; dosage modifications are obligatory in renal insufficiency." | ( Drug-induced encephalopathy secondary to non renal dosing of common medications in Two dialysis patients. Iloanya, PC; Nye, D; Onuigbo, MA, 2009) |
| "Because acyclovir is a commonly used medication, it is crucial for health providers to be aware of appropriate dosing as well as possible side effects." | ( Altered mental status from acyclovir. Hsia, R; Martinez-Diaz, GJ, 2011) |
| " In this case, renal dosing was not used in a patient on hemodialysis." | ( Altered mental status from acyclovir. Hsia, R; Martinez-Diaz, GJ, 2011) |
| " A dosing recommendation cannot be made for infants <3 months of age because of decreased clearance in this age group." | ( Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month through 11 years of age. Bradley, JS; Heitman, CK; Jacobs, RF; Kimberlin, DW; Man, CY; van der Walt, JS; Weller, S, 2010) |
| " Indwelling intrathecal catheters allowed serial CSF sampling throughout the dosing interval." | ( Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. Haas, DW; Johnson, B; Luther, JM; Nicotera, J; Smith, JP; Weller, S, 2010) |
| " Despite good adherence and increased dosing schedules, breakthrough lesions and viral shedding are still observed in some women at or near delivery." | ( Inadequacy of plasma acyclovir levels at delivery in patients with genital herpes receiving oral acyclovir suppressive therapy in late pregnancy. Blasig, A; Corey, L; Henning, PA; Leung, DT; Money, DM; Sacks, SL; Wagner, EC; Wald, A, 2009) |
| "Oral dosing of acyclovir in women in late pregnancy may result in insufficient levels at delivery to prevent viral shedding." | ( Inadequacy of plasma acyclovir levels at delivery in patients with genital herpes receiving oral acyclovir suppressive therapy in late pregnancy. Blasig, A; Corey, L; Henning, PA; Leung, DT; Money, DM; Sacks, SL; Wagner, EC; Wald, A, 2009) |
| " An eight-step dosing regimen was derived that targeted exposure in infants and children 6 months to 12 years of age to match the penciclovir AUC seen in adults after a 500-mg dose of famciclovir." | ( Single-dose pharmacokinetics of famciclovir in infants and population pharmacokinetic analysis in infants and children. Blumer, J; Hamed, K; Kaiser, G; Rodriguez, A; Sallas, W; Sánchez, PJ, 2010) |
| "A total of 484 HIV-1 and HSV type 2 seropositive Tanzanian women aged 16-35 years were enrolled in a randomized placebo-controlled trial of acyclovir administered at a dosage of 400 mg twice daily." | ( Long-term impact of acyclovir suppressive therapy on genital and plasma HIV RNA in Tanzanian women: a randomized controlled trial. Baisley, K; Belec, L; Changalucha, J; Clayton, TC; Everett, D; Hayes, RJ; Legoff, J; Mugeye, K; Ross, DA; Rusizoka, M; Tanton, C; Watson-Jones, D; Weiss, HA, 2010) |
| "Acyclovir administered at a dosage of 400 mg twice daily is unlikely to be a useful long-term intervention to reduce HIV transmission." | ( Long-term impact of acyclovir suppressive therapy on genital and plasma HIV RNA in Tanzanian women: a randomized controlled trial. Baisley, K; Belec, L; Changalucha, J; Clayton, TC; Everett, D; Hayes, RJ; Legoff, J; Mugeye, K; Ross, DA; Rusizoka, M; Tanton, C; Watson-Jones, D; Weiss, HA, 2010) |
| " Short-course (<1 year) prophylaxis with acyclovir has been shown to be effective, but compliance with five times daily dosing may be problematic." | ( A randomized, double-blind, placebo-controlled trial of valacyclovir prophylaxis to prevent zoster recurrence from months 4 to 24 after BMT. DesJardin, JA; Klein, A; Miller, KB; Snydman, DR; Sprague, K, 2011) |
| " Fifty percent of the patients received tacrolimus (TRL) and the others cyclosporine (CsA), both dosed according to weight." | ( Cytomegalovirus infection after liver transplantation: prophylaxis and preemptive treatment--a single-center experience. Campanella, L; Cuomo, O; Esposito, C; Ioia, G; Perrella, A; Taglialatela, D, 2010) |
| " Valacyclovir was discovered in 1988 and revolutionized the treatment of these infections by virtue of its less frequent dosing regimen, which promotes patient adherence." | ( Valacyclovir: approved and off-label uses for the treatment of herpes virus infections in immunocompetent and immunocompromised adults. Chemaly, RF; Vigil, KJ, 2010) |
| " Heterogeneity in patient groups, patient numbers, age groups, immunosuppressive regimens, timing, and dosage of aciclovir and/or varicella-zoster immunoglobulin (VZIG), pre-transplant vaccination or VZV wild-type infection and inconsistency of data make comparability of different studies impossible." | ( Aciclovir and varicella-zoster-immunoglobulin in solid-organ transplant recipients. Prelog, M; Schönlaub, J; Zimmerhackl, LB, 2011) |
| " All patients recovered without any complications after administration of intravenous aciclovir at a dosage of 10 mg per kg body weight." | ( Varicella outbreak in Indian students in Magdeburg with detection of the African-Indian VZV clade 5. Bonnekoh, B; Franke, I; Gollnick, H; Kolesnik, M; König, W; Sauerbrei, A, 2011) |
| " Of the 10 D+/R- patients who developed CMV disease, six were inadvertently on a dose of valaciclovir below that dictated by protocol arising from a failure to increase dosage in parallel with improving recipient renal function." | ( Low-dose valaciclovir and cytomegalovirus immunoglobulin to prevent cytomegalovirus disease in high-risk renal transplant recipients. Cohney, SJ; Nicholls, K; Tan, MB; Toussaint, ND; Walker, RG, 2011) |
| " We can conclude that a combination of hydroxypropylmethylcellulose 4000, Compritol 888, and sodium bicarbonate can be used to increase the gastric residence time of the dosage form up to 12 h." | ( Optimization of acyclovir oral tablets based on gastroretention technology: factorial design analysis and physicochemical characterization studies. Allam, AN; El Gamal, SS; Naggar, VF, 2011) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | ( FDA-approved drug labeling for the study of drug-induced liver injury. Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| "Using pharmacokinetics to explore the mechanism of honey to enhance the efficacy of acyclovir (ACV) treatment of herpes simplex keratitis (HSK), providing the basis for combination of the prescription of two drugs and dosage regimen designed." | ( [Effects of honey to acyclovir in the rabbit eye transport kinetics]. He, Q; Jiang, Y; Wang, S; Xu, J; Zhang, J; Zhang, X, 2011) |
| " Based on a linear correlation between the calculated and experimental effective molarities, the study on the systems reported herein could provide a good basis for designing prodrug systems that are less hydrophilic than their parental drugs and can be used, in different dosage forms, to release the parent drug in a controlled manner." | ( Prodrugs of acyclovir--a computational approach. Dajani, KK; Karaman, R; Khamis, M; Qtait, A, 2012) |
| " Dosing and duration of antiviral therapy after LT are not established." | ( Herpes simplex virus load to monitor antiviral treatment after liver transplantation for acute herpetic hepatitis. Ambrosioni, J; Genevay-Infante, M; Giostra, E; Kaiser, L; Mentha, G; Meylan, P; Rubbia-Brandt, L; Toso, C; van Delden, C, 2012) |
| " Furthermore, the superior pharmacokinetics and more convenient dosing regimens with the use of valaciclovir and famciclovir clearly make them the preferred treatment option." | ( Antivirals for management of herpes zoster including ophthalmicus: a systematic review of high-quality randomized controlled trials. de Kock, J; McDonald, EM; Ram, FS, 2012) |
| " Protection against mucocutaneous lesions was observed, but the dosage was probably inappropriate for the prevention of HSV activation in the central nervous system." | ( Long-term valacyclovir suppressive treatment after herpes simplex virus type 2 meningitis: a double-blind, randomized controlled trial. Akre, O; Aurelius, E; Franzen-Röhl, E; Glimåker, M; Grillner, L; Jorup-Rönström, C; Studahl, M, 2012) |
| " A total of 156 HSV strains were isolated prior to the dosing of patients, and no preexisting variants with less susceptibility to ASP2151 or acyclovir (ACV) were detected." | ( Susceptibility of herpes simplex virus isolated from genital herpes lesions to ASP2151, a novel helicase-primase inhibitor. Chono, K; Katsumata, K; Kontani, T; Suzuki, H; Takakura, S; Weinberg, A, 2012) |
| " Blood and cervicovaginal lavage (CVL) were collected after oral and IVR dosing to measure aciclovir concentrations and genital swabs were obtained to quantify HSV shedding by PCR." | ( Safety and pharmacokinetics of aciclovir in women following release from a silicone elastomer vaginal ring. Baum, MM; Carpenter, CA; Corey, L; Guerrero, D; Gunawardana, M; Herold, BC; Huang, M; Keller, MJ; Kennedy, S; Lo, Y; Malone, AM; Moss, JA; Nguyen, C; Smith, TJ; Willis, R, 2012) |
| " Median CVL aciclovir levels 2 h after oral dosing were similar to levels observed 7 (P = 0." | ( Safety and pharmacokinetics of aciclovir in women following release from a silicone elastomer vaginal ring. Baum, MM; Carpenter, CA; Corey, L; Guerrero, D; Gunawardana, M; Herold, BC; Huang, M; Keller, MJ; Kennedy, S; Lo, Y; Malone, AM; Moss, JA; Nguyen, C; Smith, TJ; Willis, R, 2012) |
| " However, it is often been forgotten that acyclovir dosage should be adjusted to renal function." | ( Varicella zoster virus reactivation in hemodialysis patients: manifestations, treatment, complications and outcome. Basić-Jukić, N; Hudolin, T; Katalinić, L; Kes, P; Mesar, I, 2011) |
| "Randomization within 72 hours in a factorial fashion to placebo plus placebo (n = 206); prednisolone, 60 mg/d for 5 days, with the dosage then tapered for 5 days, plus placebo (n = 210); valacyclovir hydrochloride, 1000 mg 3 times daily for 7 days, plus placebo (n = 207); or prednisolone plus valacyclovir (n = 206)." | ( The effect of prednisolone on sequelae in Bell's palsy. Berg, T; Bylund, N; Engström, M; Hultcrantz, M; Jonsson, L; Kanerva, M; Marsk, E, 2012) |
| "Penciclovir pharmacokinetics following oral administration of famciclovir were nonlinear within the dosage range studied, likely because of saturation of famciclovir metabolism." | ( Pharmacokinetics of penciclovir in healthy cats following oral administration of famciclovir or intravenous infusion of penciclovir. Bales, JL; Ferrone, M; Maggs, DJ; Stanley, SD; Thomasy, SM; Whittem, T, 2012) |
| " Six of 16 patients (37%) receiving long-term oral acyclovir had recurrent HSV, at least one case of which followed a growth spurt that caused the baseline dosage of acyclovir to become subtherapeutic." | ( Pediatric herpes simplex of the anterior segment: characteristics, treatment, and outcomes. Colby, KA; Liu, S; Pavan-Langston, D, 2012) |
| " Oral acyclovir is effective, but the dosage must be adjusted as the child grows." | ( Pediatric herpes simplex of the anterior segment: characteristics, treatment, and outcomes. Colby, KA; Liu, S; Pavan-Langston, D, 2012) |
| "Acyclovir possesses low solubility in water and in lipid bilayers, so that its dosage forms do not allow suitable drug levels at target sites following oral, local, or parenteral administration." | ( Design, synthesis, and in vitro evaluation of new amphiphilic cyclodextrin-based nanoparticles for the incorporation and controlled release of acyclovir. Chevalier, Y; Duffour, M; Parrot-Lopez, H; Perret, F, 2013) |
| "This study aimed at improving the oral bioavailability of acyclovir (ACV) through incorporating it into gastroretentive dosage form based on floating hollow chitosan beads." | ( Development of mucoadhesive floating hollow beads of acyclovir with gastroretentive properties. Al-Kassas, R; Chalabi, S; In Kim, JH; Langford, C; Painter, S; Seyfoddin, A; Svirskis, D, 2014) |
| " However, drug concentrations were noninhibitory during 42% of the dosing cycle." | ( Rapid viral expansion and short drug half-life explain the incomplete effectiveness of current herpes simplex virus 2-directed antiviral agents. Corey, L; Schiffer, JT; Swan, DA; Wald, A, 2013) |
| " The major physicochemical constraints and pharmacokinetics of Acyclovir such as low solubility, poor permeability, less half-life, high dose has initiated many researchers to develop diverse modified release dosage forms." | ( Dual sustained release delivery system for multiple route therapy of an antiviral drug. Ramyadevi, D; Sandhya, P, 2014) |
| "The statistical significance obtained for the trail formulations experimentally proved its suitability for this dosage form design to achieve desired level of drug release." | ( Dual sustained release delivery system for multiple route therapy of an antiviral drug. Ramyadevi, D; Sandhya, P, 2014) |
| "Acyclovir is used to treat herpes infections in preterm and term infants; however, the influence of maturation on drug disposition and dosing requirements is poorly characterized in this population." | ( Population pharmacokinetics of intravenous acyclovir in preterm and term infants. Anand, R; Benjamin, DK; Bloom, BT; Capparelli, E; Cohen-Wolkowiez, M; Harper, B; Kashuba, AD; Lenfestey, RW; Sampson, MR; Smith, PB, 2014) |
| " The primary pharmacodynamic target was acyclovir concentration ≥3 mg/L for ≥50% of the dosing interval." | ( Population pharmacokinetics of intravenous acyclovir in preterm and term infants. Anand, R; Benjamin, DK; Bloom, BT; Capparelli, E; Cohen-Wolkowiez, M; Harper, B; Kashuba, AD; Lenfestey, RW; Sampson, MR; Smith, PB, 2014) |
| " A dosing strategy based on PMA accounted for developmental changes in acyclovir disposition to achieve the surrogate pharmacodynamic target in many infants." | ( Population pharmacokinetics of intravenous acyclovir in preterm and term infants. Anand, R; Benjamin, DK; Bloom, BT; Capparelli, E; Cohen-Wolkowiez, M; Harper, B; Kashuba, AD; Lenfestey, RW; Sampson, MR; Smith, PB, 2014) |
| " Here we describe a patient who displayed perverted head-shaking and positional downbeat nystagmus after prescription of a high dosage of pregabalin." | ( Perverted head-shaking and positional downbeat nystagmus in pregabalin intoxication. Choi, JY; Jung, JM; Kim, SU; Kwon, DY; Park, YM; Woo, YS, 2014) |
| " In 2006, the American Academy of Pediatrics updated its dosing recommendations for children aged 3 months to 12 years to receive high-dose acyclovir (60 mg/kg/day)." | ( Standard-dose versus high-dose acyclovir in children treated empirically for encephalitis: a retrospective cohort study of its use and safety. Carr, RR; Ensom, MH; Kendrick, JG; Kwan, E; Steer, A; White, CT, 2014) |
| "Acyclovir, indicated in the treatment of herpes labialis ("cold sores"), is formulated as semisolid topical dosage forms and marketed in numerous countries." | ( Comparison of in vitro release rates of acyclovir from cream formulations using vertical diffusion cells. Kanfer, I; Nallagundla, S; Patnala, S, 2014) |
| " In analyzing parallel-group trials by daily dose, no clear evidence was found of a dose-response relationship for any drug." | ( Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients. Chosidow, O; Do, G; Le Cleach, L; Lebrun-Vignes, B; Maruani, A; Ravaud, P; Trinquart, L, 2014) |
| " Dosage of steroids was temporarily increased and progression of cataract monitored." | ( Anterior capsular defect with acute anterior subcapsular cataract in herpetic keratouveitis. Arora, S; Arora, T; Sharma, N; Titiyal, JS, 2014) |
| " The standard dosage of acyclovir 20 mg/kg/dose intravenously every 8 hours had been initiated, but after conversion to ECLS and CRRT, the patient's dosage was increased to 30 mg/kg/dose every 8 hours." | ( Therapeutic drug monitoring of continuous-infusion acylovir for disseminated herpes simplex virus infection in a neonate receiving concurrent extracorporeal life support and continuous renal replacement therapy. Carella, D; Chopra, A; Cies, JJ; Conley, S; Miller, K; Moore, WS; Parker, J; Shea, P; Small, C, 2015) |
| " Advances in pharmacokinetics (PK) and pharmacodynamics (PD) of antimicrobial medications have led to improved dosing guidance for neonates." | ( New antifungal and antiviral dosing. Monk, HM; Wade, KC, 2015) |
| " Outside the neonatal period, renal dysfunction may be minimized by dosing IV acyclovir below thresholds associated with nephrotoxicity (ie, ≤ 500 mg/m(2)/dose or ≤ 15 mg/kg/dose), particularly in older patients." | ( Intravenous acyclovir and renal dysfunction in children: a matched case control study. Abzug, MJ; Cadnapaphornchai, MA; Carosone-Link, P; Child, J; Peterson, T; Rao, S; Simões, EA; Siparksy, G; Soranno, D, 2015) |
| " This preliminary valacyclovir model can be used in simulations to provide dosage recommendations for children of various ages and to help design more efficiently prospective clinical trials." | ( Development of a paediatric population pharmacokinetic model for valacyclovir from literature non-compartmental values originating from sparse studies and Bayesian priors: a simulation study. Dokoumetzidis, A; Kechagia, IA, 2015) |
| " In summary, the SDs developed in this study could be considered as potential systems for solid dosage forms containing acyclovir with superior biopharmaceutical properties." | ( Ball-milled solid dispersions of BCS Class IV drugs: Impact on the dissolution rate and intestinal permeability of acyclovir. Anzilaggo, D; de Campos, CE; França, MT; Kratz, JM; Nart, V; Riekes, MK; Simões, CM; Stulzer, HK, 2015) |
| "Optimal acyclovir dosing under continuous renal replacement therapy (CRRT) in neonates is unknown." | ( Therapeutic Drug Monitoring in Neonatal HSV Infection on Continuous Renal Replacement Therapy. Enomoto, Y; Funaki, T; Kasahara, M; Miyairi, I; Miyata, I; Sakamoto, S; Shoji, K, 2015) |
| " Then a PopPK model of valacyclovir was used to determine by simulations, dosage regimens that fulfill the criteria for both targets." | ( Extrapolation of Valacyclovir Posology to Children Based on Pharmacokinetic Modeling. Dokoumetzidis, A; Kalantzi, L; Kechagia, IA, 2015) |
| "Selection of optimal dosage regimen, length of treatment course (frequency of administration), safety, tolerance and clinical effectiveness evaluation of the medical preparation fortepren in patients with chronical recurrent herpes virus infection of genital localization." | ( [TREATMENT OF PATIENTS WITH CHRONIC RECURRENT HERPES VIRUS INFECTION OF GENITAL LOCALIZATION: A CLINICAL STUDY OF FORTEPREN PREPARATION]. Grigorieva, EA; Izmestieva, AV; Kozlov, VS; Narovlyansky, AN; Parfenova, TM; Pronin, AV; Sanin, AV; Savchenko, AY; Schubelko, RV; Sedov, AM; Shulzhenko, AE; Suprun, OV; Zubashev, IK; Zuikova, IN, ) |
| "An intramuscular dose of 2 ml (8 mg) at recurrence stage 3 times at an interval of 21 days after the completion of the 10-day base course of treatment of the acute phase of chronical recurrent herpes virus infection of genital localization using acyclovir was accepted as an optimal dosage regimen." | ( [TREATMENT OF PATIENTS WITH CHRONIC RECURRENT HERPES VIRUS INFECTION OF GENITAL LOCALIZATION: A CLINICAL STUDY OF FORTEPREN PREPARATION]. Grigorieva, EA; Izmestieva, AV; Kozlov, VS; Narovlyansky, AN; Parfenova, TM; Pronin, AV; Sanin, AV; Savchenko, AY; Schubelko, RV; Sedov, AM; Shulzhenko, AE; Suprun, OV; Zubashev, IK; Zuikova, IN, ) |
| "Attempts to formulate acyclovir to improve its bioavailability and reduce the frequency of dosing from the present q4h have not materialized." | ( The Interesting Case of Acyclovir Delivered Using Chitosan in Humans: Is it a Drug Issue or Formulation Issue? Srinivas, NR, 2016) |
| " If one examines the pharmacokinetic disposition of acyclovir, it is clear that renal elimination is so rapid necessitating frequent dosing of acyclovir." | ( The Interesting Case of Acyclovir Delivered Using Chitosan in Humans: Is it a Drug Issue or Formulation Issue? Srinivas, NR, 2016) |
| ") acyclovir dosing in obese patients suggest using ideal body weight (IBW) rather than total body weight (TBW)." | ( Prospective, Controlled Study of Acyclovir Pharmacokinetics in Obese Patients. Briggs, F; Craig, M; Cumpston, A; Hamadani, M; Petros, W; Slain, D; Sweet, M; Turner, RB; Wen, S, 2016) |
| " This study indicates that not all marketed products containing the same BCS III active pharmaceutical ingredient (API) in similar strength and dosage form are necessarily in vitro equivalent as per the WHO biowaiver criteria." | ( Investigation of Biowaivers for Immediate Release Formulations Containing BCS III Drugs, Acyclovir, Atenolol, and Ciprofloxacin Hydrochloride, Using Dissolution Testing. Kanfer, I; Patnala, S; Reddy, NH, 2017) |
| "To determine national dosing practices of intravenous acyclovir across a range of patient weights." | ( Dosing Practices of Intravenous Acyclovir for Herpes Encephalitis in Obesity: Results of a Pharmacist Survey. Pickering, AJ; Potoski, BA; Wong, A, 2017) |
| " Data collected included demographic information and dosing of acyclovir, given consistent patient cases with varying patient weight." | ( Dosing Practices of Intravenous Acyclovir for Herpes Encephalitis in Obesity: Results of a Pharmacist Survey. Pickering, AJ; Potoski, BA; Wong, A, 2017) |
| " As patient weight increased, respondents were more apt to dose based on an adjusted body weight, with dosing in the obese and morbidly obese showing a clear lack of consistency." | ( Dosing Practices of Intravenous Acyclovir for Herpes Encephalitis in Obesity: Results of a Pharmacist Survey. Pickering, AJ; Potoski, BA; Wong, A, 2017) |
| "Intravenous dosing of acyclovir for herpes encephalitis is variable, especially in obese patients, and does not reflect recommendations." | ( Dosing Practices of Intravenous Acyclovir for Herpes Encephalitis in Obesity: Results of a Pharmacist Survey. Pickering, AJ; Potoski, BA; Wong, A, 2017) |
| " Finally, valacyclovir at this high dosage was extremely well tolerated." | ( In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study. Aegerter, P; Benoist, G; Bussières, L; Couderc, S; Ghout, I; Guilleminot, T; Jacquemard, F; Leruez-Ville, M; Magny, JF; Picone, O; Salomon, LJ; Stirnemann, J; Ville, Y; Winer, N, 2016) |
| "Multipurpose prevention technologies (MPTs) are preferably single dosage forms designed to simultaneously address multiple sexual and reproductive health needs, such as unintended pregnancy, HIV infection and other sexually transmitted infections (STIs)." | ( Development of a multi-layered vaginal tablet containing dapivirine, levonorgestrel and acyclovir for use as a multipurpose prevention technology. Brimer, A; Devlin, B; Major, I; McConville, C, 2016) |
| "OBJECTIVES To determine, following oral administration of famciclovir, pharmacokinetic (PK) parameters for 2 of its metabolites (penciclovir and BRL42359) in plasma and tears of healthy cats so that famciclovir dosage recommendations for the treatment of herpetic disease can be optimized." | ( Pharmacokinetic modeling of penciclovir and BRL42359 in the plasma and tears of healthy cats to optimize dosage recommendations for oral administration of famciclovir. Knych, HK; Maggs, DJ; Sebbag, L; Thomasy, SM; Woodward, AP, 2016) |
| "To assess the efficacy of oral antivirals such as acyclovir in any dosage when taken for six months or more, in preventing recurrence of herpetic keratitis in people having corneal graft surgery for herpetic keratitis." | ( Oral antivirals for preventing recurrent herpes simplex keratitis in people with corneal grafts. Abdul Karim, MN; Bhatt, UK; Fares, U; Maharajan, SV; Prydal, JI, 2016) |
| " Treatment with high-dose acyclovir, 60 mg/kg/d, is recommended; however, the safety of this dosage has not been assessed in the past 15 years, and this dosage is not currently approved for infants by the US Food and Drug Administration." | ( Safety of High-dose Acyclovir in Infants With Suspected and Confirmed Neonatal Herpes Simplex Virus Infections. Autmizguine, J; Benjamin, DK; Clark, RH; Ericson, JE; Gostelow, M; Hornik, CP; Smith, PB, 2017) |
| " We performed a pharmacokinetic modeling and simulation study by integrating the existing understanding of physiology with previously published data to evaluate the vitreal penetration of oral valacyclovir for the treatment of ARN, under various dosing scenarios." | ( Valacyclovir as Initial Treatment for Acute Retinal Necrosis: A Pharmacokinetic Modeling and Simulation Study. Fung, M; Ivaturi, V; Jain, A; Liu, T; Vinnard, C, 2017) |
| "We compared different oral valacyclovir dosing regimens with intravenous acyclovir." | ( Valacyclovir as Initial Treatment for Acute Retinal Necrosis: A Pharmacokinetic Modeling and Simulation Study. Fung, M; Ivaturi, V; Jain, A; Liu, T; Vinnard, C, 2017) |
| "Modeling and simulation data support oral valacyclovir for the treatment of ARN, although the required dosing exceeds the recommended FDA dose size for herpes zoster." | ( Valacyclovir as Initial Treatment for Acute Retinal Necrosis: A Pharmacokinetic Modeling and Simulation Study. Fung, M; Ivaturi, V; Jain, A; Liu, T; Vinnard, C, 2017) |
| " The results of in vitro release study revealed that the designed solid dosage form based on the semisolid SMEDDS loaded with the therapeutic dose of 200mg, may control partitioning of the solubilized drug from in situ formed oil-in-water microemulsion carrier into the sorrounding aqueous media, and hence decrease the risk for precipitation of the drug." | ( Development of semisolid self-microemulsifying drug delivery systems (SMEDDSs) filled in hard capsules for oral delivery of aciclovir. Čalija, B; Djekic, L; Jankovic, J; Primorac, M, 2017) |
| "The rate of release of an active pharmaceutical ingredient (API) from a topical semisolid dosage form can be influenced by its physical and structural properties." | ( A comprehensive approach to qualify and validate the essential parameters of an in vitro release test (IVRT) method for acyclovir cream, 5. Augustin, T; Kanfer, I; Raml, R; Raney, SG; Sinner, F; Tiffner, KI, 2018) |
| " This study attempted the formulation of stable, double fixed-dose acyclovir and ketoconazole novel transmucosal dosage forms, which are able to provide an efficient flux for both compounds." | ( Formulation and evaluation of selected transmucosal dosage forms containing a double fixed-dose of acyclovir and ketoconazole. Botes, D; Steenekamp, JH; Viljoen, JM, 2018) |
| " The present cases suggest that a high dosage of ACV up to 60 mg/kg/day should be considered (while monitoring for side-effects) unless symptoms improve." | ( Herpes zoster meningitis in immunocompetent children: Two case reports and a literature review. Hata, A; Hata, D; Itoh, N; Kumakura, A; Motokura, K, 2017) |
| " Insufficient dosing regimens or prolonged treatment with TK inhibitors result in the local selection of pre-existing mutant HSV viruses." | ( [Acyclovir-resistant perineal HSV infection revealing chronic lymphoid leukaemia]. Bulai Livideanu, C; Casassa, EA; Fortenfant, F; Gaudin, C; Konstantinou, MP; Lamant, L; Mengelle, C; Nicol, P; Paul, C; Viraben, R, 2018) |
| " The recommended dosage for valaciclovir is 1g×2/d and treatment duration is identical to that for aciclovir." | ( [Diagnostic and therapeutic recommendations for sexually transmitted diseases: Genital herpes]. Caumes, E; Chosidow, O; Janier, M; Milpied, B; Senat, MV; Sentilhes, L; Spenatto, N; Timsit, J, 2019) |
| " We report two cases of acute renal failure after an increase in acyclovir dosage from 10 mg to 15 mg/kg/8 h during the treatment of VZV encephalitis according to French guidelines." | ( Acute renal failure related to high doses of acyclovir (15 mg/kg/8 h) during treatment of varicella zoster virus encephalitis. Demesmay, K; Fafi-Kremer, S; Groza, M; Klein, A; Martinot, M; Mohseni-Zadeh, M; Tebacher-Alt, M, 2019) |
| " Chronic suppression with oral antiviral therapy after ARN is recommended to prevent involvement of the contralateral eye, though there is no consensus on the duration and dosage of antivirals." | ( Acute retinal necrosis in a patient with remote severe herpes simplex encephalitis. Kobayashi, T; Meier, J; Sekar, P; Streit, J, 2019) |
| " Nephrosis eased; therefore, the prednisolone dosage was reduced." | ( Successful management of visceral disseminated varicella zoster virus infection during treatment of membranous nephropathy: a case report. Furuto, Y; Kawamura, M; Namikawa, A; Shibuya, Y; Takahashi, H, 2019) |
| " Also, using murine models of corneal and genital herpes infections, we show that the topical use of drug-encapsulated carbon (DECON) reduced dosing frequency, shortened treatment duration, and exhibited higher therapeutic efficacy than currently approved topical or systemic antivirals alone." | ( Drug-encapsulated carbon (DECON): A novel platform for enhanced drug delivery. Agelidis, A; Ames, J; Hopkins, J; Jaishankar, D; Koujah, L; Shukla, D; Suryawanshi, R; Thakkar, N; Yadavalli, T, 2019) |
| " The goals of this study were to build maternal-fetal physiologically based pharmacokinetic (PBPK) models for acyclovir and emtricitabine, 2 anti(retro)viral drugs with active renal net secretion, and to (1) evaluate the predicted maternal PK at different stages of pregnancy; (2) predict the changes in PK target parameters following the current dosing regimen of these drugs throughout pregnancy; (3) evaluate the predicted concentrations of these drugs in the umbilical vein at delivery; (4) compare the model performance for predicting maternal PK of emtricitabine in the third trimester with that of previously published PBPK models; and (5) compare different previously published approaches for estimating the placental permeability of these 2 drugs." | ( Physiologically Based Pharmacokinetic Models to Predict Maternal Pharmacokinetics and Fetal Exposure to Emtricitabine and Acyclovir. Best, BM; Burckart, GJ; Capparelli, EV; Dallmann, A; Green, DJ; Liu, XI; Mirochnick, M; Momper, JD; Rakhmanina, N; van den Anker, JN, 2020) |
| " Evaluation of CSF:serum albumin ratios, renal function and CSF concentrations of aciclovir and CMMG may all contribute to the optimization of aciclovir dosing and avoidance of AINS." | ( An unexpectedly high occurrence of aciclovir-induced neuropsychiatric symptoms in patients treated for herpesvirus CNS infection: a prospective observational study. Grahn, A; Helldén, A; Lindström, J; Lycke, J; Studahl, M, 2019) |
| " The enhanced physicochemical properties of drug molecules and the use of water during whole process can make drug/cyclodextrin nanofibers a favorable dosage formulation for the desired treatments." | ( Electrospun formulation of acyclovir/cyclodextrin nanofibers for fast-dissolving antiviral drug delivery. Celebioglu, A; Uyar, T, 2021) |
| " In contrast, the animals dosed orally once daily with the HPI compounds at 10 or 4 mg/kg/day showed a significantly increased survival (70% and 100% for 10 mg/kg/day; 90% and 100% for 4 mg/kg/day, respectively) compared to the vehicle treatment (0-10%), when therapy was initiated 6 h post HSV-1 inoculation." | ( Helicase primase inhibitors (HPIs) are efficacious for therapy of human herpes simplex virus (HSV) disease in an infection mouse model. Donner, AK; Gege, C; Grunwald, T; Kleymann, G; Lange, F; Uhlig, N, 2021) |
| "A significant increase in the incidence of various forms of herpesvirus infection (HVI) determines the need to search for new approaches to the modification of one of the basic antiviral drugs aciclovir (ACV) and its dosage forms to improve their biopharmaceutical characteristics and increase the effectiveness of therapy." | ( [Antiviral activity of the organic germanium complex with aciclovir against herpes simplex virus (Herpesviridae: Alphaherpesvirinae: Simplexvirus: Human alphaherpesvirus 1/2) in the in vitro and in vivo systems]. Alimbarova, LM; Ambrosov, IV; Barinsky, IF; Matelo, SK, 2021) |
| "These results suggest to modify acyclovir management in herpetic encephalitis, for low-weight patients (< 79 kg) with a minimum dosage of 2550 mg/day (850 mg/ 8 h), when possible." | ( Herpetic encephalitis: which treatment for which body weight? Boucekine, M; Boussen, S; Brouqui, P; Felician, O; Kaphan, E; Kaplanski, G; Lagier, JC; Leone, M; Mulatero, M; Parola, P; Rossi, P; Stein, A, 2022) |
| " Therefore, the synthesized composites are not a promising basis for development of new oral dosage form of ACV." | ( Effects of synthesis conditions and release medium pH on release properties of acyclovir - mercaptopropyl modified silica composite. Akimsheva, EY; Dolinina, ES; Parfenyuk, EV, 2021) |
| " We have previously demonstrated that acyclovir loaded into activated carbon can be used to significantly decrease dosage frequency in a murine model of ocular infection." | ( Safety, efficacy and delivery of multiple nucleoside analogs via drug encapsulated carbon (DECON) based sustained drug release platform. Ames, J; Bellamkonda, N; Ramirez, B; Shukla, D; Wu, D; Yadavalli, T, 2022) |
| "We obtained demographic information and acyclovir dosing via medical records." | ( Exposure-safety relationship for acyclovir in the treatment of neonatal herpes simplex virus disease. Adler-Shohet, F; Balevic, SJ; Benjamin, DK; Boakye-Agyeman, F; Cotten, CM; Ericson, JE; Harper, B; Kaneshige, K; Laughon, M; Payne, EH; Poindexter, B; Smith, PB, 2022) |
| "We identified 49 infants with neonatal HSV treated with acyclovir; 42 infants had complete 21-day dosing information." | ( Exposure-safety relationship for acyclovir in the treatment of neonatal herpes simplex virus disease. Adler-Shohet, F; Balevic, SJ; Benjamin, DK; Boakye-Agyeman, F; Cotten, CM; Ericson, JE; Harper, B; Kaneshige, K; Laughon, M; Payne, EH; Poindexter, B; Smith, PB, 2022) |
| " These PBPK models are useful to predict the PK profiles of those five drugs in the milk for different dosing regimens." | ( Physiologically based pharmacokinetic model to predict drug concentrations of breast cancer resistance protein substrates in milk. Fang, Y; Li, Y; Zhang, T; Zou, P, 2022) |
| " The patient was treated with adapted exposure with the usual dosing, but lower dosing should be investigated with complementary studies." | ( Pharmacokinetic profile of acyclovir in a child receiving continuous kidney replacement therapy for acute liver failure. Collignon, C; de Marcellus, C; Heilbronner, C; Hirt, D; Neuranter, V; Oualha, M, 2023) |
| "There is limited guidance on the most appropriate dosing strategy for intravenous (IV) acyclovir in obese patients." | ( Comparison of dosing strategies in obese patients prescribed intravenous acyclovir and evaluation of rate of acute kidney injury. Higuita, NIA; Miller, JL; Neely, SB; Siegrist, EA; White, BP; Zelnicek, TD, 2023) |
| " Further studies are needed to confirm dosing recommendations." | ( Comparison of dosing strategies in obese patients prescribed intravenous acyclovir and evaluation of rate of acute kidney injury. Higuita, NIA; Miller, JL; Neely, SB; Siegrist, EA; White, BP; Zelnicek, TD, 2023) |
| Role | Description |
|---|---|
| antiviral drug | A substance used in the prophylaxis or therapy of virus diseases. |
| antimetabolite | A substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| oxopurine | |
| 2-aminopurines | Any aminopurine having the amino substituent at the 2-position. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| Metabolism | 1496 | 1108 |
| Biological oxidations | 150 | 276 |
| Phase I - Functionalization of compounds | 69 | 175 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 15.8489 | 0.0251 | 20.2376 | 39.8107 | AID886 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 15.8489 | 0.0251 | 20.2376 | 39.8107 | AID886 |
| Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 0.7943 | 0.1259 | 19.1169 | 125.8920 | AID2708 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 0.0001 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 2.9935 | 0.1000 | 20.8793 | 79.4328 | AID488772 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 70.7946 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
| GLS protein | Homo sapiens (human) | Potency | 5.6234 | 0.3548 | 7.9355 | 39.8107 | AID624146 |
| TDP1 protein | Homo sapiens (human) | Potency | 1.4421 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Smad3 | Homo sapiens (human) | Potency | 3.9811 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 15.8489 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 0.2957 | 0.0013 | 10.1577 | 42.8575 | AID1259256 |
| arylsulfatase A | Homo sapiens (human) | Potency | 23.9341 | 1.0691 | 13.9551 | 37.9330 | AID720538 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 19.9179 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 0.0008 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 27.4263 | 0.0391 | 47.5451 | 146.8240 | AID1224845; AID1224896 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 0.5012 | 0.5406 | 17.6392 | 96.1227 | AID2364; AID2528 |
| hemoglobin subunit beta | Homo sapiens (human) | Potency | 12.5893 | 0.3162 | 9.0861 | 31.6228 | AID910 |
| atrial natriuretic peptide receptor 1 precursor | Homo sapiens (human) | Potency | 8.4921 | 0.1346 | 10.3950 | 30.1313 | AID1347049 |
| ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 12.5893 | 0.6561 | 9.4520 | 25.1189 | AID927 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 0.0009 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | Potency | 12.5893 | 1.5849 | 13.0043 | 25.1189 | AID927 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain E, Purine nucleoside phosphorylase | Homo sapiens (human) | Ki | 90.0000 | 90.0000 | 90.0000 | 90.0000 | AID977610 |
| Thymidine kinase | Macacine alphaherpesvirus 1 | IC50 (µMol) | 1,000.0000 | 0.1500 | 2.5750 | 4.2000 | AID326127 |
| ATP-binding cassette sub-family C member 3 | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 0.6315 | 4.4531 | 9.3000 | AID1473740 |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 0.2000 | 5.6774 | 10.0000 | AID1473741 |
| Bile salt export pump | Rattus norvegicus (Norway rat) | IC50 (µMol) | 1,000.0000 | 0.4000 | 2.7500 | 8.6000 | AID1209456 |
| Bile salt export pump | Homo sapiens (human) | IC50 (µMol) | 567.0000 | 0.1100 | 7.1903 | 10.0000 | AID1209455; AID1443980; AID1449628; AID1473738 |
| Purine nucleoside phosphorylase | Homo sapiens (human) | Ki | 135.5000 | 0.0000 | 0.5289 | 7.0000 | AID156075; AID1571174 |
| Cytochrome P450 2C9 | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.0000 | 2.8005 | 10.0000 | AID1210069 |
| Cytochrome P450 2J2 | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.0120 | 2.5312 | 9.4700 | AID1210069 |
| Thymidine kinase | Human alphaherpesvirus 2 | IC50 (µMol) | 200.0000 | 0.1000 | 0.8462 | 1.6000 | AID326129 |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 2.4100 | 6.3433 | 10.0000 | AID1473739 |
| Thymidine kinase | Human alphaherpesvirus 1 (Herpes simplex virus type 1) | IC50 (µMol) | 122.0000 | 0.1500 | 4.8167 | 9.0000 | AID326128 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Solute carrier family 22 member 1 | Homo sapiens (human) | Km | 151.2000 | 0.4770 | 4.0308 | 9.0000 | AID680360 |
| Solute carrier family 22 member 6 | Rattus norvegicus (Norway rat) | Km | 242.0000 | 0.5700 | 1.3350 | 2.1000 | AID681387 |
| Thymidine kinase, cytosolic | Homo sapiens (human) | Km | 1.8500 | 0.2900 | 2.2767 | 5.0000 | AID210867; AID213328 |
| POU domain, class 2, transcription factor 2 | Homo sapiens (human) | Km | 94.0000 | 2.7000 | 2.7000 | 2.7000 | AID1219943 |
| Solute carrier family 22 member 6 | Homo sapiens (human) | Km | 590.6500 | 0.4200 | 4.6183 | 9.3000 | AID1219946; AID679320 |
| Solute carrier family 22 member 8 | Homo sapiens (human) | Km | 772.0000 | 0.3450 | 1.3217 | 3.1000 | AID1219949 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID595891 | Antiviral activity against HSV-1 by green fluorescent protein microplate assay | 2011 | Journal of natural products, Apr-25, Volume: 74, Issue:4 | Bioactive compounds from the scale insect pathogenic fungus Conoideocrella tenuis BCC 18627. |
| AID1443980 | Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch | 2010 | Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2 | Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. |
| AID84620 | In vivo efficacy of compound against HSV-2 strain A133 in the mouse system model was measured at 25 dose(mg/kg), activity expressed as Survivors counted on day 21; 2/10 | 1991 | Journal of medicinal chemistry, Mar, Volume: 34, Issue:3 | Fluorocarbocyclic nucleosides: synthesis and antiviral activity of 2'- and 6'-fluorocarbocyclic 2'-deoxy guanosines. |
| AID43639 | Antiherpes activity was tested as percent of control of plaque-formation against BVdUr virus by 5 uM of the compound | 1985 | Journal of medicinal chemistry, Jul, Volume: 28, Issue:7 | Synthesis and biological activities of 2-pyrimidinone nucleosides. 2. 5-Halo-2-pyrimidinone 2'-deoxyribonucleosides. |
| AID697736 | Antiviral activity against HSV1 strain F ATCC VR733 infected in african green monkey Vero cells assessed as inhibition of cytopathic effect after 48 hrs by plaque reduction assay | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14 | Anti-herpes simplex virus efficacies of 2-aminobenzamide derivatives as novel HSP90 inhibitors. |
| AID234560 | Selectivity as the ratio of CC50 value to that of EC50 value. | 2002 | Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23 | CycloSal-BVDUMP pronucleotides: how to convert an antiviral-inactive nucleoside analogue into a bioactive compound against EBV. |
| AID217723 | Compound was tested for antiviral activity against Herpes Simplex virus Type-2(MS) in vero cells | 1987 | Journal of medicinal chemistry, Sep, Volume: 30, Issue:9 | Synthesis and antiviral activity of 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]purines. |
| AID561626 | Half life in patient with Epstein-Barr virus infection at 500 mg/kg, po administered every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. |
| AID79169 | Effect on the development of Herpetic vesicles in Guinea pigs infected intradermally with Herpes virus Hominis, Type 1,AA strain on day 2 at 5 % concentration | 1984 | Journal of medicinal chemistry, May, Volume: 27, Issue:5 | Synthesis of some phosphonates with antiherpetic activity. |
| AID540221 | Volume of distribution at steady state in human after iv administration | 2005 | Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7 | Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. |
| AID236916 | Percentage of mass balance in hexadecane membranes model | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | Exploring the role of different drug transport routes in permeability screening. |
| AID84235 | Antiviral activity against Herpes simplex virus-1 (Schooler strain) | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID595577 | Antiviral activity against Human cytomegalovirus (strain AD169) infected in 1 hr pretreated human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | Broad-spectrum antiviral activity including human immunodeficiency and hepatitis C viruses mediated by a novel retinoid thiosemicarbazone derivative. |
| AID235476 | Selectivity index is the ratio between IC50 (Anti-VZV Activity (DM625 in HFF Cells)) and minimum cytotoxic concentration (against HFF cells) values of the compound | 1998 | Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8 | Synthesis and antiviral activity of novel acyclic nucleosides: discovery of a cyclopropyl nucleoside with potent inhibitory activity against herpesviruses. |
| AID1450224 | Antiviral activity against acyclovir and cidofovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect | 2017 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11 | New modified 2-aminobenzimidazole nucleosides: Synthesis and evaluation of their activity against herpes simplex virus type 1. |
| AID85414 | In vitro antiviral activity against herpesvirus,HSV-2,X-79 strain by plaque reduction assay in human foreskin fibroblasts | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5 | Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS. |
| AID1283348 | Antiviral activity against HSV1 KOS ATCC VR1493 infected in human iPSC cells assessed as reduction in EGFP-positive cells at 50 uM treated at 2 hrs post infection measured 24 hrs post infection by flow cytometric analysis relative to control | 2016 | ACS medicinal chemistry letters, Jan-14, Volume: 7, Issue:1 | iPSC Neuronal Assay Identifies Amaryllidaceae Pharmacophore with Multiple Effects against Herpesvirus Infections. |
| AID1211759 | Effective permeability of the compound in PepT1 knockout mouse jejunum at 100 uM by HPLC analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3 | Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice. |
| AID167136 | Minimum inhibitory concentration required to reduce virus induced cytopathogenicity in primary rabbit kidney cell cultures by 50% against HSV-2 (196) | 1983 | Journal of medicinal chemistry, Apr, Volume: 26, Issue:4 | Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl]guanine]. |
| AID1433137 | Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis | 2015 | European journal of medicinal chemistry, Aug-28, Volume: 101 | Synthesis, antiplasmodial activity and mechanistic studies of pyrimidine-5-carbonitrile and quinoline hybrids. |
| AID1361087 | Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07-1 infected in human HEL cells assessed as reduction in plaque formation after 5 days | 2018 | European journal of medicinal chemistry, Jul-15, Volume: 155 | Dihydropyrimidinone/1,2,3-triazole hybrid molecules: Synthesis and anti-varicella-zoster virus (VZV) evaluation. |
| AID280175 | Antiviral activity against HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity | 2007 | Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5 | Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds. |
| AID217803 | In vitro antiviral activity tested against herpesvirus, VZV, OKA strain by plaque reduction assay in human foreskin fibroblasts. | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5 | Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS. |
| AID86982 | Concentration required to cause microscopically visible change or disruption in about 50% of cell sheet of HeLa cells | 2001 | Journal of medicinal chemistry, May-24, Volume: 44, Issue:11 | Synthesis and biological evaluation of purine-containing butenolides. |
| AID87974 | Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by Herpes simplex virus(HSV) -1 (thymidine kinase deficient) in vero cells | 1988 | Journal of medicinal chemistry, Sep, Volume: 31, Issue:9 | Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity. |
| AID1079937 | Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source] | |||
| AID580306 | Therapeutic index, ratio of CC50 for african green monkey Vero cells to EC50 for HSV1 | 2011 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6 | Synthesis and in vitro anti-HSV-1 activity of a novel Hsp90 inhibitor BJ-B11. |
| AID118724 | Number of mice normal, without lesion after HSV-2 infection observed from day 12 to day 20 | 1987 | Journal of medicinal chemistry, Jun, Volume: 30, Issue:6 | Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases. |
| AID342112 | Antiviral activity against acyclovir-sensitive HSV2 HG32 in african green monkey Vero cells assessed as inhibition of virus plaque formation | 2008 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 18, Issue:15 | Successful kinase bypass with new acyclovir phosphoramidate prodrugs. |
| AID1055704 | Solubility of the compound in deionized water at pH 5.5 after overnight incubation by HPLC analysis | 2013 | European journal of medicinal chemistry, , Volume: 70 | Novel water-soluble prodrugs of acyclovir cleavable by the dipeptidyl-peptidase IV (DPP IV/CD26) enzyme. |
| AID401233 | Antiviral activity against HSV2 | 2004 | Journal of natural products, Apr, Volume: 67, Issue:4 | Isolation of salicin derivatives from Homalium cochinchinensis and their antiviral activities. |
| AID216529 | The compound was tested in vitro for the highest concentration (maximum tolerated level) that showed no cellular toxicity by visualization of stained cells. | 1995 | Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14 | Cyclic variations of 3-quinolinecarboxamides and effects on antiherpetic activity. |
| AID1818213 | Antiviral activity against HSV-2 infected in African green monkey Vero cells assessed as inhibition of viral replication incubated for 3 days by MTT assay | |||
| AID588216 | FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID580305 | Antiviral activity against HSV2 infected in african green monkey Vero cells assessed as inhibition of viral replication by plaque reduction assay | 2011 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6 | Synthesis and in vitro anti-HSV-1 activity of a novel Hsp90 inhibitor BJ-B11. |
| AID1337433 | Antiviral activity against thymidine Kinase expressing Varicella-Zoster virus OKA infected in HEL cells assessed as inhibition of virus plaque formation | 2016 | European journal of medicinal chemistry, Nov-29, Volume: 124 | Identification of an indol-based derivative as potent and selective varicella zoster virus (VZV) inhibitor. |
| AID1433136 | Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis | 2015 | European journal of medicinal chemistry, Aug-28, Volume: 101 | Synthesis, antiplasmodial activity and mechanistic studies of pyrimidine-5-carbonitrile and quinoline hybrids. |
| AID575039 | Antiviral activity against Herpes simplex virus 2 isolate 24 harboring G39E, -1G 440 = Stop 229 mutations in thymidine kinase and A9T, P15S, L60P, E139K, H837R mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction ass | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. |
| AID365173 | Antiviral activity against acyclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity | 2008 | Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18 | 4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action. |
| AID86969 | Ability to inhibit cytopathogenicity of herpes simplex type 1 virus (KOS) in HeLa cell culture | 2001 | Journal of medicinal chemistry, May-24, Volume: 44, Issue:11 | Synthesis and biological evaluation of purine-containing butenolides. |
| AID42131 | Cytotoxicity against uninfected monkey kidney cells (BSC-1) | 1988 | Journal of medicinal chemistry, Nov, Volume: 31, Issue:11 | Synthesis and antiviral activity of certain 4- and 4,5-disubstituted 7-[(2-hydroxyethoxy)methyl]pyrrolo[2,3-d]pyrimidines. |
| AID1055687 | Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathicity | 2013 | European journal of medicinal chemistry, , Volume: 70 | Novel water-soluble prodrugs of acyclovir cleavable by the dipeptidyl-peptidase IV (DPP IV/CD26) enzyme. |
| AID216172 | Minimum Inhibition Concentration (MIC) for activity against Varicella-Zoster Virus(VZV) using YS/R (TK-) strain. | 1996 | Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14 | Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents. |
| AID85283 | In vitro antiviral activity against herpesvirus, HSV-2, JEN strain by plaque reduction assay in human foreskin fibroblasts | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5 | Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS. |
| AID607910 | Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis | 2011 | Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14 | Design, synthesis and biological evaluation of 2'-deoxy-2',2'-difluoro-5-halouridine phosphoramidate ProTides. |
| AID63764 | The minimum inhibitory concentration was measured on E6SM cells against TK+/TK-Herpes simplex virus type 1 (VMW1837 strain) | 1994 | Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19 | Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity. |
| AID303211 | Antiviral activity against HSV2 Lyons in HEL cells assessed as reduction of virus-induced cytopathogenicity | 2007 | Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23 | Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity. |
| AID91275 | Cytotoxicity was determined at 32 uM | 1987 | Journal of medicinal chemistry, Nov, Volume: 30, Issue:11 | Synthesis and antiviral activity of carbocyclic analogues of xylofuranosides of 2-amino-6-substituted-purines and 2-amino-6-substituted-8-azapurines. |
| AID658617 | Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days | 2012 | European journal of medicinal chemistry, Jun, Volume: 52 | 2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies. |
| AID1211778 | Drug level in mouse portal vein plasma treated with valacyclovir at 100 uM by HPLC analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3 | Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice. |
| AID246626 | Effective concentration required to inhibit human cytomegalo virus AD-169 induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection | 2005 | Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7 | From 1-acyl-beta-lactam human cytomegalovirus protease inhibitors to 1-benzyloxycarbonylazetidines with improved antiviral activity. A straightforward approach to convert covalent to noncovalent inhibitors. |
| AID288918 | Antiviral activity against Vaccinia virus in E6SM cells assessed as reduction of virus-induced cytopathogenicity | 2007 | Journal of medicinal chemistry, Jun-14, Volume: 50, Issue:12 | 5-alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells. |
| AID120297 | In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through intraperitoneal at a dose 2.5 mg/kg per day; NT=Not tested | 1985 | Journal of medicinal chemistry, Nov, Volume: 28, Issue:11 | 5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue. |
| AID55082 | Tested for antiviral activity against HCMV (AD169); Not determined | 2001 | Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12 | The cyclohexene ring as bioisostere of a furanose ring: synthesis and antiviral activity of cyclohexenyl nucleosides. |
| AID106178 | Antiviral activity in plaque reduction assay was determined against varicella zoster virus (VZV) in MRC-5 cells. | 1990 | Journal of medicinal chemistry, Jan, Volume: 33, Issue:1 | Synthesis and antiviral activity of 9-alkoxypurines. 1. 9-(3-Hydroxypropoxy)- and 9-[3-hydroxymethyl)propoxy]purines. |
| AID425263 | Total AUC in horse at 20 mg/kg, po administered as single dose | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID420977 | Antiviral activity against HSV1 infected in human HeLa cells assessed as viral reduction factor preincubated for 0.5 hrs before infection measured after 36 hrs by end point titration technique relative to control | 2009 | European journal of medicinal chemistry, Jun, Volume: 44, Issue:6 | Synthesis and biological evaluation of abietic acid derivatives. |
| AID217435 | Compound was evaluated for inhibition of HSV-1 induced plaques in vero cells (African green monkey kidney cells) | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17 | Synthesis and antiviral evaluation of nucleic acid-based (NAB) libraries. |
| AID91493 | Cytotoxic concentration that produces 50% growth inhibition of human skin fibroblast in CPE assay; ND: No data | 2003 | Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23 | Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine. |
| AID216463 | Effective concentration required for reduction of plaque formation of thymidine kinase deficient Varicella-Zoster Virus (071 strain) | 2001 | Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3 | Bicyclic nucleoside inhibitors of Varicella-Zoster Virus (VZV): the effect of terminal unsaturation in the side chain. |
| AID82686 | Compound was tested for anti-viral activity against HSV-1(KOS) in HEL cells | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24 | Synthesis and antiviral evaluation of 3-hydroxy-2-methylpyridin-4-one dideoxynucleoside derivatives. |
| AID595576 | Antiviral activity against Varicella-zoster virus Ellen infected in 1 hr pretreated human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | Broad-spectrum antiviral activity including human immunodeficiency and hepatitis C viruses mediated by a novel retinoid thiosemicarbazone derivative. |
| AID84083 | Antiviral activity against Herpes simplex virus-1 (thymidine kinase deficient strains isolated as BVaraU resistant mutants of HSV-1 (KOS)) | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID1433151 | Antiviral activity against TK negative Varicella-zoster virus 07-1 infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis | 2015 | European journal of medicinal chemistry, Aug-28, Volume: 101 | Synthesis, antiplasmodial activity and mechanistic studies of pyrimidine-5-carbonitrile and quinoline hybrids. |
| AID425279 | Protein binding in horse pooled plasma at 0.5 to 15 ug/ml | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID15858 | Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day. | 1985 | Journal of medicinal chemistry, Jul, Volume: 28, Issue:7 | Synthesis and antiherpetic activity of (S)-, (R)-, and (+/-)-9-[(2,3-dihydroxy-1-propoxy)methyl]guanine, linear isomers of 2'-nor-2'-deoxyguanosine. |
| AID44363 | Antiproliferative effects on CCRF-HSB-2 (human leukemia) cells. | 1997 | Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14 | A facile, alternative synthesis of 4'-thioarabinonucleosides and their biological activities. |
| AID63767 | The minimum inhibitory concentration was measured on E6SM cells against Vesicular stomatitis virus | 1994 | Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19 | Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity. |
| AID83361 | Effective concentration required to inhibit Tyrosine kinase deficient (TK-) Varicella-Zoster virus-induced cytopathicity by 50% in YS/R strain HEL cell lines | 2001 | Journal of medicinal chemistry, Aug-16, Volume: 44, Issue:17 | Synthesis, mechanism of action, and antiviral activity of a new series of covalent mechanism-based inhibitors of S-adenosyl-L-homocysteine hydrolase. |
| AID85548 | In vitro cytotoxicity against herpes simplex virus type-1 (HSV-1) HF strain in infected KB cells | 1988 | Journal of medicinal chemistry, Jul, Volume: 31, Issue:7 | 7-Aminoquinolines. A novel class of agents active against herpesviruses. |
| AID1651496 | Antiviral activity against ACV-resistant Herpes simplex virus 1 AR-29 infected in male Balb/c mouse assessed as reduction in zosteriform lesion at 50 mg/g applied topically as cream formulation 5 times a day at 3 hrs interval for 10 days measured on day 5 | |||
| AID498408 | Antiviral activity against Macacine herpesvirus 1 isolate MR3 infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds. |
| AID82699 | Antiviral activity against herpes simplex virus-2 (HSV-2) Ms strain in HEL (human erythroleukemia) cells. | 1997 | Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14 | A facile, alternative synthesis of 4'-thioarabinonucleosides and their biological activities. |
| AID236268 | Fraction absorbed in human intestine after oral administration compound was measured | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | Exploring the role of different drug transport routes in permeability screening. |
| AID216323 | The concentration required to reduce virus plaque formation by 50% was measured on OKA strain of VZV expressing viral thymidine kinase(TK+) | 1999 | Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7 | Novel potential agents for human cytomegalovirus infection: synthesis and antiviral activity evaluation of benzothiadiazine dioxide acyclonucleosides. |
| AID273052 | Inhibition of VZV replication in HFF cells by cytopathic effect assay | 2006 | Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20 | 9-{[3-fluoro-2-(hydroxymethyl)cyclopropylidene]methyl}adenines and -guanines. Synthesis and antiviral activity of all stereoisomers1. |
| AID85428 | In vitro antiviral activity against herpesvirus, HSV-JEN strain by plaque reduction assay in human foreskin fibroblasts. | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5 | Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS. |
| AID575028 | Antiviral activity against Herpes simplex virus 2 isolate 13 harboring, M183I mutations in thymidine kinase and A9T, P15S, R41H, L60P, E139K, A232T mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. |
| AID326135 | Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides. |
| AID96357 | Cytotoxicity against human neoplastic cell line (KB) | 1989 | Journal of medicinal chemistry, Jul, Volume: 32, Issue:7 | Synthesis, cytotoxicity, and antiviral activity of certain 7-[(2-hydroxyethoxy)methyl]pyrrolo[2,3-d]pyrimidine nucleosides related to toyocamycin and sangivamycin. |
| AID426927 | Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay | 2009 | Journal of natural products, Jun, Volume: 72, Issue:6 | 7-O-methylkaempferol and -quercetin glycosides from the whole plant of Nervilia fordii. |
| AID216170 | Minimum Inhibition Concentration (MIC) for activity against Varicella-Zoster Virus(VZV) using OKA (TK+) strain | 1996 | Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14 | Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents. |
| AID1382163 | Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as reduction in viral cytopathic effect | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Highly convergent synthesis and antiviral activity of (E)-but-2-enyl nucleoside phosphonoamidates. |
| AID521921 | Tmax in human CSF with normal renal function at 2000 mg, po every 6 hrs measured after fifth dose by radioimmunoassay | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. |
| AID68270 | Concentration required to inhibit HSV-1 (McIntyre) induced cytopathogenicity in ESM cells by 50% | 1991 | Journal of medicinal chemistry, Aug, Volume: 34, Issue:8 | Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir. |
| AID1818214 | Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for HSV-2 infected in African green monkey Vero cells | |||
| AID258993 | Antiviral activity against human cytomegalovirus Davis strain | 2006 | Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1 | Synthesis and biological evaluation of 6-(alkyn-1-yl)furo[2,3-d]pyrimidin-2(3H)-one base and nucleoside derivatives. |
| AID217665 | Evaluated for the anti-VZV, the concentration of compounds in uM required to reduce VZVTK-07 ( thymidine kinase-deficient strain ) plaque formation after 5 days in HEL cell cultures compared to untreated controls. | 2000 | Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26 | Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain. |
| AID1079941 | Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source] | |||
| AID82887 | Tested for inhibitory effect on DNA virus CMV (AD-169) in HEL cell line | 1993 | Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23 | Synthesis and antiviral activity of 5'-deoxypyrazofurin. |
| AID259177 | Antiviral activity against HSV1 KOS in HEL cells | 2006 | Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1 | Synthesis and antiviral evaluation of cyclic and acyclic 2-methyl-3-hydroxy-4-pyridinone nucleoside derivatives. |
| AID83331 | The minimum inhibitory concentration was measured on HEL cells against Varicella zoster virus (OKA strain) | 1994 | Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19 | Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity. |
| AID232129 | Ratio measured as the VR of C-3''-deoxyribofuranoside to the VR at a MIC of 3 ug/mL | 1987 | Journal of medicinal chemistry, Jun, Volume: 30, Issue:6 | Synthesis and antiviral evaluation of carbocyclic analogues of 2-amino-6-substituted-purine 3'-deoxyribofuranosides. |
| AID569232 | Antiviral activity against thymidine kinase deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect | 2011 | European journal of medicinal chemistry, Feb, Volume: 46, Issue:2 | Synthesis of new C5-(1-substituted-1,2,3-triazol-4 or 5-yl)-2'-deoxyuridines and their antiviral evaluation. |
| AID235467 | Selectivity index calculated as CC50/EC50 in the VPR assay of HSV-2; ND: No data | 2003 | Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23 | Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine. |
| AID1450214 | Selectivity index, ratio of MCC for African green monkey Vero E6 cells to IC50 for HSV-1 L2 infected in African green monkey Vero E6 cells | 2017 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11 | New modified 2-aminobenzimidazole nucleosides: Synthesis and evaluation of their activity against herpes simplex virus type 1. |
| AID326132 | Activity of Herpes B virus recombinant thymidine kinase at 1 mM | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides. |
| AID1610153 | Cytotoxicity against human HELF cells assessed as minimum cytotoxic concentration by observing alteration in cell morphology incubated for 3 days by microscopic analysis | 2019 | European journal of medicinal chemistry, Dec-15, Volume: 184 | Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives. |
| AID561614 | Bioavailability in children and young patient with malignancy | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. |
| AID280186 | Cytotoxicity against HEL cells assessed as alteration in cell morphology after 3 days | 2007 | Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5 | Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds. |
| AID216300 | Compound was evaluated for the inhibition of VZV (TK-) thymidine kinases Strain 07 | 1999 | Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22 | Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base. |
| AID307431 | Antiviral activity against HSV1 KOS in Vero cells by plaque reduction assay | 2007 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12 | 2-Aryl-2-hydroxyethylamine substituted 4-oxo-4,7-dihydrothieno[2,3-b]pyridines as broad-spectrum inhibitors of human herpesvirus polymerases. |
| AID498597 | Antiviral activity against Macacine herpesvirus 1 isolate A1 infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds. |
| AID90982 | Cytotoxic activity against KB cells. | 1990 | Journal of medicinal chemistry, Jul, Volume: 33, Issue:7 | Synthesis, antiproliferative, and antiviral activity of certain 4-substituted and 4,5-disubstituted 7-[(1,3-dihydroxy-2-propoxy)methyl]pyrrolo[2,3-d]pyrimidines. |
| AID87198 | Antiherpes activity was tested as percent of control of plaque-formation against HSV-1 (KOS) virus by 5 uM of the compound | 1985 | Journal of medicinal chemistry, Jul, Volume: 28, Issue:7 | Synthesis and biological activities of 2-pyrimidinone nucleosides. 2. 5-Halo-2-pyrimidinone 2'-deoxyribonucleosides. |
| AID217483 | Inhibitory concentration against VSV in human embryonic skin muscle (ESM) fibroblast cell culture | 1993 | Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14 | Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides. |
| AID228734 | The compound was tested for its minimal cytotoxic concentration required to alter microscopically detectable cell morphology | 2000 | Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11 | Bicyclic nucleoside inhibitors of Varicella-Zoster Virus (VZV): the effect of a terminal halogen substitution in the side-chain. |
| AID1572734 | Antiviral activity against thymidine kinase deficient Varicella-zoster virus 07-1 infected in HEL cells assessed as reduction in virus plaque formation | 2019 | Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6 | Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives. |
| AID561623 | Bioavailability in immunocompromized children at 250 mg/kg, po administered every 12 hrs | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. |
| AID498599 | Antiviral activity against Macacine herpesvirus 1 isolate A3 infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds. |
| AID1312420 | Antiviral activity against TK-deficient Varicella-zoster virus infected in HEL cells | 2016 | European journal of medicinal chemistry, Aug-08, Volume: 118 | 1'-Homonucleosides and their structural analogues: A review. |
| AID84590 | Minimal inhibitory concentration to reduce virus-induced cytopathicity against KOS strain of human Herpes Simplex Virus -1 | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Fluorescent tricyclic analogues of acyclovir and ganciclovir. A structure-antiviral activity study. |
| AID1113470 | Cytotoxicity against Homo sapiens (human) HEL cells assessed as change in cellular morphology | 2013 | Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4 | Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)- |
| AID217829 | Concentration required to reduce cytopathogenicity of vaccinia virus by 50% in primary rabbit kidney (PRK) cells | 1984 | Journal of medicinal chemistry, Nov, Volume: 27, Issue:11 | Nucleic acid related compounds. 47. Synthesis and biological activities of pyrimidine and purine "acyclic" nucleoside analogues. |
| AID87191 | Concentration that protects by 50% the cytopathic effect induced by herpes simplex virus - 1. | 1985 | Journal of medicinal chemistry, Jan, Volume: 28, Issue:1 | Uridine 5'-diphosphate glucose analogues. Inhibitors of protein glycosylation that show antiviral activity. |
| AID81057 | Concentration required to inhibit TK-VZV (YSR) induced cytopathogenicity in HEL cells by 50% | 1991 | Journal of medicinal chemistry, Aug, Volume: 34, Issue:8 | Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir. |
| AID481581 | Inhibition of HCMV DNA polymerase infected in HFF cells | 2010 | Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10 | Modifications of C-2 on the pyrroloquinoline template aimed at the development of potent herpesvirus antivirals with improved aqueous solubility. |
| AID420978 | Antiviral activity against HSV1 infected in human HeLa cells assessed as maximum dose required for highest viral reduction factor preincubated for 0.5 hrs before infection measured after 36 hrs by end point titration technique | 2009 | European journal of medicinal chemistry, Jun, Volume: 44, Issue:6 | Synthesis and biological evaluation of abietic acid derivatives. |
| AID1337436 | Cytotoxicity against HEL cells assessed as growth inhibition after 3 days by coulter counter method | 2016 | European journal of medicinal chemistry, Nov-29, Volume: 124 | Identification of an indol-based derivative as potent and selective varicella zoster virus (VZV) inhibitor. |
| AID358241 | Cytotoxicity against african green monkey Vero cells by MTT assay | 2001 | Journal of natural products, Oct, Volume: 64, Issue:10 | Structure-activity relationship of in vitro antiviral and cytotoxic activity of semisynthetic analogues of scopadulane diterpenes. |
| AID326131 | Activity of Herpes B virus recombinant thymidine kinase at 100 uM | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides. |
| AID1684813 | Cytotoxicity against human HEL cells assessed as alteration in cell morphology incubated for 3 days by microscopic analysis | 2021 | ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1 | Influence of 4'-Substitution on the Activity of Gemcitabine and Its ProTide Against VZV and SARS-CoV-2. |
| AID82701 | Antiviral activity against varicella zoster virus (VZV) Oka strain in HEL (human erythroleukemia) cells. | 1997 | Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14 | A facile, alternative synthesis of 4'-thioarabinonucleosides and their biological activities. |
| AID133989 | Protective dose against Herpes simplex virus type type -1 infection in mice at 200 mg/kg | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID1726781 | Antiviral activity against VZV infected in human HFF cells assessed as reduction in virus-induced cytopathic effect incubated for 14 days by cell-titer glo assay | 2021 | RSC medicinal chemistry, May-26, Volume: 12, Issue:5 | Introduction of a cyano group at the 2-position of an ( |
| AID1450219 | Selectivity index, ratio of MCC for African green monkey Vero E6 cells to IC50 for HSV-1 L2/Rp-ACV/2 infected in African green monkey Vero E6 cells | 2017 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11 | New modified 2-aminobenzimidazole nucleosides: Synthesis and evaluation of their activity against herpes simplex virus type 1. |
| AID1473740 | Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID472786 | Cytotoxicity against african green monkey Vero cells | 2010 | Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8 | Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives. |
| AID63718 | Percent inhibition of viral DNA in the presence of 10 mg/mL compound compared to untreated infected controls in duck hepatocytes; ND means Not determined | 2001 | Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22 | Novel 5-vinyl pyrimidine nucleosides with potent anti-hepatitis B virus activity. |
| AID1055505 | Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity | 2013 | European journal of medicinal chemistry, , Volume: 70 | Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides. |
| AID699540 | Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting | 2012 | Journal of medicinal chemistry, May-24, Volume: 55, Issue:10 | Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. |
| AID1592940 | Selectivity index, ratio of Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by SRB assay to Antiviral activity against Herpes simplex virus 2-333 infected in African green monkey Vero cells assesse | |||
| AID84950 | Ability to reduce plaque formation of herpes simplex virus type 2 (HSV-2) by 50% in human embryonic lung fibroblast (HELF) cell cultures | 1988 | Journal of medicinal chemistry, Feb, Volume: 31, Issue:2 | Synthesis and biological activities of 4-O-(difluoromethyl)-5-substituted-uracil nucleoside analogues. |
| AID1211781 | AUC (0 to 180 mins) in wild type mouse treated with 25 nmol/g, po of valacyclovir | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3 | Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice. |
| AID595578 | Cytotoxicity against human HFF cells infected with Varicella-zoster virus Ellen assessed as viable cells by neutral red uptake assay | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | Broad-spectrum antiviral activity including human immunodeficiency and hepatitis C viruses mediated by a novel retinoid thiosemicarbazone derivative. |
| AID84231 | Minimum inhibitory concentration was determined against HSV-2 (G) in E6SM cell culture | 2000 | Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4 | The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine. |
| AID1450220 | Antiviral activity against foscarnet-resistant HSV-1 F+ infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect | 2017 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11 | New modified 2-aminobenzimidazole nucleosides: Synthesis and evaluation of their activity against herpes simplex virus type 1. |
| AID91306 | Concentration of the drug required to reduce the proliferation of human foreskin fibroblast cells | 1993 | Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17 | Synthesis and antiviral activity of novel 5-(1-azido-2-haloethyl) and 5-(1-azido-, amino-, or methoxyethyl) analogs of 2'-deoxyuridine. |
| AID1884105 | Antiviral activity against HSV-2 infected in African green monkey Vero cells assessed as inhibition of viral replication by measuring log suppression of virus-induced cytopathic effect at 5 uM incubated for 1 hr followed by washing with PBS and subsequent | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Synthetic derivatives of the antifungal drug ciclopirox are active against herpes simplex virus 2. |
| AID574825 | Antiviral activity against Herpes simplex virus 1 isolate 5 harboring N23S, K36E, A192V, G251C, A265T, V267L, P268T, -1G 856 = frameshift mutations in thymidine kinase and A330R, V905M, T1208A, H98Y mutations in DNA polymerase infected in african green mo | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. |
| AID1230105 | Antiviral activity against Vaccinia virus infected in HEL cells assessed as reduction of virus-induced cytopathogenicity | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Design, antiviral and cytostatic properties of isoxazolidine-containing amonafide analogues. |
| AID235581 | In vitro therapeutic index as ratio of cytotoxicity to inhibition of viral replication | 1988 | Journal of medicinal chemistry, Jul, Volume: 31, Issue:7 | 7-Aminoquinolines. A novel class of agents active against herpesviruses. |
| AID139282 | Day of death in lethal test against herpes simplex virus type-2 at 12.5 mg/kg/day (mean day of death +/-SD) | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID1869619 | Antiviral activity against VZV Ellen infected in HFF cells assessed as reduction in viral replication measured after 14 days | 2022 | Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13 | Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound. |
| AID63765 | The minimum inhibitory concentration was measured on E6SM cells against TK-Herpes simplex virus type 1 (B2006 strain) | 1994 | Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19 | Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity. |
| AID412416 | Antiviral activity against acyclovir-sensitive HSV1 K161 isolate replication in african green monkey Vero cells by plaque reduction assay | 2009 | Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1 | Synthesis and in vitro activities of a new antiviral duplex drug linking Zidovudine (AZT) and Foscarnet (PFA) via an octadecylglycerol residue. |
| AID84406 | Minimal inhibitory concentration to reduce virus-induced cytopathicity against Thymidine kinase deficient(TK-) HSV-1 (Acyclovir) | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Fluorescent tricyclic analogues of acyclovir and ganciclovir. A structure-antiviral activity study. |
| AID64099 | Minimum inhibitory concentration (MIC) required to reduce KOS strain of HSV-1 induced cytopathogenicity by 50% in E6SM cells | 1992 | Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8 | Synthesis and antiviral activity of acyclic nucleosides with a 3(S),5-dihydroxypentyl or 4(R)-methoxy-3(S),5-dihydroxypentyl side chain. |
| AID291029 | Antiviral activity against thymidine kinase expressing Varicella-Zoster virus OKA assessed as reduction of plaque formation | 2007 | Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13 | Novel C-6 fluorinated acyclic side chain pyrimidine derivatives: synthesis, (1)H and (13)C NMR conformational studies, and antiviral and cytostatic evaluations. |
| AID224195 | Inhibitory effect on 196 strain of Herper simplex virus-2 yield, in primary rabbit kidney cell culture 0.4 ug/mL concentration after 48 hours. | 1987 | Journal of medicinal chemistry, Jun, Volume: 30, Issue:6 | Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases. |
| AID117767 | Antiviral activity in terms of percentage survival at a dose of 100 mg/kg after intraperitoneal inoculation of HSV-1(BWS) in mice (7/10) | 1991 | Journal of medicinal chemistry, Jul, Volume: 34, Issue:7 | A new class of acyclic phosphonate nucleotide analogues: phosphonate isosteres of acyclovir and ganciclovir monophosphates as antiviral agents. |
| AID1407615 | Cytotoxicity against HELF cells assessed as alteration of cell morphology by microscopic analysis | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Synthesis of a 3'-C-ethynyl-β-d-ribofuranose purine nucleoside library: Discovery of C7-deazapurine analogs as potent antiproliferative nucleosides. |
| AID218419 | Anti viral activity against HSV-2(186) in WI-38 cell monolayers | 1992 | Journal of medicinal chemistry, May-15, Volume: 35, Issue:10 | Synthesis and antiviral activity of 1-cyclobutyl-5-(2-bromovinyl)uracil nucleoside analogues and related compounds. |
| AID84045 | Number of survivors per number of HSV-1 infected mice treated with 12.5 mg/kg per day; 2/10 | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5 | Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS. |
| AID1703908 | Permeability of the compound by PAMPA-TGI assay | 2020 | European journal of medicinal chemistry, Oct-15, Volume: 204 | Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies. |
| AID15861 | Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day. | 1985 | Journal of medicinal chemistry, Jul, Volume: 28, Issue:7 | Synthesis and antiherpetic activity of (S)-, (R)-, and (+/-)-9-[(2,3-dihydroxy-1-propoxy)methyl]guanine, linear isomers of 2'-nor-2'-deoxyguanosine. |
| AID217804 | In vitro antiviral activity against herpesvirus, VZV, OKA strain by plaque reduction assay in human foreskin fibroblasts. | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5 | Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS. |
| AID84752 | In vivo efficacy of compound against HSV-2 strain A133 in the mouse system model was measured at 50 dose(mg/kg), activity expressed as Survivors counted on day 21; 1/5 | 1991 | Journal of medicinal chemistry, Mar, Volume: 34, Issue:3 | Fluorocarbocyclic nucleosides: synthesis and antiviral activity of 2'- and 6'-fluorocarbocyclic 2'-deoxy guanosines. |
| AID218390 | Minimum concentration (ug/mL) for in vitro antiviral activity against herpes simplex virus type 1 (E-377 strain) in Vero host cell cultures | 1990 | Journal of medicinal chemistry, Apr, Volume: 33, Issue:4 | Synthesis and biological evaluation of carbocyclic analogues of lyxofuranosides of 2-amino-6-substituted-purines and 2-amino-6-substituted-8-azapurines. |
| AID87444 | Concentration that induces 50% cell toxicity was determined using monolayers of uninfected HeLa cells | 1985 | Journal of medicinal chemistry, Jan, Volume: 28, Issue:1 | Uridine 5'-diphosphate glucose analogues. Inhibitors of protein glycosylation that show antiviral activity. |
| AID1576578 | Fraction absorbed of the compound by PAMPA | 2019 | MedChemComm, Dec-01, Volume: 10, Issue:12 | Synthesis of new lophine-carbohydrate hybrids as cholinesterase inhibitors: cytotoxicity evaluation and molecular modeling. |
| AID85125 | Minimum inhibitory concentration was determined against HSV-2 (196) in E6SM cell culture | 2000 | Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4 | The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine. |
| AID425280 | Fraction unbound in horse plasma | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID86033 | Tested for the effective dose required to inhibit HSV-1 in infected mice | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5 | Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS. |
| AID250793 | Effect on HSV-1 encephalitis in mice following intraperitoneal dosage at 100 mg/kg; expressed as mean day of death | 2005 | Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11 | Inhibition of herpes simplex virus thymidine kinases by 2-phenylamino-6-oxopurines and related compounds: structure-activity relationships and antiherpetic activity in vivo. |
| AID409954 | Inhibition of mouse brain MAOA | 2008 | Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21 | Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. |
| AID682750 | Antiviral activity against HSV-1F ATCC 733 infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathic effect after 3 days by MTT assay | 2012 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19 | Structure based molecular design, synthesis and biological evaluation of α-pyrone analogs as anti-HSV agent. |
| AID71878 | Concentration required to cause a microscopically detectable alteration of normal cell morphology | 1990 | Journal of medicinal chemistry, Sep, Volume: 33, Issue:9 | Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives. |
| AID83195 | Minimum inhibitory conc. for 50% inhibition of growth in HEL cells | 1997 | Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9 | Carbocyclic oxetanocins lacking the C-3' methylene. |
| AID216301 | Compound was evaluated for the inhibition of VZV (TK-) thymidine kinases Strain YS-R | 1999 | Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22 | Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base. |
| AID84218 | Inhibitory activity against TK-deficient HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle | 2002 | Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25 | A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity. |
| AID296673 | Antiviral activity against TK+ VZV OKA in HEL cells assessed as reduction of virus plaque formation after 5 days | 2007 | Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16 | Synthesis and antiviral evaluation of 6-(alkyl-heteroaryl)furo[2,3-d]pyrimidin-2(3H)-one nucleosides and analogues with ethynyl, ethenyl, and ethyl spacers at C6 of the furopyrimidine core. |
| AID401234 | Antiviral activity against HIV1 | 2004 | Journal of natural products, Apr, Volume: 67, Issue:4 | Isolation of salicin derivatives from Homalium cochinchinensis and their antiviral activities. |
| AID1854963 | Antiviral activity against thymidine kinase deficient mutant Acyclovir resistant HSV-1 KOS strain infected in HEL cells assessed as reduction in virus-induced cytopathic effect by microscopic analysis | 2022 | European journal of medicinal chemistry, Nov-05, Volume: 241 | Synthesis and antiviral properties of biomimetic iminosugar-based nucleosides. |
| AID732680 | Antiviral activity against Hepatitis B virus transfected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion after 6 days by ELISA | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and biological evaluation of nucleoside analogues than contain silatrane on the basis of the structure of acyclovir (ACV) as novel inhibitors of hepatitis B virus (HBV). |
| AID96400 | Cytotoxicity against human neoplastic cell line(KB cells) | 1988 | Journal of medicinal chemistry, Nov, Volume: 31, Issue:11 | Synthesis and antiviral activity of certain 4- and 4,5-disubstituted 7-[(2-hydroxyethoxy)methyl]pyrrolo[2,3-d]pyrimidines. |
| AID1697849 | Antiviral activity against Herpes simplex virus 1 infected in neuronal progenitor cells assessed as decrease in fluorescent cells | 2020 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24 | Synthesis of non-nucleoside anti-viral cyclopropylcarboxacyl hydrazones and initial anti-HSV-1 structure-activity relationship studies. |
| AID540218 | Clearance in monkey after iv administration | 2005 | Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7 | Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. |
| AID1462036 | Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect | 2017 | Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17 | New prodrugs of two pyrimidine acyclic nucleoside phosphonates: Synthesis and antiviral activity. |
| AID256536 | Toxicity on uninfected human foreskin fibroblast cells determined in microscopic evaluation and quantitative neutral red dye uptake assay | 2005 | Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18 | 4-Oxo-4,7-dihydrothieno[2,3-b]pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases. |
| AID1402830 | Cytotoxicity against HEL cells assessed as alteration in cell morphology after 3 days by microscopic method | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Emimycin and its nucleoside derivatives: Synthesis and antiviral activity. |
| AID1503324 | Cytotoxicity against African green monkey Vero 76 cells assessed as decrease in cell viability after 48 to 96 hrs by MTT assay | 2017 | European journal of medicinal chemistry, Dec-01, Volume: 141 | Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation. |
| AID521923 | Tmax in human CSF with chronic kidney disease at 1500 mg, po every 12 hrs measured after fifth dose by radioimmunoassay | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. |
| AID625290 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID257898 | Antiviral activity against Punta Toro virus in vero cells | 2006 | Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2 | Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators. |
| AID681947 | TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, ACV: 1000 uM) in OCT1-expressing S2 cells | 2002 | The Journal of pharmacology and experimental therapeutics, Mar, Volume: 300, Issue:3 | Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. |
| AID436478 | Antiviral activity against Bovine viral diarrhea virus infected in MDBK cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay | 2009 | Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13 | Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives. |
| AID540214 | Clearance in rat after iv administration | 2005 | Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7 | Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. |
| AID83725 | In Vitro cytotoxicity against HSV-1 at 5 ug/mL concentration | 1994 | Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19 | Synthesis of new acyclic pyrimidine nucleoside analogs as potential antiviral drugs. |
| AID167747 | Antiviral Activity against herpes simplex virus-1 (McIntyre) in rabbit kidney cell | 1990 | Journal of medicinal chemistry, Sep, Volume: 33, Issue:9 | Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives. |
| AID255988 | Antiviral activity against herpes simplex virus type 2 (V826A) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO | 2005 | Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18 | 4-Oxo-4,7-dihydrothieno[2,3-b]pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases. |
| AID88302 | Evaluated for DNA polymerase inhibition activity against HeLa cells. | 1985 | Journal of medicinal chemistry, Jul, Volume: 28, Issue:7 | Synthesis and antiherpetic activity of (S)-, (R)-, and (+/-)-9-[(2,3-dihydroxy-1-propoxy)methyl]guanine, linear isomers of 2'-nor-2'-deoxyguanosine. |
| AID216006 | Concentration required to inhibit 50% of host cell replication in Vero cell used against HSV-1 and HSV-2 studies | 2000 | Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18 | Synthesis and biological evaluation of L- and D-configuration 1,3-dioxolane 5-azacytosine and 6-azathymine nucleosides. |
| AID83197 | Minimum inhibitory concentration required for antiviral activity to reduce Cytomegalovirus (CMV) (Davis) induced cytopathicity in human embryonic lung cells (HEL) | 1994 | Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9 | Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues. |
| AID425262 | Free elimination half life in horse at 20 mg/kg, po administered as single dose | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID83192 | Minimum inhibitory conc. for 50% inhibition of TK-VZV (YS/R) virus plaque formation in HEL cells | 1997 | Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9 | Carbocyclic oxetanocins lacking the C-3' methylene. |
| AID66958 | Effective concentration to show 50% of activity was measured on Epstein Barr virus(EBV) cell culture | 2000 | Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13 | Structure-activity relationships of (E)-5-(2-bromovinyl)uracil and related pyrimidine nucleosides as antiviral agents for herpes viruses. |
| AID609574 | Antiviral activity against Herpes simplex virus 1 strain KOS assessed as reduction of virus induced cytopathicity by cell based assay | 2011 | Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15 | Acyclic nucleoside phosphonates with a branched 2-(2-phosphonoethoxy)ethyl chain: efficient synthesis and antiviral activity. |
| AID96826 | Inhibitory concentration required to reduce [3H-methyl]-dThd C incorporation into cellular DNA by 50% in Murine Leukemia L1210 cells | 1984 | Journal of medicinal chemistry, Nov, Volume: 27, Issue:11 | Nucleic acid related compounds. 47. Synthesis and biological activities of pyrimidine and purine "acyclic" nucleoside analogues. |
| AID260767 | Selectivity index (CC50/EC50) in Vero cells | 2006 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4 | Synthesis and anti-HSV-1 activity of quinolonic acyclovir analogues. |
| AID575032 | Antiviral activity against Herpes simplex virus 2 isolate 17 harboring G39E, N78D Q222Stop mutations in thymidine kinase and A9T, P15S, L60P, T801P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. |
| AID682753 | Antiviral activity against HSV-1F ATCC 733 infected in african green monkey Vero cells after 2 to 3 days by plaque reduction assay | 2012 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19 | Structure based molecular design, synthesis and biological evaluation of α-pyrone analogs as anti-HSV agent. |
| AID84608 | In vitro minimum inhibitory concentration to inhibit HSV-2 (Lyons)-induced cytopathogenicity in PRK cells by 50% | 1988 | Journal of medicinal chemistry, Jul, Volume: 31, Issue:7 | Synthesis and antiviral activity of novel N-substituted derivatives of acyclovir. |
| AID65710 | Antiviral activity against herpes simplex virus-1 TK-VMW 1837 (HSV-1) in E6SM cell cultures | 2001 | Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16 | Design, synthesis, DNA binding, and biological evaluation of water-soluble hybrid molecules containing two pyrazole analogues of the alkylating cyclopropylpyrroloindole (CPI) subunit of the antitumor agent CC-1065 and polypyrrole minor groove binders. |
| AID333370 | Antiviral activity against HSV2 | 2004 | Journal of natural products, Oct, Volume: 67, Issue:10 | New pseudopterosin and seco-pseudopterosin diterpene glycosides from two Colombian isolates of Pseudopterogorgia elisabethae and their diverse biological activities. |
| AID376458 | Antiviral activity against HSV2 | 1998 | Journal of natural products, Apr, Volume: 61, Issue:4 | Cochinolide, a new gamma-alkylidene bicyclic butenolide with antiviral activity, and its beta-glucopyranoside from Homalium cochinchinensis. |
| AID1404017 | Permeability of the compound at 500 uM after 8 hrs by PAMPA | 2018 | European journal of medicinal chemistry, Feb-10, Volume: 145 | Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors. |
| AID658740 | Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days | 2012 | European journal of medicinal chemistry, Jun, Volume: 52 | 2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies. |
| AID774685 | Antiviral activity against Herpes simplex virus type 1 VR-260 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity | 2013 | Bioorganic & medicinal chemistry, Sep-15, Volume: 21, Issue:18 | Synthesis and biological evaluation of furopyrimidine N,O-nucleosides. |
| AID376986 | Cytotoxicity against MDCK cells after 3 days by MTT reduction assay | 2006 | Journal of natural products, May, Volume: 69, Issue:5 | Antiviral flavans from the leaves of Pithecellobium clypearia. |
| AID611619 | Antiviral activity against VZV 07/1 infected in HEL cells assessed as protection against virus-induced cytopathicity | 2011 | Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11 | New prodrugs of Adefovir and Cidofovir. |
| AID634755 | Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID321396 | Cytotoxicity against african green monkey Vero cells after 69 hrs by Alamar blue assay | 2008 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1 | Antiviral activities against herpes simplex virus type 1 by HPH derivatives and their structure-activity relationships. |
| AID588214 | FDA HLAED, liver enzyme composite activity | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID84223 | Effective concentration to show 50% of activity was measured on herpes simplex virus-1 KOS strain cell culture. | 2000 | Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13 | Structure-activity relationships of (E)-5-(2-bromovinyl)uracil and related pyrimidine nucleosides as antiviral agents for herpes viruses. |
| AID425652 | Total body clearance in human | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15 | Physicochemical determinants of human renal clearance. |
| AID1462039 | Cytotoxicity against HEL cells assessed as alteration of cell morphology by microscopic analysis | 2017 | Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17 | New prodrugs of two pyrimidine acyclic nucleoside phosphonates: Synthesis and antiviral activity. |
| AID434307 | Antiviral activity against HSV1 KOS infected in HEL cells assessed as protection against virus-induced cytopathogenicity | 2009 | European journal of medicinal chemistry, Sep, Volume: 44, Issue:9 | Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide. |
| AID246486 | Effective concentration required to reduce thymidine kinase-Varicella Zoster virus VZV 07/1 plaque formation by using DMSO as solvent | 2005 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 15, Issue:16 | Bicyclic nucleoside inhibitors of Varicella-Zoster virus: the effect of branching in the p-alkylphenyl side chain. |
| AID87819 | In vitro antiviral and anticellular activity was evaluated against herpes simplex virus HSV-2 (G strain) in vero cells. | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis and antiherpes simplex virus activity of 9-[(1,3-dihydroxy-2-propylthio)methyl]guanine. |
| AID139278 | Day of death in lethal test against herpes simplex virus type-1 at 200 mg/kg/day (mean day of death +/-SD) | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID1869615 | Cytotoxicity against human HEL cells assessed as reduction in cell growth measured after 3 days by coulter counting method | 2022 | Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13 | Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound. |
| AID563772 | Antiviral activity against HSV2 AG-3 harboring TK Q105P mutant gene infected in HFF after 3 days by plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides. |
| AID83181 | Concentration required to reduce VZV-07/1-TK- plaque formation by 50% in human embryonic lung (HEL) cell cultures. | 1992 | Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12 | (+-)-carbocyclic 5'-nor-2'-deoxyguanosine and related purine derivatives: synthesis and antiviral properties. |
| AID1593183 | Cytotoxicity against rhesus monkey FRhK4 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay | 2019 | European journal of medicinal chemistry, Apr-15, Volume: 168 | New 4-phenylcoumarin derivatives as potent 3C protease inhibitors: Design, synthesis, anti-HAV effect and molecular modeling. |
| AID216155 | Effective concentration against TK- Varicella-Zoster Virus (VZV) 07/1 strain | 2003 | Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23 | Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine. |
| AID1869610 | Antiviral activity against HCMV AD-169 infected in HEL cells assessed as reduction in virus plaque formation | 2022 | Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13 | Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound. |
| AID768207 | Cytotoxicity against human HEL cells | 2013 | European journal of medicinal chemistry, Aug, Volume: 66 | Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies. |
| AID574822 | Antiviral activity against Herpes simplex virus 1 isolate 2 harboring C6G, N23S, K36E, R41H, A192V, A265T, L170P mutations in thymidine kinase and S33G, A330R, N425T, V905M, T1208A mutations in DNA polymerase infected in african green monkey Vero cells by | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. |
| AID63945 | Inhibition of virus-induced cytopathicity in E6SM cell cultures of human embryonic skin-muscle | 2002 | Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25 | A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity. |
| AID1410506 | Antiviral activity against thymidine kinase expressing Varicella-Zoster virus Oka assessed as inhibition of plaque formation measured after 5 days post-infection | 2018 | ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4 | Amidate Prodrugs of Cyclic 9-( |
| AID217821 | Effective dose required for antiviral activity against Vaccinia virus | 1990 | Journal of medicinal chemistry, Oct, Volume: 33, Issue:10 | Synthesis and antimicrobial and cytotoxic activities of pyrrole-containing analogues of trichostatin A. |
| AID412419 | Antiviral activity against acyclovir-resistant HSV1 L182 isolate replication in african green monkey Vero cells by plaque reduction assay | 2009 | Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1 | Synthesis and in vitro activities of a new antiviral duplex drug linking Zidovudine (AZT) and Foscarnet (PFA) via an octadecylglycerol residue. |
| AID255991 | Antiviral activity against herpes simplex virus type 1 KOS (PAAr5) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO | 2005 | Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18 | 4-Oxo-4,7-dihydrothieno[2,3-b]pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases. |
| AID246634 | Effective concentration of compound required to reduce plaque formation by OKA strain of thymidine kinase positive VZ virus TK+ in human embryonic lung cells | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | The novel L- and D-amino acid derivatives of hydroxyurea and hydantoins: synthesis, X-ray crystal structure study, and cytostatic and antiviral activity evaluations. |
| AID1773428 | Antiviral activity against Human herpesvirus 1 MacIntyre infected in A549 cells assessed as reduction in virus titer treated 1 hr post viral infection followed by replacement with fresh medium with compounds and measured after 48 hrs by MTT assay | 2021 | European journal of medicinal chemistry, Dec-05, Volume: 225 | Novel betulin dicarboxylic acid ester derivatives as potent antiviral agents: Design, synthesis, biological evaluation, structure-activity relationship and in-silico study. |
| AID733258 | Cytotoxicity against african green monkey Vero cells by MTT assay | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Efficient synthesis of 3H,3'H-spiro[benzofuran-2,1'-isobenzofuran]-3,3'-dione as novel skeletons specifically for influenza virus type B inhibition. |
| AID87479 | Antiviral activity against Herpes simplex virus type-1 (HSV-1). | 1999 | Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15 | Nucleosides and nucleotides. 185. Synthesis and biological activities of 4'alpha-C-branched-chain sugar pyrimidine nucleosides. |
| AID563745 | Antiproliferative activity against HFF after 3 days by Coulter counting analysis | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides. |
| AID732681 | Antiviral activity against Hepatitis B virus transfected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion after 6 days by ELISA | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and biological evaluation of nucleoside analogues than contain silatrane on the basis of the structure of acyclovir (ACV) as novel inhibitors of hepatitis B virus (HBV). |
| AID87775 | Concentration required to cause microscopically visible change or disruption in about 50% of Hela cell sheet. | 1995 | Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23 | Design, synthesis, and structure-activity relationship of novel dinucleotide analogs as agents against herpes and human immunodeficiency viruses. |
| AID1427856 | Selectivity index, ratio of TC50 for African green monkey Vero cells to IC50 for Herpes simplex virus-1 F VR 733 infected in African green monkey Vero cells | |||
| AID218518 | Antiviral activity against HSV-1 (Herpes simplex virus) in vero cells | 1994 | Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1 | S-glucosylated hydantoins as new antiviral agents. |
| AID718738 | Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect | 2012 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 | Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities. |
| AID521919 | Cmax in human CSF with chronic kidney disease at 1500 mg, po every 12 hrs measured after fifth dose by radioimmunoassay | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. |
| AID1261340 | Antiviral activity against HSV1 | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID607908 | Antiviral activity against Feline herpesvirus infected in cat CRFK cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis | 2011 | Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14 | Design, synthesis and biological evaluation of 2'-deoxy-2',2'-difluoro-5-halouridine phosphoramidate ProTides. |
| AID81043 | In vitro alteration in cell morphology in HEL cells. | 2000 | Journal of medicinal chemistry, Aug-24, Volume: 43, Issue:17 | Nonnucleoside human cytomegalovirus inhibitors: synthesis and antiviral evaluation of (chlorophenylmethyl)benzothiadiazine dioxide derivatives. |
| AID218201 | Tested in vitro for minimum inhibitory concentration against herpes simplex virus-2 (HSV-2) 2011 strain by plaque-reduction assay in vero cells | 1993 | Journal of medicinal chemistry, May-28, Volume: 36, Issue:11 | 3-Quinolinecarboxamides. A series of novel orally-active antiherpetic agents. |
| AID625291 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID110459 | Cumulative mortality in percent of HSV-1 infected mice, after peroral administration of 100 mg/kg of compound | 1988 | Journal of medicinal chemistry, Sep, Volume: 31, Issue:9 | Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity. |
| AID383528 | Antiviral activity against TK- VZV 07/1 infected HEL cells assessed as reduction in virus plaque formation | 2008 | European journal of medicinal chemistry, Feb, Volume: 43, Issue:2 | Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents. |
| AID1378806 | Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for HSV-2 infected in African green monkey Vero cells | 2017 | Journal of natural products, 08-25, Volume: 80, Issue:8 | Stereochemistry of a Second Riolozane and Other Diterpenoids from Jatropha dioica. |
| AID84596 | Compound was measured for the inhibition of HSV-2 strain A133 in the mouse system model at 25 dose(mg/kg) | 1991 | Journal of medicinal chemistry, Mar, Volume: 34, Issue:3 | Fluorocarbocyclic nucleosides: synthesis and antiviral activity of 2'- and 6'-fluorocarbocyclic 2'-deoxy guanosines. |
| AID216475 | Antiviral activity was tested against TK+ Varicella-Zoster virus YS which reduces virus plaque formation by 50% | 2002 | Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19 | Synthesis and antiviral/antiproliferative activity of some N-sulphonylbenzimidazoles. |
| AID561610 | Volume of distribution in children and young patient with malignancy at 5 mg/kg, iv administered every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. |
| AID498593 | Antiviral activity against Macacine herpesvirus 1 isolate MR10 infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds. |
| AID1382166 | Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in HEL cells assessed as reduction in viral plaque formation | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Highly convergent synthesis and antiviral activity of (E)-but-2-enyl nucleoside phosphonoamidates. |
| AID1684814 | Antiviral activity against Human cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus plaque formation measured on 6 to 7 post-viral infection | 2021 | ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1 | Influence of 4'-Substitution on the Activity of Gemcitabine and Its ProTide Against VZV and SARS-CoV-2. |
| AID665759 | Antiviral activity against HSV-2 infected in human HFF cells assessed as reduction in cytopathic effect after 3 days by crystal violet staining | 2012 | Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12 | Synthesis and antiviral activity of certain second generation methylenecyclopropane nucleosides. |
| AID257887 | Antiviral activity against vero cells | 2006 | Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2 | Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators. |
| AID16015 | Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally. | 1985 | Journal of medicinal chemistry, Jul, Volume: 28, Issue:7 | Synthesis and antiherpetic activity of (S)-, (R)-, and (+/-)-9-[(2,3-dihydroxy-1-propoxy)methyl]guanine, linear isomers of 2'-nor-2'-deoxyguanosine. |
| AID96009 | The inhibition of KB cell growth was determined | 1994 | Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18 | Benzimidazole ribonucleosides: design, synthesis, and antiviral activity of certain 2-(alkylthio)- and 2-(benzylthio)-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazoles. |
| AID634834 | Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID1382164 | Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as reduction in viral cytopathic effect | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Highly convergent synthesis and antiviral activity of (E)-but-2-enyl nucleoside phosphonoamidates. |
| AID222162 | The drug concentration was determined to reduce proliferation of human foreskin fibroblasts to 50% of untreated controls in proliferation assay. | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5 | Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS. |
| AID658618 | Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days | 2012 | European journal of medicinal chemistry, Jun, Volume: 52 | 2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies. |
| AID87846 | Compound was tested for its antiviral activity against HSV-1 (SC16) using plaque reduction assay. | 1991 | Journal of medicinal chemistry, Jan, Volume: 34, Issue:1 | Synthesis and antiviral activity of 9-alkoxypurines. 2. 9-(2,3-Dihydroxypropoxy)-, 9-(3,4-dihydroxybutoxy)-, and 9-(1,4-dihydroxybut-2-oxy)purines. |
| AID218375 | Cytotoxic dose of compound required to reduce the viability of normal uninfected vero cells by 50%. | 1994 | Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1 | S-glucosylated hydantoins as new antiviral agents. |
| AID431626 | Cytotoxicity against human MT4 cells assessed as decrease in cell viability | 2009 | Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17 | The application of phosphoramidate protide technology to acyclovir confers anti-HIV inhibition. |
| AID106188 | Compound was tested for antiviral activity against Herpes Simplex virus Type-2(20605) in human lung fibroblasts (MRC-5) | 1987 | Journal of medicinal chemistry, Sep, Volume: 30, Issue:9 | Synthesis and antiviral activity of 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]purines. |
| AID697729 | Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for HSV1 strain F ATCC VR733 infected in african green monkey Vero cells | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14 | Anti-herpes simplex virus efficacies of 2-aminobenzamide derivatives as novel HSP90 inhibitors. |
| AID1714436 | Inhibition of HSV2 replication in HFF cells incubated for 7 days | 2016 | Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23 | Synthesis and Antiviral Evaluation of Octadecyloxyethyl Benzyl 9-[(2-Phosphonomethoxy)ethyl]guanine (ODE-Bn-PMEG), a Potent Inhibitor of Transient HPV DNA Amplification. |
| AID68252 | Minimum inhibitory concentration required for antiviral activity to reduce HSV-1 (KOS) induced cytopathicity in human embryonic skin-muscle cells (ESM) | 1994 | Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9 | Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues. |
| AID665388 | Cytotoxicity against human HEL cells assessed as change in cell morphology by microscopic analysis | 2012 | European journal of medicinal chemistry, Jul, Volume: 53 | Synthesis and antiviral evaluation of C5-substituted-(1,3-diyne)-2'-deoxyuridines. |
| AID1261820 | Antiviral activity against CVB-5 virus Faulkner ATCC VR-185 infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay | 2015 | European journal of medicinal chemistry, Nov-13, Volume: 105 | Synthesis, cytotoxicity and antiviral evaluation of new series of imidazo[4,5-g]quinoline and pyrido[2,3-g]quinoxalinone derivatives. |
| AID82892 | Tested for inhibitory effect on DNA virus VZV (YS) in HEL cell line | 1993 | Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23 | Synthesis and antiviral activity of 5'-deoxypyrazofurin. |
| AID569231 | Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect | 2011 | European journal of medicinal chemistry, Feb, Volume: 46, Issue:2 | Synthesis of new C5-(1-substituted-1,2,3-triazol-4 or 5-yl)-2'-deoxyuridines and their antiviral evaluation. |
| AID81038 | The compound was tested for cytotoxic concentration required to reduce human embryonic lung cell growth by 50% | 1999 | Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14 | Novel pyrimidine and purine derivatives of L-ascorbic acid: synthesis and biological evaluation. |
| AID296676 | Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 7 days | 2007 | Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16 | Synthesis and antiviral evaluation of 6-(alkyl-heteroaryl)furo[2,3-d]pyrimidin-2(3H)-one nucleosides and analogues with ethynyl, ethenyl, and ethyl spacers at C6 of the furopyrimidine core. |
| AID675217 | Antiviral activity against HCMV AD169 infected in HEL cells by viral CPE assay | 2012 | European journal of medicinal chemistry, Sep, Volume: 55 | Synthesis and antiviral activities of hexadecyloxypropyl prodrugs of acyclic nucleoside phosphonates containing guanine or hypoxanthine and a (S)-HPMP or PEE acyclic moiety. |
| AID246446 | Effective concentration required to reduce thymidine kinase-Varicella Zoster virus YS/R plaque formation by using DMSO as solvent | 2005 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 15, Issue:16 | Bicyclic nucleoside inhibitors of Varicella-Zoster virus: the effect of branching in the p-alkylphenyl side chain. |
| AID1394846 | Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of plaque formation measured after 6 to 7 days post infection | 2018 | European journal of medicinal chemistry, Apr-25, Volume: 150 | Synthesis and antiviral evaluation of cyclopentyl nucleoside phosphonates. |
| AID1464796 | Anti-viral activity against Herpes simplex virus-1 harboring EGFP infected in iPSC-derived neurons assessed as necrotic cells at 50 mM treated 2 hrs post infection measured after 72 hrs by Alexa fluor 488 staining based flow cytometric analysis (Rvb = 3.3 | 2017 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 27, Issue:20 | Discovery of potent antiviral (HSV-1) quinazolinones and initial structure-activity relationship studies. |
| AID83524 | Anti-VZV activity against OKA strain TK+ in HEL cells | 1998 | Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25 | Synthesis of imidazo[1,2-a]pyridines as antiviral agents. |
| AID64097 | Minimum inhibitory concentration (MIC) required to reduce F strain of HSV-1 induced cytopathogenicity by 50% in E6SM cells | 1992 | Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8 | Synthesis and antiviral activity of acyclic nucleosides with a 3(S),5-dihydroxypentyl or 4(R)-methoxy-3(S),5-dihydroxypentyl side chain. |
| AID575038 | Antiviral activity against Herpes simplex virus 2 isolate 23 harboring G39E, N78D, L140F, +1G 439-440 = Stop 229 mutations in thymidine kinase and A9T, P15S, L60P, I291V mutations in DNA polymerase infected in african green monkey Vero cells by plaque red | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. |
| AID634758 | Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID625279 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID84227 | Antiviral activity against Herpes simplex virus-1 (KOS strain) | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID224192 | Inhibitory effect on 196 strain of Herper simplex virus-2 yield, in primary rabbit kidney cell culture 0.1 ug/mL concentration after 24 hours. | 1987 | Journal of medicinal chemistry, Jun, Volume: 30, Issue:6 | Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases. |
| AID250783 | Effect on HSV-1 encephalitis in mice following intraperitoneal dosage at 25 mg/kg; expressed as mean day of death | 2005 | Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11 | Inhibition of herpes simplex virus thymidine kinases by 2-phenylamino-6-oxopurines and related compounds: structure-activity relationships and antiherpetic activity in vivo. |
| AID342122 | Cytotoxicity against HEL cells assessed as inhibition of cell proliferation | 2008 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 18, Issue:15 | Successful kinase bypass with new acyclovir phosphoramidate prodrugs. |
| AID689100 | Antiviral activity against HSV1 L2 infected in Vero E6 cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs | 2012 | Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19 | Phosphoramidate derivatives of acyclovir: synthesis and antiviral activity in HIV-1 and HSV-1 models in vitro. |
| AID217578 | Concentration of compound required to reduce by 50% the number of african swine fever virus (ASFV) plaques in vero cells | 1992 | Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5 | Pyrazole-related nucleosides. Synthesis and antiviral/antitumor activity of some substituted pyrazole and pyrazolo[4,3-d]-1,2,3-triazin-4-one nucleosides. |
| AID580307 | Therapeutic index, ratio of CC50 for african green monkey Vero cells to EC50 for HSV2 | 2011 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6 | Synthesis and in vitro anti-HSV-1 activity of a novel Hsp90 inhibitor BJ-B11. |
| AID82860 | Antiviral activity in TK+ varicella zoster virus (VZV) YS/R strain in HEL cell culture | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20 | Acyclic nucleotide analogs derived from 8-azapurines: synthesis and antiviral activity. |
| AID658756 | Antiviral activity against thymidine kinase-deficient VSV 07-1 infected in HEL cells assessed as reduction of virus plaque formation after 4 days | 2012 | European journal of medicinal chemistry, Jun, Volume: 52 | 2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies. |
| AID217598 | Comparative Potency (IC50s) at HSV-1 passage 2 in vero cells | 1998 | Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16 | Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. |
| AID257897 | Antiviral activity against Coxsackie virus B4 in vero cells | 2006 | Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2 | Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators. |
| AID45917 | Compound was evaluated for anti-herpesvirus activity against Cytomegalovirus (AD169) strain plaques in infected human fibroblast (MRC-5) cells. | 1993 | Journal of medicinal chemistry, May-14, Volume: 36, Issue:10 | Novel acyclonucleotides: synthesis and antiviral activity of alkenylphosphonic acid derivatives of purines and a pyrimidine. |
| AID82252 | Inhibitory concentration required to reduce HSV-2 induced cytopathogenic effect (CPE) by 50 % in HFF cells | 2003 | Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23 | Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine. |
| AID82893 | Tested for inhibitory effect on RNA virus cell growth in HEL cell line | 1993 | Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23 | Synthesis and antiviral activity of 5'-deoxypyrazofurin. |
| AID217599 | Comparative Potency (IC50s) at HSV-1 passage 3 in vero cells | 1998 | Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16 | Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. |
| AID376983 | Cytotoxicity against african green monkey Vero cells after 3 days by MTT reduction assay | 2006 | Journal of natural products, May, Volume: 69, Issue:5 | Antiviral flavans from the leaves of Pithecellobium clypearia. |
| AID45905 | In vitro minimum inhibitory concentration to inhibit CMV (AD-169)-induced cytopathogenicity in HEL cells by 50% | 1988 | Journal of medicinal chemistry, Jul, Volume: 31, Issue:7 | Synthesis and antiviral activity of novel N-substituted derivatives of acyclovir. |
| AID469283 | Antiviral activity against HSV1 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by crystal violet staining | 2009 | Journal of natural products, Sep, Volume: 72, Issue:9 | Eucalmaidins A-E, (+)-oleuropeic acid derivatives from the fresh leaves of Eucalyptus maideni. |
| AID1886801 | Cytotoxicity against African green monkey Vero E6 cells measured after 72 hrs by MTT assay | 2022 | Journal of natural products, 08-26, Volume: 85, Issue:8 | Antiviral Profiling of C-18- or C-19-Functionalized Semisynthetic Abietane Diterpenoids. |
| AID646191 | Antiherpetic activity against HSV2 at 0.25 mg/ml by MTT assay | 2012 | Journal of natural products, Jan-27, Volume: 75, Issue:1 | Dihydroagarofuran derivatives from the dried roots of Tripterygium wilfordii. |
| AID259178 | Antiviral activity against HSV1 TK- in HEL cells | 2006 | Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1 | Synthesis and antiviral evaluation of cyclic and acyclic 2-methyl-3-hydroxy-4-pyridinone nucleoside derivatives. |
| AID216161 | Tested for antiviral activity against VZV (TK-KOS) | 2001 | Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12 | The cyclohexene ring as bioisostere of a furanose ring: synthesis and antiviral activity of cyclohexenyl nucleosides. |
| AID246559 | Effective concentration to inhibit 50 % of Human immunodeficiency virus replication in a cell culture model;ND=Not determined | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | Synthesis and antiviral activity of helioxanthin analogues. |
| AID563770 | Antiviral activity against HSV1 SC16-S1 harboring TK A265T/C336Y mutant gene infected in HFF after 3 days by plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides. |
| AID96359 | Cytotoxicity was evaluated in Human neoplastic cell line (KB) | 1989 | Journal of medicinal chemistry, Feb, Volume: 32, Issue:2 | Synthesis, cytotoxicity, and antiviral activity of some acyclic analogues of the pyrrolo[2,3-d]pyrimidine nucleoside antibiotics tubercidin, toyocamycin, and sangivamycin. |
| AID365169 | Antiviral activity against ganciclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity | 2008 | Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18 | 4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action. |
| AID1869611 | Antiviral activity against HCMV Davis infected in HEL cells assessed as reduction in virus plaque formation | 2022 | Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13 | Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound. |
| AID229235 | Inhibitory activity against vesicular stomatitis virus (VSV) replication in E6SM cell cultures of human embryonic skin-muscle | 2002 | Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25 | A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity. |
| AID63760 | The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 1 (McIntyre strain) | 1994 | Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19 | Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity. |
| AID1818212 | Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for HSV-1 infected in African green monkey Vero cells | |||
| AID498607 | Antiviral activity against Macacine herpesvirus 1 isolate MJ3 infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds. |
| AID82857 | Antiviral activity in TK+ varicella zoster virus (VZV) 07/1 strain in HEL cell culture | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20 | Acyclic nucleotide analogs derived from 8-azapurines: synthesis and antiviral activity. |
| AID1378802 | Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 3 days by MTT assay | 2017 | Journal of natural products, 08-25, Volume: 80, Issue:8 | Stereochemistry of a Second Riolozane and Other Diterpenoids from Jatropha dioica. |
| AID217673 | Inhibitory concentration against VZV strain OKA in human embryonic lung (HEL) cell culture | 1993 | Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14 | Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides. |
| AID1079946 | Presence of at least one case with successful reintroduction. [column 'REINT' in source] | |||
| AID217752 | Antiviral activity determined by plaque reduction assay of HSV-2 (G) in vero cells | 1991 | Journal of medicinal chemistry, Jul, Volume: 34, Issue:7 | A new class of acyclic phosphonate nucleotide analogues: phosphonate isosteres of acyclovir and ganciclovir monophosphates as antiviral agents. |
| AID1303379 | Antiviral activity against Respiratory syncytial virus A2 infected in Vero 76 cells after 5 days by crystal violet staining based plaque reduction assay | 2016 | European journal of medicinal chemistry, Jul-19, Volume: 117 | A combined in silico/in vitro approach unveils common molecular requirements for efficient BVDV RdRp binding of linear aromatic N-polycyclic systems. |
| AID521910 | Drug level in human CSF with normal renal function at 2000 mg, po every 6 hrs measured after fifth dose by radioimmunoassay | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. |
| AID689102 | Antiviral activity against HIV1 pseudovirus infected in Jurkat cells coexpressing GFP assessed as viral growth inhibition incubated for 2 to 8 hrs prior to infection measured after 48 hrs by flow cytofluorimetric analysis | 2012 | Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19 | Phosphoramidate derivatives of acyclovir: synthesis and antiviral activity in HIV-1 and HSV-1 models in vitro. |
| AID471492 | Antiviral activity against Human herpesvirus 1 infected in african green monkey Vero cells assessed as maximal nontoxic dose caused highest viral reduction factor after 36 hrs by end point titration method | 2010 | European journal of medicinal chemistry, Feb, Volume: 45, Issue:2 | Synthesis and biological evaluation of dehydroabietic acid derivatives. |
| AID358240 | Antiviral activity against Herpes simplex virus 2 infected in african green monkey Vero cells assessed as maximal nontoxic dose that showed the highest viral reduction factor after 48 hrs by end-point titration technique | 2001 | Journal of natural products, Oct, Volume: 64, Issue:10 | Structure-activity relationship of in vitro antiviral and cytotoxic activity of semisynthetic analogues of scopadulane diterpenes. |
| AID217502 | In vitro minimum inhibitory concentration to inhibit thymidine deficient VZV (YSR)-induced cytopathogenicity in HEL cells by 50% | 1988 | Journal of medicinal chemistry, Jul, Volume: 31, Issue:7 | Synthesis and antiviral activity of novel N-substituted derivatives of acyclovir. |
| AID84425 | Inhibitory effects on HSV-1 induced mortality in NMRI mice upon (ip) administration at a dose of 100 mk/kg/day | 2001 | Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22 | Design, synthesis, and biological evaluation of novel nucleoside and nucleotide analogues as agents against DNA viruses and/or retroviruses. |
| AID121251 | Survival rate at 20th day expressed as number of mice survived infected with HSV-2; out of 10 | 1987 | Journal of medicinal chemistry, Jun, Volume: 30, Issue:6 | Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases. |
| AID46023 | Compound was tested for anti-viral activity against HIV-1 in CEM cells | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24 | Synthesis and antiviral evaluation of 3-hydroxy-2-methylpyridin-4-one dideoxynucleoside derivatives. |
| AID425247 | Total clearance in horse at 10 mg/kg, iv after 1 hr by two-compartmental study | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID218424 | Anti viral activity against VZV(Ito strain) in WI-38 cell monolayers. | 1992 | Journal of medicinal chemistry, May-15, Volume: 35, Issue:10 | Synthesis and antiviral activity of 1-cyclobutyl-5-(2-bromovinyl)uracil nucleoside analogues and related compounds. |
| AID436486 | Antiviral activity against Human poliovirus 1 strain Sabin after 2 days by plaque reduction assay | 2009 | Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13 | Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives. |
| AID246627 | Effective concentration to reduce plaque formation of Cytomegalovirus AD-169 strain in human embryonic lung cell cultures;ND=Not determined | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | The novel L- and D-amino acid derivatives of hydroxyurea and hydantoins: synthesis, X-ray crystal structure study, and cytostatic and antiviral activity evaluations. |
| AID540210 | Clearance in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID85404 | Antiviral activity against HSV-1 kinase mutant resistant to S1(ACV) was determined at a conc of 50 uM | 1987 | Journal of medicinal chemistry, Nov, Volume: 30, Issue:11 | Acetylenic nucleosides. 4. 1-beta-D-arabinofuranosyl-5-ethynylcytosine. Improved synthesis and evaluation of biochemical and antiviral properties. |
| AID588213 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID83207 | The minimum inhibitory concentration was measured on HEL cells against Cytomegalovirus virus (AD-169 strain) | 1994 | Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19 | Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity. |
| AID54954 | Effective concentration required against HCMV strain for antiviral activity | 2001 | Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12 | The cyclohexene ring as bioisostere of a furanose ring: synthesis and antiviral activity of cyclohexenyl nucleosides. |
| AID1727354 | Cytotoxicity against human HEL cells assessed as concentration required to cause visible alteration in cell morphology incubated for 3 days by coulter counter method | 2021 | European journal of medicinal chemistry, Jan-01, Volume: 209 | Extension of furopyrimidine nucleosides with 5-alkynyl substituent: Synthesis, high fluorescence, and antiviral effect in the absence of free ribose hydroxyl groups. |
| AID217738 | Inhibition of Tomioka strain of herpes simplex virus( Tomioka strain of HSV-1) by quantitative CPE reduction assay in vero cells | 1998 | Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8 | Synthesis and antiviral activity of novel acyclic nucleosides: discovery of a cyclopropyl nucleoside with potent inhibitory activity against herpesviruses. |
| AID81020 | Tested for inhibitory activity against Varicella zoster virus(VZV) by plaque reduction assay using HEL cells | 2000 | Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2 | Synthesis and antiviral activity of novel anti-VZV 5-substituted uracil nucleosides with a cyclopropane sugar moiety. |
| AID167139 | Minimum inhibitory concentration required to reduce virus induced cytopathogenicity in primary rabbit kidney cell cultures by 50% against Vaccinia virus | 1983 | Journal of medicinal chemistry, Apr, Volume: 26, Issue:4 | Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl]guanine]. |
| AID1303378 | Antiviral activity against Human poliovirus 1 strain Sabin infected in Vero 76 cells after 2 days by crystal violet staining based plaque reduction assay | 2016 | European journal of medicinal chemistry, Jul-19, Volume: 117 | A combined in silico/in vitro approach unveils common molecular requirements for efficient BVDV RdRp binding of linear aromatic N-polycyclic systems. |
| AID1246236 | Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining | 2015 | European journal of medicinal chemistry, Aug-28, Volume: 101 | Synthesis, cytotoxicity and antimicrobial activity of thiourea derivatives incorporating 3-(trifluoromethyl)phenyl moiety. |
| AID156685 | Inhibitory concentration required to reduce incorporation of 2-deoxythymidine (dThd) into DNA of Primary Rabbit kidney (PRK) cell cultures | 1984 | Journal of medicinal chemistry, Nov, Volume: 27, Issue:11 | Nucleic acid related compounds. 47. Synthesis and biological activities of pyrimidine and purine "acyclic" nucleoside analogues. |
| AID425277 | Solubility at pH 2.3 to 9.2 | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID592681 | Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis | 2011 | Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8 | QSAR-based permeability model for drug-like compounds. |
| AID1303373 | Cytotoxicity against mock-infected BHK21 cells assessed as reduction in cell viability after 72 hrs by MTT assay | 2016 | European journal of medicinal chemistry, Jul-19, Volume: 117 | A combined in silico/in vitro approach unveils common molecular requirements for efficient BVDV RdRp binding of linear aromatic N-polycyclic systems. |
| AID232885 | Ralative safety was expressed as Selective index (TC50/IC50) at HSV-1 passage 3 in vero cells | 1998 | Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16 | Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. |
| AID85395 | Antiviral activity against DNA polymerase mutant resistant to KOS(parental) was determined at a conc of 50 uM | 1987 | Journal of medicinal chemistry, Nov, Volume: 30, Issue:11 | Acetylenic nucleosides. 4. 1-beta-D-arabinofuranosyl-5-ethynylcytosine. Improved synthesis and evaluation of biochemical and antiviral properties. |
| AID569233 | Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect | 2011 | European journal of medicinal chemistry, Feb, Volume: 46, Issue:2 | Synthesis of new C5-(1-substituted-1,2,3-triazol-4 or 5-yl)-2'-deoxyuridines and their antiviral evaluation. |
| AID83497 | Inhibition of cell proliferation expressed as CC50 | 1998 | Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25 | Synthesis of imidazo[1,2-a]pyridines as antiviral agents. |
| AID498610 | Antiviral activity against HSV2 infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds. |
| AID425260 | fTmax in horse at 20 mg/kg, po administered as single dose | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID82895 | Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain OKA plaque formation by 50%. | 1995 | Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5 | Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides. |
| AID46024 | Compound was tested for anti-viral activity against HIV-2 in CEM cells | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24 | Synthesis and antiviral evaluation of 3-hydroxy-2-methylpyridin-4-one dideoxynucleoside derivatives. |
| AID217603 | Comparative Potency (IC50s) at HSV-1 passage 7 in vero cells | 1998 | Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16 | Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. |
| AID85722 | Concentration required to inhibit 50% of HSV-1 replication | 2000 | Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18 | Synthesis and biological evaluation of L- and D-configuration 1,3-dioxolane 5-azacytosine and 6-azathymine nucleosides. |
| AID326127 | Inhibition of Herpes B virus recombinant thymidine kinase-mediated [3H]TdR phosphorylation | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides. |
| AID569235 | Antiviral activity against VZV 07-1 infected in HEL cells assessed as inhibition of plaque formation | 2011 | European journal of medicinal chemistry, Feb, Volume: 46, Issue:2 | Synthesis of new C5-(1-substituted-1,2,3-triazol-4 or 5-yl)-2'-deoxyuridines and their antiviral evaluation. |
| AID444058 | Volume of distribution at steady state in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID1782673 | Antiviral activity against thymidine kinase deficient Varicella zoster virus | 2021 | European journal of medicinal chemistry, Aug-05, Volume: 220 | Phenoxazine nucleoside derivatives with a multiple activity against RNA and DNA viruses. |
| AID291031 | Cytotoxicity against HEL cells assessed as cell morphology after 7 days | 2007 | Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13 | Novel C-6 fluorinated acyclic side chain pyrimidine derivatives: synthesis, (1)H and (13)C NMR conformational studies, and antiviral and cytostatic evaluations. |
| AID280176 | Antiviral activity against ACV-resistant TK- HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity | 2007 | Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5 | Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds. |
| AID634747 | Antiviral activity against Herpes simplex virus 2 G infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID87195 | Antiherpes activity was tested as percent of control of plaque-formation against HSV-1 (CL101) virus by 5 uM of the compound | 1985 | Journal of medicinal chemistry, Jul, Volume: 28, Issue:7 | Synthesis and biological activities of 2-pyrimidinone nucleosides. 2. 5-Halo-2-pyrimidinone 2'-deoxyribonucleosides. |
| AID88268 | Inhibitory activity against HSV-1 in vero cells | 2003 | Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23 | Anti-herpes simplex virus activity of substituted 1-hydroxyacridones. |
| AID83710 | Tested for antiviral activity against HSV-1 (KOS) | 2001 | Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12 | The cyclohexene ring as bioisostere of a furanose ring: synthesis and antiviral activity of cyclohexenyl nucleosides. |
| AID120304 | In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through oral route at a dose 50 mg/kg per day | 1985 | Journal of medicinal chemistry, Nov, Volume: 28, Issue:11 | 5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue. |
| AID86971 | Ability to inhibit cytopathogenicity of thymidine kinase-positive(TK+) strain of Varicella zoster virus (YS) in HeLa cell culture | 2001 | Journal of medicinal chemistry, May-24, Volume: 44, Issue:11 | Synthesis and biological evaluation of purine-containing butenolides. |
| AID87343 | Concentration required to decrease the growth rate to 50% of control was evaluated against HSV-1 by using plaque reduction assay. | 1992 | Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3 | Synthesis, antiproliferative, and antiviral activity of certain 4-aminopyrrolo[2,3-d]pyridazine nucleosides: an entry into a novel series of adenosine analogues. |
| AID1079934 | Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source] | |||
| AID81222 | In vitro inhibition of Thymidine Kinase deficient Varicella Zoster Virus (YS/R) plaque formation. | 2000 | Journal of medicinal chemistry, Aug-24, Volume: 43, Issue:17 | Nonnucleoside human cytomegalovirus inhibitors: synthesis and antiviral evaluation of (chlorophenylmethyl)benzothiadiazine dioxide derivatives. |
| AID498594 | Antiviral activity against Macacine herpesvirus 1 isolate MR11 infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds. |
| AID218359 | Compound was evaluated for cytotoxicity against stationary Vero cells using MTT assay | 2001 | Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22 | Novel 5-vinyl pyrimidine nucleosides with potent anti-hepatitis B virus activity. |
| AID1283344 | Antiviral activity against HSV1 KOS ATCC VR1493 infected in African green monkey Vero cells assessed as reduction in EGFP-positive cells at 50 uM treated at 2 hrs post infection measured 24 hrs post infection by flow cytometric analysis relative to contro | 2016 | ACS medicinal chemistry letters, Jan-14, Volume: 7, Issue:1 | iPSC Neuronal Assay Identifies Amaryllidaceae Pharmacophore with Multiple Effects against Herpesvirus Infections. |
| AID167137 | Minimum inhibitory concentration required to reduce virus induced cytopathogenicity in primary rabbit kidney cell cultures by 50% against HSV-2 (G) | 1983 | Journal of medicinal chemistry, Apr, Volume: 26, Issue:4 | Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl]guanine]. |
| AID664264 | Antiviral activity against Herpes simplex virus type 1 KOS ATCC VR-1493 infected in african green monkey Vero-76 cells assessed as reduction in viral plaque after 3 days by crystal violet staining | 2012 | European journal of medicinal chemistry, Jul, Volume: 53 | 5-acetyl-2-arylbenzimidazoles as antiviral agents. Part 4. |
| AID42126 | Cytotoxicity was evaluated against the Monkey kidney cells (BSC) | 1989 | Journal of medicinal chemistry, Feb, Volume: 32, Issue:2 | Synthesis, cytotoxicity, and antiviral activity of some acyclic analogues of the pyrrolo[2,3-d]pyrimidine nucleoside antibiotics tubercidin, toyocamycin, and sangivamycin. |
| AID580304 | Antiviral activity against HSV1 infected in african green monkey Vero cells assessed as inhibition of viral replication by plaque reduction assay | 2011 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6 | Synthesis and in vitro anti-HSV-1 activity of a novel Hsp90 inhibitor BJ-B11. |
| AID611620 | Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as protection against virus-induced cytopathicity | 2011 | Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11 | New prodrugs of Adefovir and Cidofovir. |
| AID85399 | Antiviral activity against DNA polymerase mutant resistant to PFA 3b(PFA) was determined at a conc of 50 uM | 1987 | Journal of medicinal chemistry, Nov, Volume: 30, Issue:11 | Acetylenic nucleosides. 4. 1-beta-D-arabinofuranosyl-5-ethynylcytosine. Improved synthesis and evaluation of biochemical and antiviral properties. |
| AID257891 | Antiviral activity against Vaccinia virus in HEL cells | 2006 | Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2 | Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators. |
| AID53466 | Inhibition of DNA polymerase | 1988 | Journal of medicinal chemistry, Dec, Volume: 31, Issue:12 | Synthesis and antiherpetic activity of (+/-)-9-[[(Z)-2-(hydroxymethyl)cyclopropyl]methyl]guanine and related compounds. |
| AID429201 | Cytotoxicity against human HEL cells assessed as microscopically detectable morphological alterations after 3 days | 2009 | European journal of medicinal chemistry, Aug, Volume: 44, Issue:8 | Synthesis and anti-VZV activity of 6-heteroaryl derivatives of tricyclic acyclovir and 9-{[cis-1',2'-bis(hydroxymethyl)cycloprop-1'-yl]methyl}guanine analogues. |
| AID96379 | Tested for cytotoxic activity against human neoplastic cell line(KB cells). | 1990 | Journal of medicinal chemistry, Jul, Volume: 33, Issue:7 | Synthesis and antiviral activity of some 7-[(2-hydroxyethoxy)methyl]pyrazolo[3,4-d]pyrimidine analogues of sangivamycin and toyocamycin. |
| AID420976 | Cytotoxicity against human HeLa cells | 2009 | European journal of medicinal chemistry, Jun, Volume: 44, Issue:6 | Synthesis and biological evaluation of abietic acid derivatives. |
| AID436479 | Antiviral activity against Yellow fever virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay | 2009 | Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13 | Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives. |
| AID383510 | Cytotoxicity against human E6SM cells | 2008 | European journal of medicinal chemistry, Feb, Volume: 43, Issue:2 | Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents. |
| AID83522 | Anti-VZV activity against 07/1 TK- in HEL cells | 1998 | Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25 | Synthesis of imidazo[1,2-a]pyridines as antiviral agents. |
| AID137467 | Number of survivors against Herpes simplex virus type-1 infection in mice at 100 mg/kg/day | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID1727355 | Cytotoxicity against human HEL cells assessed as reduction in cell growth incubated for 3 days by coulter counter method | 2021 | European journal of medicinal chemistry, Jan-01, Volume: 209 | Extension of furopyrimidine nucleosides with 5-alkynyl substituent: Synthesis, high fluorescence, and antiviral effect in the absence of free ribose hydroxyl groups. |
| AID232883 | Ralative safety was expressed as Selective index (TC50/IC50) at HSV-1 passage 10 in vero cells | 1998 | Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16 | Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. |
| AID383518 | Antiviral activity against in Vesicular stomatitis virus in human E6SM cells assessed as reduction of virus-induced cytopathogenicity | 2008 | European journal of medicinal chemistry, Feb, Volume: 43, Issue:2 | Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents. |
| AID1782698 | Antiviral activity against Varicella zoster virus assessed as inhibition of viral replication | 2021 | European journal of medicinal chemistry, Aug-05, Volume: 220 | Phenoxazine nucleoside derivatives with a multiple activity against RNA and DNA viruses. |
| AID30876 | Antiherpes activity was tested as percent of control of plaque-formation against ACG (Tr7) virus by 5 uM of the compound | 1985 | Journal of medicinal chemistry, Jul, Volume: 28, Issue:7 | Synthesis and biological activities of 2-pyrimidinone nucleosides. 2. 5-Halo-2-pyrimidinone 2'-deoxyribonucleosides. |
| AID17096 | Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10 | 1985 | Journal of medicinal chemistry, Jul, Volume: 28, Issue:7 | Synthesis and antiherpetic activity of (S)-, (R)-, and (+/-)-9-[(2,3-dihydroxy-1-propoxy)methyl]guanine, linear isomers of 2'-nor-2'-deoxyguanosine. |
| AID83022 | Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain Davis plaque formation by 50%. | 1995 | Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5 | Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides. |
| AID1427827 | Cytotoxicity against HEL cells infected with Varicella-Zoster virus assessed as alteration in cell morphology by microscopic method | |||
| AID280179 | Antiviral activity against VZV OKA in HEL cells assessed as inhibition of plaque formation | 2007 | Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5 | Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds. |
| AID676760 | Antiviral activity against HSV-1 infected in african green monkey Vero cells assessed as inhibition of viral ICP4 gene expression after 48 hrs by RT-PCR analysis | 2012 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16 | Antiviral activity and synthesis of quaternized promazine derivatives against HSV-1. |
| AID401232 | Antiviral activity against HSV1 | 2004 | Journal of natural products, Apr, Volume: 67, Issue:4 | Isolation of salicin derivatives from Homalium cochinchinensis and their antiviral activities. |
| AID85545 | Compound was measured for the inhibition of HSV-1 strain A133 in the mouse system model at 25 dose(mg/kg) | 1991 | Journal of medicinal chemistry, Mar, Volume: 34, Issue:3 | Fluorocarbocyclic nucleosides: synthesis and antiviral activity of 2'- and 6'-fluorocarbocyclic 2'-deoxy guanosines. |
| AID216213 | In vitro anti-herpetic activity against HSV-2 plaque formation in vero cells. | 1995 | Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14 | Cyclic variations of 3-quinolinecarboxamides and effects on antiherpetic activity. |
| AID246529 | Effective concentration required to reduce TK+ (thymidine kinase presence) VZV strain OKA virus plaque formation by 50% in HEL cell culture | 2004 | Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22 | 6-azapyrimidine-2'-deoxy-4'-thionucleosides: antiviral agents against TK+ and TK- HSV and VZV strains. |
| AID521928 | Apparent oral clearance in human systemic circulation with normal renal function at 2000 mg, po every 6 hrs measured after fifth dose by radioimmunoassay | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. |
| AID167135 | Minimum inhibitory concentration required to reduce virus induced cytopathogenicity in primary rabbit kidney cell cultures by 50% against HSV-1 (McIntyre) | 1983 | Journal of medicinal chemistry, Apr, Volume: 26, Issue:4 | Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl]guanine]. |
| AID217607 | Comparative Potency (IC50s) at HSV-2 passage 2 in vero cells | 1998 | Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16 | Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. |
| AID521925 | AUC (0 to 6 hrs) in human CSF with normal renal function at 2000 mg, po every 6 hrs measured after fifth dose by radioimmunoassay | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. |
| AID210507 | Maximum velocity constant of the rate of phosphorylation was determined against HSV thymidine kinase | 2001 | Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22 | Design, synthesis, and biological evaluation of novel nucleoside and nucleotide analogues as agents against DNA viruses and/or retroviruses. |
| AID516962 | Cytotoxicity against HEL assessed as change in cell morphology | 2010 | Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19 | Synthesis of ester prodrugs of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) as anti-poxvirus agents. |
| AID1378804 | Antiviral activity against HSV-2 infected in African green monkey Vero cells assessed as inhibition of virus plaque formation after 72 hrs by Giemsa staining based assay | 2017 | Journal of natural products, 08-25, Volume: 80, Issue:8 | Stereochemistry of a Second Riolozane and Other Diterpenoids from Jatropha dioica. |
| AID1079940 | Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source] | |||
| AID286287 | Cytotoxicity against DG75 cells after 120 hrs by MTT assay | 2007 | Journal of medicinal chemistry, May-03, Volume: 50, Issue:9 | 9-(2-C-Cyano-2-deoxy-beta-D-arabino-pentofuranosyl)guanine, a potential antitumor agent against B-lymphoma infected with Kaposi's sarcoma-associated herpesvirus. |
| AID1186332 | Antiviral activity against Yellow fever virus infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay | 2014 | Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17 | Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents. |
| AID275067 | Antiviral activity against HSV1 KOS in HEL cells | 2006 | Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26 | Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine. |
| AID589393 | Cytotoxicity against human RD cells | 2011 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7 | Isatin-β-thiosemicarbazones as potent herpes simplex virus inhibitors. |
| AID699539 | Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting | 2012 | Journal of medicinal chemistry, May-24, Volume: 55, Issue:10 | Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. |
| AID749439 | Antiviral activity against Human simplex virus 2 G infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis | 2013 | European journal of medicinal chemistry, May, Volume: 63 | Ester prodrugs of acyclic nucleoside thiophosphonates compared to phosphonates: synthesis, antiviral activity and decomposition study. |
| AID521220 | Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay | 2007 | Nature chemical biology, May, Volume: 3, Issue:5 | Chemical genetics reveals a complex functional ground state of neural stem cells. |
| AID82251 | Inhibitory concentration required to reduce HSV-1 induced cytopathogenic effect (CPE) by 50 % in HFF cells | 2003 | Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23 | Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine. |
| AID217747 | Anticellular activity was determined by plaque reduction assay in vero cells. | 1991 | Journal of medicinal chemistry, Jul, Volume: 34, Issue:7 | A new class of acyclic phosphonate nucleotide analogues: phosphonate isosteres of acyclovir and ganciclovir monophosphates as antiviral agents. |
| AID81190 | Concentration required to inhibit VZV (oka) induced cytopathogenicity in HEL cells by 50% | 1991 | Journal of medicinal chemistry, Aug, Volume: 34, Issue:8 | Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir. |
| AID1237436 | Antiviral activity against MERS-CoV EMC/2012 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 | Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity. |
| AID68255 | Minimum inhibitory concentration required for antiviral activity to reduce Vaccinia virus (VV) induced cytopathicity in human embryonic skin-muscle cells (ESM) | 1994 | Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9 | Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues. |
| AID85430 | Inhibitory concentration required to reduce HSV-1 induced cytopathogenic effect (CPE) in human skin fibroblast | 2003 | Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23 | Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine. |
| AID1283359 | Cytotoxicity against human iPSC cells assessed as cell viability at 0.1 to 50 uM after 24 to 48 hrs by live/dead fixable viability dye-based flow cytometric analysis | 2016 | ACS medicinal chemistry letters, Jan-14, Volume: 7, Issue:1 | iPSC Neuronal Assay Identifies Amaryllidaceae Pharmacophore with Multiple Effects against Herpesvirus Infections. |
| AID436484 | Antiviral activity against HSV1 infected in Vero-76 cells after 3 days by plaque reduction assay | 2009 | Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13 | Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives. |
| AID1219950 | Transport efficiency, ratio of maximal rate of transport to Km for drug transport in human OAT3 expressed in HEK Flp-In cells measured per mg of protein | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3 | Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs. |
| AID273048 | Inhibition of EBV replication in Daudi cells by viral capsid antigen-ELISA | 2006 | Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20 | 9-{[3-fluoro-2-(hydroxymethyl)cyclopropylidene]methyl}adenines and -guanines. Synthesis and antiviral activity of all stereoisomers1. |
| AID766698 | Antiviral activity against Vaccinia virus Lederle infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity | 2013 | European journal of medicinal chemistry, Sep, Volume: 67 | Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity. |
| AID444053 | Renal clearance in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID85546 | Effective dose required for antiviral activity against HSV-1 virus | 1990 | Journal of medicinal chemistry, Oct, Volume: 33, Issue:10 | Synthesis and antimicrobial and cytotoxic activities of pyrrole-containing analogues of trichostatin A. |
| AID216153 | Effective concentration against TK+ Varicella-Zoster Virus (VZV) OKA strain | 2003 | Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23 | Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine. |
| AID245939 | Cytotoxic concentration required to inhibit herpes simplex virus 2 infected vero cells | 2005 | Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1 | Nucleotides and pronucleotides of 2,2-bis(hydroxymethyl)methylenecyclopropane analogues of purine nucleosides: synthesis and antiviral activity. |
| AID106191 | Compound was tested for antiviral activity against Herpes Simplexin human lung fibroblasts (MRC-5)in vero cells | 1987 | Journal of medicinal chemistry, Sep, Volume: 30, Issue:9 | Synthesis and antiviral activity of 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]purines. |
| AID732670 | Immunoregulatory activity in Hepatitis B virus infected transgenic mouse assessed as increase in CD4+ population in peripheral blood at 100 mg/kg qd for 1 month by flow cytometry (Rvb = 13.6 +/-2.7%) | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and biological evaluation of nucleoside analogues than contain silatrane on the basis of the structure of acyclovir (ACV) as novel inhibitors of hepatitis B virus (HBV). |
| AID275070 | Antiviral activity against vesicular somatitis virus in HEL cells | 2006 | Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26 | Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine. |
| AID82055 | Cytotoxicity produced in human foreskin fibroblasts (HFF) cells estimated by visual scoring of cells unaffected by virus infection. | 1996 | Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18 | Synthesis of non-nucleoside analogs of toyocamycin, sangivamycin, and thiosangivamycin: the effect of certain 4- and 4,6-substituents on the antiviral activity of pyrrolo[2,3-d]pyrimidines. |
| AID1854962 | Antiviral activity against HSV-2 G strain infected in HEL cells assessed as reduction in virus-induced cytopathic effect by microscopic analysis | 2022 | European journal of medicinal chemistry, Nov-05, Volume: 241 | Synthesis and antiviral properties of biomimetic iminosugar-based nucleosides. |
| AID1884113 | Selectivity index, ratio of CC50 for cytotoxicity against African green monkey Vero cells to EC50 for antiviral activity against HSV-2 infected in African green monkey Vero cells | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Synthetic derivatives of the antifungal drug ciclopirox are active against herpes simplex virus 2. |
| AID392722 | Antiviral activity against HSV1 assessed as inhibition of virus-induced cytopathicity | 2009 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4 | Synthesis of 5-isoxazol-5-yl-2'-deoxyuridines exhibiting antiviral activity against HSV and several RNA viruses. |
| AID286286 | Cytotoxicity against Kaposi's sarcoma-associated herpesvirus infected BC2 cells after 120 hrs by MTT assay | 2007 | Journal of medicinal chemistry, May-03, Volume: 50, Issue:9 | 9-(2-C-Cyano-2-deoxy-beta-D-arabino-pentofuranosyl)guanine, a potential antitumor agent against B-lymphoma infected with Kaposi's sarcoma-associated herpesvirus. |
| AID246316 | Effective concentration required to reduce HSV-1 strain KOS virus plaque formation by 50% in E6SM Cell Culture | 2004 | Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22 | 6-azapyrimidine-2'-deoxy-4'-thionucleosides: antiviral agents against TK+ and TK- HSV and VZV strains. |
| AID87025 | Minimum inhibitory concentration against Herpes simplex Virus-1(F) | 2002 | Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23 | Synthesis and biological activity of strongly fluorescent tricyclic analogues of acyclovir and ganciclovir. |
| AID246470 | Effective concentration required to reduce Varicella-Zoster virus OKA(TK) plaque formation after 5 days in HEL fibroblast cell line | 2005 | Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7 | From 1-acyl-beta-lactam human cytomegalovirus protease inhibitors to 1-benzyloxycarbonylazetidines with improved antiviral activity. A straightforward approach to convert covalent to noncovalent inhibitors. |
| AID236913 | Permeability Coefficient in Caco-2 cell culture model | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | Exploring the role of different drug transport routes in permeability screening. |
| AID87847 | Minimum inhibitory concentration causing 25% inhibition cytopathic effect induced by Herpes simplex virus-1 (Brand) in HEp-2 cells | 1988 | Journal of medicinal chemistry, Sep, Volume: 31, Issue:9 | Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity. |
| AID216302 | Compound was evaluated for the inhibition of VZV strains of OKA | 1999 | Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22 | Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base. |
| AID31890 | Effective dose required for antiviral activity against ASFV virus | 1990 | Journal of medicinal chemistry, Oct, Volume: 33, Issue:10 | Synthesis and antimicrobial and cytotoxic activities of pyrrole-containing analogues of trichostatin A. |
| AID65844 | Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of E6SM cells | 1996 | Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14 | Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents. |
| AID1186338 | Antiviral activity against Vesicular stomatitis virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay | 2014 | Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17 | Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents. |
| AID1139392 | Antiviral activity against thymidine kinase-deficient ACV-resistant Herpes simplex virus 1 B-2006 infected in HEL cells assessed as reduction in virus-induced cytopathicity after 3 days | 2014 | Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9 | ProTides of N-(3-(5-(2'-deoxyuridine))prop-2-ynyl)octanamide as potential anti-tubercular and anti-viral agents. |
| AID250784 | Effect on HSV-1 encephalitis in mice following intraperitoneal dosage at 50 mg/kg; expressed as mean day of death | 2005 | Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11 | Inhibition of herpes simplex virus thymidine kinases by 2-phenylamino-6-oxopurines and related compounds: structure-activity relationships and antiherpetic activity in vivo. |
| AID88114 | Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by Herpes simplex virus(HSV) -2 (thymidine kinase deficient) in HEp-2 cells | 1988 | Journal of medicinal chemistry, Sep, Volume: 31, Issue:9 | Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity. |
| AID1219947 | Transport efficiency, ratio of maximal rate of transport to Km for drug transport in human OAT1 expressed in HEK Flp-In cells measured per mg of protein | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3 | Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs. |
| AID1451464 | Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07-1 infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect | 2017 | Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18 | Virtual Screening of Acyclovir Derivatives as Potential Antiviral Agents: Design, Synthesis, and Biological Evaluation of New Acyclic Nucleoside ProTides. |
| AID217650 | Antiviral activity against Varicella zoster virus (Oka strain) | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID87347 | In vitro antiviral activity of the compound, determined by plaque-reduction assay against Herpes simplex virus (HSV) type 1, BW5 strain in Vero cells | 1989 | Journal of medicinal chemistry, Jul, Volume: 32, Issue:7 | Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. |
| AID1451461 | Cytotoxicity against human HEL cells assessed as alteration to cell morphology by microscopic analysis | 2017 | Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18 | Virtual Screening of Acyclovir Derivatives as Potential Antiviral Agents: Design, Synthesis, and Biological Evaluation of New Acyclic Nucleoside ProTides. |
| AID400434 | Cytotoxicity against HSV1 infected human Hep2 cells after 3 days | 1998 | Journal of natural products, May, Volume: 61, Issue:5 | Antiviral phenylpropanoid glycosides from the medicinal plant Markhamia lutea. |
| AID1886810 | Antiviral activity against DENV2 infected in hamster BHK-21 cells assessed as inhibition of plaque formation by measuring reduction in PFU per well incubated for 6 days by crystal violet staining based assay | 2022 | Journal of natural products, 08-26, Volume: 85, Issue:8 | Antiviral Profiling of C-18- or C-19-Functionalized Semisynthetic Abietane Diterpenoids. |
| AID218421 | Anti viral activity against VZV(40a2 (TK-) strain) in WI-38 cell monolayers. | 1992 | Journal of medicinal chemistry, May-15, Volume: 35, Issue:10 | Synthesis and antiviral activity of 1-cyclobutyl-5-(2-bromovinyl)uracil nucleoside analogues and related compounds. |
| AID83332 | The minimum inhibitory concentration was measured on HEL cells against Varicella zoster virus (YS strain) | 1994 | Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19 | Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity. |
| AID326138 | Cytotoxicity against african green monkey Vero cells after 2 days | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides. |
| AID217799 | In vitro antiviral activity tested against herpesvirus, VZV, Ellen strain by plaque reduction assay in human foreskin fibroblasts. | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5 | Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS. |
| AID1451452 | Antiviral activity against human cytomegalovirus AD-169 infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect | 2017 | Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18 | Virtual Screening of Acyclovir Derivatives as Potential Antiviral Agents: Design, Synthesis, and Biological Evaluation of New Acyclic Nucleoside ProTides. |
| AID1079947 | Comments (NB not yet translated). [column 'COMMENTAIRES' in source] | |||
| AID1884108 | Antiviral activity against HSV-1 infected in African green monkey Vero cells assessed as inhibition of viral replication by measuring log suppression of virus-induced cytopathic effect at 1 uM incubated for 1 hr followed by washing with PBS and subsequent | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Synthetic derivatives of the antifungal drug ciclopirox are active against herpes simplex virus 2. |
| AID246292 | Effective concentration required to inhibit herpes simplex virus 2 in vero cells in plaque reduction assay | 2005 | Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1 | Nucleotides and pronucleotides of 2,2-bis(hydroxymethyl)methylenecyclopropane analogues of purine nucleosides: synthesis and antiviral activity. |
| AID1394850 | Cytostatic activity against HEL cells after 3 days by Coulter counting method | 2018 | European journal of medicinal chemistry, Apr-25, Volume: 150 | Synthesis and antiviral evaluation of cyclopentyl nucleoside phosphonates. |
| AID218069 | Toxic dose that reduced by 50% the number of cells with respect to untreated controls. | 1990 | Journal of medicinal chemistry, Oct, Volume: 33, Issue:10 | Synthesis and antimicrobial and cytotoxic activities of pyrrole-containing analogues of trichostatin A. |
| AID607907 | Antiviral activity against acyclovir-resistant TK-deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis | 2011 | Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14 | Design, synthesis and biological evaluation of 2'-deoxy-2',2'-difluoro-5-halouridine phosphoramidate ProTides. |
| AID282664 | Cytotoxicity against HFF cells | 2004 | Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27 | (Z)- and (E)-[2-Fluoro-2-(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines, a new class of methylenecyclopropane analogues of nucleosides: synthesis and antiviral activity. |
| AID218425 | Anti viral activity against VZV (Kanno-Kohmura(TK-) strain) in WI-38 cell monolayers. | 1992 | Journal of medicinal chemistry, May-15, Volume: 35, Issue:10 | Synthesis and antiviral activity of 1-cyclobutyl-5-(2-bromovinyl)uracil nucleoside analogues and related compounds. |
| AID65712 | Antiviral activity against vesicular simplex virus-1 in E6SM cell cultures | 2001 | Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16 | Design, synthesis, DNA binding, and biological evaluation of water-soluble hybrid molecules containing two pyrazole analogues of the alkylating cyclopropylpyrroloindole (CPI) subunit of the antitumor agent CC-1065 and polypyrrole minor groove binders. |
| AID81037 | The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against cytomegalo virus Davis strain; Not determined | 1999 | Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14 | Novel pyrimidine and purine derivatives of L-ascorbic acid: synthesis and biological evaluation. |
| AID297307 | Antiviral activity against thymidine kinase deficient VZV 07/1 in human HEL cells after 7 days | 2007 | Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17 | Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives. |
| AID1427825 | Antiviral activity against thymidine kinase expressing Varicella-Zoster virus OKA infected in HEL cells assessed as reduction in virus plaque formation | |||
| AID85552 | Inhibitory activity against herpes simplex virus type-1 (HSV-1) replication in KB cells | 1988 | Journal of medicinal chemistry, Jul, Volume: 31, Issue:7 | 7-Aminoquinolines. A novel class of agents active against herpesviruses. |
| AID106008 | Tested for Antiherpetic activity against HSV-2 from 186 strain in MRC-5 cell lines. | 2000 | Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2 | Synthesis and antiviral activity of novel anti-VZV 5-substituted uracil nucleosides with a cyclopropane sugar moiety. |
| AID561609 | Clearance in children and young patient with malignancy at 10 mg/kg, po administered every 12 hrs | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. |
| AID1572730 | Antiviral activity against herpes simplex virus 2 G infected in HEL cells assessed as reduction in virus-induced cytopathogenicity by microscopic analysis | 2019 | Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6 | Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives. |
| AID81050 | Concentration required to inhibit CMV (AD-169) induced cytopathogenicity in HEL cells by 50% | 1991 | Journal of medicinal chemistry, Aug, Volume: 34, Issue:8 | Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir. |
| AID1427826 | Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07-1 infected in HEL cells assessed as reduction in virus plaque formation | |||
| AID227702 | Ratio of ID50 for dThd or dUrd incorporation to ID50 for HSV-1, HSV-2 or VV(whatever was lowest) | 1984 | Journal of medicinal chemistry, Nov, Volume: 27, Issue:11 | Nucleic acid related compounds. 47. Synthesis and biological activities of pyrimidine and purine "acyclic" nucleoside analogues. |
| AID326128 | Inhibition of Herpes simplex virus 1 recombinant thymidine kinase | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides. |
| AID91297 | Inhibitory concentration of the drug against the cytopathic effect for E-377 strain of herpes simplex virus-1 (HSV-1) in human HFF cells | 1993 | Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17 | Synthesis and antiviral activity of novel 5-(1-azido-2-haloethyl) and 5-(1-azido-, amino-, or methoxyethyl) analogs of 2'-deoxyuridine. |
| AID68256 | Minimum inhibitory concentration required for antiviral activity to reduce Vesicular stomatitis virus (VSV) induced cytopathicity in human embryonic skin-muscle cells (ESM) | 1994 | Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9 | Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues. |
| AID87184 | Virus rating is measurement of degree of inhibition of virus-induced cytopathogenic effects and the degree of cytotoxicity produced by the test compound for Herpes simplex virus (HSV) -2 | 1987 | Journal of medicinal chemistry, May, Volume: 30, Issue:5 | Synthesis and biological activity of unsaturated carboacyclic purine nucleoside analogues. |
| AID574829 | Antiviral activity against Herpes simplex virus 1 isolate 9 harboring N23S, K36E, R89Q, +1G 437-438 = Stop 228 mutations in thymidine kinase and S33G, A330R, V905M, A1203T, T1208A mutations in DNA polymerase infected in african green monkey Vero cells by | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. |
| AID472791 | Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay | 2010 | Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8 | Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives. |
| AID332491 | Antiviral activity against HSV1 H29S in african green monkey Vero cells assessed as log reduction in viral titers after 0.001 multiple round of replication at 25 ug/ml after 72 hrs | 1994 | Journal of natural products, May, Volume: 57, Issue:5 | Comparison of the anti-herpes simplex virus activities of propolis and 3-methyl-but-2-enyl caffeate. |
| AID625284 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID625285 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID63600 | Minimum inhibitory conc. for 50% inhibition of vaccinia virus induced cytopathicity in E6SM cells | 1997 | Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9 | Carbocyclic oxetanocins lacking the C-3' methylene. |
| AID588218 | FDA HLAED, lactate dehydrogenase (LDH) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID139415 | Day of death in lethal test against herpes simplex virus type-2 at 25 mg/kg/day (mean day of death +/-SD) | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID679516 | TP_TRANSPORTER: inhibition of PAH uptake (PAH: 5 uM, ACV: 1000 uM) in OAT1-expressing S2 cells | 2002 | The Journal of pharmacology and experimental therapeutics, Mar, Volume: 300, Issue:3 | Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. |
| AID681141 | TP_TRANSPORTER: uptake in Xenopus laevis oocytes | 2001 | Molecular pharmacology, May, Volume: 59, Issue:5 | Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. |
| AID66019 | Compound was evaluated for the minimum inhibition concentration required to reduce virus-induced cytopathogenicity by 50%, determined against HSV-2 virus as means of G, 196, and Lyons strains | 1998 | Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22 | 5-Substituted pyrimidines with a 1,5-anhydro-2, 3-dideoxy-D-arabino-hexitol moiety at N-1: synthesis, antiviral activity, conformational analysis, and interaction with viral thymidine kinase. |
| AID290509 | Antiviral activity against HSV1 SC16 in Vero cells by capture hybrid method | 2007 | Bioorganic & medicinal chemistry letters, May-15, Volume: 17, Issue:10 | Imidazo[1,2-a]pyridines with potent activity against herpesviruses. |
| AID46576 | Inhibitory concentration for spectrum antiviral activity against herpes viruses; ND= Not determined | 2002 | Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3 | 5-Bromo (or chloro)-6-azido-5,6-dihydro-2' -deoxyuridine and -thymidine derivatives with potent antiviral activity. |
| AID86493 | Tested for antiviral activity against thymidine kinase deficient Varicella zoster virus in human embryonic lung fibroblasts | 2002 | Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5 | New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation. |
| AID84426 | Inhibitory effects on HSV-1 induced mortality in NMRI mice upon (ip) administration at a dose of 150 mk/kg/day | 2001 | Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22 | Design, synthesis, and biological evaluation of novel nucleoside and nucleotide analogues as agents against DNA viruses and/or retroviruses. |
| AID458871 | Cytotoxicity against HEL cells assessed as microscopically detectable alteration of cell morphology | 2010 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3 | Practical and efficient synthesis of pyrano[3,2-c]pyridone, pyrano[4,3-b]pyran and their hybrids with nucleoside as potential antiviral and antileishmanial agents. |
| AID66937 | Compounds was evaluated for its inhibitory effect on cytopathogenicity of vaccinia virus (VV) in E6SM cells | 1992 | Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8 | Synthesis and antiviral activity of acyclic nucleosides with a 3(S),5-dihydroxypentyl or 4(R)-methoxy-3(S),5-dihydroxypentyl side chain. |
| AID83359 | Effective concentration required to inhibit Tyrosine kinase (TK+) Varicella-Zoster virus-induced cytopathicity by 50% in YS strain HEL cell lines | 2001 | Journal of medicinal chemistry, Aug-16, Volume: 44, Issue:17 | Synthesis, mechanism of action, and antiviral activity of a new series of covalent mechanism-based inhibitors of S-adenosyl-L-homocysteine hydrolase. |
| AID83329 | The minimum inhibitory concentration was measured on HEL cells against TK-Varicella zoster virus (YS-R strain) | 1994 | Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19 | Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity. |
| AID393964 | Antiviral activity against ganciclovir-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity | 2009 | Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6 | 4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus. |
| AID90618 | Concentration required to decrease the growth rate to 50% of control was evaluated against HCMV by using yield reduction assay. | 1992 | Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3 | Synthesis, antiproliferative, and antiviral activity of certain 4-aminopyrrolo[2,3-d]pyridazine nucleosides: an entry into a novel series of adenosine analogues. |
| AID217753 | Antiviral activity determined against herpes simplex type 1 (F strain) by plaque reduction in Vero cells | 1986 | Journal of medicinal chemistry, Aug, Volume: 29, Issue:8 | Synthesis and anti-herpes-virus activity of acyclic 2'-deoxyguanosine analogues related to 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine. |
| AID1337434 | Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07-1 infected in HEL cells assessed as inhibition of virus plaque formation | 2016 | European journal of medicinal chemistry, Nov-29, Volume: 124 | Identification of an indol-based derivative as potent and selective varicella zoster virus (VZV) inhibitor. |
| AID718737 | Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect | 2012 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 | Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities. |
| AID277836 | Antiviral activity against HSV1 TK KOS ACVr | 2007 | Journal of natural products, Feb, Volume: 70, Issue:2 | Cinnamacrins A-C, cinnafragrin D, and cytostatic metabolites with alpha-glucosidase inhibitory activity from Cinnamosma macrocarpa. |
| AID167886 | Antiviral Activity against vaccinia virus in rabbit kidney cell | 1990 | Journal of medicinal chemistry, Sep, Volume: 33, Issue:9 | Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives. |
| AID498600 | Antiviral activity against Macacine herpesvirus 1 isolate A4 infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds. |
| AID106186 | Compound was tested for antiviral activity against Herpes Simplex virus Type-1(20132) in human lung fibroblasts (MRC-5) | 1987 | Journal of medicinal chemistry, Sep, Volume: 30, Issue:9 | Synthesis and antiviral activity of 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]purines. |
| AID1773425 | Antiviral activity against Enterovirus E LCR-4 infected in A549 cells assessed as inhibition of viral adsorption at early stage of replication treated for 1 hr during viral infection followed by replacement with fresh medium and measured after 72 hrs by M | 2021 | European journal of medicinal chemistry, Dec-05, Volume: 225 | Novel betulin dicarboxylic acid ester derivatives as potent antiviral agents: Design, synthesis, biological evaluation, structure-activity relationship and in-silico study. |
| AID472794 | Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay | 2010 | Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8 | Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives. |
| AID309813 | Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 5 days | 2007 | Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22 | Influence of 6 or 8-substitution on the antiviral activity of 3-phenethylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (HCMV) and varicella-zoster virus (VZV). |
| AID87041 | Dose of compound required to inhibit the herpes simplex type-2 MS virus induced cytopathogenic effects | 1988 | Journal of medicinal chemistry, Sep, Volume: 31, Issue:9 | Cyclopentenylcytosine. A carbocyclic nucleoside with antitumor and antiviral properties. |
| AID217489 | Minimal inhibitory concentration to reduce virus-induced cytopathicity against VV | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Fluorescent tricyclic analogues of acyclovir and ganciclovir. A structure-antiviral activity study. |
| AID21263 | Permeability coefficient reported (Expressed as Permeability coefficient x 10 e 4 cm/s) | 1996 | Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24 | Computation of brain-blood partitioning of organic solutes via free energy calculations. |
| AID431629 | Antiviral activity against acyclovir 5-monophosphate-resistant thymidine kinase-deficient HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity | 2009 | Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17 | The application of phosphoramidate protide technology to acyclovir confers anti-HIV inhibition. |
| AID1498126 | Antiviral activity against thymidine kinase expressing Varicella-Zoster virus infected in HEL cells assessed as reduction in virus plaque formation | 2018 | Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12 | Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs. |
| AID1219940 | Drug transport in human OCT2 expressed in HEK Flp-In cells at 0.06 uM for 10 mins relative to control | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3 | Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs. |
| AID313909 | Cytotoxicity against african green monkey Vero cells | 2008 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 | Pyrazolopyridines with potent activity against herpesviruses: effects of C5 substituents on antiviral activity. |
| AID218388 | In vitro minimum drug concentration that inhibited herpes simplex virus type 1 (E-377 strain) virus-induced cytopathogenic effects by 50% in vero cells | 1990 | Journal of medicinal chemistry, Apr, Volume: 33, Issue:4 | Synthesis and biological evaluation of carbocyclic analogues of lyxofuranosides of 2-amino-6-substituted-purines and 2-amino-6-substituted-8-azapurines. |
| AID217768 | Inhibitory dose required to reduce the viability of vero cells by 50% | 1991 | Journal of medicinal chemistry, Sep, Volume: 34, Issue:9 | The synthesis and antiviral activity of some 4'-thio-2'-deoxy nucleoside analogues. |
| AID232884 | Ralative safety was expressed as Selective index (TC50/IC50) at HSV-1 passage 2 in vero cells | 1998 | Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16 | Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. |
| AID68254 | Minimum inhibitory concentration required for antiviral activity to reduce TK-HSV-1 (B2006) induced cytopathicity in human embryonic skin-muscle cells (ESM) | 1994 | Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9 | Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues. |
| AID1854967 | Antiviral activity against thymidine kinase deficient Varicella zoster-virus O7-1 strain infected in HEL cells assessed as reduction in plaque formation by microscopic analysis | 2022 | European journal of medicinal chemistry, Nov-05, Volume: 241 | Synthesis and antiviral properties of biomimetic iminosugar-based nucleosides. |
| AID136144 | Percentage survival of mice after intraperitoneal administration of compound at 10 mg/kg per day in experiment 1; survival/ tested =2/10 | 1989 | Journal of medicinal chemistry, Jul, Volume: 32, Issue:7 | Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. |
| AID216304 | The compound was tested for its effective concentration required to reduce virus plaque formation by using TK (thymidine kinase -deficient) -Varicella-Zoster virus YS/R strain | 2000 | Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11 | Bicyclic nucleoside inhibitors of Varicella-Zoster Virus (VZV): the effect of a terminal halogen substitution in the side-chain. |
| AID1593182 | Antiviral activity against Hepatitis A virus infected in rhesus monkey FRhK4 cells assessed as reduction in virus-induced cytopathic effect incubated for 72 hrs by MTT assay | 2019 | European journal of medicinal chemistry, Apr-15, Volume: 168 | New 4-phenylcoumarin derivatives as potent 3C protease inhibitors: Design, synthesis, anti-HAV effect and molecular modeling. |
| AID1610151 | Antiviral activity against thymidine kinase deficient Varicella zoster virus infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by Giemsa staining based microscopic analysis | 2019 | European journal of medicinal chemistry, Dec-15, Volume: 184 | Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives. |
| AID83023 | Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain 07/1 plaque formation by 50%. | 1995 | Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5 | Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides. |
| AID575034 | Antiviral activity against Herpes simplex virus 2 isolate 19 harboring G39E, +2G 439-440 = Stop 184 mutations in thymidine kinase and A9T, P15S, L60P, del, DGDE683-686 mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduc | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. |
| AID83182 | Concentration required to reduce VZV-YS/R-TK- plaque formation by 50% in human embryonic lung (HEL) cell cultures. | 1992 | Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12 | (+-)-carbocyclic 5'-nor-2'-deoxyguanosine and related purine derivatives: synthesis and antiviral properties. |
| AID258994 | Cytotoxic activity against cultured human embryonic lung (HEL) cells | 2006 | Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1 | Synthesis and biological evaluation of 6-(alkyn-1-yl)furo[2,3-d]pyrimidin-2(3H)-one base and nucleoside derivatives. |
| AID521922 | Tmax in human systemic circulation with chronic kidney disease at 1500 mg, po every 12 hrs measured after fifth dose by radioimmunoassay | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. |
| AID113235 | Efficacy expressed as number of surviving mice infected with herpetic encephalitis at dose of 150 mg/kg; Not determined | 1986 | Journal of medicinal chemistry, Feb, Volume: 29, Issue:2 | Systematic synthesis and biological evaluation of alpha- and beta-D-xylofuranosyl nucleosides of the five naturally occurring bases in nucleic acids and related analogues. |
| AID458869 | Antiviral activity against thymidine kinase expressing Varicella Zoster Virus OKA infected in HEL cells assessed as reduction of viral plaque formation | 2010 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3 | Practical and efficient synthesis of pyrano[3,2-c]pyridone, pyrano[4,3-b]pyran and their hybrids with nucleoside as potential antiviral and antileishmanial agents. |
| AID1433148 | Antiviral activity against Human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis | 2015 | European journal of medicinal chemistry, Aug-28, Volume: 101 | Synthesis, antiplasmodial activity and mechanistic studies of pyrimidine-5-carbonitrile and quinoline hybrids. |
| AID87028 | Minimum inhibitory concentration against Herpes simplex Virus-1 (McIntyre) | 2002 | Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23 | Synthesis and biological activity of strongly fluorescent tricyclic analogues of acyclovir and ganciclovir. |
| AID91286 | Antiviral activity against Varicella-Zoster virus (VV) in human foreskin cell cultures in virus plaque reduction assay at 3.2 uM | 1987 | Journal of medicinal chemistry, Nov, Volume: 30, Issue:11 | Synthesis and antiviral activity of carbocyclic analogues of xylofuranosides of 2-amino-6-substituted-purines and 2-amino-6-substituted-8-azapurines. |
| AID296674 | Antiviral activity against thymidine kinase deficient VZV 07/1 in HEL cells assessed as reduction of virus plaque formation after 5 days | 2007 | Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16 | Synthesis and antiviral evaluation of 6-(alkyl-heteroaryl)furo[2,3-d]pyrimidin-2(3H)-one nucleosides and analogues with ethynyl, ethenyl, and ethyl spacers at C6 of the furopyrimidine core. |
| AID1211758 | Effective permeability of the compound assessed as PepT1-mediated drug uptake in wild type mouse jejunum at 100 uM by HPLC analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3 | Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice. |
| AID425269 | Renal toxicity in horse assessed as changes in urea level | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID350202 | Cytotoxicity against human Akata cells | 2009 | Journal of medicinal chemistry, May-28, Volume: 52, Issue:10 | (Z)- and (E)-2-(1,2-dihydroxyethyl)methylenecyclopropane analogues of 2'-deoxyadenosine and 2'-deoxyguanosine. Synthesis of all stereoisomers, absolute configuration, and antiviral activity. |
| AID76488 | Effect on the growth of Herpes simplex Type 1 on the skin of Guinea pigs infected intradermally on day 2 at 5 % concentration | 1984 | Journal of medicinal chemistry, May, Volume: 27, Issue:5 | Synthesis of some phosphonates with antiherpetic activity. |
| AID217488 | Inhibitory concentration against VV in human embryonic skin muscle (ESM) fibroblast cell culture | 1993 | Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14 | Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides. |
| AID246562 | Effective concentration required to reduce TK+ (thymidine kinase deficient) VZV strain YS/R virus plaque formation by 50% in HEL cell culture | 2004 | Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22 | 6-azapyrimidine-2'-deoxy-4'-thionucleosides: antiviral agents against TK+ and TK- HSV and VZV strains. |
| AID412415 | Antiviral activity against acyclovir-resistant HSV1 KOS-M isolate replication in african green monkey Vero cells by plaque reduction assay | 2009 | Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1 | Synthesis and in vitro activities of a new antiviral duplex drug linking Zidovudine (AZT) and Foscarnet (PFA) via an octadecylglycerol residue. |
| AID65995 | Compound was evaluated for the minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology. | 1998 | Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22 | 5-Substituted pyrimidines with a 1,5-anhydro-2, 3-dideoxy-D-arabino-hexitol moiety at N-1: synthesis, antiviral activity, conformational analysis, and interaction with viral thymidine kinase. |
| AID68268 | Concentration required to inhibit HSV-1 (F) induced cytopathogenicity in ESM cells by 50% | 1991 | Journal of medicinal chemistry, Aug, Volume: 34, Issue:8 | Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir. |
| AID297310 | Cytotoxicity against human HEL cells assessed as alteration in cell morphology | 2007 | Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17 | Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives. |
| AID82552 | The compound was tested for cytotoxic concentration required to inhibit Hel cell growth by 50% | 2000 | Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11 | Bicyclic nucleoside inhibitors of Varicella-Zoster Virus (VZV): the effect of a terminal halogen substitution in the side-chain. |
| AID429196 | Antiviral activity against Varicella zoster virus YS infected in human HEL cells assessed as inhibition of virus induced cytopathicity after 5 days | 2009 | European journal of medicinal chemistry, Aug, Volume: 44, Issue:8 | Synthesis and anti-VZV activity of 6-heteroaryl derivatives of tricyclic acyclovir and 9-{[cis-1',2'-bis(hydroxymethyl)cycloprop-1'-yl]methyl}guanine analogues. |
| AID95686 | Cytotoxicity (growth inhibition) against human epidermoid oral carcinoma KB cell line. | 1996 | Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18 | Synthesis of non-nucleoside analogs of toyocamycin, sangivamycin, and thiosangivamycin: the effect of certain 4- and 4,6-substituents on the antiviral activity of pyrrolo[2,3-d]pyrimidines. |
| AID425272 | Cmax in horse at 10 mg/kg, iv after 15 mins | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID578851 | Antiviral activity against Herpes simplex viruses 1 infected in vero cells assessed as inhibition of viral replication at 50 uM after 72 hrs by XTT assay | 2011 | Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6 | Synthesis and anti-HSV-1 activity of new 1,2,3-triazole derivatives. |
| AID774688 | Antiviral activity against Human echovirus 9 VR-1050 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity | 2013 | Bioorganic & medicinal chemistry, Sep-15, Volume: 21, Issue:18 | Synthesis and biological evaluation of furopyrimidine N,O-nucleosides. |
| AID575035 | Antiviral activity against Herpes simplex virus 2 isolate 20 harboring G39E, -1C 467 = Stop 183 mutations in thymidine kinase and A9T, P15S, L60P, E139K, T801P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction ass | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. |
| AID1274003 | Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation after 72 hrs | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Anti-herpetic and anti-dengue activity of abietane ferruginol analogues synthesized from (+)-dehydroabietylamine. |
| AID625281 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID376980 | Cytotoxicity against human Hep2 cells after 3 days by MTT reduction assay | 2006 | Journal of natural products, May, Volume: 69, Issue:5 | Antiviral flavans from the leaves of Pithecellobium clypearia. |
| AID82688 | Compound was tested for anti-viral activity against HSV-1TK neg in HEL cells | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24 | Synthesis and antiviral evaluation of 3-hydroxy-2-methylpyridin-4-one dideoxynucleoside derivatives. |
| AID1237434 | Antiviral activity against MERS-CoV EMC/2012 infected in human HuH7 cells assessed as inhibition of virus-induced cytopathic effect after 2 days by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 | Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity. |
| AID1055501 | Cytotoxicity against HEL cells | 2013 | European journal of medicinal chemistry, , Volume: 70 | Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides. |
| AID111521 | Tested for the appearance of skin lesions or paralysis of the legs after 39 days when administered intraperitoneally at 100 mg/kg per day | 1990 | Journal of medicinal chemistry, Sep, Volume: 33, Issue:9 | Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives. |
| AID563746 | Antiviral activity against HSV1 E377 infected in HFF after 3 days by plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides. |
| AID90936 | Tested for the activity against human cytomegalovirus (HCMV) using yield reduction assay | 1994 | Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18 | Benzimidazole ribonucleosides: design, synthesis, and antiviral activity of certain 2-(alkylthio)- and 2-(benzylthio)-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazoles. |
| AID467613 | Volume of distribution at steady state in human | 2009 | European journal of medicinal chemistry, Nov, Volume: 44, Issue:11 | Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data. |
| AID42129 | Tested in vitro for cytotoxicity against the monkey kidney cells (BSC-1 cells). | 1990 | Journal of medicinal chemistry, Dec, Volume: 33, Issue:12 | Arabinofuranosylpyrrolo[2,3-d]pyrimidines as potential agents for human cytomegalovirus infections. |
| AID1055504 | Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathicity | 2013 | European journal of medicinal chemistry, , Volume: 70 | Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides. |
| AID1647655 | Antiviral activity against Herpes simplex virus 2 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenic effect after 24 hrs by crystal violet staining based assay | 2020 | Journal of natural products, 02-28, Volume: 83, Issue:2 | Amphiepicoccins A-J: Epipolythiodioxopiperazines from the Fish-Gill-Derived Fungus |
| AID1139393 | Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction in virus-induced cytopathicity after 3 days | 2014 | Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9 | ProTides of N-(3-(5-(2'-deoxyuridine))prop-2-ynyl)octanamide as potential anti-tubercular and anti-viral agents. |
| AID1261341 | Antiviral activity against VSV | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID1261312 | Antiviral activity against BVDV infected in MDBK cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID436482 | Antiviral activity against Coxsackie virus type B2 virus infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay | 2009 | Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13 | Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives. |
| AID365171 | Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl adenine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity | 2008 | Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18 | 4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action. |
| AID85112 | Inhibitory activity against HSV-2 (196) replication in E6SM cell cultures of human embryonic skin-muscle | 2002 | Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25 | A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity. |
| AID200837 | Number of living cells on the proliferation of mouse myeloma cells SP2 was measured at concentration 1 ug/mL at 96 h. | 1986 | Journal of medicinal chemistry, Feb, Volume: 29, Issue:2 | Systematic synthesis and biological evaluation of alpha- and beta-D-xylofuranosyl nucleosides of the five naturally occurring bases in nucleic acids and related analogues. |
| AID116571 | Compound tested for its effect on mean survival time in mice against HSV-1(BWS) at a dose of 300 mg/kg. | 1991 | Journal of medicinal chemistry, Jul, Volume: 34, Issue:7 | A new class of acyclic phosphonate nucleotide analogues: phosphonate isosteres of acyclovir and ganciclovir monophosphates as antiviral agents. |
| AID137476 | Number of survivors against Herpes simplex virus type-2 infection in mice at 200 mg/kg/day | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID1079935 | Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source] | |||
| AID1261315 | Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID1422437 | Cytotoxicity against HEL cells assessed as alteration in cell morphology after 3 days by microscopic method | 2018 | Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21 | Synthesis, biological evaluation and molecular modeling of a novel series of fused 1,2,3-triazoles as potential anti-coronavirus agents. |
| AID87026 | Minimum inhibitory concentration against Herpes simplex Virus-1(KOS) | 2002 | Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23 | Synthesis and biological activity of strongly fluorescent tricyclic analogues of acyclovir and ganciclovir. |
| AID425281 | Cmax in iv dosed adult horse | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID340473 | Antiviral activity against EBV lytic replication in GG68 cells after 72 hrs by Southern blot analysis | 2008 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14 | Synthesis of 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamides with broad-spectrum human herpesvirus polymerase inhibition. |
| AID521918 | Cmax in human systemic circulation with chronic kidney disease at 1500 mg, po every 12 hrs measured after fifth dose by radioimmunoassay | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. |
| AID561617 | Clearance in immunocompromized children at 10.5 mg/kg, iv | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. |
| AID83721 | In Vitro antiviral activity against HSV-1 at 0.5 ug/mL concentration | 1994 | Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19 | Synthesis of new acyclic pyrimidine nucleoside analogs as potential antiviral drugs. |
| AID87969 | Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by Herpes simplex virus-1 (Brand) in vero cells | 1988 | Journal of medicinal chemistry, Sep, Volume: 31, Issue:9 | Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity. |
| AID1474166 | Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index | 2016 | Drug discovery today, Apr, Volume: 21, Issue:4 | DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. |
| AID1394848 | Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of plaque formation measured after 2 to 3 days post infection | 2018 | European journal of medicinal chemistry, Apr-25, Volume: 150 | Synthesis and antiviral evaluation of cyclopentyl nucleoside phosphonates. |
| AID79167 | Effect on the development of Herpetic vesicles in Guinea pigs infected intradermally with Herpes virus Hominis, Type 1,AA strain on day 1 at 5% concentration | 1984 | Journal of medicinal chemistry, May, Volume: 27, Issue:5 | Synthesis of some phosphonates with antiherpetic activity. |
| AID259182 | Antiviral activity against HIV2 ROD in CEM cells | 2006 | Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1 | Synthesis and antiviral evaluation of cyclic and acyclic 2-methyl-3-hydroxy-4-pyridinone nucleoside derivatives. |
| AID1451459 | Antiviral activity against Herpes simplex virus 2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect | 2017 | Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18 | Virtual Screening of Acyclovir Derivatives as Potential Antiviral Agents: Design, Synthesis, and Biological Evaluation of New Acyclic Nucleoside ProTides. |
| AID218197 | Tested in vitro for minimum inhibitory concentration against herpes simplex virus-1 (HSV-1) F strain by plaque-reduction assay in vero cells | 1993 | Journal of medicinal chemistry, May-28, Volume: 36, Issue:11 | 3-Quinolinecarboxamides. A series of novel orally-active antiherpetic agents. |
| AID376988 | Selectivity index, CC50 for MDCK cells to IC50 for influenza A virus H1N1 A/NWS/33 | 2006 | Journal of natural products, May, Volume: 69, Issue:5 | Antiviral flavans from the leaves of Pithecellobium clypearia. |
| AID1782676 | Cytotoxicity against human HEL cells assessed as reduction in cell viability measured after 3 days by beckman coulter counting method | 2021 | European journal of medicinal chemistry, Aug-05, Volume: 220 | Phenoxazine nucleoside derivatives with a multiple activity against RNA and DNA viruses. |
| AID625283 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID85708 | The compound was tested for plaque inhibition in HSV-1 in cell culture, activity is determined by plaque reduction assay | 1981 | Journal of medicinal chemistry, Dec, Volume: 24, Issue:12 | Purine acyclic nucleosides. Nitrogen isosteres of 9-[(2-hydroxyethoxy)methyl]guanine as candidate antivirals. |
| AID1593184 | Antiviral activity against Hepatitis A virus infected in rhesus monkey FRhK4 cells assessed as inhibition in viral adsorption using cells pre-incubated with compound for 24 hrs before viral infection for 1 hr by MTT assay | 2019 | European journal of medicinal chemistry, Apr-15, Volume: 168 | New 4-phenylcoumarin derivatives as potent 3C protease inhibitors: Design, synthesis, anti-HAV effect and molecular modeling. |
| AID84408 | Minimal inhibitory concentration to reduce virus-induced cytopathicity against TK-/TK+ HSV-1 (VMW 837) | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Fluorescent tricyclic analogues of acyclovir and ganciclovir. A structure-antiviral activity study. |
| AID436477 | Cytotoxicity against MDBK cells after 48 to 96 hrs by MTT assay | 2009 | Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13 | Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives. |
| AID1684816 | Antiviral activity against thymidine kinase deficient Varicella zoster virus 07-1 infected in human HEL cells assessed as reduction in virus plaque formation measured on day 5 post-viral infection | 2021 | ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1 | Influence of 4'-Substitution on the Activity of Gemcitabine and Its ProTide Against VZV and SARS-CoV-2. |
| AID1661188 | Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity measured after 6 to 7 days | 2020 | ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7 | Amidate Prodrugs of |
| AID1404016 | Permeability of the compound by PAMPA | 2018 | European journal of medicinal chemistry, Feb-10, Volume: 145 | Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors. |
| AID472789 | Antiviral activity against Bovine viral diarrhea virus NADL infected in MDBK cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method | 2010 | Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8 | Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives. |
| AID498407 | Antiviral activity against Macacine herpesvirus 1 isolate E2490 infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds. |
| AID284529 | Antiviral activity against Vaccinia virus-induced cytopathogenicity in E6SM cells | 2007 | Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2 | The novel C-5 aryl, alkenyl, and alkynyl substituted uracil derivatives of L-ascorbic acid: synthesis, cytostatic, and antiviral activity evaluations. |
| AID563773 | Antiviral activity against HSV2 12247 harboring TK C337Y mutant gene infected in HFF after 3 days by plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides. |
| AID297315 | Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity | 2007 | Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17 | Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives. |
| AID471490 | Cytotoxicity against african green monkey Vero cells assessed as minimal toxic dosed detached 100% of the cell monolayer | 2010 | European journal of medicinal chemistry, Feb, Volume: 45, Issue:2 | Synthesis and biological evaluation of dehydroabietic acid derivatives. |
| AID1869614 | Cytotoxicity against human HEL cells assessed as change in cell morphology measured after 3 days by coulter counting method | 2022 | Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13 | Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound. |
| AID83020 | Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain AD-169 plaque formation by 50%. | 1995 | Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5 | Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides. |
| AID498596 | Antiviral activity against Macacine herpesvirus 1 isolate MR2 infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds. |
| AID1219933 | Drug transport in human OAT3 expressed in HEK Flp-In cells at 0.06 uM for 10 mins relative to control | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3 | Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs. |
| AID1857467 | Oral bioavailability in monkey | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Treatment Option for Acyclovir-Resistant Herpes Simplex Virus Infections. |
| AID255993 | Antiviral activity against herpes simplex virus type 1 KOS (V823A) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO | 2005 | Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18 | 4-Oxo-4,7-dihydrothieno[2,3-b]pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases. |
| AID245963 | Cytotoxic concentration to reduce the 50% cell growth of human embryonic lung cells | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | The novel L- and D-amino acid derivatives of hydroxyurea and hydantoins: synthesis, X-ray crystal structure study, and cytostatic and antiviral activity evaluations. |
| AID1274009 | Antiviral activity against HHV-2 VR-734-G infected in African green monkey Vero cells assessed as reduction in plaque formation administered post viral infection after 72 hrs by crystal violet staining technique | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Anti-herpetic and anti-dengue activity of abietane ferruginol analogues synthesized from (+)-dehydroabietylamine. |
| AID217608 | Comparative Potency (IC50s) at HSV-2 passage 3 in vero cells | 1998 | Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16 | Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. |
| AID378845 | Antiviral activity against HSV1 ATCC VR260 by colorimetry | 2006 | Journal of natural products, Oct, Volume: 69, Issue:10 | Integerrimides A and B, cyclic heptapeptides from the latex of Jatropha integerrima. |
| AID1237433 | Cytotoxicity against mock-infected African green monkey Vero118 cells assessed as inhibition of cell survival after 5 days by microscopic analysis | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 | Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity. |
| AID658619 | Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days | 2012 | European journal of medicinal chemistry, Jun, Volume: 52 | 2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies. |
| AID42128 | Tested for cytotoxic activity against monkey kidney cells(BSC-1) cells. | 1990 | Journal of medicinal chemistry, Jul, Volume: 33, Issue:7 | Synthesis and antiviral activity of some 7-[(2-hydroxyethoxy)methyl]pyrazolo[3,4-d]pyrimidine analogues of sangivamycin and toyocamycin. |
| AID91278 | Antiviral activity against Varicella-Zoster virus (VV) in human foreskin cell cultures in virus plaque reduction assay at 1 uM | 1987 | Journal of medicinal chemistry, Nov, Volume: 30, Issue:11 | Synthesis and antiviral activity of carbocyclic analogues of xylofuranosides of 2-amino-6-substituted-purines and 2-amino-6-substituted-8-azapurines. |
| AID106189 | Compound was tested for antiviral activity against Herpes Simplex virus Type-2(21929) in human lung fibroblasts (MRC-5) | 1987 | Journal of medicinal chemistry, Sep, Volume: 30, Issue:9 | Synthesis and antiviral activity of 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]purines. |
| AID90612 | Inhibition of human cytomegalovirus (HCMV) in plaque reduction assay | 1990 | Journal of medicinal chemistry, Jul, Volume: 33, Issue:7 | Synthesis, antiproliferative, and antiviral activity of certain 4-substituted and 4,5-disubstituted 7-[(1,3-dihydroxy-2-propoxy)methyl]pyrrolo[2,3-d]pyrimidines. |
| AID429200 | Antiviral activity against human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection | 2009 | European journal of medicinal chemistry, Aug, Volume: 44, Issue:8 | Synthesis and anti-VZV activity of 6-heteroaryl derivatives of tricyclic acyclovir and 9-{[cis-1',2'-bis(hydroxymethyl)cycloprop-1'-yl]methyl}guanine analogues. |
| AID1857468 | Oral bioavailability in human at 350 mg administered as 1 hr intravenous infusion once a week and measured upto 24 hrs | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Treatment Option for Acyclovir-Resistant Herpes Simplex Virus Infections. |
| AID1274010 | Antiviral activity against DENV-2 New guinea infected in African green monkey Vero cells assessed as reduction in plaque formation administered post viral infection after 8 days by crystal violet staining technique | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Anti-herpetic and anti-dengue activity of abietane ferruginol analogues synthesized from (+)-dehydroabietylamine. |
| AID1473738 | Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID498608 | Antiviral activity against Macacine herpesvirus 1 isolate MP1 infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds. |
| AID588215 | FDA HLAED, alkaline phosphatase increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID86022 | Inhibition of plaque formation in monolayers of HSV-1 KOS Vero cells by 50% | 2001 | Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21 | Synthesis and antiviral activity of novel 5-(1-cyanamido-2-haloethyl) and 5-(1-hydroxy(or methoxy)-2-azidoethyl) analogues of uracil nucleosides. |
| AID575037 | Antiviral activity against Herpes simplex virus 2 isolate 22 harboring G39E, N78D, L140F, +1G 439-440 = Stop 229 mutations in thymidine kinase and A9T, P15S, L60P, E678G, Y823C mutations in DNA polymerase infected in african green monkey Vero cells by pla | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. |
| AID83717 | Evaluated for the antiviral activity against Herpes simplex virus type 1 (HSV-1) strain BWS by the plaque reduction assay | 1990 | Journal of medicinal chemistry, Apr, Volume: 33, Issue:4 | Acyclic purine phosphonate analogues as antiviral agents. Synthesis and structure-activity relationships. |
| AID1246241 | Antiviral activity against Human herpesvirus 1 KOS ATCC VR-1493 infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation after 3 days by crystal violet staining | 2015 | European journal of medicinal chemistry, Aug-28, Volume: 101 | Synthesis, cytotoxicity and antimicrobial activity of thiourea derivatives incorporating 3-(trifluoromethyl)phenyl moiety. |
| AID65858 | Antiviral activity against herpes simplex virus-1 KOS in E6SM cell culture | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20 | Acyclic nucleotide analogs derived from 8-azapurines: synthesis and antiviral activity. |
| AID118707 | Number of dead, after HSV-2 infection observed from day 12 to day 20 | 1987 | Journal of medicinal chemistry, Jun, Volume: 30, Issue:6 | Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases. |
| AID151170 | Cytotoxic concentration that causes growth inhibition of VZV infected Osteosarcoma cells | 2003 | Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23 | Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine. |
| AID361403 | Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay | 2002 | Journal of natural products, Nov, Volume: 65, Issue:11 | New saponins from the starfish Certonardoa semiregularis. |
| AID85886 | Antiviral activity against HSV-1 (herpes simplex virus) | 1999 | Bioorganic & medicinal chemistry letters, Feb-08, Volume: 9, Issue:3 | Nucleosides and nucleotides. 183. Synthesis of 4'alpha-branched thymidines as a new type of antiviral agent. |
| AID679320 | TP_TRANSPORTER: uptake in OAT1-expressing S2 cells | 2002 | The Journal of pharmacology and experimental therapeutics, Mar, Volume: 300, Issue:3 | Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. |
| AID216171 | Minimum Inhibition Concentration (MIC) for activity against Varicella-Zoster Virus(VZV) using YS(TK+) strain. | 1996 | Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14 | Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents. |
| AID1410505 | Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 2 to 3 days post-infection | 2018 | ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4 | Amidate Prodrugs of Cyclic 9-( |
| AID400423 | Antiviral activity against HSV1 infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days | 1998 | Journal of natural products, May, Volume: 61, Issue:5 | Antiviral phenylpropanoid glycosides from the medicinal plant Markhamia lutea. |
| AID224193 | Inhibitory effect on 196 strain of Herper simplex virus-2 yield, in primary rabbit kidney cell culture 0.1 ug/mL concentration after 48 hours. | 1987 | Journal of medicinal chemistry, Jun, Volume: 30, Issue:6 | Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases. |
| AID216303 | Compound was evaluated for the inhibition of VZV strains of YS | 1999 | Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22 | Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base. |
| AID578854 | Selectivity index, ratio of CC50 for african green monkey vero cells to IC50 for Herpes simplex viruses 1 | 2011 | Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6 | Synthesis and anti-HSV-1 activity of new 1,2,3-triazole derivatives. |
| AID1230099 | Cytotoxicity against HEL cells assessed as alternation of cell morphology by microscopic analysis | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Design, antiviral and cytostatic properties of isoxazolidine-containing amonafide analogues. |
| AID1230103 | Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Design, antiviral and cytostatic properties of isoxazolidine-containing amonafide analogues. |
| AID595581 | Selectivity index, ratio of CC50 for human HFF cells infected with Hepatitis C virus to EC50 for Human cytomegalovirus AD169 | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | Broad-spectrum antiviral activity including human immunodeficiency and hepatitis C viruses mediated by a novel retinoid thiosemicarbazone derivative. |
| AID425267 | Antiviral activity against EHV1 assessed as inhibition of plaque formation | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID246179 | Effective concentration required to inhibit varicella zoster virus replication in HFF cells | 2005 | Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1 | Nucleotides and pronucleotides of 2,2-bis(hydroxymethyl)methylenecyclopropane analogues of purine nucleosides: synthesis and antiviral activity. |
| AID246411 | Effective concentration to inhibit 50 % of Herpes simplex virus type 1 replication in a cell culture model | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | Synthesis and antiviral activity of helioxanthin analogues. |
| AID83035 | Minimum cytotoxic concentration to reduce the HEL cell proliferation by 50% | 1996 | Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14 | Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents. |
| AID1055508 | Cytotoxicity against human MT4 cells assessed as cell viability by propidium iodide staining-based cell counting analysis | 2013 | European journal of medicinal chemistry, , Volume: 70 | Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides. |
| AID1427832 | Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction in virus-induced cytopathogenicity | |||
| AID201611 | In vitro minimum inhibitory concentration to inhibit SHV-1-induced cytopathogenicity in PRK cells by 50% | 1988 | Journal of medicinal chemistry, Jul, Volume: 31, Issue:7 | Synthesis and antiviral activity of novel N-substituted derivatives of acyclovir. |
| AID332489 | Antiviral activity against HSV1 H29S in african green monkey Vero cells assessed as log reduction in viral titers after 0.001 multiple round of replication at 6.25 ug/ml after 72 hrs | 1994 | Journal of natural products, May, Volume: 57, Issue:5 | Comparison of the anti-herpes simplex virus activities of propolis and 3-methyl-but-2-enyl caffeate. |
| AID104821 | Compound was tested for antiviral activity indicative of 50% cytopathic concentration in virus (HIV-1) infected MT-4 cells; ND is not determined | 2002 | Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17 | Synthesis and biological evaluation of novel D-2'-azido-2',3'-dideoxyarabinofuranosyl-4'-thiopyrimidines and purines. |
| AID425270 | Renal toxicity in horse assessed as changes in creatinine level | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID91273 | Cytotoxicity was determined at 1000 uM | 1987 | Journal of medicinal chemistry, Nov, Volume: 30, Issue:11 | Synthesis and antiviral activity of carbocyclic analogues of xylofuranosides of 2-amino-6-substituted-purines and 2-amino-6-substituted-8-azapurines. |
| AID96824 | Inhibitory activity against L1210 cell line | 1990 | Journal of medicinal chemistry, Sep, Volume: 33, Issue:9 | Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives. |
| AID139279 | Day of death in lethal test against herpes simplex virus type-1 at 25 mg/kg/day (mean day of death +/-SD) | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID444056 | Fraction escaping gut-wall elimination in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID82551 | Tested for the cytotoxic concentration, required to reduce cell growth by 50% in human embryonic lung (HEL) cells. | 1995 | Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5 | Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides. |
| AID282647 | Cytotoxicity against BSC1 cells | 2004 | Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27 | (Z)- and (E)-[2-Fluoro-2-(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines, a new class of methylenecyclopropane analogues of nucleosides: synthesis and antiviral activity. |
| AID1427837 | Cytotoxicity against virus infected HEL cells assessed as alteration in cell morphology by microscopic method | |||
| AID1886804 | Antiviral activity against ZIKV infected in African green monkey Vero E6 cells assessed as inhibition of virus induced cytopathic effect measured after 72 hrs by crystal violet staining based inverted microscopic analysis | 2022 | Journal of natural products, 08-26, Volume: 85, Issue:8 | Antiviral Profiling of C-18- or C-19-Functionalized Semisynthetic Abietane Diterpenoids. |
| AID288915 | Cytotoxicity against E6SM cells assessed as alteration in cell morphology | 2007 | Journal of medicinal chemistry, Jun-14, Volume: 50, Issue:12 | 5-alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells. |
| AID282653 | Inhibition of EBV replication in Daudi cells by DNA hybridization assay | 2004 | Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27 | (Z)- and (E)-[2-Fluoro-2-(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines, a new class of methylenecyclopropane analogues of nucleosides: synthesis and antiviral activity. |
| AID83194 | Minimum inhibitory conc. for 50% inhibition of VZV (YS) virus plaque formation in HEL cells | 1997 | Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9 | Carbocyclic oxetanocins lacking the C-3' methylene. |
| AID84588 | Minimal inhibitory concentration to reduce virus-induced cytopathicity against F strain of human Herpes Simplex Virus-1 (HSV-1) | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Fluorescent tricyclic analogues of acyclovir and ganciclovir. A structure-antiviral activity study. |
| AID218422 | Anti viral activity against VZV(9021 strain) in WI-38 cell monolayers. | 1992 | Journal of medicinal chemistry, May-15, Volume: 35, Issue:10 | Synthesis and antiviral activity of 1-cyclobutyl-5-(2-bromovinyl)uracil nucleoside analogues and related compounds. |
| AID1186331 | Cytotoxicity against mock-infected BHK21 cells after 48 to 96 hrs by MTT assay | 2014 | Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17 | Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents. |
| AID1433135 | Antiviral activity against Herpes simplex virus 2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis | 2015 | European journal of medicinal chemistry, Aug-28, Volume: 101 | Synthesis, antiplasmodial activity and mechanistic studies of pyrimidine-5-carbonitrile and quinoline hybrids. |
| AID675211 | Antiviral activity against thymidine kinase positive VZV OKa infected in HEL cells by plaque formation assay | 2012 | European journal of medicinal chemistry, Sep, Volume: 55 | Synthesis and antiviral activities of hexadecyloxypropyl prodrugs of acyclic nucleoside phosphonates containing guanine or hypoxanthine and a (S)-HPMP or PEE acyclic moiety. |
| AID1886814 | Antiviral activity against CHIKV infected in African green monkey Vero E6 cells assessed as concentration required for higher viral reduction factor measured after 72 hrs by crystal violet staining based inverted microscopic analysis | 2022 | Journal of natural products, 08-26, Volume: 85, Issue:8 | Antiviral Profiling of C-18- or C-19-Functionalized Semisynthetic Abietane Diterpenoids. |
| AID246456 | Effective concentration to inhibit 50 % of hepatitis C virus replication in a cell culture model;ND=Not determined | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | Synthesis and antiviral activity of helioxanthin analogues. |
| AID498589 | Antiviral activity against Macacine herpesvirus 1 isolate MR6 infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds. |
| AID574384 | Cytotoxicity against HELF cells assessed as after 3 days by Coulter counting analysis | 2011 | Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3 | Synthesis and SAR studies on azetidine-containing dipeptides as HCMV inhibitors. |
| AID85728 | Tested for antiviral activity against herpes simplex virus-1(HSV-1) by means of plaque reduction assay. | 1990 | Journal of medicinal chemistry, Jul, Volume: 33, Issue:7 | Synthesis and antiviral activity of some 7-[(2-hydroxyethoxy)methyl]pyrazolo[3,4-d]pyrimidine analogues of sangivamycin and toyocamycin. |
| AID1651467 | Antiviral activity against ACV-sensitive Herpes simplex virus 1 KOS infected in female Balb/c mouse assessed as reduction in ulcerated lesion at 50 mg/g applied topically as cream formulation 5 times a day at 3 hrs interval for 10 days measured on day 3 t | |||
| AID1592934 | Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by SRB assay | |||
| AID768203 | Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity | 2013 | European journal of medicinal chemistry, Aug, Volume: 66 | Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies. |
| AID561616 | Renal clearance in immunocompromized children assessed per m'2 at 250 mg/kg, po administered every 12 hrs | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. |
| AID1402829 | Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Emimycin and its nucleoside derivatives: Synthesis and antiviral activity. |
| AID84605 | Concentration required to reduce the number of viral plaques in vivo cell monolayers of herpes simplex virus type 2. | 1989 | Journal of medicinal chemistry, Feb, Volume: 32, Issue:2 | Synthesis and antiviral activity of phosphonoacetic and phosphonoformic acid esters of 5-bromo-2'-deoxyuridine and related pyrimidine nucleosides and acyclonucleosides. |
| AID1237432 | Antiviral activity against Human coronavirus NL63 infected in African green monkey Vero118 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by microscopic analysis | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 | Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity. |
| AID1661191 | Cytotoxicity against human HEL cells assessed as minimum cytotoxic concentration for change in cellular morphology incubated for 3 days by microscopic analysis | 2020 | ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7 | Amidate Prodrugs of |
| AID689098 | Selectivity ratio of CC50 for african green monkey Vero cells to EC50 for HSV1 L2 | 2012 | Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19 | Phosphoramidate derivatives of acyclovir: synthesis and antiviral activity in HIV-1 and HSV-1 models in vitro. |
| AID139281 | Day of death in lethal test against herpes simplex virus type-2 at 100 mg/kg/day (mean day of death +/-SD) | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID87779 | Inhibition of cytopathogenicity of Varicella-Zoster virus(VZV)(YS) in Hela cell culture. | 1995 | Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23 | Design, synthesis, and structure-activity relationship of novel dinucleotide analogs as agents against herpes and human immunodeficiency viruses. |
| AID393980 | Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed reduction in viral plaque formation | 2009 | Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6 | 4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus. |
| AID575036 | Antiviral activity against Herpes simplex virus 2 isolate 21 harboring G39E, N78D, L140F, -1C 452 = Stop 183 mutations in thymidine kinase and P15S, L60P, E678G mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction as | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. |
| AID1261311 | Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID324739 | Antiviral activity against TK- HSV2 AG3 in HFF cells after 72 hrs by plaque reduction assay | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase. |
| AID766697 | Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity | 2013 | European journal of medicinal chemistry, Sep, Volume: 67 | Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity. |
| AID768200 | Antiviral activity against TK-negative Herpes simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity | 2013 | European journal of medicinal chemistry, Aug, Volume: 66 | Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies. |
| AID718733 | Toxicity in HEL cells assessed as induction of cell morphology changes | 2012 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 | Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities. |
| AID1667300 | Antiviral activity against Herpes simplex virus 1 infected in African green monkey vero cells assessed as reduction in plaque formation treated 1 hr post viral infection by plaque reduction assay | 2020 | Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7 | DNA sequence-specific ligands. XVIII. Synthesis, physico-chemical properties; genetic, virological, and biochemical studies of fluorescent dimeric bisbenzimidazoles DBPA(n). |
| AID1303380 | Antiviral activity against Vesicular stomatitis virus Indiana infected in Vero 76 cells after 2 days by crystal violet staining based plaque reduction assay | 2016 | European journal of medicinal chemistry, Jul-19, Volume: 117 | A combined in silico/in vitro approach unveils common molecular requirements for efficient BVDV RdRp binding of linear aromatic N-polycyclic systems. |
| AID1079944 | Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source] | |||
| AID1382170 | Selectivity index, ratio of CC50 for HEL cells to EC50 for thymidine kinase deficient Varicella zoster virus 07/1 infected in HEL cells | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Highly convergent synthesis and antiviral activity of (E)-but-2-enyl nucleoside phosphonoamidates. |
| AID501209 | Antiviral activity against HSV1 infected african green monkey Vero cells assessed as reduction of plaque formation after 3 days by using crystal violet stain | 2010 | Journal of natural products, Feb-26, Volume: 73, Issue:2 | Phloroglucinol glycosides from the fresh fruits of Eucalyptus maideni. |
| AID28924 | Effective permeability (Pe) across a hexadecane membrane (pH 6.8) | 2001 | Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6 | High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. |
| AID675215 | Antiviral activity against HSV2 G infected in HEL cells by viral CPE assay | 2012 | European journal of medicinal chemistry, Sep, Volume: 55 | Synthesis and antiviral activities of hexadecyloxypropyl prodrugs of acyclic nucleoside phosphonates containing guanine or hypoxanthine and a (S)-HPMP or PEE acyclic moiety. |
| AID607913 | Antiviral activity against Varicella-zoster virus YS expressing thymidine kinase infected in human HEL cells assessed as reduction in the virus plaque formation | 2011 | Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14 | Design, synthesis and biological evaluation of 2'-deoxy-2',2'-difluoro-5-halouridine phosphoramidate ProTides. |
| AID393982 | Cytotoxicity against human HEL cells assessed as reduction of growth after 3 days | 2009 | Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6 | 4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus. |
| AID540217 | Volume of distribution at steady state in dog after iv administration | 2005 | Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7 | Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. |
| AID284531 | Antiviral activity against in Vesicular stomatitis virus-induced cytopathogenicity in E6SM cells | 2007 | Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2 | The novel C-5 aryl, alkenyl, and alkynyl substituted uracil derivatives of L-ascorbic acid: synthesis, cytostatic, and antiviral activity evaluations. |
| AID80122 | Antiviral activity against Human cytomegalovirus (AD169 strain) | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID682755 | Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for HSV-1F ATCC 733 by plaque reduction assay | 2012 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19 | Structure based molecular design, synthesis and biological evaluation of α-pyrone analogs as anti-HSV agent. |
| AID436476 | Cytotoxicity against human MT4 cells after 96 hrs by MTT assay | 2009 | Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13 | Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives. |
| AID1337439 | Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation | 2016 | European journal of medicinal chemistry, Nov-29, Volume: 124 | Identification of an indol-based derivative as potent and selective varicella zoster virus (VZV) inhibitor. |
| AID1773420 | Antiviral activity against Enterovirus E LCR-4 infected in A549 cells assessed as reduction in virus titer preincubated for 24 hrs followed by viral infection and measured after 72 hrs by microscopic analysis | 2021 | European journal of medicinal chemistry, Dec-05, Volume: 225 | Novel betulin dicarboxylic acid ester derivatives as potent antiviral agents: Design, synthesis, biological evaluation, structure-activity relationship and in-silico study. |
| AID81101 | Antiviral activity against HIV-1 (human immunodeficiency virus type 1); Not determined | 1999 | Bioorganic & medicinal chemistry letters, Feb-08, Volume: 9, Issue:3 | Nucleosides and nucleotides. 183. Synthesis of 4'alpha-branched thymidines as a new type of antiviral agent. |
| AID216459 | In vitro antiviral activity against Varicella zoster virus (VZV) was determined | 2002 | Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3 | 5-Bromo (or chloro)-6-azido-5,6-dihydro-2' -deoxyuridine and -thymidine derivatives with potent antiviral activity. |
| AID137469 | Number of survivors against Herpes simplex virus type-1 infection in mice at 150 mg/kg/day | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID68275 | Concentration required to inhibit TK-HSV-1 (VMW2837) induced cytopathogenicity in ESM cells by 50% | 1991 | Journal of medicinal chemistry, Aug, Volume: 34, Issue:8 | Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir. |
| AID120300 | In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through oral route at a dose 100 mg/kg per day; NT=Not tested | 1985 | Journal of medicinal chemistry, Nov, Volume: 28, Issue:11 | 5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue. |
| AID81025 | The compound was tested for anti CMV (Cytomegalovirus- virus) activity against Davis strain in HEL cells;d ='not determined' | 1998 | Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25 | Synthesis of imidazo[1,2-a]pyridines as antiviral agents. |
| AID1378805 | Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for HSV-1 infected in African green monkey Vero cells | 2017 | Journal of natural products, 08-25, Volume: 80, Issue:8 | Stereochemistry of a Second Riolozane and Other Diterpenoids from Jatropha dioica. |
| AID1451460 | Antiviral activity against ACV-resistant thymidine kinase deficient Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect | 2017 | Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18 | Virtual Screening of Acyclovir Derivatives as Potential Antiviral Agents: Design, Synthesis, and Biological Evaluation of New Acyclic Nucleoside ProTides. |
| AID209951 | Concentration required to reduce the proliferation of PHA stimulated human peripheral blood T lymphocytes | 2001 | Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22 | Novel 5-vinyl pyrimidine nucleosides with potent anti-hepatitis B virus activity. |
| AID1464790 | Anti-viral activity against Herpes simplex virus-1 harboring EGFP infected in iPSC-derived neurons assessed as early apoptotic cells at 10 mM treated 2 hrs post infection measured after 72 hrs by Alexa fluor 488 staining based flow cytometric analysis (Rv | 2017 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 27, Issue:20 | Discovery of potent antiviral (HSV-1) quinazolinones and initial structure-activity relationship studies. |
| AID688919 | Antiviral activity against Herpes simplex virus (type 1 / strain F) infected in Vero cells assessed as reduction of number of viral plaques after 2 days | 2012 | Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19 | Synthesis and biological evaluation of novel homochiral carbocyclic nucleosides from 1-amino-2-indanols. |
| AID1273994 | Antiviral activity against DENV-2 New guinea infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by crystal violet staining based inverted microscopic analysis relative to control | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Anti-herpetic and anti-dengue activity of abietane ferruginol analogues synthesized from (+)-dehydroabietylamine. |
| AID425249 | Total volume of distribution in central compartment in horse at 10 mg/kg, iv after 1 hr by two-compartmental study | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID625282 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1869613 | Antiviral activity against VZV TK- infected in HEL cells assessed as reduction in virus plaque formation | 2022 | Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13 | Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound. |
| AID425243 | Total terminal half life in horse at elimination phase at 10 mg/kg, iv after 1 hr by two-compartmental study | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID76492 | Effect on the growth of Herpes simplex Type 1 on the skin of Guinea pigs infected intradermally on day 4 at 5 % concentration | 1984 | Journal of medicinal chemistry, May, Volume: 27, Issue:5 | Synthesis of some phosphonates with antiherpetic activity. |
| AID1886811 | Antiviral activity against HHV-1 29R strain infected in African green monkey Vero E6 cells assessed as reduction factor at 3.1 to 25 ug/ml measured after 72 hrs by crystal violet staining based inverted microscopic analysis | 2022 | Journal of natural products, 08-26, Volume: 85, Issue:8 | Antiviral Profiling of C-18- or C-19-Functionalized Semisynthetic Abietane Diterpenoids. |
| AID246291 | Effective concentration required to inhibit herpes simplex virus 1 in vero cells in plaque reduction assay | 2005 | Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1 | Nucleotides and pronucleotides of 2,2-bis(hydroxymethyl)methylenecyclopropane analogues of purine nucleosides: synthesis and antiviral activity. |
| AID84241 | Minimum inhibitory concentration was determined against VZV (YS) in HEL cells | 2000 | Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4 | The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine. |
| AID87992 | Tested for inhibitory activity against Herpes simplex virus type-1(HSV-1), activity is expressed as IC50. | 2000 | Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2 | Synthesis and antiviral activity of novel anti-VZV 5-substituted uracil nucleosides with a cyclopropane sugar moiety. |
| AID79171 | Effect on the development of Herpetic vesicles in Guinea pigs infected intradermally with Herpes virus Hominis, Type 1,AA strain on day 3 at 5 % concentration | 1984 | Journal of medicinal chemistry, May, Volume: 27, Issue:5 | Synthesis of some phosphonates with antiherpetic activity. |
| AID68267 | Concentration required to cause a microscopically detectable alteration of normal cell morphology in ESM cells | 1991 | Journal of medicinal chemistry, Aug, Volume: 34, Issue:8 | Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir. |
| AID91301 | Inhibitory concentration of the drug against the cytopathic effect for ellen strain of varicella zoster virus-2 (VZV-2) in human HFF cells | 1993 | Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17 | Synthesis and antiviral activity of novel 5-(1-azido-2-haloethyl) and 5-(1-azido-, amino-, or methoxyethyl) analogs of 2'-deoxyuridine. |
| AID609580 | Cytotoxicity against human HEL cells assessed as alteration of cell morphology after 3 days by microscopic analysis | 2011 | Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15 | Acyclic nucleoside phosphonates with a branched 2-(2-phosphonoethoxy)ethyl chain: efficient synthesis and antiviral activity. |
| AID472793 | Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay | 2010 | Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8 | Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives. |
| AID66936 | Compounds was evaluated for its inhibitory effect on cytopathogenicity of vesicular stomatitis virus (VSV) in E6SM cells | 1992 | Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8 | Synthesis and antiviral activity of acyclic nucleosides with a 3(S),5-dihydroxypentyl or 4(R)-methoxy-3(S),5-dihydroxypentyl side chain. |
| AID1210069 | Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors. |
| AID447282 | Antiviral activity against HSV1 SC16 infected in african green monkey Vero cells by hybrid capture method | 2009 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19 | Pyrazolopyrimidines and pyrazolotriazines with potent activity against herpesviruses. |
| AID87493 | In vitro antiviral and anticellular activity was evaluated against herpes simplex virus HSV-1 (F strain) in vero cells tissue culture | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis and antiherpes simplex virus activity of 9-[(1,3-dihydroxy-2-propylthio)methyl]guanine. |
| AID244767 | Minimal cytotoxic concentration required to alter microscopically detectable cell morphology | 2005 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 15, Issue:16 | Bicyclic nucleoside inhibitors of Varicella-Zoster virus: the effect of branching in the p-alkylphenyl side chain. |
| AID64095 | Minimum inhibitory concentration (MIC) required to reduce 196 strain of HSV-2 induced cytopathogenicity by 50% in E6SM cells | 1992 | Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8 | Synthesis and antiviral activity of acyclic nucleosides with a 3(S),5-dihydroxypentyl or 4(R)-methoxy-3(S),5-dihydroxypentyl side chain. |
| AID1337442 | Cytotoxicity against HEL cells assessed as alteration of cell morphology after 3 days by microscopic method | 2016 | European journal of medicinal chemistry, Nov-29, Volume: 124 | Identification of an indol-based derivative as potent and selective varicella zoster virus (VZV) inhibitor. |
| AID87443 | Percentage of triphosphates (TP) in the second step of staggered assay mixture from step 1 was incubated with GMP kinase and crude extract of HSV-1 infected HeLa cells over night | 1988 | Journal of medicinal chemistry, Dec, Volume: 31, Issue:12 | Synthesis and antiherpetic activity of (+/-)-9-[[(Z)-2-(hydroxymethyl)cyclopropyl]methyl]guanine and related compounds. |
| AID246324 | Effective concentration required to reduce Varicella Zoster virus OKA plaque formation by using DMSO as solvent | 2005 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 15, Issue:16 | Bicyclic nucleoside inhibitors of Varicella-Zoster virus: the effect of branching in the p-alkylphenyl side chain. |
| AID82553 | The concentration required to reduce cell growth by 50% was measured on Human Embryonic Lung (HEL) cells | 1999 | Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7 | Novel potential agents for human cytomegalovirus infection: synthesis and antiviral activity evaluation of benzothiadiazine dioxide acyclonucleosides. |
| AID471491 | Antiviral activity against Human herpesvirus 1 infected in african green monkey Vero cells assessed as ratio of viral titer in absence of drug over viral titer in presence of drug after 36 hrs by end point titration method | 2010 | European journal of medicinal chemistry, Feb, Volume: 45, Issue:2 | Synthesis and biological evaluation of dehydroabietic acid derivatives. |
| AID611624 | Cytotoxicity against human HEL cells assessed as alteration of cell morphology after 3 days by microscopy | 2011 | Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11 | New prodrugs of Adefovir and Cidofovir. |
| AID425276 | Oral bioavailability in horse at 20 mg/kg administered as single dose | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID358242 | Antiviral activity against Herpes simplex virus 2 infected in african green monkey Vero cells assessed inhibition of virus-induced effect after 48 hrs by MTT assay | 2001 | Journal of natural products, Oct, Volume: 64, Issue:10 | Structure-activity relationship of in vitro antiviral and cytotoxic activity of semisynthetic analogues of scopadulane diterpenes. |
| AID84248 | In vitro antiviral activity against herpesvirus, HSV-1,E-377 strain by plaque reduction assay in human foreskin fibroblasts | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5 | Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS. |
| AID540215 | Volume of distribution at steady state in rat after iv administration | 2005 | Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7 | Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. |
| AID611622 | Antiviral activity against Feline herpesvirus infected in CRFK cells assessed as protection against virus-induced cytopathicity | 2011 | Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11 | New prodrugs of Adefovir and Cidofovir. |
| AID83528 | Anti-VZV activity against YS/R TK- in HEL cells | 1998 | Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25 | Synthesis of imidazo[1,2-a]pyridines as antiviral agents. |
| AID1592935 | Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in African green monkey Vero cells assessed as inhibition of viral replication after 48 hrs by naphthol blue-black staining-based plaque reduction assay | |||
| AID87971 | Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by herpes simplex virus (HSV)-1 (K979) in vero cells. | 1988 | Journal of medicinal chemistry, Sep, Volume: 31, Issue:9 | Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity. |
| AID1079938 | Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source] | |||
| AID340472 | Antiviral activity against VZV Webster by plaque reduction assay | 2008 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14 | Synthesis of 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamides with broad-spectrum human herpesvirus polymerase inhibition. |
| AID297316 | Antiviral activity against Vaccinia virus in HEL cells assessed as reduction of virus-induced cytopathogenicity | 2007 | Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17 | Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives. |
| AID561625 | Volume of distribution in patient with Epstein-Barr virus infection at 500 mg/kg, po administered every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. |
| AID217597 | Comparative Potency (IC50s) at HSV-1 passage 10 in vero cells | 1998 | Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16 | Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. |
| AID277828 | Cytotoxicity against E6SM cells | 2007 | Journal of natural products, Feb, Volume: 70, Issue:2 | Cinnamacrins A-C, cinnafragrin D, and cytostatic metabolites with alpha-glucosidase inhibitory activity from Cinnamosma macrocarpa. |
| AID1450225 | Selectivity index, ratio of MCC for African green monkey Vero E6 cells to IC50 for acyclovir and cidofovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells | 2017 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11 | New modified 2-aminobenzimidazole nucleosides: Synthesis and evaluation of their activity against herpes simplex virus type 1. |
| AID235465 | Selectivity index calculated as CC50/EC50 in the VPR assay of HSV-1; ND: No data | 2003 | Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23 | Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine. |
| AID561619 | Volume of distribution in immunocompromized children at 10.5 mg/kg, iv | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. |
| AID83183 | Concentration required to reduce varicella zoster virus(VZV)OKA plaque formation by 50% at 20 plaque forming units(PFU) in human embryonic lung (HEL) cell cultures. | 1992 | Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12 | (+-)-carbocyclic 5'-nor-2'-deoxyguanosine and related purine derivatives: synthesis and antiviral properties. |
| AID436485 | Cytotoxicity against hamster BHK21 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay | 2009 | Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13 | Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives. |
| AID1450221 | Selectivity index, ratio of MCC for African green monkey Vero E6 cells to IC50 for HSV-1 F+ infected in African green monkey Vero E6 cells | 2017 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11 | New modified 2-aminobenzimidazole nucleosides: Synthesis and evaluation of their activity against herpes simplex virus type 1. |
| AID116782 | Mean survival time in HSV-1 infected mice, after peroral administration of 100 mg/kg | 1988 | Journal of medicinal chemistry, Sep, Volume: 31, Issue:9 | Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity. |
| AID611616 | Antiviral activity against acyclovir-resistant Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity | 2011 | Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11 | New prodrugs of Adefovir and Cidofovir. |
| AID575029 | Antiviral activity against Herpes simplex virus 2 isolate 14 harboring G39E, N78D, M70R mutations in thymidine kinase and A724V mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. |
| AID224336 | Inhibitory effect on KOS strain of Herper simplex virus-1 yield, in primary rabbit kidney cell culture at 0.1 ug/mL concentration after 24 hours | 1987 | Journal of medicinal chemistry, Jun, Volume: 30, Issue:6 | Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases. |
| AID64101 | Minimum inhibitory concentration (MIC) required to reduce McIntyre strain of HSV-1 induced cytopathogenicity by 50% in E6SM cells | 1992 | Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8 | Synthesis and antiviral activity of acyclic nucleosides with a 3(S),5-dihydroxypentyl or 4(R)-methoxy-3(S),5-dihydroxypentyl side chain. |
| AID1572732 | Cytotoxicity against HEL cells assessed as effect on cell morphology at 0.32 to 200 uM by microscopic analysis | 2019 | Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6 | Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives. |
| AID563742 | Selectivity index, ratio of CC50 for HFF to EC50 for HSV2 MS infected in HFF | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides. |
| AID1593187 | Therapeutic index, ratio of CC50 of rhesus monkey FRhK cells to IC50 of antiviral activity against Hepatitis A virus infected in rhesus monkey FRhK4 cells assessed as inhibition in viral adsorption using cells pre-incubated with compound for 24 hrs before | 2019 | European journal of medicinal chemistry, Apr-15, Volume: 168 | New 4-phenylcoumarin derivatives as potent 3C protease inhibitors: Design, synthesis, anti-HAV effect and molecular modeling. |
| AID1651494 | Antiviral activity against ACV-resistant Herpes simplex virus 1 AR-29 infected in female Balb/c mouse assessed as reduction in zosteriform lesion at 50 mg/g applied topically as cream formulation 5 times a day at 3 hrs interval for 10 days measured on day | |||
| AID574386 | Antiviral activity against Thymidine kinase-deficient Varicella-zoster virus 07-1 infected in HELF assessed as virus-induced cytopathogenicity after 5 days by microscopy | 2011 | Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3 | Synthesis and SAR studies on azetidine-containing dipeptides as HCMV inhibitors. |
| AID431636 | Cytotoxicity against human CEM cells assessed as decrease in cell viability | 2009 | Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17 | The application of phosphoramidate protide technology to acyclovir confers anti-HIV inhibition. |
| AID82858 | Antiviral activity in TK+ varicella zoster virus (VZV) OKA strain in HEL cell culture | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20 | Acyclic nucleotide analogs derived from 8-azapurines: synthesis and antiviral activity. |
| AID1071712 | Antiviral activity against HSV1 assessed as inhibition of viral infection | 2014 | European journal of medicinal chemistry, Mar-03, Volume: 74 | Synthesis and biological evaluation of 2-oxonicotinonitriles and 2-oxonicotinonitrile based nucleoside analogues. |
| AID386623 | Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy | 2008 | Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19 | Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. |
| AID155219 | Antiherpes activity was tested as percent of control of plaque-formation against PFAr virus by 5 uM of the compound | 1985 | Journal of medicinal chemistry, Jul, Volume: 28, Issue:7 | Synthesis and biological activities of 2-pyrimidinone nucleosides. 2. 5-Halo-2-pyrimidinone 2'-deoxyribonucleosides. |
| AID91500 | Inhibitory concentration required to reduce HSV-1 induced virus plaque reduction (VPR) in human skin fibroblast | 2003 | Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23 | Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine. |
| AID260294 | Cytotoxicity against HEL cells | 2006 | Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4 | Inactivation of S-adenosyl-L-homocysteine hydrolase by 6'-cyano-5',6'-didehydro-6'-deoxyhomoadenosine and 6'-chloro-6'-cyano-5',6'-didehydro-6'-deoxyhomoadenosine. Antiviral and cytotoxic effects. |
| AID83501 | Cytotoxic concentration required to inhibit HEL cell growth by 50 % | 2001 | Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3 | Bicyclic nucleoside inhibitors of Varicella-Zoster Virus (VZV): the effect of terminal unsaturation in the side chain. |
| AID425241 | fCmax in horse at 10 mg/kg, iv after 1 hr by three-compartmental study | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID218506 | Concentration required to inhibit plaque formation by HSV-1 strain KOSSB (TK-) in monolayers of vero cells | 2001 | Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22 | Novel 5-vinyl pyrimidine nucleosides with potent anti-hepatitis B virus activity. |
| AID280177 | Antiviral activity against HSV2 Lyons in HEL cells assessed as inhibition of virus-induced cytopathicity | 2007 | Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5 | Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds. |
| AID304886 | Cytotoxicity against HEL cells assessed as alteration in cell morphology | 2007 | Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26 | Synthesis and antiviral activity of the carbocyclic analogue of the highly potent and selective anti-VZV bicyclo furano pyrimidines. |
| AID246708 | Effective concentration to reduce plaque formation of thymidine kinase positive Varicella zoster virus TK+ VZ OKA strain in human embryonic lung cell cultures | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | The novel L- and D-amino acid derivatives of hydroxyurea and hydantoins: synthesis, X-ray crystal structure study, and cytostatic and antiviral activity evaluations. |
| AID425255 | Total mean residence time in horse at 10 mg/kg, iv after 1 hr by two-compartmental study | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID83360 | Effective concentration required to inhibit Tyrosine kinase deficient (TK-) Varicella-Zoster virus-induced cytopathicity by 50% in 07/01 strain HEL cell lines | 2001 | Journal of medicinal chemistry, Aug-16, Volume: 44, Issue:17 | Synthesis, mechanism of action, and antiviral activity of a new series of covalent mechanism-based inhibitors of S-adenosyl-L-homocysteine hydrolase. |
| AID768206 | Antiviral activity against TK-positive Varicella-zoster virus OKA infected in human HEL cells assessed as reduction of plaque formation | 2013 | European journal of medicinal chemistry, Aug, Volume: 66 | Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies. |
| AID85558 | Concentration required to reduce cytopathogenicity of Herpes simplex virus type 1 (strain KOS) by 50% in primary rabbit kidney (PRK) cells | 1984 | Journal of medicinal chemistry, Nov, Volume: 27, Issue:11 | Nucleic acid related compounds. 47. Synthesis and biological activities of pyrimidine and purine "acyclic" nucleoside analogues. |
| AID84225 | Minimum inhibitory concentration was determined against HSV-1 (KOS) in E6SM cell culture | 2000 | Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4 | The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine. |
| AID88116 | Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by Herpes simplex virus(HSV) -2 (thymidine kinase deficient) in vero cells | 1988 | Journal of medicinal chemistry, Sep, Volume: 31, Issue:9 | Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity. |
| AID85401 | Antiviral activity against DNA polymerase mutant resistant to PFA 5a(PFA) was determined at a conc of 50 uM | 1987 | Journal of medicinal chemistry, Nov, Volume: 30, Issue:11 | Acetylenic nucleosides. 4. 1-beta-D-arabinofuranosyl-5-ethynylcytosine. Improved synthesis and evaluation of biochemical and antiviral properties. |
| AID429199 | Antiviral activity against human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection | 2009 | European journal of medicinal chemistry, Aug, Volume: 44, Issue:8 | Synthesis and anti-VZV activity of 6-heteroaryl derivatives of tricyclic acyclovir and 9-{[cis-1',2'-bis(hydroxymethyl)cycloprop-1'-yl]methyl}guanine analogues. |
| AID563771 | Antiviral activity against HSV1 B-2006 harboring frameshift mutation at Q185 in TK infected in HFF after 3 days by plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides. |
| AID282644 | Inhibition of HSV1 replication in BSC1 cells by ELISA | 2004 | Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27 | (Z)- and (E)-[2-Fluoro-2-(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines, a new class of methylenecyclopropane analogues of nucleosides: synthesis and antiviral activity. |
| AID85424 | In vitro antiviral activity against herpesvirus, HSV-HEET strain by plaque reduction assay in human foreskin fibroblasts. | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5 | Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS. |
| AID1402827 | Antiviral activity against acyclovir-resistant HSV1 KOS harboring TK- mutant infected in HEL cells assessed as reduction in virus-induced cytopathic effect after 2 to 3 days | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Emimycin and its nucleoside derivatives: Synthesis and antiviral activity. |
| AID1869620 | Cytotoxicity against human HFF cells infected with VZV Ellen virus assessed as reduction in cell viability by cell titer-glo assay | 2022 | Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13 | Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound. |
| AID467612 | Fraction unbound in human plasma | 2009 | European journal of medicinal chemistry, Nov, Volume: 44, Issue:11 | Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data. |
| AID259181 | Antiviral activity against HIV1 IIIB in CEM cells | 2006 | Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1 | Synthesis and antiviral evaluation of cyclic and acyclic 2-methyl-3-hydroxy-4-pyridinone nucleoside derivatives. |
| AID90777 | Antiviral activity against human cytomegalovirus Davis which reduces virus plaque formation by 50%; ND denotes no data | 2002 | Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19 | Synthesis and antiviral/antiproliferative activity of some N-sulphonylbenzimidazoles. |
| AID636698 | Antiviral activity against HCMV Towne infected in HFF cells incubated for 10 days by plaque reduction assay | 2011 | Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16 | Tyrosine-based 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine and -adenine ((S)-HPMPC and (S)-HPMPA) prodrugs: synthesis, stability, antiviral activity, and in vivo transport studies. |
| AID1407619 | Antiviral activity against Human cytomegalovirus AD169 strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Synthesis of a 3'-C-ethynyl-β-d-ribofuranose purine nucleoside library: Discovery of C7-deazapurine analogs as potent antiproliferative nucleosides. |
| AID1394845 | Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07-1 infected in HEL cells assessed as inhibition of plaque formation measured after 5 days post infection | 2018 | European journal of medicinal chemistry, Apr-25, Volume: 150 | Synthesis and antiviral evaluation of cyclopentyl nucleoside phosphonates. |
| AID85422 | Minimal inhibitory concentration to reduce virus-induced cytopathicity against G strain of human Herpes Simplex Virus-2 | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Fluorescent tricyclic analogues of acyclovir and ganciclovir. A structure-antiviral activity study. |
| AID218248 | Evaluated for the antiviral activity against Vero cells by proliferation assays (in uninfected cells) | 1990 | Journal of medicinal chemistry, Apr, Volume: 33, Issue:4 | Acyclic purine phosphonate analogues as antiviral agents. Synthesis and structure-activity relationships. |
| AID697724 | Antiviral activity against HSV1 infected herpes simplex keratitis New zealand rabbit model assessed as reduction in corneal epithelia involvement score at 0.025% to 0.1% administered twice daily as gel 24 hrs post inoculation measured on day 9 post infect | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14 | Anti-herpes simplex virus efficacies of 2-aminobenzamide derivatives as novel HSP90 inhibitors. |
| AID120294 | In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through intraperitoneal at a dose 100 mg/kg per day | 1985 | Journal of medicinal chemistry, Nov, Volume: 28, Issue:11 | 5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue. |
| AID634759 | Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID634761 | Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID116781 | Mean survival time in HSV-1 infected mice, after intraperitoneal administration of 25 mg/kg | 1988 | Journal of medicinal chemistry, Sep, Volume: 31, Issue:9 | Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity. |
| AID595590 | Cytotoxicity against human HFF cells infected with Cowpox virus (Brighton Red) assessed as viable cells by neutral red uptake assay | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | Broad-spectrum antiviral activity including human immunodeficiency and hepatitis C viruses mediated by a novel retinoid thiosemicarbazone derivative. |
| AID122719 | Toxicity of compound against mice was determined at a concentration of 100 mg/kg | 1986 | Journal of medicinal chemistry, Feb, Volume: 29, Issue:2 | Systematic synthesis and biological evaluation of alpha- and beta-D-xylofuranosyl nucleosides of the five naturally occurring bases in nucleic acids and related analogues. |
| AID218207 | Tested in vitro for minimum inhibitory concentration against herpes simplex virus-2 (HSV-2) curtis strain by plaque-reduction assay in vero cells | 1993 | Journal of medicinal chemistry, May-28, Volume: 36, Issue:11 | 3-Quinolinecarboxamides. A series of novel orally-active antiherpetic agents. |
| AID732671 | Immunoregulatory activity in Hepatitis B virus infected transgenic mouse assessed as increase in CD3+ population in peripheral blood at 100 mg/kg qd for 1 month by flow cytometry (Rvb = 30.1 +/-2.9%) | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and biological evaluation of nucleoside analogues than contain silatrane on the basis of the structure of acyclovir (ACV) as novel inhibitors of hepatitis B virus (HBV). |
| AID429197 | Antiviral activity against Varicella zoster virus OKA infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days | 2009 | European journal of medicinal chemistry, Aug, Volume: 44, Issue:8 | Synthesis and anti-VZV activity of 6-heteroaryl derivatives of tricyclic acyclovir and 9-{[cis-1',2'-bis(hydroxymethyl)cycloprop-1'-yl]methyl}guanine analogues. |
| AID83723 | In Vitro antiviral activity against HSV-1 at 50 ug/mL concentration | 1994 | Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19 | Synthesis of new acyclic pyrimidine nucleoside analogs as potential antiviral drugs. |
| AID697728 | Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for HSV2 strain 333 infected in african green monkey Vero cells | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14 | Anti-herpes simplex virus efficacies of 2-aminobenzamide derivatives as novel HSP90 inhibitors. |
| AID1884110 | Antiviral activity against HSV-2 infected in African green monkey Vero cells assessed as inhibition of viral replication incubated for 1 hr followed by washing with PBS and subsequent treatment with compound for 24 hrs by plaque reduction assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Synthetic derivatives of the antifungal drug ciclopirox are active against herpes simplex virus 2. |
| AID1504160 | Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for HSV1/F | 2017 | Journal of natural products, 11-22, Volume: 80, Issue:11 | Houttuynoid M, an Anti-HSV Active Houttuynoid from Houttuynia cordata Featuring a Bis-houttuynin Chain Tethered to a Flavonoid Core. |
| AID383519 | Antiviral activity against in Vesicular stomatitis virus in human HEL cells assessed as reduction of virus-induced cytopathogenicity | 2008 | European journal of medicinal chemistry, Feb, Volume: 43, Issue:2 | Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents. |
| AID87486 | Antiviral activity against Herpes simplex virus type-1 (HSV-1). | 1999 | Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15 | Nucleosides and nucleotides. 185. Synthesis and biological activities of 4'alpha-C-branched-chain sugar pyrimidine nucleosides. |
| AID491531 | Binding affinity to Mycobacterium tuberculosis purine nucleoside phosphorylase by spectrophotometric analysis | 2010 | Bioorganic & medicinal chemistry, Jul-01, Volume: 18, Issue:13 | Crystallographic and docking studies of purine nucleoside phosphorylase from Mycobacterium tuberculosis. |
| AID1323834 | Displacement of [3H]rosiglitazone from recombinant human C-terminal His-tagged MitoNEET cytosolic domain (32 to 108 residues) expressed in Escherichia coli BL21 by scintillation proximity assay | 2016 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21 | Identification of small molecules that bind to the mitochondrial protein mitoNEET. |
| AID280188 | Cytotoxicity against HEL cells assessed as inhibition of cell growth after 3 days | 2007 | Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5 | Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds. |
| AID81052 | Concentration required to inhibit CMV (Davis) induced cytopathogenicity in HEL cells by 50% | 1991 | Journal of medicinal chemistry, Aug, Volume: 34, Issue:8 | Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir. |
| AID1857461 | Elimination half life in rat | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Treatment Option for Acyclovir-Resistant Herpes Simplex Virus Infections. |
| AID63761 | The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 2 (196 strain) | 1994 | Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19 | Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity. |
| AID425240 | Total Cmax in horse at 10 mg/kg, iv after 1 hr by two-compartmental study | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID216465 | Antiviral activity against Varicella-Zoster virus (OKA) | 2004 | Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10 | Bicyclic anti-VZV nucleosides: thieno analogues bearing an alkylphenyl side chain have reduced antiviral activity. |
| AID1464789 | Anti-viral activity against Herpes simplex virus-1 harboring EGFP infected in iPSC-derived neurons assessed as viable cells at 10 mM treated 2 hrs post infection measured after 72 hrs by Alexa fluor 488 staining based flow cytometric analysis (Rvb = 17.8% | 2017 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 27, Issue:20 | Discovery of potent antiviral (HSV-1) quinazolinones and initial structure-activity relationship studies. |
| AID388923 | Cytotoxicity against HEL cells assessed as reduction of growth after 3 days | 2008 | Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21 | Influence of 6- or 8-substitution on the antiviral activity of 3-arylalkylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (CMV) and varicella-zoster virus (VZV): part II. |
| AID1274005 | Antiviral activity against HHV-1 CDC Atlanta infected in African green monkey Vero cells assessed as reduction in plaque formation administered simultaneously with virus for 1 hr measured after 72 hrs by crystal violet staining technique | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Anti-herpetic and anti-dengue activity of abietane ferruginol analogues synthesized from (+)-dehydroabietylamine. |
| AID342119 | Antiviral activity against TK+ VZV YS infected HEL cells assessed as reduction in virus plaque formation after 5 days | 2008 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 18, Issue:15 | Successful kinase bypass with new acyclovir phosphoramidate prodrugs. |
| AID217601 | Comparative Potency (IC50s) at HSV-1 passage 5 in vero cells | 1998 | Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16 | Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. |
| AID260291 | Antiviral activity against TK+ VZV OKA in human embryonic lung cells | 2006 | Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4 | Inactivation of S-adenosyl-L-homocysteine hydrolase by 6'-cyano-5',6'-didehydro-6'-deoxyhomoadenosine and 6'-chloro-6'-cyano-5',6'-didehydro-6'-deoxyhomoadenosine. Antiviral and cytotoxic effects. |
| AID218429 | Tested for growth inhibition against WI-38 cells | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID216308 | The compound was tested for its effective concentration required to reduce virus plaque formation by using Varicella-Zoster virus YS strain | 2000 | Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11 | Bicyclic nucleoside inhibitors of Varicella-Zoster Virus (VZV): the effect of a terminal halogen substitution in the side-chain. |
| AID87970 | Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by Herpes simplex virus-1 (K979) in HEp-2 cells | 1988 | Journal of medicinal chemistry, Sep, Volume: 31, Issue:9 | Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity. |
| AID1337441 | Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus plaque formation | 2016 | European journal of medicinal chemistry, Nov-29, Volume: 124 | Identification of an indol-based derivative as potent and selective varicella zoster virus (VZV) inhibitor. |
| AID81030 | The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK-(deficient) 07/1 strain | 1999 | Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14 | Novel pyrimidine and purine derivatives of L-ascorbic acid: synthesis and biological evaluation. |
| AID563783 | Selectivity ratio of EC50 for 4'-thioIDU-resistant HSV2 infected in HFF to EC50 for HSV2 MS infected in HFF | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides. |
| AID296677 | Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 7 days | 2007 | Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16 | Synthesis and antiviral evaluation of 6-(alkyl-heteroaryl)furo[2,3-d]pyrimidin-2(3H)-one nucleosides and analogues with ethynyl, ethenyl, and ethyl spacers at C6 of the furopyrimidine core. |
| AID53487 | Inhibition of DNA polymerase | 1988 | Journal of medicinal chemistry, Dec, Volume: 31, Issue:12 | Synthesis and antiherpetic activity of (+/-)-9-[[(Z)-2-(hydroxymethyl)cyclopropyl]methyl]guanine and related compounds. |
| AID1283373 | Antiviral activity against HSV1 KOS ATCC VR1493 infected in human iPSC cells assessed as reduction in expression of ICP4 at 50 uM measured 24 hrs post infection by western blot analysis | 2016 | ACS medicinal chemistry letters, Jan-14, Volume: 7, Issue:1 | iPSC Neuronal Assay Identifies Amaryllidaceae Pharmacophore with Multiple Effects against Herpesvirus Infections. |
| AID137475 | Number of survivors against Herpes simplex virus type-2 infection in mice at 150 mg/kg/day | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID217808 | Antiviral activity against vaccinia virus (CL strain) | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID81032 | The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK-(deficient) YS/R strain | 1999 | Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14 | Novel pyrimidine and purine derivatives of L-ascorbic acid: synthesis and biological evaluation. |
| AID425250 | Free volume of distribution in central compartment in horse at 10 mg/kg, iv after 1 hr by three-compartmental study | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID1382167 | Cytotoxicity against HEL cells assessed as alteration of cell morphology by microscopic method | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Highly convergent synthesis and antiviral activity of (E)-but-2-enyl nucleoside phosphonoamidates. |
| AID1407618 | Antiviral activity against thymidine kinase-deficient Varicella Zoster virus 07-1 strain infected in HELF cells assessed as inhibition of virus-induced plaque formation | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Synthesis of a 3'-C-ethynyl-β-d-ribofuranose purine nucleoside library: Discovery of C7-deazapurine analogs as potent antiproliferative nucleosides. |
| AID609576 | Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 strain KOS assessed as reduction of virus induced cytopathicity by cell based assay | 2011 | Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15 | Acyclic nucleoside phosphonates with a branched 2-(2-phosphonoethoxy)ethyl chain: efficient synthesis and antiviral activity. |
| AID1219932 | Drug transport in human OAT1 expressed in HEK Flp-In cells at 0.06 uM for 10 mins relative to control | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3 | Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs. |
| AID218504 | Concentration required to inhibit plaque formation by HSV-1 strain KOS (TK+) in monolayers of vero cells | 2001 | Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22 | Novel 5-vinyl pyrimidine nucleosides with potent anti-hepatitis B virus activity. |
| AID309815 | Cytotoxicity against HEL cells assessed as reduction of cell growth after 3 days | 2007 | Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22 | Influence of 6 or 8-substitution on the antiviral activity of 3-phenethylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (HCMV) and varicella-zoster virus (VZV). |
| AID84939 | Compound was evaluated for antiviral activity against HSV-2 reported as ED50 value | 1987 | Journal of medicinal chemistry, Jan, Volume: 30, Issue:1 | Synthesis and biological evaluation of acyclic neplanocin analogues. |
| AID76486 | Effect on the growth of Herpes simplex Type 1 on the skin of Guinea pigs infected intradermally on day 1 at 5% concentration | 1984 | Journal of medicinal chemistry, May, Volume: 27, Issue:5 | Synthesis of some phosphonates with antiherpetic activity. |
| AID1450218 | Antiviral activity against HSV-1 L2/Rp-ACV/2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect | 2017 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11 | New modified 2-aminobenzimidazole nucleosides: Synthesis and evaluation of their activity against herpes simplex virus type 1. |
| AID250796 | Effect on HSV-2 encephalitis in mice following intraperitoneal dosage at 100 mg/kg; expressed as mean day of death | 2005 | Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11 | Inhibition of herpes simplex virus thymidine kinases by 2-phenylamino-6-oxopurines and related compounds: structure-activity relationships and antiherpetic activity in vivo. |
| AID595579 | Cytotoxicity against human HFF cells infected with Human cytomegalovirus AD169 assessed as viable cells by neutral red uptake assay | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | Broad-spectrum antiviral activity including human immunodeficiency and hepatitis C viruses mediated by a novel retinoid thiosemicarbazone derivative. |
| AID1450212 | Cytotoxicity against African green monkey Vero E6 cells measured after 3 days by trypan blue assay | 2017 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11 | New modified 2-aminobenzimidazole nucleosides: Synthesis and evaluation of their activity against herpes simplex virus type 1. |
| AID447283 | Cytotoxicity against african green monkey Vero cells | 2009 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19 | Pyrazolopyrimidines and pyrazolotriazines with potent activity against herpesviruses. |
| AID218226 | Zone of inhibition of plaque formation in vero cells inoculated with HSV-1 virus along with disks containing 50 ug of compound; 11-50 mm zone of inhibition | 1985 | Journal of medicinal chemistry, Aug, Volume: 28, Issue:8 | Modifications on the heterocyclic base of acyclovir: syntheses and antiviral properties. |
| AID217662 | Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV OKA Plaque formation after 5 days in HEL cell cultures compared to untreated controls. | 2000 | Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26 | Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain. |
| AID1869618 | Selectivity index, ratio of CC50 for cytotoxicity against human HFF cells infected with HCMV AD-169 virus assessed as reduction in cell viability by cell titer-glo assay to EC50 for antiviral activity against HCMV AD-169 infected in HFF cells assessed as | 2022 | Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13 | Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound. |
| AID246317 | Effective concentration required to reduce Varicella Zoster virus YS plaque formation by using DMSO as solvent | 2005 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 15, Issue:16 | Bicyclic nucleoside inhibitors of Varicella-Zoster virus: the effect of branching in the p-alkylphenyl side chain. |
| AID84084 | Inhibitory activity against HSV-1 (F) replication in E6SM cell cultures of human embryonic skin-muscle | 2002 | Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25 | A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity. |
| AID85373 | Inhibitory concentration against HSV type 1 strain KOS in human embryonic skin muscle (ESM) fibroblast cell culture | 1993 | Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14 | Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides. |
| AID1572733 | Antiviral activity against Varicella-zoster virus Oka harboring thymidine kinase infected in HEL cells assessed as reduction in virus plaque formation | 2019 | Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6 | Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives. |
| AID458870 | Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in HEL cells assessed as reduction of viral plaque formation | 2010 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3 | Practical and efficient synthesis of pyrano[3,2-c]pyridone, pyrano[4,3-b]pyran and their hybrids with nucleoside as potential antiviral and antileishmanial agents. |
| AID595588 | Antiviral activity against Cowpox virus (Brighton Red) infected in human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | Broad-spectrum antiviral activity including human immunodeficiency and hepatitis C viruses mediated by a novel retinoid thiosemicarbazone derivative. |
| AID246356 | Effective concentration required to reduce HSV-1 strain KOS ACV virus plaque formation by 50% in E6SM Cell Culture | 2004 | Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22 | 6-azapyrimidine-2'-deoxy-4'-thionucleosides: antiviral agents against TK+ and TK- HSV and VZV strains. |
| AID687660 | Antiviral activity against Vaccinia virus infected in HEL assessed as inhibition of virus-induced cytopathicity after 3 days | 2012 | European journal of medicinal chemistry, Nov, Volume: 57 | Synthesis and antiviral evaluation of bis(POM) prodrugs of (E)-[4'-phosphono-but-2'-en-1'-yl]purine nucleosides. |
| AID46567 | In vitro anti-HIV screen using HIV-1 infected CD4 lymphocytes (CEM cell line), determines cytotoxicity | 2002 | Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3 | 5-Bromo (or chloro)-6-azido-5,6-dihydro-2' -deoxyuridine and -thymidine derivatives with potent antiviral activity. |
| AID1113471 | Antiviral activity against Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay | 2013 | Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4 | Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)- |
| AID342117 | Cytotoxicity against HEL cells assessed as alteration of cell morphology | 2008 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 18, Issue:15 | Successful kinase bypass with new acyclovir phosphoramidate prodrugs. |
| AID136149 | Percentage survival of mice after intraperitoneal administration of compound at 200 mg/kg per day in experiment 2; survival/ tested =7/9 | 1989 | Journal of medicinal chemistry, Jul, Volume: 32, Issue:7 | Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. |
| AID218202 | Tested in vitro for minimum inhibitory concentration against herpes simplex virus-2 (HSV-2) 2115 strain by plaque-reduction assay in vero cells | 1993 | Journal of medicinal chemistry, May-28, Volume: 36, Issue:11 | 3-Quinolinecarboxamides. A series of novel orally-active antiherpetic agents. |
| AID1230102 | Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Design, antiviral and cytostatic properties of isoxazolidine-containing amonafide analogues. |
| AID521920 | Tmax in human systemic circulation with normal renal function at 2000 mg, po every 6 hrs measured after fifth dose by radioimmunoassay | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. |
| AID575027 | Antiviral activity against Herpes simplex virus 2 isolate 12 harboring G39E, N78D, L140F, S66P, A72S mutations in thymidine kinase and A9T, P15S, L60P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. |
| AID260293 | Cytotoxicity as determined by alteration in the cell morphology of HEL cells | 2006 | Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4 | Inactivation of S-adenosyl-L-homocysteine hydrolase by 6'-cyano-5',6'-didehydro-6'-deoxyhomoadenosine and 6'-chloro-6'-cyano-5',6'-didehydro-6'-deoxyhomoadenosine. Antiviral and cytotoxic effects. |
| AID88300 | In vitro anti viral activity tested against HSV-2(Curtis) virus on Rabbit kidney cell cultures; 1-3 | 1985 | Journal of medicinal chemistry, Jul, Volume: 28, Issue:7 | Synthesis and antiherpetic activity of (S)-, (R)-, and (+/-)-9-[(2,3-dihydroxy-1-propoxy)methyl]guanine, linear isomers of 2'-nor-2'-deoxyguanosine. |
| AID444050 | Fraction unbound in human plasma | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID365174 | Antiviral activity against HCMV 6 with U97 mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity | 2008 | Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18 | 4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action. |
| AID1211782 | AUC (0 to 180 mins) in PepT1 knockout mouse treated with 25 nmol/g, po of valacyclovir | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3 | Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice. |
| AID217646 | Antiviral activity against Varicella zoster virus (Kanno-Kohmura thymidine kinase deficient strain) | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID106177 | Antiviral activity in plaque reduction assay was determined against herpes simplex virus type 2 (HSV-2) in MRC-5 cells. | 1990 | Journal of medicinal chemistry, Jan, Volume: 33, Issue:1 | Synthesis and antiviral activity of 9-alkoxypurines. 1. 9-(3-Hydroxypropoxy)- and 9-[3-hydroxymethyl)propoxy]purines. |
| AID436483 | Antiviral activity against Respiratory syncytial virus A2 infected in Vero-76 cells after 5 days by plaque reduction assay | 2009 | Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13 | Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives. |
| AID106187 | Compound was tested for antiviral activity against Herpes Simplex virus Type-1(HFEM) in human lung fibroblasts (MRC-5) | 1987 | Journal of medicinal chemistry, Sep, Volume: 30, Issue:9 | Synthesis and antiviral activity of 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]purines. |
| AID232895 | Ralative safety was expressed as Selective index (TC50/IC50) at HSV-2 passage 4 in vero cells | 1998 | Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16 | Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. |
| AID82891 | Tested for inhibitory effect on DNA virus VZV (Oka) in HEL cell line | 1993 | Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23 | Synthesis and antiviral activity of 5'-deoxypyrazofurin. |
| AID580315 | Antiviral activity against HSV1 infected in african green monkey Vero cells assessed as reduction of UL27 expression at 1 uM after up to 24 hrs by RT-PCR analysis | 2011 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6 | Synthesis and in vitro anti-HSV-1 activity of a novel Hsp90 inhibitor BJ-B11. |
| AID510175 | Cytotoxicity against MDBK cells after 48 hrs | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities. |
| AID425256 | Free mean residence time in horse at 10 mg/kg, iv after 1 hr by three-compartmental study | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID434320 | Cytotoxicity against HEL cells assessed as change in cell morphology | 2009 | European journal of medicinal chemistry, Sep, Volume: 44, Issue:9 | Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide. |
| AID83199 | Minimum inhibitory concentration required for antiviral activity to reduce Varicella Zoster virus (VZV) (Oka) induced cytopathicity in human embryonic lung cells (HEL) | 1994 | Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9 | Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues. |
| AID115157 | In vivo maximum tolerated dose against herpes simplex virus-2 (HSV-2) by oral administration in female mice | 1993 | Journal of medicinal chemistry, May-28, Volume: 36, Issue:11 | 3-Quinolinecarboxamides. A series of novel orally-active antiherpetic agents. |
| AID589394 | Antiviral activity against HSV1 by plaque reduction assay | 2011 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7 | Isatin-β-thiosemicarbazones as potent herpes simplex virus inhibitors. |
| AID218392 | In vitro antiviral activity against herpes simplex virus type 1 (E-377 strain) in Vero host cell cultures (MTC/ID50) | 1990 | Journal of medicinal chemistry, Apr, Volume: 33, Issue:4 | Synthesis and biological evaluation of carbocyclic analogues of lyxofuranosides of 2-amino-6-substituted-purines and 2-amino-6-substituted-8-azapurines. |
| AID218203 | In vitro minimum inhibitory concentration against herpes simplex virus-2 (HSV-2) by plaque-reduction assay in vero cells | 1993 | Journal of medicinal chemistry, May-28, Volume: 36, Issue:11 | 3-Quinolinecarboxamides. A series of novel orally-active antiherpetic agents. |
| AID85699 | In vivo efficacy of compound against HSV-1 strain A133 in the mouse system model was measured at 6.25 dose(mg/kg), activity expressed as Survivors counted on day 21; 0/10 | 1991 | Journal of medicinal chemistry, Mar, Volume: 34, Issue:3 | Fluorocarbocyclic nucleosides: synthesis and antiviral activity of 2'- and 6'-fluorocarbocyclic 2'-deoxy guanosines. |
| AID1545452 | Antiviral activity against Herpes simplex virus 1 at 20 ug/10'5 | 2019 | Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7 | Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances. |
| AID236912 | Permeability Coefficient in 2/4/A1 cell model | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | Exploring the role of different drug transport routes in permeability screening. |
| AID1427828 | Cytotoxicity against HEL cells infected with Varicella-Zoster virus assessed as growth inhibition | |||
| AID1450223 | Selectivity index, ratio of MCC for African green monkey Vero E6 cells to IC50 for acyclovir and foscarnet-resistant HSV-1 L2 infected in African green monkey Vero E6 cells | 2017 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11 | New modified 2-aminobenzimidazole nucleosides: Synthesis and evaluation of their activity against herpes simplex virus type 1. |
| AID1464795 | Anti-viral activity against Herpes simplex virus-1 harboring EGFP infected in iPSC-derived neurons assessed as late apoptotic cells at 50 mM treated 2 hrs post infection measured after 72 hrs by Alexa fluor 488 staining based flow cytometric analysis (Rvb | 2017 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 27, Issue:20 | Discovery of potent antiviral (HSV-1) quinazolinones and initial structure-activity relationship studies. |
| AID1854964 | Antiviral activity against Human cytomegalovirus AD-169 infected in HEL cells assessed as reduction in virus-induced cytopathic effect by microscopic analysis | 2022 | European journal of medicinal chemistry, Nov-05, Volume: 241 | Synthesis and antiviral properties of biomimetic iminosugar-based nucleosides. |
| AID376981 | Antiviral activity against RSV Long in human Hep2 cells assessed as reduction of virus induced cytopathic effect | 2006 | Journal of natural products, May, Volume: 69, Issue:5 | Antiviral flavans from the leaves of Pithecellobium clypearia. |
| AID84618 | In vivo efficacy of compound against HSV-2 strain A133 in the mouse system model was measured at 100 dose(mg/kg), activity expressed as Survivors counted on day 21; 7/10 | 1991 | Journal of medicinal chemistry, Mar, Volume: 34, Issue:3 | Fluorocarbocyclic nucleosides: synthesis and antiviral activity of 2'- and 6'-fluorocarbocyclic 2'-deoxy guanosines. |
| AID1261317 | Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID1385609 | Antiviral activity against HSV1 F VR 733 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect | 2018 | Journal of natural products, 08-24, Volume: 81, Issue:8 | Minor Nortriterpenoids from the Twigs and Leaves of Rhododendron latoucheae. |
| AID609571 | Antiviral activity against Varicella-zoster virus strain OKA expressing thymidine kinase assessed as reduction of virus induced cytopathicity by cell based assay | 2011 | Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15 | Acyclic nucleoside phosphonates with a branched 2-(2-phosphonoethoxy)ethyl chain: efficient synthesis and antiviral activity. |
| AID1422438 | Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method | 2018 | Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21 | Synthesis, biological evaluation and molecular modeling of a novel series of fused 1,2,3-triazoles as potential anti-coronavirus agents. |
| AID625292 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID257892 | Antiviral activity against Vesicular stomatitis virus in HEL cells | 2006 | Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2 | Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators. |
| AID1457765 | Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect | 2017 | Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14 | Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs. |
| AID210528 | Phosphorylation of compound by purified HSV-1 (F strain) thymidine kinase | 1986 | Journal of medicinal chemistry, Aug, Volume: 29, Issue:8 | Synthesis and anti-herpes-virus activity of acyclic 2'-deoxyguanosine analogues related to 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine. |
| AID218061 | Maximum nontoxic dose that allow exponential cell growth for three cell cycles | 1990 | Journal of medicinal chemistry, Oct, Volume: 33, Issue:10 | Synthesis and antimicrobial and cytotoxic activities of pyrrole-containing analogues of trichostatin A. |
| AID246523 | Effective concentration required to reduce TK+ (thymidine kinase presence) VZV strain YS virus plaque formation by 50% in HEL cell culture | 2004 | Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22 | 6-azapyrimidine-2'-deoxy-4'-thionucleosides: antiviral agents against TK+ and TK- HSV and VZV strains. |
| AID1420631 | Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for HSV1 KOS | 2018 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20 | Synthesis and biological evaluation of isoxazolyl-sulfonamides: A non-cytotoxic scaffold active against Trypanosoma cruzi, Leishmania amazonensis and Herpes Simplex Virus. |
| AID1451463 | Antiviral activity against Varicella-Zoster virus OKA infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect | 2017 | Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18 | Virtual Screening of Acyclovir Derivatives as Potential Antiviral Agents: Design, Synthesis, and Biological Evaluation of New Acyclic Nucleoside ProTides. |
| AID218415 | Anti viral activity against HCMV(AD169) in WI-38 cell monolayers | 1992 | Journal of medicinal chemistry, May-15, Volume: 35, Issue:10 | Synthesis and antiviral activity of 1-cyclobutyl-5-(2-bromovinyl)uracil nucleoside analogues and related compounds. |
| AID216154 | Effective concentration against TK+ Varicella-Zoster Virus (VZV)YS strain | 2003 | Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23 | Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine. |
| AID217656 | Minimum inhibitory concentration was determined against VZV (OKA) in HEL cells | 2000 | Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4 | The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine. |
| AID63592 | Minimum inhibitory conc. for 50% inhibition of HSV-1 (KOS) virus induced cytopathicity in E6SM cells | 1997 | Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9 | Carbocyclic oxetanocins lacking the C-3' methylene. |
| AID217580 | Concentration of compound required to reduce by 50% the number of herpes simplex virus (HSV-1) plaques in vero cells | 1992 | Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5 | Pyrazole-related nucleosides. Synthesis and antiviral/antitumor activity of some substituted pyrazole and pyrazolo[4,3-d]-1,2,3-triazin-4-one nucleosides. |
| AID1782678 | Selectivity index, ratio of CC50 for human HEL cells to EC50 for antiviral activity against thymidine kinase deficient Varicella zoster virus | 2021 | European journal of medicinal chemistry, Aug-05, Volume: 220 | Phenoxazine nucleoside derivatives with a multiple activity against RNA and DNA viruses. |
| AID84587 | Inhibitory effects on HSV-1 induced mortality in NMRI mice upon (ip) administration at a dose of 250 mk/kg/day | 2001 | Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22 | Design, synthesis, and biological evaluation of novel nucleoside and nucleotide analogues as agents against DNA viruses and/or retroviruses. |
| AID85709 | The compound was tested for plaque inhibition in HSV-1 in cell culture; +=active at 50 ug per disk | 1981 | Journal of medicinal chemistry, Dec, Volume: 24, Issue:12 | Purine acyclic nucleosides. Nitrogen isosteres of 9-[(2-hydroxyethoxy)methyl]guanine as candidate antivirals. |
| AID91276 | Cytotoxicity was determined at 320 uM | 1987 | Journal of medicinal chemistry, Nov, Volume: 30, Issue:11 | Synthesis and antiviral activity of carbocyclic analogues of xylofuranosides of 2-amino-6-substituted-purines and 2-amino-6-substituted-8-azapurines. |
| AID245947 | Cytotoxic concentration to inhibit Herpes simplex virus 1 infected HFF cells | 2005 | Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1 | Nucleotides and pronucleotides of 2,2-bis(hydroxymethyl)methylenecyclopropane analogues of purine nucleosides: synthesis and antiviral activity. |
| AID607906 | Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis | 2011 | Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14 | Design, synthesis and biological evaluation of 2'-deoxy-2',2'-difluoro-5-halouridine phosphoramidate ProTides. |
| AID588217 | FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID81035 | The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against cytomegalo virus AD-169 strain; Not determined | 1999 | Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14 | Novel pyrimidine and purine derivatives of L-ascorbic acid: synthesis and biological evaluation. |
| AID425268 | Oral bioavailability in human | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID1684811 | Selectivity index, ratio of CC50 for human HEL cells to EC50 for antiviral activity against thymidine kinase positive Varicella zoster virus OKA infected in human HEL cells | 2021 | ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1 | Influence of 4'-Substitution on the Activity of Gemcitabine and Its ProTide Against VZV and SARS-CoV-2. |
| AID96604 | Antitumor activity against murine leukemia L1210 cells | 1988 | Journal of medicinal chemistry, Jul, Volume: 31, Issue:7 | Synthesis and antiviral activity of novel N-substituted derivatives of acyclovir. |
| AID569238 | Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect | 2011 | European journal of medicinal chemistry, Feb, Volume: 46, Issue:2 | Synthesis of new C5-(1-substituted-1,2,3-triazol-4 or 5-yl)-2'-deoxyuridines and their antiviral evaluation. |
| AID218393 | In vitro antiviral activity against herpes simplex virus type 1 (E-377 strain) in Vero host cell cultures | 1990 | Journal of medicinal chemistry, Apr, Volume: 33, Issue:4 | Synthesis and biological evaluation of carbocyclic analogues of lyxofuranosides of 2-amino-6-substituted-purines and 2-amino-6-substituted-8-azapurines. |
| AID120299 | In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through intraperitoneal at a dose 5 mg/kg per day | 1985 | Journal of medicinal chemistry, Nov, Volume: 28, Issue:11 | 5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue. |
| AID218208 | In vitro maximum tolerated level against herpes simplex virus-2 (HSV-2) by plaque-reduction assay in vero cells | 1993 | Journal of medicinal chemistry, May-28, Volume: 36, Issue:11 | 3-Quinolinecarboxamides. A series of novel orally-active antiherpetic agents. |
| AID1183091 | Antiviral activity against Human herpesvirus 1 strain KOS ATCC VR- 1493 infected in Vero 76 cells after 3 days by plaque reduction assays | 2014 | European journal of medicinal chemistry, Sep-12, Volume: 84 | Synthesis and antiviral activity of new phenylimidazopyridines and N-benzylidenequinolinamines derived by molecular simplification of phenylimidazo[4,5-g]quinolines. |
| AID1610154 | Cytotoxicity against human HELF cells assessed as reduction in cell viability incubated for 3 days by coulter counter method | 2019 | European journal of medicinal chemistry, Dec-15, Volume: 184 | Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives. |
| AID436481 | Cytotoxicity against african green monkey Vero 76 cells by crystal violet staining | 2009 | Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13 | Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives. |
| AID91497 | Cytotoxic concentration that produces 50% growth inhibition of human skin fibroblast in VPR assay; ND: No data | 2003 | Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23 | Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine. |
| AID1283346 | Antiviral activity against HSV1 KOS ATCC VR1493 infected in African green monkey Vero cells assessed as viral titre at 50 uM treated at 2 hrs post infection measured 48 hrs post infection by flow cytometric analysis relative to control | 2016 | ACS medicinal chemistry letters, Jan-14, Volume: 7, Issue:1 | iPSC Neuronal Assay Identifies Amaryllidaceae Pharmacophore with Multiple Effects against Herpesvirus Infections. |
| AID218198 | Tested in vitro for minimum inhibitory concentration against herpes simplex virus-1 (HSV-1) KOS strain by plaque-reduction assay in vero cells | 1993 | Journal of medicinal chemistry, May-28, Volume: 36, Issue:11 | 3-Quinolinecarboxamides. A series of novel orally-active antiherpetic agents. |
| AID681039 | TP_TRANSPORTER: inhibition of Estrone sulfate uptake (E1S: 0.05 uM, ACV: 1000 uM) in OAT3-expressing S2 cells | 2002 | The Journal of pharmacology and experimental therapeutics, Mar, Volume: 300, Issue:3 | Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. |
| AID246376 | Effective concentration required to inhibit herpes simplex virus type 1 Kos strain induced cytopathicity in Hel cells | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | Synthesis and antiviral evaluation of cis-substituted cyclohexenyl and cyclohexanyl nucleosides. |
| AID85280 | In vitro antiviral activity against herpesvirus,HSV-2,HEET strain by plaque reduction assay in human foreskin fibroblasts | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5 | Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS. |
| AID113234 | Efficacy expressed as number of surviving mice infected with herpetic encephalitis at dose of 0 mg/kg | 1986 | Journal of medicinal chemistry, Feb, Volume: 29, Issue:2 | Systematic synthesis and biological evaluation of alpha- and beta-D-xylofuranosyl nucleosides of the five naturally occurring bases in nucleic acids and related analogues. |
| AID574385 | Antiviral activity against Thymidine kinase-positive Varicella-zoster virus Oka infected in HELF assessed as virus-induced cytopathogenicity after 5 days by microscopy | 2011 | Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3 | Synthesis and SAR studies on azetidine-containing dipeptides as HCMV inhibitors. |
| AID1256244 | Antiviral activity against Herpes simplex virus 2 strain MS VR-540 infected in African green monkey Vero cells after 3 days by MTT assay | 2015 | Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21 | Selenoacyclovir and Selenoganciclovir: Discovery of a New Template for Antiviral Agents. |
| AID682752 | Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for HSV-1F ATCC 733 | 2012 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19 | Structure based molecular design, synthesis and biological evaluation of α-pyrone analogs as anti-HSV agent. |
| AID425271 | Plasma concentration in horse at 20 mg/kg, po administered as single dose after 5 hrs | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID498602 | Antiviral activity against Macacine herpesvirus 1 isolate A6 infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds. |
| AID766700 | Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity | 2013 | European journal of medicinal chemistry, Sep, Volume: 67 | Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity. |
| AID383713 | Antiviral activity against HSV1 by colorimetric method | 2008 | Journal of natural products, May, Volume: 71, Issue:5 | Phenolic glycosides from the filamentous fungus Acremonium sp. BCC 14080. |
| AID83722 | In Vitro antiviral activity against HSV-1 at 5 ug/mL concentration | 1994 | Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19 | Synthesis of new acyclic pyrimidine nucleoside analogs as potential antiviral drugs. |
| AID218428 | Growth inhibitory activity against WI-38 cells | 1992 | Journal of medicinal chemistry, May-15, Volume: 35, Issue:10 | Synthesis and antiviral activity of 1-cyclobutyl-5-(2-bromovinyl)uracil nucleoside analogues and related compounds. |
| AID83045 | The minimum cytotoxic concentration was measured on Human Embryonic Lung (HEL) cells | 1999 | Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7 | Novel potential agents for human cytomegalovirus infection: synthesis and antiviral activity evaluation of benzothiadiazine dioxide acyclonucleosides. |
| AID118723 | Number of mice normal, without lesion after HSV-2 infection observed from day 0 to day 3 | 1987 | Journal of medicinal chemistry, Jun, Volume: 30, Issue:6 | Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases. |
| AID611621 | Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as protection against virus-induced cytopathicity | 2011 | Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11 | New prodrugs of Adefovir and Cidofovir. |
| AID1727352 | Antiviral activity against thymidine kinase positive Varicella zoster virus OKA infected in human HEL cells assessed as reduction in virus-induced cytopathogenic effect measured after 3 days coulter counter method | 2021 | European journal of medicinal chemistry, Jan-01, Volume: 209 | Extension of furopyrimidine nucleosides with 5-alkynyl substituent: Synthesis, high fluorescence, and antiviral effect in the absence of free ribose hydroxyl groups. |
| AID383516 | Antiviral activity against Vaccinia virus in human E6SM cells assessed as reduction of virus-induced cytopathogenicity | 2008 | European journal of medicinal chemistry, Feb, Volume: 43, Issue:2 | Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents. |
| AID588219 | FDA HLAED, gamma-glutamyl transferase (GGT) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID634754 | Antiviral activity against thymidine kinase-deficient Varicella Zoster virus 07/1 infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID255996 | Antiviral activity against herpes simplex virus type 1 KOS (AraAr13) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO | 2005 | Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18 | 4-Oxo-4,7-dihydrothieno[2,3-b]pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases. |
| AID501210 | Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay | 2010 | Journal of natural products, Feb-26, Volume: 73, Issue:2 | Phloroglucinol glycosides from the fresh fruits of Eucalyptus maideni. |
| AID82557 | Antiviral activity was measured as effective concentration required to reduce Varicella Zoster virus (YS)-induced plaque formation in human embryonic lung cells | 2001 | Bioorganic & medicinal chemistry letters, Sep-17, Volume: 11, Issue:18 | Bicyclic anti-VZV nucleosides: Thieno analogues retain full antiviral activity. |
| AID498588 | Antiviral activity against Macacine herpesvirus 1 isolate MR5 infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds. |
| AID1337435 | Antiviral activity against thymidine kinase deficient Varicella-Zoster virus YS-R infected in HEL cells assessed as inhibition of virus plaque formation | 2016 | European journal of medicinal chemistry, Nov-29, Volume: 124 | Identification of an indol-based derivative as potent and selective varicella zoster virus (VZV) inhibitor. |
| AID676764 | Antiviral activity against HSV-1 infected in african green monkey Vero cells assessed as inhibition of viral replication at 50 uM after 48 hrs by GFP reduction assay | 2012 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16 | Antiviral activity and synthesis of quaternized promazine derivatives against HSV-1. |
| AID498606 | Antiviral activity against Macacine herpesvirus 1 isolate MJ2 infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds. |
| AID350201 | Antiviral activity against Epstein-Barr virus infected in human Akata cells by DNA hybridization assay | 2009 | Journal of medicinal chemistry, May-28, Volume: 52, Issue:10 | (Z)- and (E)-2-(1,2-dihydroxyethyl)methylenecyclopropane analogues of 2'-deoxyadenosine and 2'-deoxyguanosine. Synthesis of all stereoisomers, absolute configuration, and antiviral activity. |
| AID1186335 | Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay | 2014 | Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17 | Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents. |
| AID217486 | Effective dose required for antiviral activity against VSV virus | 1990 | Journal of medicinal chemistry, Oct, Volume: 33, Issue:10 | Synthesis and antimicrobial and cytotoxic activities of pyrrole-containing analogues of trichostatin A. |
| AID250786 | Effect on HSV-2 encephalitis in mice following intraperitoneal dosage at 50 mg/kg; expressed as mean day of death | 2005 | Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11 | Inhibition of herpes simplex virus thymidine kinases by 2-phenylamino-6-oxopurines and related compounds: structure-activity relationships and antiherpetic activity in vivo. |
| AID83883 | Tested for mean day to death of nonsurvivors against HSV-1 infection in mice at 200 mg/kg per day | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5 | Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS. |
| AID84586 | Inhibitory effects on HSV-1 induced mortality in NMRI mice upon (ip) administration at a dose of 150 mk/kg/day | 2001 | Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22 | Design, synthesis, and biological evaluation of novel nucleoside and nucleotide analogues as agents against DNA viruses and/or retroviruses. |
| AID1651479 | Antiviral activity against ACV-sensitive Herpes simplex virus 1 KOS infected in male Balb/c mouse assessed as reduction in ulcerated lesion at 50 mg/g applied topically as cream formulation 5 times a day at 3 hrs interval for 10 days measured on day 2 pos | |||
| AID304885 | Antiviral activity against TK- VZV YS in HEL cells after 5 days | 2007 | Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26 | Synthesis and antiviral activity of the carbocyclic analogue of the highly potent and selective anti-VZV bicyclo furano pyrimidines. |
| AID245948 | Cytotoxic concentration to inhibit Herpes simplex virus 2 infected HFF cells | 2005 | Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1 | Nucleotides and pronucleotides of 2,2-bis(hydroxymethyl)methylenecyclopropane analogues of purine nucleosides: synthesis and antiviral activity. |
| AID425274 | Total body clearance in horse at 10 mg/kg, iv | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID1450216 | Antiviral activity against acyclovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect | 2017 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11 | New modified 2-aminobenzimidazole nucleosides: Synthesis and evaluation of their activity against herpes simplex virus type 1. |
| AID1610163 | Antiviral activity against Herpes simplex virus 1 KOS infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis | 2019 | European journal of medicinal chemistry, Dec-15, Volume: 184 | Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives. |
| AID217484 | Minimal inhibitory concentration to reduce virus-induced cytopathicity against VSV | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Fluorescent tricyclic analogues of acyclovir and ganciclovir. A structure-antiviral activity study. |
| AID1451458 | Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect | 2017 | Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18 | Virtual Screening of Acyclovir Derivatives as Potential Antiviral Agents: Design, Synthesis, and Biological Evaluation of New Acyclic Nucleoside ProTides. |
| AID388920 | Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as inhibition of viral cytopathicity | 2008 | Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21 | Influence of 6- or 8-substitution on the antiviral activity of 3-arylalkylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (CMV) and varicella-zoster virus (VZV): part II. |
| AID1211768 | Cmax in PepT1 knockout mouse treated with 25 nmol/g, po of valacyclovir | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3 | Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice. |
| AID444055 | Fraction absorbed in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID1385611 | Selectivity index, ratio of TC50 for African green monkey Vero cells to IC50 for HSV1 strain F VR 733 infected in African green monkey Vero cells | 2018 | Journal of natural products, 08-24, Volume: 81, Issue:8 | Minor Nortriterpenoids from the Twigs and Leaves of Rhododendron latoucheae. |
| AID481810 | Cytotoxicity against HFF cells after 3 days by neutral red dye uptake assay | 2010 | Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10 | Modifications of C-2 on the pyrroloquinoline template aimed at the development of potent herpesvirus antivirals with improved aqueous solubility. |
| AID361404 | Antiviral activity against HSV1 F infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay | 2002 | Journal of natural products, Nov, Volume: 65, Issue:11 | New saponins from the starfish Certonardoa semiregularis. |
| AID1886808 | Antiviral activity against DENV2 infected in African green monkey Vero E6 cells assessed as inhibition of virus induced cytopathic effect measured after 72 hrs by crystal violet staining based inverted microscopic analysis | 2022 | Journal of natural products, 08-26, Volume: 85, Issue:8 | Antiviral Profiling of C-18- or C-19-Functionalized Semisynthetic Abietane Diterpenoids. |
| AID675219 | Antiviral activity against Feline herpesvirus infected in CRFK cells by viral CPE assay | 2012 | European journal of medicinal chemistry, Sep, Volume: 55 | Synthesis and antiviral activities of hexadecyloxypropyl prodrugs of acyclic nucleoside phosphonates containing guanine or hypoxanthine and a (S)-HPMP or PEE acyclic moiety. |
| AID224327 | Inhibitory effect on KOS strain of Herper simplex virus-1 yield, in primary rabbit kidney cell culture 0.1 ug/mL concentration after 48 hours. | 1987 | Journal of medicinal chemistry, Jun, Volume: 30, Issue:6 | Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases. |
| AID224343 | Inhibitory effect on KOS strain of Herper simplex virus-1 yield, in primary rabbit kidney cell culture at 4 ug/mL concentration after 24 hours | 1987 | Journal of medicinal chemistry, Jun, Volume: 30, Issue:6 | Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases. |
| AID732672 | Immunoregulatory activity in Hepatitis B virus infected transgenic mouse assessed as increase in cytokine IL-2 level in serum at 100 mg/kg qd for 1 month by ELISA | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and biological evaluation of nucleoside analogues than contain silatrane on the basis of the structure of acyclovir (ACV) as novel inhibitors of hepatitis B virus (HBV). |
| AID1219945 | Drug transport in human OAT1 expressed in HEK Flp-In cells assessed as maximal rate of transport measured per mg of protein | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3 | Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs. |
| AID1071713 | Antiviral activity against HSV2 assessed as inhibition of viral infection | 2014 | European journal of medicinal chemistry, Mar-03, Volume: 74 | Synthesis and biological evaluation of 2-oxonicotinonitriles and 2-oxonicotinonitrile based nucleoside analogues. |
| AID402535 | Cytotoxicity against african green monkey Vero cells by MTT assay | 1997 | Journal of natural products, Jun, Volume: 60, Issue:6 | Two new lignans with activity against influenza virus from the medicinal plant Rhinacanthus nasutus. |
| AID83748 | Tested for mean day to death of nonsurvivors against HSV-1 infection in mice at 12.5 mg/kg per day | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5 | Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS. |
| AID697722 | Antiviral activity against HSV1 infected herpes simplex keratitis New zealand rabbit model assessed as reduction in viral DNA level in corneal sample compound administered twice daily as gel 24 hrs post inoculation measured on day 9 post infection by RT-P | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14 | Anti-herpes simplex virus efficacies of 2-aminobenzamide derivatives as novel HSP90 inhibitors. |
| AID87038 | Dose of compound required to inhibit the herpes simplex type-1 virusE-377(TK+ ) induced cytopathogenic effects | 1988 | Journal of medicinal chemistry, Sep, Volume: 31, Issue:9 | Cyclopentenylcytosine. A carbocyclic nucleoside with antitumor and antiviral properties. |
| AID118722 | Number of mice normal, without lesion after HSV-1 infection observed from day 12 to day 20 | 1987 | Journal of medicinal chemistry, Jun, Volume: 30, Issue:6 | Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases. |
| AID498604 | Antiviral activity against Macacine herpesvirus 1 isolate MC2 infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds. |
| AID1079939 | Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source] | |||
| AID680360 | TP_TRANSPORTER: uptake in OCT1-expressing S2 cells | 2002 | The Journal of pharmacology and experimental therapeutics, Mar, Volume: 300, Issue:3 | Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. |
| AID1382165 | Antiviral activity against Varicella zoster virus Oka infected in HEL cells assessed as reduction in viral plaque formation | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Highly convergent synthesis and antiviral activity of (E)-but-2-enyl nucleoside phosphonoamidates. |
| AID1230101 | Antiviral activity against thymidine kinase-deficient Varicella-zoster virus infected in HEL cells assessed as reduction of virus-induced plaque formation | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Design, antiviral and cytostatic properties of isoxazolidine-containing amonafide analogues. |
| AID498595 | Antiviral activity against Macacine herpesvirus 1 isolate MR1 infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds. |
| AID88284 | Evaluated for DNA polymerase inhibition activity against herpes simplex virus-1 (HSV-1) | 1985 | Journal of medicinal chemistry, Jul, Volume: 28, Issue:7 | Synthesis and antiherpetic activity of (S)-, (R)-, and (+/-)-9-[(2,3-dihydroxy-1-propoxy)methyl]guanine, linear isomers of 2'-nor-2'-deoxyguanosine. |
| AID85879 | Cytotoxicity against HSV-1 (herpes simplex virus) | 1999 | Bioorganic & medicinal chemistry letters, Feb-08, Volume: 9, Issue:3 | Nucleosides and nucleotides. 183. Synthesis of 4'alpha-branched thymidines as a new type of antiviral agent. |
| AID1410503 | Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 2 to 3 days post-infection | 2018 | ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4 | Amidate Prodrugs of Cyclic 9-( |
| AID246578 | Effective concentration of compound required to reduce plaque formation by Davis strain of CMV virus in Human embryonic lung cells; ND=Not determined | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | The novel L- and D-amino acid derivatives of hydroxyurea and hydantoins: synthesis, X-ray crystal structure study, and cytostatic and antiviral activity evaluations. |
| AID137468 | Number of survivors against Herpes simplex virus type-1 infection in mice at 12.5 mg/kg/day | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID646190 | Antiherpetic activity against HSV2 at 0.5 mg/ml by MTT assay | 2012 | Journal of natural products, Jan-27, Volume: 75, Issue:1 | Dihydroagarofuran derivatives from the dried roots of Tripterygium wilfordii. |
| AID498601 | Antiviral activity against Macacine herpesvirus 1 isolate A5 infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds. |
| AID216388 | Concentration required to reduce cytopathogenicity of Vesicular stomatitis virus by 50% in primary rabbit kidney (PRK) cells | 1984 | Journal of medicinal chemistry, Nov, Volume: 27, Issue:11 | Nucleic acid related compounds. 47. Synthesis and biological activities of pyrimidine and purine "acyclic" nucleoside analogues. |
| AID402533 | Antiviral activity against HSV2 MS in african green monkey Vero cells by viral cytopathic effect assay | 1997 | Journal of natural products, Jun, Volume: 60, Issue:6 | Two new lignans with activity against influenza virus from the medicinal plant Rhinacanthus nasutus. |
| AID681387 | TP_TRANSPORTER: uptake in Xenopus laevis oocytes | 2000 | The Journal of pharmacology and experimental therapeutics, Sep, Volume: 294, Issue:3 | Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs. |
| AID774682 | Antiviral activity against Varicella-zoster virus VR-1367 infected in African green monkey BSC1 cells assessed as inhibition of virus plaque formation | 2013 | Bioorganic & medicinal chemistry, Sep-15, Volume: 21, Issue:18 | Synthesis and biological evaluation of furopyrimidine N,O-nucleosides. |
| AID88279 | In vitro antiviral activity against herpes simplex virus/1(HSV/1) expressed as viral rating (VR) | 1981 | Journal of medicinal chemistry, Oct, Volume: 24, Issue:10 | Synthesis and biological activity of certain derivatives of oxazinomycin and related oxadiazole nucleosides. |
| AID1055511 | Antiviral activity against HIV1 3B infected in human MT4 cells assessed as p24 production after 3 days by microscopic analysis | 2013 | European journal of medicinal chemistry, , Volume: 70 | Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides. |
| AID1464792 | Anti-viral activity against Herpes simplex virus-1 harboring EGFP infected in iPSC-derived neurons assessed as necrotic cells at 10 mM treated 2 hrs post infection measured after 72 hrs by Alexa fluor 488 staining based flow cytometric analysis (Rvb = 3.3 | 2017 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 27, Issue:20 | Discovery of potent antiviral (HSV-1) quinazolinones and initial structure-activity relationship studies. |
| AID1451465 | Cytotoxicity against human HEL cells assessed as cell growth inhibition by cell counting method | 2017 | Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18 | Virtual Screening of Acyclovir Derivatives as Potential Antiviral Agents: Design, Synthesis, and Biological Evaluation of New Acyclic Nucleoside ProTides. |
| AID1773431 | Selectivity index, ratio of CC50 for cytotoxicity against human A549 cells to EC50 for antiviral activity against Human herpesvirus 1 MacIntyre infected in A549 cells assessed as reduction in virus titer treated 1 hr post viral infection followed by repla | 2021 | European journal of medicinal chemistry, Dec-05, Volume: 225 | Novel betulin dicarboxylic acid ester derivatives as potent antiviral agents: Design, synthesis, biological evaluation, structure-activity relationship and in-silico study. |
| AID425282 | AUC in iv dosed adult horse | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID333369 | Antiviral activity against HSV1 | 2004 | Journal of natural products, Oct, Volume: 67, Issue:10 | New pseudopterosin and seco-pseudopterosin diterpene glycosides from two Colombian isolates of Pseudopterogorgia elisabethae and their diverse biological activities. |
| AID290510 | Cytotoxicity against Vero cells | 2007 | Bioorganic & medicinal chemistry letters, May-15, Volume: 17, Issue:10 | Imidazo[1,2-a]pyridines with potent activity against herpesviruses. |
| AID84245 | Antiviral activity against the HSV-1 377 strain from monolayers of vero cells | 1987 | Journal of medicinal chemistry, Jun, Volume: 30, Issue:6 | Synthesis and antiviral evaluation of carbocyclic analogues of 2-amino-6-substituted-purine 3'-deoxyribofuranosides. |
| AID139277 | Day of death in lethal test against herpes simplex virus type-1 at 150 mg/kg/day (mean day of death +/-SD) | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID625289 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1079945 | Animal toxicity known. [column 'TOXIC' in source] | |||
| AID256005 | Antiviral activity against herpes simplex virus type 1 (KOS strain) grown on human foreskin fibroblast cells determined by vedduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO until plaque were formed [nd = no | 2005 | Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18 | 4-Oxo-4,7-dihydrothieno[2,3-b]pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases. |
| AID521929 | Apparent oral clearance in human systemic circulation with chronic kidney disease at 1500 mg, po every 12 hrs measured after fifth dose by radioimmunoassay | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. |
| AID636699 | Cytotoxicity against human KB cells after 48 hrs by crystal violet staining based spectrophotometric analysis | 2011 | Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16 | Tyrosine-based 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine and -adenine ((S)-HPMPC and (S)-HPMPA) prodrugs: synthesis, stability, antiviral activity, and in vivo transport studies. |
| AID41544 | In vitro minimum inhibitory concentration to inhibit BHV-1-induced cytopathogenicity in PRK cells by 50% | 1988 | Journal of medicinal chemistry, Jul, Volume: 31, Issue:7 | Synthesis and antiviral activity of novel N-substituted derivatives of acyclovir. |
| AID516965 | Antiviral activity against HSV1 KOS infected in HEL assessed as reduction in virus-induce cytopathicity | 2010 | Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19 | Synthesis of ester prodrugs of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) as anti-poxvirus agents. |
| AID84246 | Antiviral activity is expressed as virus rating (VR) against the HSV-1 377 strain | 1987 | Journal of medicinal chemistry, Jun, Volume: 30, Issue:6 | Synthesis and antiviral evaluation of carbocyclic analogues of 2-amino-6-substituted-purine 3'-deoxyribofuranosides. |
| AID732676 | Immunoregulatory activity in Hepatitis B virus infected transgenic mouse assessed as increase in cytokine IL-2 mRNA level in liver at 100 mg/kg qd for 1 month by qPCR analysis | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and biological evaluation of nucleoside analogues than contain silatrane on the basis of the structure of acyclovir (ACV) as novel inhibitors of hepatitis B virus (HBV). |
| AID85378 | Inhibitory concentration against HSV type 2 strain 196 in human embryonic skin muscle (ESM) fibroblast cell culture | 1993 | Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14 | Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides. |
| AID1209455 | Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1 | In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. |
| AID122846 | Toxicity of compound against mice was determined at a concentration of 2000 mg/kg | 1986 | Journal of medicinal chemistry, Feb, Volume: 29, Issue:2 | Systematic synthesis and biological evaluation of alpha- and beta-D-xylofuranosyl nucleosides of the five naturally occurring bases in nucleic acids and related analogues. |
| AID87027 | Minimum inhibitory concentration against Herpes simplex Virus-1 (KOS) (ACV) | 2002 | Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23 | Synthesis and biological activity of strongly fluorescent tricyclic analogues of acyclovir and ganciclovir. |
| AID464410 | Antiviral activity against Herpes simplex virus type 1 | 2010 | Journal of natural products, Jan, Volume: 73, Issue:1 | Oblongolides from the endophytic fungus Phomopsis sp. BCC 9789. |
| AID246311 | Effective concentration required to reduce CMV AD169 strain virus plaque formation by 50% in HEL cell culture | 2004 | Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22 | 6-azapyrimidine-2'-deoxy-4'-thionucleosides: antiviral agents against TK+ and TK- HSV and VZV strains. |
| AID1139391 | Antiviral activity against thymidine kinase-positive Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathicity after 3 days | 2014 | Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9 | ProTides of N-(3-(5-(2'-deoxyuridine))prop-2-ynyl)octanamide as potential anti-tubercular and anti-viral agents. |
| AID768202 | Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity | 2013 | European journal of medicinal chemistry, Aug, Volume: 66 | Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies. |
| AID340471 | Antiviral activity against HCMV Davis by plaque reduction assay | 2008 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14 | Synthesis of 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamides with broad-spectrum human herpesvirus polymerase inhibition. |
| AID210521 | Relative substrate velocity was evaluated against Mac strain by using HSV-1 TK assay | 1985 | Journal of medicinal chemistry, Aug, Volume: 28, Issue:8 | Modifications on the heterocyclic base of acyclovir: syntheses and antiviral properties. |
| AID72158 | Inhibitory activity against FMBA TK-/HSV-2 TK+ cell line | 1990 | Journal of medicinal chemistry, Sep, Volume: 33, Issue:9 | Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives. |
| AID768201 | Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity | 2013 | European journal of medicinal chemistry, Aug, Volume: 66 | Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies. |
| AID1433138 | Antiviral activity against acyclovir-resistant TK-negative Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis | 2015 | European journal of medicinal chemistry, Aug-28, Volume: 101 | Synthesis, antiplasmodial activity and mechanistic studies of pyrimidine-5-carbonitrile and quinoline hybrids. |
| AID425254 | fAUC in horse at 10 mg/kg, iv after 1 hr by three-compartmental study | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID275087 | Cytotoxicity against HEL cells | 2006 | Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26 | Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine. |
| AID476929 | Human intestinal absorption in po dosed human | 2010 | European journal of medicinal chemistry, Mar, Volume: 45, Issue:3 | Neural computational prediction of oral drug absorption based on CODES 2D descriptors. |
| AID383512 | Antiviral activity against HSV1 KOS in human E6SM cells assessed as reduction of virus-induced cytopathogenicity | 2008 | European journal of medicinal chemistry, Feb, Volume: 43, Issue:2 | Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents. |
| AID81234 | Compound was evaluated for the antiviral activity against HIV-1; Not determined | 1998 | Bioorganic & medicinal chemistry letters, Apr-07, Volume: 8, Issue:7 | Synthesis and antiviral activity of novel isodideoxy nucleosides with exocyclic methylene. |
| AID425284 | Mean residence time in iv dosed adult horse | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID1283351 | Antiviral activity against HSV1 KOS ATCC VR1493 infected in human iPSC cells assessed as viral DNA replication at 50 uM measured 24 hrs post infection by FISH analysis | 2016 | ACS medicinal chemistry letters, Jan-14, Volume: 7, Issue:1 | iPSC Neuronal Assay Identifies Amaryllidaceae Pharmacophore with Multiple Effects against Herpesvirus Infections. |
| AID1283363 | Cytotoxicity against human ARPE19 cells assessed as cell viability at 0.1 to 50 uM after 24 to 48 hrs by live/dead fixable viability dye-based flow cytometric analysis | 2016 | ACS medicinal chemistry letters, Jan-14, Volume: 7, Issue:1 | iPSC Neuronal Assay Identifies Amaryllidaceae Pharmacophore with Multiple Effects against Herpesvirus Infections. |
| AID216467 | Antiviral activity against Varicella-Zoster virus (YS) | 2004 | Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10 | Bicyclic anti-VZV nucleosides: thieno analogues bearing an alkylphenyl side chain have reduced antiviral activity. |
| AID658741 | Cytotoxicity against human HEL cells assessed as minimum compound concentration required to causes microscopically detectable alteration of normal cell morphology | 2012 | European journal of medicinal chemistry, Jun, Volume: 52 | 2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies. |
| AID90788 | Activity against human cytomegalovirus (HCMV) using plaque reduction assay | 1994 | Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18 | Benzimidazole ribonucleosides: design, synthesis, and antiviral activity of certain 2-(alkylthio)- and 2-(benzylthio)-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazoles. |
| AID425257 | Total Cmax in horse at 20 mg/kg, po administered as single dose | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID1283357 | Antiviral activity against HSV1 KOS ATCC VR1493 infected in human iPSC cells assessed as reduction in expression of DNA polymerase gene at 50 uM measured 24 hrs post infection by RT-qPCR analysis | 2016 | ACS medicinal chemistry letters, Jan-14, Volume: 7, Issue:1 | iPSC Neuronal Assay Identifies Amaryllidaceae Pharmacophore with Multiple Effects against Herpesvirus Infections. |
| AID91502 | Inhibitory concentration required to reduce HSV-2 induced cytopathogenic effect in human skin fibroblast | 2003 | Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23 | Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine. |
| AID658754 | Cytotoxicity against human HeLa cells assessed as cell viability by colorimetric formazan-based MTS assay | 2012 | European journal of medicinal chemistry, Jun, Volume: 52 | 2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies. |
| AID137470 | Number of survivors against Herpes simplex virus type-1 infection in mice at 200 mg/kg/day | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID246308 | Effective concentration required to reduce HSV-2 strain G virus plaque formation by 50% in E6SM Cell Culture | 2004 | Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22 | 6-azapyrimidine-2'-deoxy-4'-thionucleosides: antiviral agents against TK+ and TK- HSV and VZV strains. |
| AID387854 | Cytotoxicity against HEL cells assessed as alteration in cell morphology by MTS assay | 2008 | Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18 | Synthesis and antiviral evaluation of acyclic azanucleosides developed from sulfanilamide as a lead structure. |
| AID85696 | In vivo efficacy of compound against HSV-1 strain A133 in the mouse system model was measured at 25 dose(mg/kg), activity expressed as Survivors counted on day 21; 2/5 | 1991 | Journal of medicinal chemistry, Mar, Volume: 34, Issue:3 | Fluorocarbocyclic nucleosides: synthesis and antiviral activity of 2'- and 6'-fluorocarbocyclic 2'-deoxy guanosines. |
| AID76490 | Effect on the growth of Herpes simplex Type 1 on the skin of Guinea pigs infected intradermally on day 3 at 5 % concentration | 1984 | Journal of medicinal chemistry, May, Volume: 27, Issue:5 | Synthesis of some phosphonates with antiherpetic activity. |
| AID458872 | Cytotoxicity against HEL cells assessed as reduction of cell growth | 2010 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3 | Practical and efficient synthesis of pyrano[3,2-c]pyridone, pyrano[4,3-b]pyran and their hybrids with nucleoside as potential antiviral and antileishmanial agents. |
| AID66950 | Minimum cytotoxic concentration in E6SM fibroblast cells | 2002 | Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23 | Synthesis and biological activity of strongly fluorescent tricyclic analogues of acyclovir and ganciclovir. |
| AID303221 | Cytotoxicity against HEL cells assessed as alteration in morphology after 3 days | 2007 | Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23 | Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity. |
| AID732677 | Immunoregulatory activity in Hepatitis B virus infected transgenic mouse assessed as increase in cytokine IFN gamma mRNA level in liver at 100 mg/kg qd for 1 month by qPCR analysis | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and biological evaluation of nucleoside analogues than contain silatrane on the basis of the structure of acyclovir (ACV) as novel inhibitors of hepatitis B virus (HBV). |
| AID1854960 | Cytotoxicity against HEL cells assessed as alteration of cell morphology by microscopic analysis | 2022 | European journal of medicinal chemistry, Nov-05, Volume: 241 | Synthesis and antiviral properties of biomimetic iminosugar-based nucleosides. |
| AID733256 | Antiviral activity against Herpes simplex virus 2 MS infected in Vero cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Efficient synthesis of 3H,3'H-spiro[benzofuran-2,1'-isobenzofuran]-3,3'-dione as novel skeletons specifically for influenza virus type B inhibition. |
| AID218196 | Tested in vitro for minimum inhibitory concentration against herpes simplex virus-1 (HSV-1) 2992 strain by plaque-reduction assay in vero cells | 1993 | Journal of medicinal chemistry, May-28, Volume: 36, Issue:11 | 3-Quinolinecarboxamides. A series of novel orally-active antiherpetic agents. |
| AID392723 | Antiviral activity against HSV2 assessed as inhibition of virus-induced cytopathicity | 2009 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4 | Synthesis of 5-isoxazol-5-yl-2'-deoxyuridines exhibiting antiviral activity against HSV and several RNA viruses. |
| AID217762 | In vitro antiviral activity against herpes simplex virus type-1 in vero cells | 1989 | Journal of medicinal chemistry, May, Volume: 32, Issue:5 | Synthesis of 5-[1-hydroxy(or methoxy)-2-bromo(or chloro)ethyl]-2'-deoxyuridines and related halohydrin analogues with antiviral and cytotoxic activity. |
| AID82855 | Antiviral activity against cytomegalovirus (CMV) AD169 strain in HEL cell culture | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20 | Acyclic nucleotide analogs derived from 8-azapurines: synthesis and antiviral activity. |
| AID469284 | Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay | 2009 | Journal of natural products, Sep, Volume: 72, Issue:9 | Eucalmaidins A-E, (+)-oleuropeic acid derivatives from the fresh leaves of Eucalyptus maideni. |
| AID574824 | Antiviral activity against Herpes simplex virus 1 isolate 4 harboring N23S, K36E -1C 553 = frameshift mutations in thymidine kinase and S33G, A330R, A899V, L1188F mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. |
| AID1261313 | Antiviral activity against YFV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID303209 | Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity | 2007 | Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23 | Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity. |
| AID1545453 | Antiviral activity against Herpes simplex virus 1 at 50 ug/10'5 | 2019 | Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7 | Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances. |
| AID217515 | Antiviral activity against Varicella zoster virus (9021 strain) | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID22166 | Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally; Total mice tested 10 | 1985 | Journal of medicinal chemistry, Jul, Volume: 28, Issue:7 | Synthesis and antiherpetic activity of (S)-, (R)-, and (+/-)-9-[(2,3-dihydroxy-1-propoxy)methyl]guanine, linear isomers of 2'-nor-2'-deoxyguanosine. |
| AID116570 | Compound tested for its effect on mean survival time in mice against HSV-1(BWS) at a dose of 100 mg/kg. | 1991 | Journal of medicinal chemistry, Jul, Volume: 34, Issue:7 | A new class of acyclic phosphonate nucleotide analogues: phosphonate isosteres of acyclovir and ganciclovir monophosphates as antiviral agents. |
| AID376990 | Selectivity index, CC50 for human Hep2 cells to IC50 for Cox B3 virus | 2006 | Journal of natural products, May, Volume: 69, Issue:5 | Antiviral flavans from the leaves of Pithecellobium clypearia. |
| AID82419 | Tested for cytotoxic activity against human foreskin fibroblasts (HFF) cells. | 1990 | Journal of medicinal chemistry, Jul, Volume: 33, Issue:7 | Synthesis and antiviral activity of some 7-[(2-hydroxyethoxy)methyl]pyrazolo[3,4-d]pyrimidine analogues of sangivamycin and toyocamycin. |
| AID1186330 | Antiviral activity against Bovine viral diarrhea virus infected in MDBK cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay | 2014 | Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17 | Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents. |
| AID1854961 | Antiviral activity against HSV-1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathic effect by microscopic analysis | 2022 | European journal of medicinal chemistry, Nov-05, Volume: 241 | Synthesis and antiviral properties of biomimetic iminosugar-based nucleosides. |
| AID88272 | Therapeutic index (vero CC50/ED50) against HSV-1 | 2003 | Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23 | Anti-herpes simplex virus activity of substituted 1-hydroxyacridones. |
| AID324736 | Antiviral activity against TK+ HSV1 E377 in HFF cells after 72 hrs by plaque reduction assay | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase. |
| AID1261324 | Antiviral activity against HIV-1 infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID280178 | Antiviral activity against HSV2 G in HEL cells assessed as inhibition of virus-induced cytopathicity | 2007 | Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5 | Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds. |
| AID91296 | Inhibitory concentration of the drug against the cytopathic effect for AD169 strain of epstein barr virus-2 (HCMV) in human HFF cells; ND is Not Determined | 1993 | Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17 | Synthesis and antiviral activity of novel 5-(1-azido-2-haloethyl) and 5-(1-azido-, amino-, or methoxyethyl) analogs of 2'-deoxyuridine. |
| AID393989 | Antiviral activity against PMEDAP-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity | 2009 | Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6 | 4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus. |
| AID84228 | Inhibitory activity against HSV-1 (McIntyre) replication in E6SM cell cultures of human embryonic skin-muscle | 2002 | Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25 | A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity. |
| AID210867 | Michaelis rate constant is determined by the Lineweaver and Burk method against Vero cell thymidine kinase | 2001 | Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22 | Design, synthesis, and biological evaluation of novel nucleoside and nucleotide analogues as agents against DNA viruses and/or retroviruses. |
| AID136150 | Percentage survival of mice after intraperitoneal administration of compound at 50 mg/kg per day in experiment 1; survival/ tested =5/10 | 1989 | Journal of medicinal chemistry, Jul, Volume: 32, Issue:7 | Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. |
| AID257901 | Antiviral activity against Vesicular stomatitis virus in HeLa cells | 2006 | Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2 | Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators. |
| AID75801 | Duration of time of lesion formation in HSV-1 cutaneous infection in guinea pig at 5%ACV | 1989 | Journal of medicinal chemistry, Jul, Volume: 32, Issue:7 | Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. |
| AID85287 | In vitro antiviral activity against herpesvirus, HSV-2, MS strain by plaque reduction assay in human foreskin fibroblasts | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5 | Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS. |
| AID81028 | The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK+YS strain | 1999 | Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14 | Novel pyrimidine and purine derivatives of L-ascorbic acid: synthesis and biological evaluation. |
| AID217658 | Antiviral activity against Varicella zoster virus (ppIIa strain) | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID235470 | Selectivity index calculated as CC50/EC50 in the study of cytopathogenic effect by HSV-1; ND: No data | 2003 | Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23 | Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine. |
| AID235554 | Ratio of Cytotoxicity concentration to that of virus-inhibitory concentration;d ='not determined' | 1998 | Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25 | Synthesis of imidazo[1,2-a]pyridines as antiviral agents. |
| AID63762 | The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 2 (G strain) | 1994 | Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19 | Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity. |
| AID259180 | Minimum toxic concentration in HEL cells | 2006 | Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1 | Synthesis and antiviral evaluation of cyclic and acyclic 2-methyl-3-hydroxy-4-pyridinone nucleoside derivatives. |
| AID85556 | Antiviral activity against various strains of Herpes Simplex virus type I | 1982 | Journal of medicinal chemistry, Nov, Volume: 25, Issue:11 | Synthesis and antiviral properties of some 2'-deoxy-5-(fluoroalkenyl)uridines. |
| AID244774 | Minimum cytotoxic concentration that caused a microscopically detectable alteration of cell morphology in E6SM Cell Culture | 2004 | Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22 | 6-azapyrimidine-2'-deoxy-4'-thionucleosides: antiviral agents against TK+ and TK- HSV and VZV strains. |
| AID217670 | Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV TS plaque formation after 5 days in HEL cell cultures compared to untreated controls. | 2000 | Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26 | Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain. |
| AID90775 | Antiviral activity against human cytomegalovirus AD-169 which reduces virus plaque formation by 50%; ND denotes no data | 2002 | Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19 | Synthesis and antiviral/antiproliferative activity of some N-sulphonylbenzimidazoles. |
| AID221295 | Tested for antiviral activity against HBV (Hep AD79) | 2001 | Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12 | The cyclohexene ring as bioisostere of a furanose ring: synthesis and antiviral activity of cyclohexenyl nucleosides. |
| AID376989 | Antiviral activity against Cox B3 virus in human Hep2 cells assessed as reduction of virus induced cytopathic effect | 2006 | Journal of natural products, May, Volume: 69, Issue:5 | Antiviral flavans from the leaves of Pithecellobium clypearia. |
| AID65709 | Antiviral activity against herpes simplex virus-1 TK-KOS ACV (HSV-1) in E6SM cell cultures | 2001 | Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16 | Design, synthesis, DNA binding, and biological evaluation of water-soluble hybrid molecules containing two pyrazole analogues of the alkylating cyclopropylpyrroloindole (CPI) subunit of the antitumor agent CC-1065 and polypyrrole minor groove binders. |
| AID90979 | Cytotoxicity of compound was determined by assaying cell growth in human neoplastic cell line(KB). | 1992 | Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3 | Synthesis, antiproliferative, and antiviral activity of certain 4-aminopyrrolo[2,3-d]pyridazine nucleosides: an entry into a novel series of adenosine analogues. |
| AID1385610 | Cytotoxicity against African green monkey Vero cells measured after 48 hrs | 2018 | Journal of natural products, 08-24, Volume: 81, Issue:8 | Minor Nortriterpenoids from the Twigs and Leaves of Rhododendron latoucheae. |
| AID83500 | Cytotoxic concentration to reduce HEL cell growth by 50%; ND denotes no data | 2002 | Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19 | Synthesis and antiviral/antiproliferative activity of some N-sulphonylbenzimidazoles. |
| AID665760 | Antiviral activity against VZV infected in human HFF cells assessed as reduction in cytopathic effect after 7 days by crystal violet staining | 2012 | Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12 | Synthesis and antiviral activity of certain second generation methylenecyclopropane nucleosides. |
| AID1474167 | Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status | 2016 | Drug discovery today, Apr, Volume: 21, Issue:4 | DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. |
| AID77817 | Total score of lesion formation in HSV-1 cutaneous infection in guinea pig at 5% ACV | 1989 | Journal of medicinal chemistry, Jul, Volume: 32, Issue:7 | Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. |
| AID1176317 | Cytotoxicity against human WISH cells | 2015 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2 | Synthesis and quantitative structure-activity relationship (QSAR) analysis of some novel oxadiazolo[3,4-d]pyrimidine nucleosides derivatives as antiviral agents. |
| AID1571174 | Inhibition of human PNP | 2018 | MedChemComm, Dec-01, Volume: 9, Issue:12 | The transition to magic bullets - transition state analogue drug design. |
| AID64100 | Minimum inhibitory concentration (MIC) required to reduce Lyons strain of HSV-2 induced cytopathogenicity by 50% in E6SM cells | 1992 | Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8 | Synthesis and antiviral activity of acyclic nucleosides with a 3(S),5-dihydroxypentyl or 4(R)-methoxy-3(S),5-dihydroxypentyl side chain. |
| AID66938 | Cytotoxicity concentration required to microscopically detectable alteration of cell morphology in E6SM | 2000 | Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4 | The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine. |
| AID82436 | Minimum cytotoxic concentration against uninfected HFF cells | 1998 | Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8 | Synthesis and antiviral activity of novel acyclic nucleosides: discovery of a cyclopropyl nucleoside with potent inhibitory activity against herpesviruses. |
| AID595580 | Selectivity index, ratio of CC50 for human HFF cells infected with Hepatitis C virus to EC50 for Varicella-zoster virus Ellen | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | Broad-spectrum antiviral activity including human immunodeficiency and hepatitis C viruses mediated by a novel retinoid thiosemicarbazone derivative. |
| AID1462034 | Antiviral activity against wild type thymidine kinase expressing Varicella-Zoster virus Oka infected in HEL cells assessed as inhibition of virus-induced plaque formation | 2017 | Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17 | New prodrugs of two pyrimidine acyclic nucleoside phosphonates: Synthesis and antiviral activity. |
| AID84057 | Compound was evaluated for antiviral activity against HSV-1 reported as virus rating | 1987 | Journal of medicinal chemistry, Jan, Volume: 30, Issue:1 | Synthesis and biological evaluation of acyclic neplanocin analogues. |
| AID85695 | In vivo efficacy of compound against HSV-1 strain A133 in the mouse system model was measured at 25 dose(mg/kg), activity expressed as Survivors counted on day 21; 1/10 | 1991 | Journal of medicinal chemistry, Mar, Volume: 34, Issue:3 | Fluorocarbocyclic nucleosides: synthesis and antiviral activity of 2'- and 6'-fluorocarbocyclic 2'-deoxy guanosines. |
| AID82683 | Antiviral activity was measured as effective concentration required to reduce thymidine kinase-deficient. Varicella Zoster virus (YS/R)-induced plaque formation in human embryonic lung cells | 2001 | Bioorganic & medicinal chemistry letters, Sep-17, Volume: 11, Issue:18 | Bicyclic anti-VZV nucleosides: Thieno analogues retain full antiviral activity. |
| AID68277 | Concentration required to inhibit VV induced cytopathogenicity in ESM cells by 50%. | 1991 | Journal of medicinal chemistry, Aug, Volume: 34, Issue:8 | Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir. |
| AID553343 | Antiviral activity against thymidine kinase-deficient VZV 07/1 infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 5 days | 2011 | Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1 | Novel antiviral C5-substituted pyrimidine acyclic nucleoside phosphonates selected as human thymidylate kinase substrates. |
| AID87039 | Degree of inhibition of virus-induced cytopathogenic effect and the degree of cytotoxicity produced by compound against herpes simplex type-1 virus E-377(TK+ ) | 1988 | Journal of medicinal chemistry, Sep, Volume: 31, Issue:9 | Cyclopentenylcytosine. A carbocyclic nucleoside with antitumor and antiviral properties. |
| AID636695 | Antiviral activity against Cowpox virus Brighton infected in HFF cells incubated for 3 days by plaque reduction assay | 2011 | Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16 | Tyrosine-based 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine and -adenine ((S)-HPMPC and (S)-HPMPA) prodrugs: synthesis, stability, antiviral activity, and in vivo transport studies. |
| AID277830 | Antiviral activity against VSV | 2007 | Journal of natural products, Feb, Volume: 70, Issue:2 | Cinnamacrins A-C, cinnafragrin D, and cytostatic metabolites with alpha-glucosidase inhibitory activity from Cinnamosma macrocarpa. |
| AID383513 | Antiviral activity against HSV1 KOS in human HEL cells assessed as reduction of virus-induced cytopathogenicity | 2008 | European journal of medicinal chemistry, Feb, Volume: 43, Issue:2 | Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents. |
| AID15859 | Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day. | 1985 | Journal of medicinal chemistry, Jul, Volume: 28, Issue:7 | Synthesis and antiherpetic activity of (S)-, (R)-, and (+/-)-9-[(2,3-dihydroxy-1-propoxy)methyl]guanine, linear isomers of 2'-nor-2'-deoxyguanosine. |
| AID296679 | Cytotoxicity against HEL cells after 3 days | 2007 | Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16 | Synthesis and antiviral evaluation of 6-(alkyl-heteroaryl)furo[2,3-d]pyrimidin-2(3H)-one nucleosides and analogues with ethynyl, ethenyl, and ethyl spacers at C6 of the furopyrimidine core. |
| AID224325 | Inhibitory effect on 196 strain of Herper simplex virus-2 yield, in primary rabbit kidney cell culture 4 ug/mL concentration after 48 hours. | 1987 | Journal of medicinal chemistry, Jun, Volume: 30, Issue:6 | Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases. |
| AID139275 | Day of death in lethal test against herpes simplex virus type-1 at 100 mg/kg/day (mean day of death +/-SD) | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID977602 | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID87344 | Inhibitory concentration against HCMV in plaque reduction assay | 1988 | Journal of medicinal chemistry, Nov, Volume: 31, Issue:11 | Synthesis and antiviral activity of certain 4- and 4,5-disubstituted 7-[(2-hydroxyethoxy)methyl]pyrrolo[2,3-d]pyrimidines. |
| AID1473739 | Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID1473741 | Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID275069 | Antiviral activity against vaccinia virus in HEL cells | 2006 | Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26 | Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine. |
| AID63598 | Minimum inhibitory conc. for 50% inhibition of TK HSV-1 (B2006) virus induced cytopathicity in E6SM cells | 1997 | Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9 | Carbocyclic oxetanocins lacking the C-3' methylene. |
| AID245891 | Cytotoxic concentration required to reduce HEL cell growth | 2005 | Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7 | From 1-acyl-beta-lactam human cytomegalovirus protease inhibitors to 1-benzyloxycarbonylazetidines with improved antiviral activity. A straightforward approach to convert covalent to noncovalent inhibitors. |
| AID774684 | Antiviral activity against Herpes simplex virus type 2 VR-734 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity | 2013 | Bioorganic & medicinal chemistry, Sep-15, Volume: 21, Issue:18 | Synthesis and biological evaluation of furopyrimidine N,O-nucleosides. |
| AID561624 | Clearance in patient with Epstein-Barr virus infection at 500 mg/kg, po administered every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. |
| AID1886813 | Antiviral activity against CHIKV infected in African green monkey Vero E6 cells assessed as reduction factor at 3.1 to 25 ug/ml measured after 72 hrs by crystal violet staining based inverted microscopic analysis | 2022 | Journal of natural products, 08-26, Volume: 85, Issue:8 | Antiviral Profiling of C-18- or C-19-Functionalized Semisynthetic Abietane Diterpenoids. |
| AID96829 | Inhibitory concentration required to reduce cell growth of Murine Leukemia L1210 cells | 1984 | Journal of medicinal chemistry, Nov, Volume: 27, Issue:11 | Nucleic acid related compounds. 47. Synthesis and biological activities of pyrimidine and purine "acyclic" nucleoside analogues. |
| AID81193 | Inhibitory concentration required to inhibit cell growth by 50% in human embryonic lung (HEL) cell culture | 1993 | Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14 | Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides. |
| AID561608 | Clearance in children and young patient with malignancy at 5 mg/kg, iv administered every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. |
| AID139276 | Day of death in lethal test against herpes simplex virus type-1 at 12.5 mg/kg/day (mean day of death +/-SD) | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID634746 | Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID277829 | Antiviral activity against vaccinia virus | 2007 | Journal of natural products, Feb, Volume: 70, Issue:2 | Cinnamacrins A-C, cinnafragrin D, and cytostatic metabolites with alpha-glucosidase inhibitory activity from Cinnamosma macrocarpa. |
| AID676761 | Antiviral activity against HSV-1 infected in african green monkey Vero cells assessed as inhibition of GFP gene expression after 48 hrs by RT-PCR analysis | 2012 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16 | Antiviral activity and synthesis of quaternized promazine derivatives against HSV-1. |
| AID122845 | Toxicity of compound against mice was determined at a concentration of 1200 mg/kg | 1986 | Journal of medicinal chemistry, Feb, Volume: 29, Issue:2 | Systematic synthesis and biological evaluation of alpha- and beta-D-xylofuranosyl nucleosides of the five naturally occurring bases in nucleic acids and related analogues. |
| AID257899 | Antiviral activity against Respiratory syncytial virus in HeLa cells | 2006 | Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2 | Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators. |
| AID139280 | Day of death in lethal test against herpes simplex virus type-1 at 50 mg/kg/day (mean day of death +/-SD) | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID257888 | Antiviral activity against HeLa cells | 2006 | Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2 | Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators. |
| AID156684 | Inhibitory concentration required to reduce 2-deoxyuridine ([3H-1'2']dUrd) incorporation into DNA of Primary Rabbit kidney (PRK) cell cultures | 1984 | Journal of medicinal chemistry, Nov, Volume: 27, Issue:11 | Nucleic acid related compounds. 47. Synthesis and biological activities of pyrimidine and purine "acyclic" nucleoside analogues. |
| AID91280 | Antiviral activity against Varicella-Zoster virus (VV) in human foreskin cell cultures in virus plaque reduction assay at 10 uM | 1987 | Journal of medicinal chemistry, Nov, Volume: 30, Issue:11 | Synthesis and antiviral activity of carbocyclic analogues of xylofuranosides of 2-amino-6-substituted-purines and 2-amino-6-substituted-8-azapurines. |
| AID75797 | Duration of time of healing period in HSV-1 cutaneous infection in guinea pig at 5%ACV | 1989 | Journal of medicinal chemistry, Jul, Volume: 32, Issue:7 | Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. |
| AID307430 | Antiviral activity against HCMV Davis in HFF cells by plaque reduction assay | 2007 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12 | 2-Aryl-2-hydroxyethylamine substituted 4-oxo-4,7-dihydrothieno[2,3-b]pyridines as broad-spectrum inhibitors of human herpesvirus polymerases. |
| AID575040 | Antiviral activity against Herpes simplex virus 2 isolate 25 harboring I101S mutations in thymidine kinase and D785N, V544A mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. |
| AID1773418 | Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay | 2021 | European journal of medicinal chemistry, Dec-05, Volume: 225 | Novel betulin dicarboxylic acid ester derivatives as potent antiviral agents: Design, synthesis, biological evaluation, structure-activity relationship and in-silico study. |
| AID681407 | TP_TRANSPORTER: inhibition of Indoxyl sulfate uptake (Indoxyl sulfate: 2 uM, ACV: 1000 uM) in Xenopus laevis oocytes | 2002 | Journal of neurochemistry, Oct, Volume: 83, Issue:1 | Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain. |
| AID83184 | Concentration required to reduce varicella zoster virus (VZV)YS-TK-PFU plaque formation by 50% in human embryonic lung (HEL) cell cultures. | 1992 | Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12 | (+-)-carbocyclic 5'-nor-2'-deoxyguanosine and related purine derivatives: synthesis and antiviral properties. |
| AID79966 | Evaluated for the antiviral activity against Human cytomegalovirus (HCMV) strain AD-169 by the plaque reduction assay | 1990 | Journal of medicinal chemistry, Apr, Volume: 33, Issue:4 | Acyclic purine phosphonate analogues as antiviral agents. Synthesis and structure-activity relationships. |
| AID445446 | Oral bioavailability in human | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. |
| AID250856 | Effect on HSV-1 encephalitis in mice following intraperitoneal dosage at 25 mg/kg; expressed as number of survivors/10 | 2005 | Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11 | Inhibition of herpes simplex virus thymidine kinases by 2-phenylamino-6-oxopurines and related compounds: structure-activity relationships and antiherpetic activity in vivo. |
| AID574823 | Antiviral activity against Herpes simplex virus 1 isolate 3 harboring N23S, K36E, R89Q, A265T, Y53D mutations in thymidine kinase and S33G, A330R, V905M, E1005K mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction as | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. |
| AID1186339 | Antiviral activity against Vaccinia Virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay | 2014 | Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17 | Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents. |
| AID342120 | Antiviral activity against thymidine kinase deficient VZV 07/1 infected HEL cells assessed as reduction in virus plaque formation after 5 days | 2008 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 18, Issue:15 | Successful kinase bypass with new acyclovir phosphoramidate prodrugs. |
| AID400421 | Antiviral activity against HSV2 infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days | 1998 | Journal of natural products, May, Volume: 61, Issue:5 | Antiviral phenylpropanoid glycosides from the medicinal plant Markhamia lutea. |
| AID1714437 | Cytotoxicity in HFF cells incubated for 7 days by CellTiter-Glo assay | 2016 | Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23 | Synthesis and Antiviral Evaluation of Octadecyloxyethyl Benzyl 9-[(2-Phosphonomethoxy)ethyl]guanine (ODE-Bn-PMEG), a Potent Inhibitor of Transient HPV DNA Amplification. |
| AID218247 | Cytotoxicity was evaluated by measuring the inhibition of HSV replication in vero cells | 1991 | Journal of medicinal chemistry, Mar, Volume: 34, Issue:3 | Fluorocarbocyclic nucleosides: synthesis and antiviral activity of 2'- and 6'-fluorocarbocyclic 2'-deoxy guanosines. |
| AID218048 | Inhibition of cytopathogenic effect was determined against Herpes simplex virus (HSV) -2 in vero cell monolayer culture | 1987 | Journal of medicinal chemistry, May, Volume: 30, Issue:5 | Synthesis and biological activity of unsaturated carboacyclic purine nucleoside analogues. |
| AID1402826 | Antiviral activity against HSV1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathic effect after 2 to 3 days | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Emimycin and its nucleoside derivatives: Synthesis and antiviral activity. |
| AID774689 | Antiviral activity against Poliovirus 1 Sabin VR-1562 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity | 2013 | Bioorganic & medicinal chemistry, Sep-15, Volume: 21, Issue:18 | Synthesis and biological evaluation of furopyrimidine N,O-nucleosides. |
| AID85888 | Compound was evaluated for the antiviral activity against HSV-1 | 1998 | Bioorganic & medicinal chemistry letters, Apr-07, Volume: 8, Issue:7 | Synthesis and antiviral activity of novel isodideoxy nucleosides with exocyclic methylene. |
| AID383514 | Antiviral activity against HSV2 G in human E6SM cells assessed as reduction of virus-induced cytopathogenicity | 2008 | European journal of medicinal chemistry, Feb, Volume: 43, Issue:2 | Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents. |
| AID392536 | Antiviral activity against Vaccinia virus | 2009 | Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2 | Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. |
| AID609512 | Antiviral activity against Varicella-zoster virus YS expressing thymidine kinase assessed as reduction of virus induced cytopathicity by cell based assay | 2011 | Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15 | Acyclic nucleoside phosphonates with a branched 2-(2-phosphonoethoxy)ethyl chain: efficient synthesis and antiviral activity. |
| AID521916 | Cmax in human systemic circulation with normal renal function at 2000 mg, po every 6 hrs measured after fifth dose by radioimmunoassay | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. |
| AID1886802 | Cytotoxicity against golden hamster BHK-21 cells measured after 6 days by MTT assay | 2022 | Journal of natural products, 08-26, Volume: 85, Issue:8 | Antiviral Profiling of C-18- or C-19-Functionalized Semisynthetic Abietane Diterpenoids. |
| AID120305 | In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through oral route at a dose 5 mg/kg per day | 1985 | Journal of medicinal chemistry, Nov, Volume: 28, Issue:11 | 5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue. |
| AID1394847 | Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of plaque formation measured after 6 to 7 days post infection | 2018 | European journal of medicinal chemistry, Apr-25, Volume: 150 | Synthesis and antiviral evaluation of cyclopentyl nucleoside phosphonates. |
| AID1661192 | Cytotoxicity against human HEL cells assessed as reduction in cell proliferation incubated for 3 days by Coulter counter method | 2020 | ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7 | Amidate Prodrugs of |
| AID1055502 | Antiviral activity against Feline herpesvirus infected in cat CRFK cells assessed as inhibition of virus-induced cytopathicity | 2013 | European journal of medicinal chemistry, , Volume: 70 | Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides. |
| AID84427 | Inhibitory effects on HSV-1 induced mortality in NMRI mice upon (ip) administration at a dose of 250 mk/kg/day | 2001 | Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22 | Design, synthesis, and biological evaluation of novel nucleoside and nucleotide analogues as agents against DNA viruses and/or retroviruses. |
| AID85564 | In vitro minimum inhibitory concentration to inhibit thymidine deficient HSV-1 (VMV 1837)- induced cytopathogenicity in PRK cells by 50% | 1988 | Journal of medicinal chemistry, Jul, Volume: 31, Issue:7 | Synthesis and antiviral activity of novel N-substituted derivatives of acyclovir. |
| AID106753 | Cytotoxicity indicative of 50% survival concentration in HSV-2-uninfected MT-4 cells. | 2002 | Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17 | Synthesis and biological evaluation of novel D-2'-azido-2',3'-dideoxyarabinofuranosyl-4'-thiopyrimidines and purines. |
| AID393990 | Antiviral activity against HPMPA-resistant HCMV AD169 clone 2 mutant infected in HEL cells assessed as inhibition of virus-induced cytopathicity | 2009 | Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6 | 4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus. |
| AID574826 | Antiviral activity against Herpes simplex virus 1 isolate 6 harboring N23S, K36E, R89Q, +1G 437-438 = Stop 225 mutations in thymidine kinase and S33G, A330R, A646T, S1123L, P1124H, T1208A, R1229I mutations in DNA polymerase infected in african green monke | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. |
| AID768205 | Antiviral activity against TK-positive Varicella-zoster virus 07-1 infected in human HEL cells assessed as reduction of plaque formation | 2013 | European journal of medicinal chemistry, Aug, Volume: 66 | Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies. |
| AID1592939 | Antiviral activity against Herpes simplex virus 2-333 infected in African green monkey Vero cells assessed as inhibition of viral replication after 48 hrs by naphthol blue-black staining-based plaque reduction assay | |||
| AID383527 | Antiviral activity against TK+ VZV OKA infected HEL cells assessed as reduction in virus plaque formation | 2008 | European journal of medicinal chemistry, Feb, Volume: 43, Issue:2 | Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents. |
| AID106024 | Compound was evaluated for the inhibition of cell replication of human fibroblast (MRC-5) cells. | 1993 | Journal of medicinal chemistry, May-14, Volume: 36, Issue:10 | Novel acyclonucleotides: synthesis and antiviral activity of alkenylphosphonic acid derivatives of purines and a pyrimidine. |
| AID232882 | Ralative safety was expressed as Selective index (TC50/IC50) at HSV-1 passage 1 in vero cells | 1998 | Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16 | Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. |
| AID400427 | Selectivity index, ratio of EC50 for HSV1 by cytopathic effect over IC50 for human Hep2 cells | 1998 | Journal of natural products, May, Volume: 61, Issue:5 | Antiviral phenylpropanoid glycosides from the medicinal plant Markhamia lutea. |
| AID1361088 | Cytostatic activity against human HEL cells after 3 days by coulter counter method | 2018 | European journal of medicinal chemistry, Jul-15, Volume: 155 | Dihydropyrimidinone/1,2,3-triazole hybrid molecules: Synthesis and anti-varicella-zoster virus (VZV) evaluation. |
| AID249056 | Cytotoxicity against CEM cell lines of human | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | Synthesis and antiviral activity of helioxanthin analogues. |
| AID521904 | Drug level in human plasma with normal renal function at 2000 mg, po every 6 hrs measured after fifth dose by radioimmunoassay | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. |
| AID246458 | Effective concentration required to inhibit Epstein-barr virus replication in daudi cells in viral capsid immunofluorescence ELISA | 2005 | Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1 | Nucleotides and pronucleotides of 2,2-bis(hydroxymethyl)methylenecyclopropane analogues of purine nucleosides: synthesis and antiviral activity. |
| AID217487 | In vitro minimum inhibitory concentration to inhibit VV-induced cytopathogenicity in PRK cells by 50% | 1988 | Journal of medicinal chemistry, Jul, Volume: 31, Issue:7 | Synthesis and antiviral activity of novel N-substituted derivatives of acyclovir. |
| AID309810 | Antiviral activity against TK+ VZV OKA in HEL cells assessed as reduction of virus plaque formation | 2007 | Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22 | Influence of 6 or 8-substitution on the antiviral activity of 3-phenethylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (HCMV) and varicella-zoster virus (VZV). |
| AID84607 | In vitro minimum inhibitory concentration to inhibit HSV-2 (G)-induced cytopathogenicity in PRK cells by 50% | 1988 | Journal of medicinal chemistry, Jul, Volume: 31, Issue:7 | Synthesis and antiviral activity of novel N-substituted derivatives of acyclovir. |
| AID85893 | Inhibition of plaque formation in monolayers of HSV-1 E-377 Vero cells by 50% | 2001 | Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21 | Synthesis and antiviral activity of novel 5-(1-cyanamido-2-haloethyl) and 5-(1-hydroxy(or methoxy)-2-azidoethyl) analogues of uracil nucleosides. |
| AID218238 | Antiviral activity in plaque reduction assay was determined against herpes simplex virus type 1 (HSV-1) in Vero cells. | 1990 | Journal of medicinal chemistry, Jan, Volume: 33, Issue:1 | Synthesis and antiviral activity of 9-alkoxypurines. 1. 9-(3-Hydroxypropoxy)- and 9-[3-hydroxymethyl)propoxy]purines. |
| AID1219948 | Drug transport in human OAT3 expressed in HEK Flp-In cells assessed as maximal rate of transport measured per mg of protein | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3 | Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs. |
| AID1462040 | Cytotoxicity against HEL cells assessed as reduction in cell growth after 3 days by coulter counter method | 2017 | Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17 | New prodrugs of two pyrimidine acyclic nucleoside phosphonates: Synthesis and antiviral activity. |
| AID388922 | Cytotoxicity against HEL cells assessed as morphological alteration after 3 days | 2008 | Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21 | Influence of 6- or 8-substitution on the antiviral activity of 3-arylalkylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (CMV) and varicella-zoster virus (VZV): part II. |
| AID167150 | Minimum cytotoxic concentration causing toxic effects on uninfected cells in rabbit | 1988 | Journal of medicinal chemistry, Sep, Volume: 31, Issue:9 | Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity. |
| AID246587 | Effective concentration of compound required to reduce plaque formation by AD-169 strain of CMV virus in Human embryonic lung cells; ND=Not determined | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | The novel L- and D-amino acid derivatives of hydroxyurea and hydantoins: synthesis, X-ray crystal structure study, and cytostatic and antiviral activity evaluations. |
| AID1869612 | Antiviral activity against VZV TK+ infected in HEL cells assessed as reduction in virus plaque formation | 2022 | Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13 | Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound. |
| AID1457770 | Cytotoxic activity against HEL cells assessed as reduction in cell proliferation after 3 days by coulter counting method | 2017 | Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14 | Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs. |
| AID66020 | Compound was evaluated for the minimum inhibition concentration required to reduce virus-induced cytopathogenicity by 50%, determined against KOS,F,McIntyre strains of HSV-1 virus. | 1998 | Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22 | 5-Substituted pyrimidines with a 1,5-anhydro-2, 3-dideoxy-D-arabino-hexitol moiety at N-1: synthesis, antiviral activity, conformational analysis, and interaction with viral thymidine kinase. |
| AID388918 | Antiviral activity against thymidine kinase expressing Varicella-Zoster virus Oka in HEL cells assessed as inhibition of viral cytopathicity | 2008 | Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21 | Influence of 6- or 8-substitution on the antiviral activity of 3-arylalkylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (CMV) and varicella-zoster virus (VZV): part II. |
| AID498598 | Antiviral activity against Macacine herpesvirus 1 isolate A2 infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds. |
| AID121250 | Survival rate at 20th day expressed as number of mice survived infected with HSV-1; out of 10 | 1987 | Journal of medicinal chemistry, Jun, Volume: 30, Issue:6 | Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases. |
| AID41528 | Effective concentration was evaluated against HSV-1 by using serum starved baby hamster kidney cells in a colorimetric viral yield assay. | 1996 | Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21 | Peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase with improved in vivo antiviral activity. |
| AID732673 | Immunoregulatory activity in Hepatitis B virus infected transgenic mouse assessed as increase in cytokine IFN gamma level in serum at 100 mg/kg qd for 1 month by ELISA | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and biological evaluation of nucleoside analogues than contain silatrane on the basis of the structure of acyclovir (ACV) as novel inhibitors of hepatitis B virus (HBV). |
| AID232770 | Selectivity index against HSV-1 was determined as CD50/ED50 ratio | 1994 | Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1 | S-glucosylated hydantoins as new antiviral agents. |
| AID326136 | Antiviral activity against Herpes B virus E90-136 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides. |
| AID86044 | Antiviral activity against herpes simplex virus using ELISA | 1996 | Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18 | Synthesis of non-nucleoside analogs of toyocamycin, sangivamycin, and thiosangivamycin: the effect of certain 4- and 4,6-substituents on the antiviral activity of pyrrolo[2,3-d]pyrimidines. |
| AID1079949 | Proposed mechanism(s) of liver damage. [column 'MEC' in source] | |||
| AID106002 | Inhibitory activity against human cytomegalovirus (HCMV) strain AD169 in MRC-5 cells. | 1996 | Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3 | Synthesis and anti-herpes virus activity of 2'-deoxy-4'-thiopyrimidine nucleosides. |
| AID1869617 | Cytotoxicity against human HFF cells infected with HCMV AD-169 virus assessed as reduction in cell viability by cell titer-glo assay | 2022 | Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13 | Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound. |
| AID85105 | Antiviral activity against Herpes simplex virus-2 (186 strain) | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID83886 | Tested for mean day to death of nonsurvivors against HSV-1 infection in mice at 50 mg/kg per day | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5 | Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS. |
| AID85694 | In vivo efficacy of compound against HSV-1 strain A133 in the mouse system model was measured at 100 dose(mg/kg), activity expressed as Survivors counted on day 21; 8/10 | 1991 | Journal of medicinal chemistry, Mar, Volume: 34, Issue:3 | Fluorocarbocyclic nucleosides: synthesis and antiviral activity of 2'- and 6'-fluorocarbocyclic 2'-deoxy guanosines. |
| AID218374 | Inhibitory dose required to reduce the growth of vero cells by 50% over a 4 day period. | 1996 | Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3 | Synthesis and anti-herpes virus activity of 2'-deoxy-4'-thiopyrimidine nucleosides. |
| AID65707 | Antiviral activity against Vaccinia virus in E6SM cell cultures | 2001 | Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16 | Design, synthesis, DNA binding, and biological evaluation of water-soluble hybrid molecules containing two pyrazole analogues of the alkylating cyclopropylpyrroloindole (CPI) subunit of the antitumor agent CC-1065 and polypyrrole minor groove binders. |
| AID634757 | Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID260292 | Antiviral activity against TK- VZV 07/10 in human embryonic lung cells | 2006 | Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4 | Inactivation of S-adenosyl-L-homocysteine hydrolase by 6'-cyano-5',6'-didehydro-6'-deoxyhomoadenosine and 6'-chloro-6'-cyano-5',6'-didehydro-6'-deoxyhomoadenosine. Antiviral and cytotoxic effects. |
| AID87042 | Degree of inhibition of virus-induced cytopathogenic effect and the degree of cytotoxicity produced by compound against herpes simplex type-2 MS virus | 1988 | Journal of medicinal chemistry, Sep, Volume: 31, Issue:9 | Cyclopentenylcytosine. A carbocyclic nucleoside with antitumor and antiviral properties. |
| AID1402822 | Antiviral activity against HCMV AD169 infected in HEL cells assessed as reduction in virus-induced cytopathic effect after 6 to 7 days | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Emimycin and its nucleoside derivatives: Synthesis and antiviral activity. |
| AID516968 | Antiviral activity against acyclovir-resistant VZV OKA infected in HEL assessed as reduction in virus-induce cytopathicity | 2010 | Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19 | Synthesis of ester prodrugs of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) as anti-poxvirus agents. |
| AID1667299 | Antiviral activity against Herpes simplex virus 1 infected in African green monkey Vero cells assessed as reduction in plaque formation pretreated with compound for 1 hr followed by viral infection at 0.01 PFU/cells for 1 hr by plaque reduction assay | 2020 | Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7 | DNA sequence-specific ligands. XVIII. Synthesis, physico-chemical properties; genetic, virological, and biochemical studies of fluorescent dimeric bisbenzimidazoles DBPA(n). |
| AID137472 | Number of survivors against Herpes simplex virus type-1 infection in mice at 50 mg/kg/day | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID83726 | In Vitro cytotoxicity against HSV-1 at 50 ug/mL concentration | 1994 | Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19 | Synthesis of new acyclic pyrimidine nucleoside analogs as potential antiviral drugs. |
| AID217717 | Comparative Potency (IC50s) at HSV-2 passage 4 in vero cells | 1998 | Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16 | Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. |
| AID425253 | Total AUC in horse at 10 mg/kg, iv after 1 hr by two-compartmental study | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID733257 | Antiviral activity against Herpes simplex virus 1 F infected in Vero cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Efficient synthesis of 3H,3'H-spiro[benzofuran-2,1'-isobenzofuran]-3,3'-dione as novel skeletons specifically for influenza virus type B inhibition. |
| AID83333 | The minimum inhibitory concentration was measured on HEL cells in cell growth | 1994 | Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19 | Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity. |
| AID412418 | Antiviral activity against acyclovir-sensitive HSV1 L177 isolate replication in african green monkey Vero cells by plaque reduction assay | 2009 | Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1 | Synthesis and in vitro activities of a new antiviral duplex drug linking Zidovudine (AZT) and Foscarnet (PFA) via an octadecylglycerol residue. |
| AID332245 | Cytotoxicity against african green monkey Vero cells by EPTT method | 2002 | Journal of natural products, Feb, Volume: 65, Issue:2 | Cytotoxic effect (on tumor cells) and in vitro antiviral activity against herpes simplex virus of synthetic spongiane diterpenes. |
| AID82896 | Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain YS plaque formation by 50% | 1995 | Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5 | Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides. |
| AID1394844 | Antiviral activity against thymidine kinase expressing Varicella-Zoster virus Oka infected in HEL cells assessed as inhibition of plaque formation measured after 5 days post infection | 2018 | European journal of medicinal chemistry, Apr-25, Volume: 150 | Synthesis and antiviral evaluation of cyclopentyl nucleoside phosphonates. |
| AID87203 | Tested in vitro for antiviral activity against HSV-1 in plaque reduction assay. | 1990 | Journal of medicinal chemistry, Dec, Volume: 33, Issue:12 | Arabinofuranosylpyrrolo[2,3-d]pyrimidines as potential agents for human cytomegalovirus infections. |
| AID1186333 | Antiviral activity against Reovirus type-1 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay | 2014 | Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17 | Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents. |
| AID258990 | Antiviral activity against Varicella-Zoster virus 07/1 strain | 2006 | Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1 | Synthesis and biological evaluation of 6-(alkyn-1-yl)furo[2,3-d]pyrimidin-2(3H)-one base and nucleoside derivatives. |
| AID498605 | Antiviral activity against Macacine herpesvirus 1 isolate MJ1 infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds. |
| AID1857434 | Antiviral activity against HSV-1 infected in po dosed BALB/c mouse administered twice on infection day and three times daily from day 1 to 4 post infection | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Treatment Option for Acyclovir-Resistant Herpes Simplex Virus Infections. |
| AID284527 | Antiviral activity against HSV2 G-induced cytopathogenicity in E6SM cells | 2007 | Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2 | The novel C-5 aryl, alkenyl, and alkynyl substituted uracil derivatives of L-ascorbic acid: synthesis, cytostatic, and antiviral activity evaluations. |
| AID288916 | Antiviral activity against HSV1 KOS in E6SM cells assessed as reduction of virus-induced cytopathogenicity | 2007 | Journal of medicinal chemistry, Jun-14, Volume: 50, Issue:12 | 5-alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells. |
| AID167883 | Antiviral Activity against herpes simplex virus-2 (G) in rabbit kidney cell | 1990 | Journal of medicinal chemistry, Sep, Volume: 33, Issue:9 | Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives. |
| AID425244 | Free primary phase half life in horse at rapid distribution phase at 10 mg/kg, iv after 1 hr by three-compartmental study | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID561613 | Half life in children and young patient with malignancy at 10 mg/kg, po administered every 12 hrs | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. |
| AID217606 | Comparative Potency (IC50s) at HSV-2 passage 1 in vero cells | 1998 | Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16 | Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. |
| AID697731 | Antiviral activity against HSV1 strain F ATCC VR733 infected in african green monkey Vero cells assessed as inhibition of cytopathic effect at 3.5 uM after 48 hrs by plaque reduction assay | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14 | Anti-herpes simplex virus efficacies of 2-aminobenzamide derivatives as novel HSP90 inhibitors. |
| AID574828 | Antiviral activity against Herpes simplex virus 1 isolate 8 harboring N23S, K36E, R89Q, +1G 437-438 = Stop 228 mutations in thymidine kinase and A330R, P875S, V905M, P1124H, T1208A mutations in DNA polymerase infected in african green monkey Vero cells by | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. |
| AID1273995 | Antiviral activity against DENV-2 New guinea infected in African green monkey Vero cells assessed as maximal non toxic concentration causing inhibition of virus-induced cytopathic effect after 3 days by crystal violet staining based inverted microscopic a | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Anti-herpetic and anti-dengue activity of abietane ferruginol analogues synthesized from (+)-dehydroabietylamine. |
| AID498592 | Antiviral activity against Macacine herpesvirus 1 isolate MR9 infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds. |
| AID419662 | Antiviral activity against Herpes simplex virus type 1 in african green monkey BSC1 cells by plaque reduction assay | 2009 | Bioorganic & medicinal chemistry, Jun-01, Volume: 17, Issue:11 | Phosphonate analogues of cyclopropavir phosphates and their E-isomers. Synthesis and antiviral activity. |
| AID687662 | Antiviral activity against HSV2 G infected in HEL assessed as inhibition of virus-induced cytopathicity after 3 days | 2012 | European journal of medicinal chemistry, Nov, Volume: 57 | Synthesis and antiviral evaluation of bis(POM) prodrugs of (E)-[4'-phosphono-but-2'-en-1'-yl]purine nucleosides. |
| AID1283358 | Antiviral activity against HSV1 KOS ATCC VR1493 infected in African green monkey Vero cells assessed as reduction in EGFP-positive cells treated at 2 hrs post infection measured 24 hrs post infection by flow cytometric analysis | 2016 | ACS medicinal chemistry letters, Jan-14, Volume: 7, Issue:1 | iPSC Neuronal Assay Identifies Amaryllidaceae Pharmacophore with Multiple Effects against Herpesvirus Infections. |
| AID574821 | Antiviral activity against Herpes simplex virus 1 isolate 1 harboring C6G N23S K36E L42P G240E A265T and A207P mutations in thymidine kinase and S33G, A330R, N425T, V905M mutations in DNA polymerase infected in african green monkey Vero cells by plaque re | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. |
| AID84604 | Concentration required to reduce cytopathogenicity of Herpes simplex virus type 2 (strain G) by 50% in primary rabbit kidney (PRK) cells | 1984 | Journal of medicinal chemistry, Nov, Volume: 27, Issue:11 | Nucleic acid related compounds. 47. Synthesis and biological activities of pyrimidine and purine "acyclic" nucleoside analogues. |
| AID85700 | In vivo efficacy of compound against HSV-1 strain A133 in the mouse system model was measured at 6.25 dose(mg/kg), activity expressed as Survivors counted on day 21; 0/5 | 1991 | Journal of medicinal chemistry, Mar, Volume: 34, Issue:3 | Fluorocarbocyclic nucleosides: synthesis and antiviral activity of 2'- and 6'-fluorocarbocyclic 2'-deoxy guanosines. |
| AID1462033 | Antiviral activity against thymidine kinase-deficient ACV-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect | 2017 | Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17 | New prodrugs of two pyrimidine acyclic nucleoside phosphonates: Synthesis and antiviral activity. |
| AID575031 | Antiviral activity against Herpes simplex virus 2 isolate 16 harboring D137Stop mutations in thymidine kinase and A9T, P15S, L60P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. |
| AID383521 | Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as reduction of virus-induced cytopathogenicity | 2008 | European journal of medicinal chemistry, Feb, Volume: 43, Issue:2 | Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents. |
| AID732669 | Immunoregulatory activity in Hepatitis B virus infected transgenic mouse assessed as increase in CD8+ population in peripheral blood at 100 mg/kg qd for 1 month by flow cytometry (Rvb = 14.1 +/-1.4%) | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and biological evaluation of nucleoside analogues than contain silatrane on the basis of the structure of acyclovir (ACV) as novel inhibitors of hepatitis B virus (HBV). |
| AID246536 | Effective concentration to inhibit 50 % of herpes simplex virus type 2 replication in a cell culture model;ND=Not determined | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | Synthesis and antiviral activity of helioxanthin analogues. |
| AID257893 | Antiviral activity against herpes simplex virus 1 TK- KOS ACVr strain in HEL cells | 2006 | Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2 | Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators. |
| AID273047 | Cytotoxicity against KB cells | 2006 | Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20 | 9-{[3-fluoro-2-(hydroxymethyl)cyclopropylidene]methyl}adenines and -guanines. Synthesis and antiviral activity of all stereoisomers1. |
| AID1230100 | Antiviral activity against Varicella-zoster virus expressing thymidine kinase infected in HEL cells assessed as reduction of virus-induced plaque formation | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Design, antiviral and cytostatic properties of isoxazolidine-containing amonafide analogues. |
| AID83526 | Anti-VZV activity against YS TK+ in HEL cells | 1998 | Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25 | Synthesis of imidazo[1,2-a]pyridines as antiviral agents. |
| AID82888 | Tested for inhibitory effect on DNA virus CMV (Davis) in HEL cell line | 1993 | Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23 | Synthesis and antiviral activity of 5'-deoxypyrazofurin. |
| AID1274007 | Antiviral activity against DENV-2 New guinea infected in African green monkey Vero cells assessed as reduction in plaque formation administered simultaneously with virus for 1 hr measured after 8 days by crystal violet staining technique | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Anti-herpetic and anti-dengue activity of abietane ferruginol analogues synthesized from (+)-dehydroabietylamine. |
| AID88669 | Inhibition of [3H]thymidine incorporation into the DNA of uninfected HeLa cells | 1995 | Journal of medicinal chemistry, May-12, Volume: 38, Issue:10 | Inhibition of herpes simplex virus type 1 helicase-primase by (dichloroanilino)purines and -pyrimidines. |
| AID1283362 | Antiviral activity against VZV infected in human ARPE19 cells at 50 uM treated at 2 hrs post infection measured 48 hrs post infection by luciferase assay relative to control | 2016 | ACS medicinal chemistry letters, Jan-14, Volume: 7, Issue:1 | iPSC Neuronal Assay Identifies Amaryllidaceae Pharmacophore with Multiple Effects against Herpesvirus Infections. |
| AID245893 | Cytotoxic concentration to inhibit replication in daudi cells | 2005 | Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1 | Nucleotides and pronucleotides of 2,2-bis(hydroxymethyl)methylenecyclopropane analogues of purine nucleosides: synthesis and antiviral activity. |
| AID481585 | Antiviral activity against HSV1 KOS infected in african green monkey Vero cells assessed as reduction in plaque formation | 2010 | Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10 | Modifications of C-2 on the pyrroloquinoline template aimed at the development of potent herpesvirus antivirals with improved aqueous solubility. |
| AID216169 | Minimum Inhibition Concentration (MIC) for activity against Varicella-Zoster Virus(VZV) using 07/1 (TK-) strain. | 1996 | Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14 | Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents. |
| AID1261316 | Antiviral activity against human RSV infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by plaque reduction assay | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID431628 | Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathicity | 2009 | Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17 | The application of phosphoramidate protide technology to acyclovir confers anti-HIV inhibition. |
| AID91299 | Inhibitory concentration of the drug against the cytopathic effect for MS strain of herpes simplex virus-2 (HSV-2) in human HFF cells | 1993 | Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17 | Synthesis and antiviral activity of novel 5-(1-azido-2-haloethyl) and 5-(1-azido-, amino-, or methoxyethyl) analogs of 2'-deoxyuridine. |
| AID425248 | Free clearance in horse at 10 mg/kg, iv after 1 hr by three-compartmental study | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID636697 | Antiviral activity against HSV1 KOS infected in HFF cells incubated for 3 days by plaque reduction assay | 2011 | Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16 | Tyrosine-based 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine and -adenine ((S)-HPMPC and (S)-HPMPA) prodrugs: synthesis, stability, antiviral activity, and in vivo transport studies. |
| AID609573 | Antiviral activity against thymidine kinase-deficient Varicella-zoster virus YS/R assessed as reduction of virus induced cytopathicity by cell based assay | 2011 | Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15 | Acyclic nucleoside phosphonates with a branched 2-(2-phosphonoethoxy)ethyl chain: efficient synthesis and antiviral activity. |
| AID611626 | Cytotoxicity against cat CRFK cells assessed as growth inhibition after 3 days by coulter counter | 2011 | Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11 | New prodrugs of Adefovir and Cidofovir. |
| AID218199 | Tested in vitro for minimum inhibitory concentration against herpes simplex virus-1 (HSV-1) KOS, ACG strain by plaque-reduction assay in vero cells | 1993 | Journal of medicinal chemistry, May-28, Volume: 36, Issue:11 | 3-Quinolinecarboxamides. A series of novel orally-active antiherpetic agents. |
| AID85406 | Antiviral activity against HSV-1 kinase mutant resistant to SCS(parental) was determined at a conc of 50 uM | 1987 | Journal of medicinal chemistry, Nov, Volume: 30, Issue:11 | Acetylenic nucleosides. 4. 1-beta-D-arabinofuranosyl-5-ethynylcytosine. Improved synthesis and evaluation of biochemical and antiviral properties. |
| AID232887 | Ralative safety was expressed as Selective index (TC50/IC50) at HSV-1 passage 5 in vero cells | 1998 | Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16 | Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. |
| AID218427 | Anti viral activity against VZV(pplla strain) in WI-38 cell monolayers. | 1992 | Journal of medicinal chemistry, May-15, Volume: 35, Issue:10 | Synthesis and antiviral activity of 1-cyclobutyl-5-(2-bromovinyl)uracil nucleoside analogues and related compounds. |
| AID85127 | Inhibitory activity against HSV-2 (Lyons) replication in E6SM cell cultures of human embryonic skin-muscle | 2002 | Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25 | A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity. |
| AID340469 | Antiviral activity against HSV1 KOS by plaque reduction assay | 2008 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14 | Synthesis of 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamides with broad-spectrum human herpesvirus polymerase inhibition. |
| AID540219 | Volume of distribution at steady state in monkey after iv administration | 2005 | Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7 | Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. |
| AID1251995 | Antiviral activity against thymidine kinase-deficient Varicella zoster virus Oka infected in HEL cells assessed as reduction in viral plaque formation | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Toward the discovery of dual HCMV-VZV inhibitors: Synthesis, structure activity relationship analysis, and cytotoxicity studies of long chained 2-uracil-3-yl-N-(4-phenoxyphenyl)acetamides. |
| AID216322 | The concentration required to reduce virus plaque formation by 50% was measured on 07/1 strain of VZV expressing viral thymidine kinase(TK-) | 1999 | Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7 | Novel potential agents for human cytomegalovirus infection: synthesis and antiviral activity evaluation of benzothiadiazine dioxide acyclonucleosides. |
| AID425266 | Free oral bioavailability in horse at 20 mg/kg administered as single dose | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID255984 | Antiviral activity against herpes simplex virus type 2 (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO | 2005 | Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18 | 4-Oxo-4,7-dihydrothieno[2,3-b]pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases. |
| AID83191 | Minimum inhibitory conc. for 50% inhibition of TK VZV (07/1) virus plaque formation in HEL cells | 1997 | Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9 | Carbocyclic oxetanocins lacking the C-3' methylene. |
| AID84226 | Minimum inhibitory concentration was determined against HSV-1 (McIntyre) in E6SM cell culture | 2000 | Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4 | The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine. |
| AID1457768 | Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07-1 infected in HEL cells assessed as inhibition of plaque formation | 2017 | Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14 | Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs. |
| AID167140 | Minimum inhibitory concentration required to reduce virus induced cytopathogenicity in primary rabbit kidney cell cultures by 50% against Vesicular stomatitis virus | 1983 | Journal of medicinal chemistry, Apr, Volume: 26, Issue:4 | Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl]guanine]. |
| AID250987 | Effect on ocular HSV-2 reactivation in mice following intraperitoneal dosage at 200 mg/kg; expressed as HSV-2 positive cultures/15 mice | 2005 | Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11 | Inhibition of herpes simplex virus thymidine kinases by 2-phenylamino-6-oxopurines and related compounds: structure-activity relationships and antiherpetic activity in vivo. |
| AID284535 | Cytotoxicity against E6SM cells | 2007 | Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2 | The novel C-5 aryl, alkenyl, and alkynyl substituted uracil derivatives of L-ascorbic acid: synthesis, cytostatic, and antiviral activity evaluations. |
| AID464097 | Antiviral activity against Human cytomegalovirus infected in HFF cells by plaque reduction assay | 2010 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 20, Issue:6 | The design and development of 2-aryl-2-hydroxy ethylamine substituted 1H,7H-pyrido[1,2,3-de]quinoxaline-6-carboxamides as inhibitors of human cytomegalovirus polymerase. |
| AID607911 | Cytotoxicity against human HEL cells assessed as alteration of normal cell morphology by microscopic analysis | 2011 | Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14 | Design, synthesis and biological evaluation of 2'-deoxy-2',2'-difluoro-5-halouridine phosphoramidate ProTides. |
| AID115158 | The maximum tolerated dose (MTD) was defined as the highest dose of compound that did not show any signs of toxicity in mice after po administration. | 1995 | Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14 | Cyclic variations of 3-quinolinecarboxamides and effects on antiherpetic activity. |
| AID1186337 | Antiviral activity against Respiratory syncytial virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 5 days by plaque reduction assay | 2014 | Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17 | Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents. |
| AID1433149 | Antiviral activity against Human cytomegalovirus strain Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis | 2015 | European journal of medicinal chemistry, Aug-28, Volume: 101 | Synthesis, antiplasmodial activity and mechanistic studies of pyrimidine-5-carbonitrile and quinoline hybrids. |
| AID675214 | Antiviral activity against HSV1 KOS infected in HEL cells by viral CPE assay | 2012 | European journal of medicinal chemistry, Sep, Volume: 55 | Synthesis and antiviral activities of hexadecyloxypropyl prodrugs of acyclic nucleoside phosphonates containing guanine or hypoxanthine and a (S)-HPMP or PEE acyclic moiety. |
| AID675221 | Cytotoxicity against HEL cells assessed as effect on cell morphology incubated for 3 days by microscopy | 2012 | European journal of medicinal chemistry, Sep, Volume: 55 | Synthesis and antiviral activities of hexadecyloxypropyl prodrugs of acyclic nucleoside phosphonates containing guanine or hypoxanthine and a (S)-HPMP or PEE acyclic moiety. |
| AID82859 | Antiviral activity in TK+ varicella zoster virus (VZV) YS strain in HEL cell culture | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20 | Acyclic nucleotide analogs derived from 8-azapurines: synthesis and antiviral activity. |
| AID16020 | Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally. | 1985 | Journal of medicinal chemistry, Jul, Volume: 28, Issue:7 | Synthesis and antiherpetic activity of (S)-, (R)-, and (+/-)-9-[(2,3-dihydroxy-1-propoxy)methyl]guanine, linear isomers of 2'-nor-2'-deoxyguanosine. |
| AID232890 | Ralative safety was expressed as Selective index (TC50/IC50) at HSV-1 passage 8 in vero cells | 1998 | Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16 | Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. |
| AID419664 | Antiviral activity against Herpes simplex virus type 1 in HFF assessed as inhibition of virus-induced cytopathic effect | 2009 | Bioorganic & medicinal chemistry, Jun-01, Volume: 17, Issue:11 | Phosphonate analogues of cyclopropavir phosphates and their E-isomers. Synthesis and antiviral activity. |
| AID83488 | Minimum inhibitory concentration required to elicit microscopically visible cell morphology in HEL cell lines | 2001 | Journal of medicinal chemistry, Aug-16, Volume: 44, Issue:17 | Synthesis, mechanism of action, and antiviral activity of a new series of covalent mechanism-based inhibitors of S-adenosyl-L-homocysteine hydrolase. |
| AID137473 | Number of survivors against Herpes simplex virus type-2 infection in mice at 100 mg/kg/day | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID498611 | Antiviral activity against Macacine herpesvirus 1 infected in rabbits assessed as survival after 5 months | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds. |
| AID213328 | Michaelis rate constant is determined by the Lineweaver and Burk method against HSV thymidine kinase | 2001 | Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22 | Design, synthesis, and biological evaluation of novel nucleoside and nucleotide analogues as agents against DNA viruses and/or retroviruses. |
| AID256537 | Toxicity on uninfected African green monkey kidney cells determined in microscopic evaluation and quantitative neutral red dye uptake assay | 2005 | Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18 | 4-Oxo-4,7-dihydrothieno[2,3-b]pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases. |
| AID106009 | Tested for Antiherpetic activity against VZV from clinical isolates of MRC-5 cell lines.(average of six isolates) | 2000 | Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2 | Synthesis and antiviral activity of novel anti-VZV 5-substituted uracil nucleosides with a cyclopropane sugar moiety. |
| AID1407613 | Antiviral activity against thymidine kinase-deficient acyclovir-resistant Human herpesvirus 1 KOS strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Synthesis of a 3'-C-ethynyl-β-d-ribofuranose purine nucleoside library: Discovery of C7-deazapurine analogs as potent antiproliferative nucleosides. |
| AID723372 | Antiviral activity against Varicella zoster virus Ellen infected in human MRC5 cells assessed as inhibition of viral replication by viral reduction plaque assay | 2013 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 23, Issue:2 | Antiviral activity of (+)-sattabacin against varicella zoster. |
| AID1667301 | Selectivity index, ratio of CC50 for cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTT assay to EC50 for antiviral activity against Herpes simplex virus 1 infected in African green mo | 2020 | Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7 | DNA sequence-specific ligands. XVIII. Synthesis, physico-chemical properties; genetic, virological, and biochemical studies of fluorescent dimeric bisbenzimidazoles DBPA(n). |
| AID1219929 | Drug transport in human OAT2 expressed in HEK Flp-In cells at 0.06 uM for 10 mins relative to control | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3 | Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs. |
| AID66018 | Compound was evaluated for the minimum inhibition concentration required to reduce virus-induced cytopathogenicity by 50%, determined against HSV-1 (TK-B2006) virus | 1998 | Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22 | 5-Substituted pyrimidines with a 1,5-anhydro-2, 3-dideoxy-D-arabino-hexitol moiety at N-1: synthesis, antiviral activity, conformational analysis, and interaction with viral thymidine kinase. |
| AID425245 | Free terminal half life in horse at slow distribution phase at 10 mg/kg, iv after 1 hr by three-compartmental study | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID82556 | Antiviral activity was measured as effective concentration required to reduce Varicella Zoster virus (OKA)-induced plaque formation in human embryonic lung cells | 2001 | Bioorganic & medicinal chemistry letters, Sep-17, Volume: 11, Issue:18 | Bicyclic anti-VZV nucleosides: Thieno analogues retain full antiviral activity. |
| AID85131 | Compound was evaluated for anti-herpesvirus activity against Herpes simplex virus-2 (MS) strain. | 1993 | Journal of medicinal chemistry, May-14, Volume: 36, Issue:10 | Novel acyclonucleotides: synthesis and antiviral activity of alkenylphosphonic acid derivatives of purines and a pyrimidine. |
| AID429198 | Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days | 2009 | European journal of medicinal chemistry, Aug, Volume: 44, Issue:8 | Synthesis and anti-VZV activity of 6-heteroaryl derivatives of tricyclic acyclovir and 9-{[cis-1',2'-bis(hydroxymethyl)cycloprop-1'-yl]methyl}guanine analogues. |
| AID83044 | Tested for cytotoxic activity in human embryonic lung fibroblast (HEL) | 2002 | Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5 | New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation. |
| AID84619 | In vivo efficacy of compound against HSV-2 strain A133 in the mouse system model was measured at 100dose(mg/kg), activity expressed as Survivors counted on day 21; 2/5 | 1991 | Journal of medicinal chemistry, Mar, Volume: 34, Issue:3 | Fluorocarbocyclic nucleosides: synthesis and antiviral activity of 2'- and 6'-fluorocarbocyclic 2'-deoxy guanosines. |
| AID82412 | Inhibitory activity against DM625 strain of zoster virus(VZV) by plaque reduction assay in HFF cells | 1998 | Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8 | Synthesis and antiviral activity of novel acyclic nucleosides: discovery of a cyclopropyl nucleoside with potent inhibitory activity against herpesviruses. |
| AID521917 | Cmax in human CSF with normal renal function at 2000 mg, po every 6 hrs measured after fifth dose by radioimmunoassay | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. |
| AID1420630 | Antiviral activity against acyclovir-resistant HSV1 KOS infected in African green monkey Vero cells assessed as inhibition of viral replication after 48 hrs by naphthol blue-black staining-based assay | 2018 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20 | Synthesis and biological evaluation of isoxazolyl-sulfonamides: A non-cytotoxic scaffold active against Trypanosoma cruzi, Leishmania amazonensis and Herpes Simplex Virus. |
| AID1261310 | Cytotoxicity against BHK cells assessed as cell viability after 48 to 96 hrs by MTT assay | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID304883 | Antiviral activity against TK+ VZV YS in HEL cells after 5 days | 2007 | Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26 | Synthesis and antiviral activity of the carbocyclic analogue of the highly potent and selective anti-VZV bicyclo furano pyrimidines. |
| AID245935 | Cytotoxic concentration required to inhibit Hel cell growth by using DMSO as solvent | 2005 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 15, Issue:16 | Bicyclic nucleoside inhibitors of Varicella-Zoster virus: the effect of branching in the p-alkylphenyl side chain. |
| AID273046 | Inhibition of HSV1 replication in BSC1 cells by ELISA | 2006 | Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20 | 9-{[3-fluoro-2-(hydroxymethyl)cyclopropylidene]methyl}adenines and -guanines. Synthesis and antiviral activity of all stereoisomers1. |
| AID1857435 | Antiviral activity against HSV-2 infected in po dosed BALB/c mouse administered twice on infection day and three times daily from day 1 to 4 post infection | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Treatment Option for Acyclovir-Resistant Herpes Simplex Virus Infections. |
| AID83034 | Compound was evaluated for the cytotoxicity against HEL cells | 1999 | Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22 | Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base. |
| AID595589 | Antiviral activity against Vaccinia virus Copenhagen infected in human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | Broad-spectrum antiviral activity including human immunodeficiency and hepatitis C viruses mediated by a novel retinoid thiosemicarbazone derivative. |
| AID1273992 | Antiviral activity against HHV-2 VR-734-G infected in African green monkey Vero cells assessed as reduction of viral titer at maximal non-toxic concentration after 72 hrs by crystal violet staining assay relative to control | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Anti-herpetic and anti-dengue activity of abietane ferruginol analogues synthesized from (+)-dehydroabietylamine. |
| AID1230104 | Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction of virus-induced cytopathogenicity | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Design, antiviral and cytostatic properties of isoxazolidine-containing amonafide analogues. |
| AID117770 | Antiviral activity in terms of percentage survival at a dose of 300 mg/kg after intraperitoneal inoculation of HSV-1(BWS) in mice (6/7) | 1991 | Journal of medicinal chemistry, Jul, Volume: 34, Issue:7 | A new class of acyclic phosphonate nucleotide analogues: phosphonate isosteres of acyclovir and ganciclovir monophosphates as antiviral agents. |
| AID90615 | Antiviral activity against Human cytomegalovirus in a plaque-reduction assay | 1989 | Journal of medicinal chemistry, Jul, Volume: 32, Issue:7 | Synthesis, cytotoxicity, and antiviral activity of certain 7-[(2-hydroxyethoxy)methyl]pyrrolo[2,3-d]pyrimidine nucleosides related to toyocamycin and sangivamycin. |
| AID82062 | Tested for the visual cytotoxicity on HFF cells at the time of human cytomegalovirus (HCMV) plaque enumeration | 1994 | Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18 | Benzimidazole ribonucleosides: design, synthesis, and antiviral activity of certain 2-(alkylthio)- and 2-(benzylthio)-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazoles. |
| AID84603 | Concentration required to inhibit HSV-2 strain 186 cytopathic effect by 50% was measured by plaque reduction assay | 1991 | Journal of medicinal chemistry, Mar, Volume: 34, Issue:3 | Fluorocarbocyclic nucleosides: synthesis and antiviral activity of 2'- and 6'-fluorocarbocyclic 2'-deoxy guanosines. |
| AID84931 | Compound was tested for antiviral activity against HSV-2 | 2002 | Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17 | Synthesis and biological evaluation of novel D-2'-azido-2',3'-dideoxyarabinofuranosyl-4'-thiopyrimidines and purines. |
| AID22159 | Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally; Total mice tested 10 | 1985 | Journal of medicinal chemistry, Jul, Volume: 28, Issue:7 | Synthesis and antiherpetic activity of (S)-, (R)-, and (+/-)-9-[(2,3-dihydroxy-1-propoxy)methyl]guanine, linear isomers of 2'-nor-2'-deoxyguanosine. |
| AID84249 | In vitro antiviral activity against herpesvirus, HSV-1, E-377 strain by plaque reduction assay in human foreskin fibroblasts. | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5 | Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS. |
| AID1204074 | Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method | 2015 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11 | N-((1,3-Diphenyl-1H-pyrazol-4-yl)methyl)anilines: A novel class of anti-RSV agents. |
| AID122848 | Toxicity of compound against mice was determined at a concentration of 750 mg/kg | 1986 | Journal of medicinal chemistry, Feb, Volume: 29, Issue:2 | Systematic synthesis and biological evaluation of alpha- and beta-D-xylofuranosyl nucleosides of the five naturally occurring bases in nucleic acids and related analogues. |
| AID1857465 | Oral bioavailability in rat | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Treatment Option for Acyclovir-Resistant Herpes Simplex Virus Infections. |
| AID1410504 | Antiviral activity against ACV-resistant thymidine kinase deficient Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 2 to 3 days post-infection | 2018 | ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4 | Amidate Prodrugs of Cyclic 9-( |
| AID326137 | Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides. |
| AID88283 | In vitro anti viral activity tested against HSV-1(Schooler) virus on Rabbit kidney cell cultures; 1-3 | 1985 | Journal of medicinal chemistry, Jul, Volume: 28, Issue:7 | Synthesis and antiherpetic activity of (S)-, (R)-, and (+/-)-9-[(2,3-dihydroxy-1-propoxy)methyl]guanine, linear isomers of 2'-nor-2'-deoxyguanosine. |
| AID277833 | Antiviral activity against HSV1 KOS | 2007 | Journal of natural products, Feb, Volume: 70, Issue:2 | Cinnamacrins A-C, cinnafragrin D, and cytostatic metabolites with alpha-glucosidase inhibitory activity from Cinnamosma macrocarpa. |
| AID774686 | Antiviral activity against Adenovirus 2 VR-1080 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity | 2013 | Bioorganic & medicinal chemistry, Sep-15, Volume: 21, Issue:18 | Synthesis and biological evaluation of furopyrimidine N,O-nucleosides. |
| AID1186329 | Cytotoxicity against mock-infected MDBK cells after 48 to 96 hrs by MTT assay | 2014 | Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17 | Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents. |
| AID376457 | Antiviral activity against HSV1 | 1998 | Journal of natural products, Apr, Volume: 61, Issue:4 | Cochinolide, a new gamma-alkylidene bicyclic butenolide with antiviral activity, and its beta-glucopyranoside from Homalium cochinchinensis. |
| AID575030 | Antiviral activity against Herpes simplex virus 2 isolate 15 harboring R221H mutations in thymidine kinase and A9T, P15S, L60P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. |
| AID45906 | In vitro minimum inhibitory concentration to inhibit CMV (Davis)-induced cytopathogenicity in HEL cells by 50% | 1988 | Journal of medicinal chemistry, Jul, Volume: 31, Issue:7 | Synthesis and antiviral activity of novel N-substituted derivatives of acyclovir. |
| AID232771 | Selectivity index against HSV-2 was determined as CD50/ED50 ratio | 1994 | Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1 | S-glucosylated hydantoins as new antiviral agents. |
| AID1382173 | Antiviral activity against Human simplex virus 2 G infected in HEL cells assessed as reduction in viral cytopathic effect | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Highly convergent synthesis and antiviral activity of (E)-but-2-enyl nucleoside phosphonoamidates. |
| AID365170 | Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl cytosine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity | 2008 | Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18 | 4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action. |
| AID419665 | Antiviral activity against Herpes simplex virus type 2 in HFF assessed as inhibition of virus-induced cytopathic effect | 2009 | Bioorganic & medicinal chemistry, Jun-01, Volume: 17, Issue:11 | Phosphonate analogues of cyclopropavir phosphates and their E-isomers. Synthesis and antiviral activity. |
| AID1273991 | Antiviral activity against HHV-1 CDC Atlanta infected in African green monkey Vero cells assessed as maximal non toxic concentration causing reduction of viral titer after 48 hrs by crystal violet staining assay | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Anti-herpetic and anti-dengue activity of abietane ferruginol analogues synthesized from (+)-dehydroabietylamine. |
| AID1884111 | Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 24 hrs by MTS assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Synthetic derivatives of the antifungal drug ciclopirox are active against herpes simplex virus 2. |
| AID665758 | Antiviral activity against HSV-1 infected in human HFF cells assessed as reduction in cytopathic effect after 3 days by crystal violet staining | 2012 | Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12 | Synthesis and antiviral activity of certain second generation methylenecyclopropane nucleosides. |
| AID563774 | Antiviral activity against HSV2 13077 harboring TK R223H mutant gene infected in HFF after 3 days by plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides. |
| AID689099 | Antiviral activity against acyclovir-resistant HSV1 L2 infected in Vero E6 cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs | 2012 | Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19 | Phosphoramidate derivatives of acyclovir: synthesis and antiviral activity in HIV-1 and HSV-1 models in vitro. |
| AID90937 | Tested in vitro for antiviral activity against human cytomegalovirus (HCMV) in yield reduction assay. | 1990 | Journal of medicinal chemistry, Dec, Volume: 33, Issue:12 | Arabinofuranosylpyrrolo[2,3-d]pyrimidines as potential agents for human cytomegalovirus infections. |
| AID675222 | Cytotoxicity against HEL cells assessed as effect on cell growth incubated for 3 days by Coulter counter assay | 2012 | European journal of medicinal chemistry, Sep, Volume: 55 | Synthesis and antiviral activities of hexadecyloxypropyl prodrugs of acyclic nucleoside phosphonates containing guanine or hypoxanthine and a (S)-HPMP or PEE acyclic moiety. |
| AID732679 | Cytotoxicity against human HepG2.2.15 cells assessed as reduction in number of viable cells after 3 days by MTT assay | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and biological evaluation of nucleoside analogues than contain silatrane on the basis of the structure of acyclovir (ACV) as novel inhibitors of hepatitis B virus (HBV). |
| AID342121 | Antiviral activity against thymidine kinase deficient VZV YS/R infected HEL cells assessed as reduction in virus plaque formation after 5 days | 2008 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 18, Issue:15 | Successful kinase bypass with new acyclovir phosphoramidate prodrugs. |
| AID1237438 | Antiviral activity against SARS-CoV Frankfurt 1 infected in African green monkey Vero E6 cells assessed as inhibition of virus-induced cytopathic effect after 3 days by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 | Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity. |
| AID81227 | In vitro inhibition of Thymidine Kinase-Varicella-Zoster Virus(OKA) plaque formation. | 2000 | Journal of medicinal chemistry, Aug-24, Volume: 43, Issue:17 | Nonnucleoside human cytomegalovirus inhibitors: synthesis and antiviral evaluation of (chlorophenylmethyl)benzothiadiazine dioxide derivatives. |
| AID1818210 | Antiviral activity against HSV-1 infected in African green monkey Vero cells assessed as inhibition of viral replication incubated for 3 days by MTT assay | |||
| AID365172 | Antiviral activity against foscarnet-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity | 2008 | Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18 | 4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action. |
| AID393981 | Cytotoxicity against human HEL cells assessed as morphological alteration after 3 days | 2009 | Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6 | 4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus. |
| AID246675 | Reduction of plaque formation by VZV07/1 strain of thymidine kinase(TK-) deficient VZ virus in human embryonic lung cells | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | The novel L- and D-amino acid derivatives of hydroxyurea and hydantoins: synthesis, X-ray crystal structure study, and cytostatic and antiviral activity evaluations. |
| AID244770 | Minimum cytotoxic concentration of compound that causes alteration of cell morphology in human embryonic lung cells | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | The novel L- and D-amino acid derivatives of hydroxyurea and hydantoins: synthesis, X-ray crystal structure study, and cytostatic and antiviral activity evaluations. |
| AID83024 | Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain YS/R plaque formation by 50%. | 1995 | Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5 | Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides. |
| AID83499 | Cytotoxic concentration reducing HEL cell growth by 50%. | 2002 | Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19 | Synthesis and antiviral/antiproliferative activity of some N-sulphonylbenzimidazoles. |
| AID402538 | Selectivity index, ratio of IC50 for african green monkey Vero cells to EC50 for HSV2 MS | 1997 | Journal of natural products, Jun, Volume: 60, Issue:6 | Two new lignans with activity against influenza virus from the medicinal plant Rhinacanthus nasutus. |
| AID246614 | Effective concentration required to inhibit human cytomegalo virus Davis induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection | 2005 | Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7 | From 1-acyl-beta-lactam human cytomegalovirus protease inhibitors to 1-benzyloxycarbonylazetidines with improved antiviral activity. A straightforward approach to convert covalent to noncovalent inhibitors. |
| AID87664 | Antiviral activity against Herpes simplex virus type-2 (HSV-2). | 1999 | Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15 | Nucleosides and nucleotides. 185. Synthesis and biological activities of 4'alpha-C-branched-chain sugar pyrimidine nucleosides. |
| AID86029 | Compound was evaluated for antiviral activity against HSV-1 reported as ED50 value | 1987 | Journal of medicinal chemistry, Jan, Volume: 30, Issue:1 | Synthesis and biological evaluation of acyclic neplanocin analogues. |
| AID425278 | Distribution coefficient, log P of the compound | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID1274008 | Antiviral activity against HHV-1 CDC Atlanta infected in African green monkey Vero cells assessed as reduction in plaque formation administered post viral infection after 72 hrs by crystal violet staining technique | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Anti-herpetic and anti-dengue activity of abietane ferruginol analogues synthesized from (+)-dehydroabietylamine. |
| AID324737 | Antiviral activity against TK- HSV1 DM2.1 in HFF cells after 72 hrs by plaque reduction assay | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase. |
| AID90617 | Inhibitory concentration against human cytomegalovirus (HCMV) in plaque reduction assay | 1988 | Journal of medicinal chemistry, Nov, Volume: 31, Issue:11 | Synthesis and antiviral activity of certain 4- and 4,5-disubstituted 7-[(2-hydroxyethoxy)methyl]pyrrolo[2,3-d]pyrimidines. |
| AID1303374 | Antiviral activity against Yellow fever virus 17D infected in BHK21 cells assessed as inhibition of virus induced cytopathogenicity after 3 to 4 days by MTT assay | 2016 | European journal of medicinal chemistry, Jul-19, Volume: 117 | A combined in silico/in vitro approach unveils common molecular requirements for efficient BVDV RdRp binding of linear aromatic N-polycyclic systems. |
| AID1703888 | Drug absorption of the compound incubated for 8 hrs by PAMPA-TGI assay | 2020 | European journal of medicinal chemistry, Oct-15, Volume: 204 | Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies. |
| AID226670 | Compound was evaluated for its cytotoxicity. | 1998 | Bioorganic & medicinal chemistry letters, Apr-07, Volume: 8, Issue:7 | Synthesis and antiviral activity of novel isodideoxy nucleosides with exocyclic methylene. |
| AID718120 | Antiviral activity against HSV1 F ATCC VR733 infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days | 2012 | Journal of natural products, Dec-28, Volume: 75, Issue:12 | Clerodane diterpenoids from Croton crassifolius. |
| AID217602 | Comparative Potency (IC50s) at HSV-1 passage 6 in vero cells | 1998 | Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16 | Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. |
| AID250858 | Effect on HSV-2 encephalitis in mice following intraperitoneal dosage at 25 mg/kg; expressed as number of survivors/10 | 2005 | Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11 | Inhibition of herpes simplex virus thymidine kinases by 2-phenylamino-6-oxopurines and related compounds: structure-activity relationships and antiherpetic activity in vivo. |
| AID361405 | Antiviral activity against HSV2 MS infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay | 2002 | Journal of natural products, Nov, Volume: 65, Issue:11 | New saponins from the starfish Certonardoa semiregularis. |
| AID83711 | Tested for antiviral activity against HSV-1 (TK-KOS) | 2001 | Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12 | The cyclohexene ring as bioisostere of a furanose ring: synthesis and antiviral activity of cyclohexenyl nucleosides. |
| AID326202 | Antiviral activity against Epstein-Barr virus infected in human akata cells | 2008 | Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5 | Fluorinated methylenecyclopropane analogues of nucleosides. Synthesis and antiviral activity of (Z)- and (E)-9-{[(2-fluoromethyl-2-hydroxymethyl)-cyclopropylidene]methyl}adenine and -guanine. |
| AID87997 | Compound was tested for its antiviral activity against HSV-2(MS) using plaque reduction assay. | 1991 | Journal of medicinal chemistry, Jan, Volume: 34, Issue:1 | Synthesis and antiviral activity of 9-alkoxypurines. 2. 9-(2,3-Dihydroxypropoxy)-, 9-(3,4-dihydroxybutoxy)-, and 9-(1,4-dihydroxybut-2-oxy)purines. |
| AID84047 | Number of survivors per number of HSV-1 infected mice treated with 200 mg/kg per day; 4/10 | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5 | Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS. |
| AID774687 | Antiviral activity against Coxsackievirus B4 VR-1035 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity | 2013 | Bioorganic & medicinal chemistry, Sep-15, Volume: 21, Issue:18 | Synthesis and biological evaluation of furopyrimidine N,O-nucleosides. |
| AID563782 | Antiviral activity against 4'-thioIDU-resistant HSV2 infected in HFF after 3 days by plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides. |
| AID217517 | Compound was evaluated for anti-herpesvirus activity against Varicella Zoster virus (Ellen) strain. | 1993 | Journal of medicinal chemistry, May-14, Volume: 36, Issue:10 | Novel acyclonucleotides: synthesis and antiviral activity of alkenylphosphonic acid derivatives of purines and a pyrimidine. |
| AID434309 | Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity | 2009 | European journal of medicinal chemistry, Sep, Volume: 44, Issue:9 | Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide. |
| AID634833 | Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID1684815 | Antiviral activity against Human cytomegalovirus AD169 infected in human HEL cells assessed as reduction in virus plaque formation measured on day 6 to 7 post-viral infection | 2021 | ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1 | Influence of 4'-Substitution on the Activity of Gemcitabine and Its ProTide Against VZV and SARS-CoV-2. |
| AID1610167 | Antiviral activity against Human adenovirus 2 infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis | 2019 | European journal of medicinal chemistry, Dec-15, Volume: 184 | Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives. |
| AID472784 | Cytotoxicity against MDBK cells after 48 to 96 hrs by MTT assay | 2010 | Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8 | Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives. |
| AID22163 | Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally; Total mice tested 10 | 1985 | Journal of medicinal chemistry, Jul, Volume: 28, Issue:7 | Synthesis and antiherpetic activity of (S)-, (R)-, and (+/-)-9-[(2,3-dihydroxy-1-propoxy)methyl]guanine, linear isomers of 2'-nor-2'-deoxyguanosine. |
| AID246469 | Effective concentration to inhibit 50 % of epstein Barr virus replication in a cell culture model;ND=Not determined | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | Synthesis and antiviral activity of helioxanthin analogues. |
| AID1773423 | Antiviral activity against Vesicular stomatitis virus Indiana infected in A549 cells assessed as inhibition of viral adsorption at early stage of replication treated for 1 hr during viral infection followed by replacement with fresh medium and measured af | 2021 | European journal of medicinal chemistry, Dec-05, Volume: 225 | Novel betulin dicarboxylic acid ester derivatives as potent antiviral agents: Design, synthesis, biological evaluation, structure-activity relationship and in-silico study. |
| AID216189 | Antiviral activity was determined in plaque reduction assay in vero cells against HSV-1 F strain | 1985 | Journal of medicinal chemistry, Mar, Volume: 28, Issue:3 | Acyclic analogues of 2'-deoxynucleosides related to 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine as potential antiviral agents. |
| AID165904 | Inhibitory concentration of the drug against the antigen production against P3HR-1 strain of epstein barr virus-2 (EBV) in Raji cells | 1993 | Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17 | Synthesis and antiviral activity of novel 5-(1-azido-2-haloethyl) and 5-(1-azido-, amino-, or methoxyethyl) analogs of 2'-deoxyuridine. |
| AID1361086 | Antiviral activity against thymidine kinase expressing Varicella-Zoster virus Oka infected in human HEL cells assessed as reduction in plaque formation after 5 days | 2018 | European journal of medicinal chemistry, Jul-15, Volume: 155 | Dihydropyrimidinone/1,2,3-triazole hybrid molecules: Synthesis and anti-varicella-zoster virus (VZV) evaluation. |
| AID977599 | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID96218 | Average percent inhibition of DNA, RNA, and protein synthesis determined in KB cells | 1988 | Journal of medicinal chemistry, Aug, Volume: 31, Issue:8 | Synthesis and antiviral activity of certain 4-substituted and 2,4-disubstituted 7-[(2-hydroxyethoxy)methyl]pyrrolo[2,3-d]pyrimidines. |
| AID217512 | Minimal cytotoxic concentration, the concentration required to cause a microscopically visible alteration of normal cell morphology. | 2000 | Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26 | Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain. |
| AID1219949 | Drug transport in human OAT3 expressed in HEK Flp-In cells | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3 | Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs. |
| AID85693 | In vivo efficacy of compound against HSV-1 strain A133 in the mouse system model was measured at 100 dose(mg/kg), activity expressed as Survivors counted on day 21; 3/5 | 1991 | Journal of medicinal chemistry, Mar, Volume: 34, Issue:3 | Fluorocarbocyclic nucleosides: synthesis and antiviral activity of 2'- and 6'-fluorocarbocyclic 2'-deoxy guanosines. |
| AID106003 | Inhibitory activity against varicella zoster virus (VZV) strain G31 in MRC-5 cells. | 1996 | Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3 | Synthesis and anti-herpes virus activity of 2'-deoxy-4'-thiopyrimidine nucleosides. |
| AID1183085 | Cytotoxicity against mock-infected African green monkey Vero 76 cells assessed as reduction in proliferation after 48 to 96 hrs by MTT method | 2014 | European journal of medicinal chemistry, Sep-12, Volume: 84 | Synthesis and antiviral activity of new phenylimidazopyridines and N-benzylidenequinolinamines derived by molecular simplification of phenylimidazo[4,5-g]quinolines. |
| AID83328 | The minimum inhibitory concentration was measured on HEL cells against TK-Varicella zoster virus (07/1 strain) | 1994 | Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19 | Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity. |
| AID91503 | Inhibitory concentration required to reduce HSV-2 induced virus plaque reduction (VPR) in human skin fibroblast | 2003 | Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23 | Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine. |
| AID96827 | Inhibitory concentration required to reduce [3H1',2']dUrd incorporation into cellular DNA by 50% in Murine Leukemia L1210 cells | 1984 | Journal of medicinal chemistry, Nov, Volume: 27, Issue:11 | Nucleic acid related compounds. 47. Synthesis and biological activities of pyrimidine and purine "acyclic" nucleoside analogues. |
| AID1593185 | Antiviral activity against Hepatitis A virus infected in rhesus monkey FRhK4 cells assessed as inhibition in viral replication using cells pre-infected with virus before compound exposure for 72 hrs by MTT assay | 2019 | European journal of medicinal chemistry, Apr-15, Volume: 168 | New 4-phenylcoumarin derivatives as potent 3C protease inhibitors: Design, synthesis, anti-HAV effect and molecular modeling. |
| AID1884109 | Antiviral activity against HSV-1 infected in African green monkey Vero cells assessed as inhibition of viral replication incubated for 1 hr followed by washing with PBS and subsequent treatment with compound for 24 hrs by plaque reduction assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Synthetic derivatives of the antifungal drug ciclopirox are active against herpes simplex virus 2. |
| AID120298 | In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through intraperitoneal at a dose 50 mg/kg per day | 1985 | Journal of medicinal chemistry, Nov, Volume: 28, Issue:11 | 5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue. |
| AID665762 | Cytotoxicity against human HFF cells after 3 to 8 days by crystal voilet staining | 2012 | Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12 | Synthesis and antiviral activity of certain second generation methylenecyclopropane nucleosides. |
| AID658739 | Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days | 2012 | European journal of medicinal chemistry, Jun, Volume: 52 | 2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies. |
| AID257889 | Antiviral activity against Herpes simplex virus 1 KOS strain in HEL cells | 2006 | Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2 | Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators. |
| AID83198 | Minimum inhibitory concentration required for antiviral activity to reduce TK Varicella Zoster virus (VZV) (07/1) induced cytopathicity in human embryonic lung cells (HEL) | 1994 | Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9 | Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues. |
| AID1610152 | Antiviral activity against thymidine kinase positive Varicella zoster virus infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by Giemsa staining based microscopic analysis | 2019 | European journal of medicinal chemistry, Dec-15, Volume: 184 | Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives. |
| AID1684812 | Cytotoxicity against human HEL cells assessed as reduce in cell growth incubated for 3 days by coulter counter analysis | 2021 | ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1 | Influence of 4'-Substitution on the Activity of Gemcitabine and Its ProTide Against VZV and SARS-CoV-2. |
| AID85561 | In vitro minimum inhibitory concentration to inhibit HSV-1 (KOS)-induced cytopathogenicity in primary rabbit kidney cells by 50% | 1988 | Journal of medicinal chemistry, Jul, Volume: 31, Issue:7 | Synthesis and antiviral activity of novel N-substituted derivatives of acyclovir. |
| AID89264 | Cytotoxicity against Normal human diploid cells (human foreskin fibroblasts cells) | 1989 | Journal of medicinal chemistry, Jul, Volume: 32, Issue:7 | Synthesis, cytotoxicity, and antiviral activity of certain 7-[(2-hydroxyethoxy)methyl]pyrrolo[2,3-d]pyrimidine nucleosides related to toyocamycin and sangivamycin. |
| AID96382 | Tested in vitro for cytotoxicity against the human neoplastic cell line (KB cells). | 1990 | Journal of medicinal chemistry, Dec, Volume: 33, Issue:12 | Arabinofuranosylpyrrolo[2,3-d]pyrimidines as potential agents for human cytomegalovirus infections. |
| AID216305 | The compound was tested for its effective concentration required to reduce virus plaque formation by using TK (thymidine kinase -deficient)-Varicella-Zoster virus 07/1 strain | 2000 | Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11 | Bicyclic nucleoside inhibitors of Varicella-Zoster Virus (VZV): the effect of a terminal halogen substitution in the side-chain. |
| AID120303 | In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through oral route at a dose 25 mg/kg per day | 1985 | Journal of medicinal chemistry, Nov, Volume: 28, Issue:11 | 5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue. |
| AID1592937 | Antiviral activity against acyclovir-resistant Herpes simplex virus 1 29-R infected in African green monkey Vero cells assessed as inhibition of viral replication after 48 hrs by naphthol blue-black staining-based plaque reduction assay | |||
| AID342115 | Antiviral activity against HSV2 G in HEL cells assessed as inhibition of virus induced cytopathicity within 48 hrs | 2008 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 18, Issue:15 | Successful kinase bypass with new acyclovir phosphoramidate prodrugs. |
| AID412422 | Antiviral activity against ganciclovir-resistant HCMV U405 isolate replication in HFF cells by plaque reduction assay | 2009 | Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1 | Synthesis and in vitro activities of a new antiviral duplex drug linking Zidovudine (AZT) and Foscarnet (PFA) via an octadecylglycerol residue. |
| AID634832 | Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID232889 | Ralative safety was expressed as Selective index (TC50/IC50) at HSV-1 passage 7 in vero cells | 1998 | Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16 | Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. |
| AID1410511 | Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method | 2018 | ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4 | Amidate Prodrugs of Cyclic 9-( |
| AID687661 | Antiviral activity against HSV1 KOS infected in HEL assessed as inhibition of virus-induced cytopathicity after 3 days | 2012 | European journal of medicinal chemistry, Nov, Volume: 57 | Synthesis and antiviral evaluation of bis(POM) prodrugs of (E)-[4'-phosphono-but-2'-en-1'-yl]purine nucleosides. |
| AID768204 | Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity | 2013 | European journal of medicinal chemistry, Aug, Volume: 66 | Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies. |
| AID521924 | AUC (0 to 6 hrs) in human systemic circulation with normal renal function at 2000 mg, po every 6 hrs measured after fifth dose by radioimmunoassay | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. |
| AID1572736 | Antiviral activity against Human cytomegalovirus Davis assessed as reduction in virus-induced cytopathogenicity by microscopic analysis | 2019 | Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6 | Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives. |
| AID228729 | Minimal cytotoxic concentration (MCC) to cause a microscopically detectable change in normal cell morphology | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Fluorescent tricyclic analogues of acyclovir and ganciclovir. A structure-antiviral activity study. |
| AID216473 | Antiviral activity was tested against TK+ Varicella-Zoster virus OKA which reduces virus plaque formation by 50% | 2002 | Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19 | Synthesis and antiviral/antiproliferative activity of some N-sulphonylbenzimidazoles. |
| AID1636440 | Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA | 2016 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16 | Development of a cell viability assay to assess drug metabolite structure-toxicity relationships. |
| AID388921 | Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as inhibition of viral cytopathicity | 2008 | Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21 | Influence of 6- or 8-substitution on the antiviral activity of 3-arylalkylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (CMV) and varicella-zoster virus (VZV): part II. |
| AID258989 | Antiviral activity against Varicella-Zoster virus YS strain | 2006 | Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1 | Synthesis and biological evaluation of 6-(alkyn-1-yl)furo[2,3-d]pyrimidin-2(3H)-one base and nucleoside derivatives. |
| AID561449 | Renal clearance in children and young patient with malignancy assessed per m'2 at 10 mg/kg, po administered every 12 hrs | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. |
| AID65711 | Antiviral activity against herpes simplex virus-2 G (HSV-2) in E6SM cell cultures | 2001 | Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16 | Design, synthesis, DNA binding, and biological evaluation of water-soluble hybrid molecules containing two pyrazole analogues of the alkylating cyclopropylpyrroloindole (CPI) subunit of the antitumor agent CC-1065 and polypyrrole minor groove binders. |
| AID427229 | Antiviral activity against HSV1 by green fluorescent protein microplate assay | 2009 | Journal of natural products, Jul, Volume: 72, Issue:7 | Isocoumarin glucosides from the scale insect fungus Torrubiella tenuis BCC 12732. |
| AID84621 | In vivo efficacy of compound against HSV-2 strain A133 in the mouse system model was measured at 25 dose(mg/kg), activity expressed as Survivors counted on day 21; 3/5 | 1991 | Journal of medicinal chemistry, Mar, Volume: 34, Issue:3 | Fluorocarbocyclic nucleosides: synthesis and antiviral activity of 2'- and 6'-fluorocarbocyclic 2'-deoxy guanosines. |
| AID676759 | Antiviral activity against HSV-1 infected in african green monkey Vero cells assessed as inhibition of viral replication at 48 uM after 48 hrs by plaque reduction assay | 2012 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16 | Antiviral activity and synthesis of quaternized promazine derivatives against HSV-1. |
| AID120301 | In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through oral route at a dose 10 mg/kg per day; NT=Not tested | 1985 | Journal of medicinal chemistry, Nov, Volume: 28, Issue:11 | 5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue. |
| AID85412 | In vitro antiviral activity against herpesvirus, HSV-2, MS strain by plaque reduction assay in human foreskin fibroblasts. | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5 | Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS. |
| AID216325 | The concentration required to reduce virus plaque formation by 50% was measured on YS/Rstrain of VZV expressing viral thymidine kinase(TK-) | 1999 | Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7 | Novel potential agents for human cytomegalovirus infection: synthesis and antiviral activity evaluation of benzothiadiazine dioxide acyclonucleosides. |
| AID217604 | Comparative Potency (IC50s) at HSV-1 passage 8 in vero cells | 1998 | Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16 | Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. |
| AID250868 | Effect on HSV-2 encephalitis in mice following intraperitoneal dosage at 100 mg/kg; expressed as number of survivors/10 | 2005 | Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11 | Inhibition of herpes simplex virus thymidine kinases by 2-phenylamino-6-oxopurines and related compounds: structure-activity relationships and antiherpetic activity in vivo. |
| AID749436 | Cytotoxicity against human HEL cells assessed as effect on cell morphology | 2013 | European journal of medicinal chemistry, May, Volume: 63 | Ester prodrugs of acyclic nucleoside thiophosphonates compared to phosphonates: synthesis, antiviral activity and decomposition study. |
| AID365175 | Antiviral activity against HCMV 521 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity | 2008 | Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18 | 4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action. |
| AID137478 | Number of survivors against Herpes simplex virus type-2 infection in mice at 50 mg/kg/day | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID1450222 | Antiviral activity against acyclovir and foscarnet-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect | 2017 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11 | New modified 2-aminobenzimidazole nucleosides: Synthesis and evaluation of their activity against herpes simplex virus type 1. |
| AID81221 | In vitro inhibition of Thymidine Kinase deficient Varicella Zoster Virus (07/1) plaque formation. | 2000 | Journal of medicinal chemistry, Aug-24, Volume: 43, Issue:17 | Nonnucleoside human cytomegalovirus inhibitors: synthesis and antiviral evaluation of (chlorophenylmethyl)benzothiadiazine dioxide derivatives. |
| AID83720 | In Vitro antiviral activity against HSV-1 at 0.05 ug/mL concentration | 1994 | Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19 | Synthesis of new acyclic pyrimidine nucleoside analogs as potential antiviral drugs. |
| AID1464794 | Anti-viral activity against Herpes simplex virus-1 harboring EGFP infected in iPSC-derived neurons assessed as early apoptotic cells at 50 mM treated 2 hrs post infection measured after 72 hrs by Alexa fluor 488 staining based flow cytometric analysis (Rv | 2017 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 27, Issue:20 | Discovery of potent antiviral (HSV-1) quinazolinones and initial structure-activity relationship studies. |
| AID87186 | Inhibition of herpes simplex virus (HSV-1) in plaque reduction assay | 1990 | Journal of medicinal chemistry, Jul, Volume: 33, Issue:7 | Synthesis, antiproliferative, and antiviral activity of certain 4-substituted and 4,5-disubstituted 7-[(1,3-dihydroxy-2-propoxy)methyl]pyrrolo[2,3-d]pyrimidines. |
| AID309811 | Antiviral activity against TK- VZV 07/1 in HEL cells assessed as reduction of virus plaque formation | 2007 | Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22 | Influence of 6 or 8-substitution on the antiviral activity of 3-phenethylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (HCMV) and varicella-zoster virus (VZV). |
| AID444057 | Fraction escaping hepatic elimination in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID1498130 | Cytotoxicity against HEL cells assessed as alteration of cell morphology by microscopic analysis | 2018 | Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12 | Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs. |
| AID224540 | Day of death in lethal test against herpes simplex virus type-2 at 150 mg/kg/day (mean day of death +/-SD) | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID609578 | Antiviral activity against Human cytomegalovirus Davis assessed as reduction of virus induced cytopathicity by cell based assay | 2011 | Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15 | Acyclic nucleoside phosphonates with a branched 2-(2-phosphonoethoxy)ethyl chain: efficient synthesis and antiviral activity. |
| AID201670 | Antiviral activity against Simina varicella virus (G815 strain) | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID122847 | Toxicity of compound against mice was determined at a concentration of 250 mg/kg | 1986 | Journal of medicinal chemistry, Feb, Volume: 29, Issue:2 | Systematic synthesis and biological evaluation of alpha- and beta-D-xylofuranosyl nucleosides of the five naturally occurring bases in nucleic acids and related analogues. |
| AID85379 | Inhibitory concentration against HSV type 2 strain G in human embryonic skin muscle (ESM) fibroblast cell culture | 1993 | Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14 | Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides. |
| AID634831 | Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID1661187 | Antiviral activity against Cytomegalovirus AD169 infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity measured after 6 to 7 days | 2020 | ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7 | Amidate Prodrugs of |
| AID431633 | Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days | 2009 | Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17 | The application of phosphoramidate protide technology to acyclovir confers anti-HIV inhibition. |
| AID1434778 | Antiviral activity against HSV-1 infected in African green monkey Vero cells by plaque reduction assay | 2017 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4 | Anti-HSV-1, antioxidant and antifouling phenolic compounds from the deep-sea-derived fungus Aspergillus versicolor SCSIO 41502. |
| AID17094 | Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10 | 1985 | Journal of medicinal chemistry, Jul, Volume: 28, Issue:7 | Synthesis and antiherpetic activity of (S)-, (R)-, and (+/-)-9-[(2,3-dihydroxy-1-propoxy)methyl]guanine, linear isomers of 2'-nor-2'-deoxyguanosine. |
| AID257894 | Antiviral activity against Parainfluenza-3 virus in vero cells | 2006 | Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2 | Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators. |
| AID63596 | Minimum inhibitory conc. for 50% inhibition of HSV-2 (G) virus induced cytopathicity in E6SM cells | 1997 | Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9 | Carbocyclic oxetanocins lacking the C-3' methylene. |
| AID81371 | Inhibitory dose for HELF cell proliferation during 3-day treatment period | 1988 | Journal of medicinal chemistry, Feb, Volume: 31, Issue:2 | Synthesis and biological activities of 4-O-(difluoromethyl)-5-substituted-uracil nucleoside analogues. |
| AID28679 | Partition coefficient (logD6.8) | 2001 | Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6 | High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. |
| AID425283 | Elimination half life in iv dosed adult horse | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID77813 | Total score of healing period in HSV-1 cutaneous infection in guinea pig at 5% ACV | 1989 | Journal of medicinal chemistry, Jul, Volume: 32, Issue:7 | Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. |
| AID83201 | Minimum inhibitory concentration to reduce cytopathicity by 50% in proliferation of human embryonic lung cells (HEL) | 1994 | Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9 | Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues. |
| AID563769 | Antiviral activity against HSV1 PAA5 harboring polymerase R842S mutant gene infected in HFF after 3 days by plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides. |
| AID209532 | Inhibitory concentration against TK-HSV type 1 strain B2006 in human embryonic skin muscle (ESM) fibroblast cell culture | 1993 | Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14 | Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides. |
| AID87776 | Inhibition of cytopathogenicity of herpes simplex type 1 virus (HSV-1)(KOS) in Hela cell culture. | 1995 | Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23 | Design, synthesis, and structure-activity relationship of novel dinucleotide analogs as agents against herpes and human immunodeficiency viruses. |
| AID1139395 | Cytotoxicity against HEL cells assessed as morphological changes after 3 to 5 days by Coulter counting analysis | 2014 | Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9 | ProTides of N-(3-(5-(2'-deoxyuridine))prop-2-ynyl)octanamide as potential anti-tubercular and anti-viral agents. |
| AID1283353 | Antiviral activity against HSV1 KOS ATCC VR1493 infected in human iPSC cells assessed as reduction in viral DNA copy at 50 uM measured 24 hrs post infection by RT-qPCR analysis relative to control | 2016 | ACS medicinal chemistry letters, Jan-14, Volume: 7, Issue:1 | iPSC Neuronal Assay Identifies Amaryllidaceae Pharmacophore with Multiple Effects against Herpesvirus Infections. |
| AID498591 | Antiviral activity against Macacine herpesvirus 1 isolate MR8 infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds. |
| AID154154 | Cytotoxic concentration for the inhibition of P3HR-1 cell growth | 2002 | Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23 | CycloSal-BVDUMP pronucleotides: how to convert an antiviral-inactive nucleoside analogue into a bioactive compound against EBV. |
| AID1498115 | Antiviral activity against acyclovir-resistant thymidine kinase deficient Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity | 2018 | Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12 | Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs. |
| AID224337 | Inhibitory effect on KOS strain of Herper simplex virus-1 yield, in primary rabbit kidney cell culture at 0.4 ug/mL concentration after 24 hours | 1987 | Journal of medicinal chemistry, Jun, Volume: 30, Issue:6 | Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases. |
| AID282652 | Inhibition of EBV replication in Daudi cells by VCA ELISA | 2004 | Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27 | (Z)- and (E)-[2-Fluoro-2-(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines, a new class of methylenecyclopropane analogues of nucleosides: synthesis and antiviral activity. |
| AID699541 | Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting | 2012 | Journal of medicinal chemistry, May-24, Volume: 55, Issue:10 | Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. |
| AID90940 | Antiviral activity against HCMV was determined; No inhibition | 1990 | Journal of medicinal chemistry, Sep, Volume: 33, Issue:9 | Synthesis of new (+-)-3,5-dihydroxypentyl nucleoside analogues from 1-amino-5-(benzyloxy)pentan-3-ol and their antiviral evaluation. |
| AID85115 | Antiviral activity against Herpes simplex virus-2 (thymidine kinase deficient strains isolated as BVaraU resistant mutants of HSV-1 (KOS)) | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID376985 | Selectivity index, CC50 for african green monkey Vero cells to IC50 for HSV1 15577 | 2006 | Journal of natural products, May, Volume: 69, Issue:5 | Antiviral flavans from the leaves of Pithecellobium clypearia. |
| AID1211767 | Cmax in wild type mouse treated with 25 nmol/g, po of valacyclovir | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3 | Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice. |
| AID425242 | Total primary phase half life in horse at distribution phase at 10 mg/kg, iv after 1 hr by two-compartmental study | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID84753 | In vivo efficacy of compound against HSV-2 strain A133 in the mouse system model was measured at 6.25 dose(mg/kg), activity expressed as Survivors counted on day 21 | 1991 | Journal of medicinal chemistry, Mar, Volume: 34, Issue:3 | Fluorocarbocyclic nucleosides: synthesis and antiviral activity of 2'- and 6'-fluorocarbocyclic 2'-deoxy guanosines. |
| AID561622 | Half life in immunocompromized children at 250 mg/kg, po administered every 12 hrs | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. |
| AID303210 | Antiviral activity against acyclovir-resistant HSV1 KOS TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity | 2007 | Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23 | Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity. |
| AID1211772 | Chemical stability of the compound | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3 | Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice. |
| AID642284 | Antiviral activity against Human herpesvirus 1 strain KOS infected in african green monkey Vero 76 cells assessed as reduction of virus-induced plaque formation after 3 days using crystal violet staining | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Quinoline tricyclic derivatives. Design, synthesis and evaluation of the antiviral activity of three new classes of RNA-dependent RNA polymerase inhibitors. |
| AID1394851 | Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of plaque formation measured after 2 to 3 days post infection | 2018 | European journal of medicinal chemistry, Apr-25, Volume: 150 | Synthesis and antiviral evaluation of cyclopentyl nucleoside phosphonates. |
| AID1451462 | Antiviral activity against human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect | 2017 | Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18 | Virtual Screening of Acyclovir Derivatives as Potential Antiviral Agents: Design, Synthesis, and Biological Evaluation of New Acyclic Nucleoside ProTides. |
| AID120295 | In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through intraperitoneal at a dose 10 mg/kg per day | 1985 | Journal of medicinal chemistry, Nov, Volume: 28, Issue:11 | 5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue. |
| AID167884 | Antiviral Activity against herpes simplex virus-2 (Lyons) in rabbit kidney cell | 1990 | Journal of medicinal chemistry, Sep, Volume: 33, Issue:9 | Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives. |
| AID246628 | Effective concentration to reduce plaque formation of Cytomegalovirus Davis strain in human embryonic lung cell cultures; ND=Not determined | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | The novel L- and D-amino acid derivatives of hydroxyurea and hydantoins: synthesis, X-ray crystal structure study, and cytostatic and antiviral activity evaluations. |
| AID609572 | Antiviral activity against thymidine kinase-deficient Varicella-zoster virus 07/1 assessed as reduction of virus induced cytopathicity by cell based assay | 2011 | Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15 | Acyclic nucleoside phosphonates with a branched 2-(2-phosphonoethoxy)ethyl chain: efficient synthesis and antiviral activity. |
| AID1662683 | Lipophilicity, log P of the compound | 2020 | Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18 | Essential Medicinal Chemistry of Essential Medicines. |
| AID732668 | Immunoregulatory activity in Hepatitis B virus infected transgenic mouse assessed as increase in CD4+/CD8+ population in peripheral blood at 100 mg/kg qd for 1 month by flow cytometry (Rvb = 0.9 +/-0.2%) | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and biological evaluation of nucleoside analogues than contain silatrane on the basis of the structure of acyclovir (ACV) as novel inhibitors of hepatitis B virus (HBV). |
| AID218417 | Anti viral activity against HSV-1(Schooler) in WI-38 cell monolayers | 1992 | Journal of medicinal chemistry, May-15, Volume: 35, Issue:10 | Synthesis and antiviral activity of 1-cyclobutyl-5-(2-bromovinyl)uracil nucleoside analogues and related compounds. |
| AID313908 | Antiviral activity against HSV1 SC16 in african green monkey Vero cells | 2008 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 | Pyrazolopyridines with potent activity against herpesviruses: effects of C5 substituents on antiviral activity. |
| AID1139389 | Antiviral activity against thymidine kinase-positive Varicella zoster virus Oka infected in HEL cells assessed as reduction in viral plaque formation after 5 days | 2014 | Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9 | ProTides of N-(3-(5-(2'-deoxyuridine))prop-2-ynyl)octanamide as potential anti-tubercular and anti-viral agents. |
| AID217511 | cytostatic concentration required to reduce the HEL cell number by 50%. after 5 days in the absence of virus | 2000 | Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26 | Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain. |
| AID256004 | Antiviral activity against Varicella-Zoster virus (Webster strain) grown on human foreskin fibroblast cells determined by vedduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO until plaque were formed [nd = not | 2005 | Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18 | 4-Oxo-4,7-dihydrothieno[2,3-b]pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases. |
| AID516966 | Antiviral activity against acyclovir-resistant HSV1 KOS infected in HEL assessed as reduction in virus-induce cytopathicity | 2010 | Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19 | Synthesis of ester prodrugs of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) as anti-poxvirus agents. |
| AID217806 | Evaluated for the anti-VZV, the concentration of compounds in uM required to reduce VZVTK-YS-R ( thymidine kinase-deficient strain ) plaque formation after 5 days in HEL cell cultures compared to untreated controls. | 2000 | Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26 | Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain. |
| AID136148 | Percentage survival of mice after intraperitoneal administration of compound at 200 mg/kg per day in experiment 1; survival/ tested =3/4 | 1989 | Journal of medicinal chemistry, Jul, Volume: 32, Issue:7 | Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. |
| AID81218 | Cytotoxicity concentration required to microscopically detectable alteration of cell morphology HEL | 2000 | Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4 | The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine. |
| AID425252 | Free apparent volume of distribution in horse at 10 mg/kg, iv after 1 hr by three-compartmental study | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID1773426 | Antiviral activity against Human adenovirus 5 Adenoid 75 infected in A549 cells assessed as inhibition of viral adsorption at early stage of replication treated for 1 hr during viral infection followed by replacement with fresh medium and measured after 7 | 2021 | European journal of medicinal chemistry, Dec-05, Volume: 225 | Novel betulin dicarboxylic acid ester derivatives as potent antiviral agents: Design, synthesis, biological evaluation, structure-activity relationship and in-silico study. |
| AID1433134 | Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis | 2015 | European journal of medicinal chemistry, Aug-28, Volume: 101 | Synthesis, antiplasmodial activity and mechanistic studies of pyrimidine-5-carbonitrile and quinoline hybrids. |
| AID609579 | Antiviral activity against Vaccinia virus Lederle assessed as reduction of virus induced cytopathicity by cell based assay | 2011 | Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15 | Acyclic nucleoside phosphonates with a branched 2-(2-phosphonoethoxy)ethyl chain: efficient synthesis and antiviral activity. |
| AID749440 | Antiviral activity against thymidine kinase-deficient Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis | 2013 | European journal of medicinal chemistry, May, Volume: 63 | Ester prodrugs of acyclic nucleoside thiophosphonates compared to phosphonates: synthesis, antiviral activity and decomposition study. |
| AID115760 | Minimum effective dose against herpes simplex virus-2 (HSV-2) by oral administration in female mice. | 1993 | Journal of medicinal chemistry, May-28, Volume: 36, Issue:11 | 3-Quinolinecarboxamides. A series of novel orally-active antiherpetic agents. |
| AID1498114 | Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathicity | 2018 | Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12 | Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs. |
| AID255992 | Antiviral activity against herpes simplex virus type 1 KOS (PFAr2) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO | 2005 | Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18 | 4-Oxo-4,7-dihydrothieno[2,3-b]pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases. |
| AID425251 | Total apparent volume of distribution in horse at 10 mg/kg, iv after 1 hr by two-compartmental study | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID1703889 | Permeability of the compound incubated for 8 hrs by PAMPA-TGI assay | 2020 | European journal of medicinal chemistry, Oct-15, Volume: 204 | Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies. |
| AID634751 | Antiviral activity against Human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID350211 | Antiviral activity against Hepatitis C virus | 2009 | Journal of medicinal chemistry, May-28, Volume: 52, Issue:10 | (Z)- and (E)-2-(1,2-dihydroxyethyl)methylenecyclopropane analogues of 2'-deoxyadenosine and 2'-deoxyguanosine. Synthesis of all stereoisomers, absolute configuration, and antiviral activity. |
| AID313343 | Cytotoxicity against african green monkey Vero cells assessed as cell viability after 72 hrs by MTT assay | 2008 | Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1 | SAR of a series of anti-HSV-1 acridone derivatives, and a rational acridone-based design of a new anti-HSV-1 3H-benzo[b]pyrazolo[3,4-h]-1,6-naphthyridine series. |
| AID676758 | Antiviral activity against HSV-1 infected in african green monkey Vero cells assessed as inhibition of viral replication at 48 uM after 48 hrs by GFP reduction assay | 2012 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16 | Antiviral activity and synthesis of quaternized promazine derivatives against HSV-1. |
| AID83358 | Effective concentration required to inhibit Tyrosine kinase (TK+) Varicella-Zoster virus-induced cytopathicity by 50% in OKA strain HEL cell lines | 2001 | Journal of medicinal chemistry, Aug-16, Volume: 44, Issue:17 | Synthesis, mechanism of action, and antiviral activity of a new series of covalent mechanism-based inhibitors of S-adenosyl-L-homocysteine hydrolase. |
| AID217508 | Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of VZV Ellen Vero cells by 50% | 2001 | Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21 | Synthesis and antiviral activity of novel 5-(1-cyanamido-2-haloethyl) and 5-(1-hydroxy(or methoxy)-2-azidoethyl) analogues of uracil nucleosides. |
| AID436480 | Antiviral activity against Reovirus-1 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay | 2009 | Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13 | Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives. |
| AID87972 | Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by Herpes simplex virus(HSV) -1 (thymidine kinase deficient) in HEp-2 cells | 1988 | Journal of medicinal chemistry, Sep, Volume: 31, Issue:9 | Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity. |
| AID1071703 | Selectivity index, ratio of CC50 for cytotoxicity to EC50 for HSV2 | 2014 | European journal of medicinal chemistry, Mar-03, Volume: 74 | Synthesis and biological evaluation of 2-oxonicotinonitriles and 2-oxonicotinonitrile based nucleoside analogues. |
| AID258992 | Antiviral activity against human cytomegalovirus AD169 strain | 2006 | Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1 | Synthesis and biological evaluation of 6-(alkyn-1-yl)furo[2,3-d]pyrimidin-2(3H)-one base and nucleoside derivatives. |
| AID83727 | In Vitro cytotoxicity against HSV-1 at 500 ug/mL concentration | 1994 | Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19 | Synthesis of new acyclic pyrimidine nucleoside analogs as potential antiviral drugs. |
| AID1433130 | Cytotoxicity against human HEL cells assessed as alteration of normal cell morphology by microscopic analysis | 2015 | European journal of medicinal chemistry, Aug-28, Volume: 101 | Synthesis, antiplasmodial activity and mechanistic studies of pyrimidine-5-carbonitrile and quinoline hybrids. |
| AID85372 | Inhibitory concentration against HSV type 1 strain F in human embryonic skin muscle (ESM) fibroblast cell culture | 1993 | Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14 | Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides. |
| AID260765 | Antiviral activity against HSV1 in vero cells | 2006 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4 | Synthesis and anti-HSV-1 activity of quinolonic acyclovir analogues. |
| AID1857462 | Elimination half life in monkey | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Treatment Option for Acyclovir-Resistant Herpes Simplex Virus Infections. |
| AID303212 | Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity | 2007 | Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23 | Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity. |
| AID1273990 | Antiviral activity against HHV1 CDC Atlanta infected in African green monkey Vero cells assessed as reduction of viral titer at maximal non-toxic concentration after 48 hrs by crystal violet staining assay relative to control | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Anti-herpetic and anti-dengue activity of abietane ferruginol analogues synthesized from (+)-dehydroabietylamine. |
| AID137477 | Number of survivors against Herpes simplex virus type-2 infection in mice at 25 mg/kg/day | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID84929 | Compound was evaluated for the antiviral activity against HSV-2 | 1998 | Bioorganic & medicinal chemistry letters, Apr-07, Volume: 8, Issue:7 | Synthesis and antiviral activity of novel isodideoxy nucleosides with exocyclic methylene. |
| AID358238 | Cytotoxicity against african green monkey Vero cells by end-point titration technique | 2001 | Journal of natural products, Oct, Volume: 64, Issue:10 | Structure-activity relationship of in vitro antiviral and cytotoxic activity of semisynthetic analogues of scopadulane diterpenes. |
| AID83503 | Inhibition of cell growth in HEL cells. | 2000 | Journal of medicinal chemistry, Aug-24, Volume: 43, Issue:17 | Nonnucleoside human cytomegalovirus inhibitors: synthesis and antiviral evaluation of (chlorophenylmethyl)benzothiadiazine dioxide derivatives. |
| AID1651480 | Antiviral activity against ACV-sensitive Herpes simplex virus 1 KOS infected in male Balb/c mouse assessed as reduction in ulcerated lesion at 50 mg/g applied topically as cream formulation 5 times a day at 3 hrs interval for 10 days measured on day 7 pos | |||
| AID1503329 | Antiviral activity against Human herpesvirus 1 KOS ATCC VR 1493 infected in African green monkey Vero 76 cells assessed as protection against virus-induced cytopathic effect after 3 days by crystal violet staining-based plaque reduction assay | 2017 | European journal of medicinal chemistry, Dec-01, Volume: 141 | Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation. |
| AID299438 | Antiviral activity against HCMV in human foreskin fibroblast assessed as inhibition of virus plaque formation | 2007 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14 | 7-Oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamides: synthesis and biological activity of a new class of highly potent inhibitors of human cytomegalovirus DNA polymerase. |
| AID1457767 | Antiviral activity against thymidine kinase expressing Varicella-Zoster virus Oka strain assessed as inhibition of plaque formation | 2017 | Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14 | Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs. |
| AID1261328 | Antiviral activity against WNV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID1886812 | Antiviral activity against HHV-1 29R strain infected in African green monkey Vero E6 cells assessed as concentration required for higher viral reduction factor measured after 72 hrs by crystal violet staining based inverted microscopic analysis | 2022 | Journal of natural products, 08-26, Volume: 85, Issue:8 | Antiviral Profiling of C-18- or C-19-Functionalized Semisynthetic Abietane Diterpenoids. |
| AID63757 | The compound was tested for antiviral activity against thymidine kinase-deficient (TK-HSV-1)virus in E6SM cell line(human embryonic skin-muscle fibroblasts) | 2002 | Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5 | New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation. |
| AID91290 | Antiviral activity against Varicella-Zoster virus (VV) in human foreskin cell cultures in virus plaque reduction assay at 320 uM | 1987 | Journal of medicinal chemistry, Nov, Volume: 30, Issue:11 | Synthesis and antiviral activity of carbocyclic analogues of xylofuranosides of 2-amino-6-substituted-purines and 2-amino-6-substituted-8-azapurines. |
| AID87769 | Cytotoxic concentration required to inhibit Hel cell growth | 2004 | Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10 | Bicyclic anti-VZV nucleosides: thieno analogues bearing an alkylphenyl side chain have reduced antiviral activity. |
| AID82423 | The compound was tested for cytotoxicity against human foreskin fibroblast cell | 1988 | Journal of medicinal chemistry, Aug, Volume: 31, Issue:8 | Synthesis and antiviral activity of certain 4-substituted and 2,4-disubstituted 7-[(2-hydroxyethoxy)methyl]pyrrolo[2,3-d]pyrimidines. |
| AID216192 | Dose to inhibit plaque formation in vero cells infected with herpes simplex virus type 1 (HSV-1,strainJLJ) was determined | 1990 | Journal of medicinal chemistry, Feb, Volume: 33, Issue:2 | Synthesis and antiviral and cytotoxic activity of iodohydrin and iodomethoxy derivatives of 5-vinyl-2'-deoxyuridines, 2'-fluoro-2'-deoxyuridine, and uridine. |
| AID63605 | Tested for antiviral activity against herpes simplex virus type 1(KOS) in E6SM cell line(human embryonic skin-muscle fibroblasts) | 2002 | Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5 | New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation. |
| AID85252 | Antiviral activity against HSV-2 cell line (concentration required to prevent viral cytopathic effect in half of primary rabbit kidney cell cultures) | 1988 | Journal of medicinal chemistry, Dec, Volume: 31, Issue:12 | Synthesis and antiherpetic activity of (+/-)-9-[[(Z)-2-(hydroxymethyl)cyclopropyl]methyl]guanine and related compounds. |
| AID1378803 | Antiviral activity against HSV-1 infected in African green monkey Vero cells assessed as inhibition of virus plaque formation after 72 hrs by Giemsa staining based assay | 2017 | Journal of natural products, 08-25, Volume: 80, Issue:8 | Stereochemistry of a Second Riolozane and Other Diterpenoids from Jatropha dioica. |
| AID167887 | Antiviral Activity against vesicular stomatitis virus in rabbit kidney cell | 1990 | Journal of medicinal chemistry, Sep, Volume: 33, Issue:9 | Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives. |
| AID1382168 | Cytostatic activity against HEL cells after 3 days by Coulter counting method | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Highly convergent synthesis and antiviral activity of (E)-but-2-enyl nucleoside phosphonoamidates. |
| AID63759 | The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 1 (F strain) | 1994 | Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19 | Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity. |
| AID87654 | In vitro antiviral activity determined by plaque-reduction assay against Herpes simplex virus type 2, G strain in Vero cells | 1989 | Journal of medicinal chemistry, Jul, Volume: 32, Issue:7 | Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. |
| AID1610166 | Antiviral activity against Vaccinia virus infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis | 2019 | European journal of medicinal chemistry, Dec-15, Volume: 184 | Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives. |
| AID245942 | Cytotoxic concentration required to inhibit herpes simplex virus 1 infected BSC-1 cells | 2005 | Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1 | Nucleotides and pronucleotides of 2,2-bis(hydroxymethyl)methylenecyclopropane analogues of purine nucleosides: synthesis and antiviral activity. |
| AID87340 | Antiviral activity against Herpes simplex virus type 1 determined by plaque reduction assay | 1988 | Journal of medicinal chemistry, Aug, Volume: 31, Issue:8 | Synthesis and antiviral activity of certain 4-substituted and 2,4-disubstituted 7-[(2-hydroxyethoxy)methyl]pyrrolo[2,3-d]pyrimidines. |
| AID1261342 | Antiviral activity against Vaccinia virus | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID575033 | Antiviral activity against Herpes simplex virus 2 isolate 18 harboring A27T, G39E, N78D, -1C 556 = Stop 263, S29A mutations in thymidine kinase and A9T, P15S, L60P, E678G, del, DD676-677 mutations in DNA polymerase infected in african green monkey Vero ce | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. |
| AID217497 | Effective concentration to show 50% of activity was measured on varicella zoster virus(VZV) cell culture | 2000 | Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13 | Structure-activity relationships of (E)-5-(2-bromovinyl)uracil and related pyrimidine nucleosides as antiviral agents for herpes viruses. |
| AID607916 | Antiviral activity against thymidine kinase-deficient Varicella-zoster virus YS/R infected in human HEL cells assessed as reduction in the virus plaque formation | 2011 | Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14 | Design, synthesis and biological evaluation of 2'-deoxy-2',2'-difluoro-5-halouridine phosphoramidate ProTides. |
| AID216307 | The compound was tested for its effective concentration required to reduce virus plaque formation by using Varicella-Zoster virus OKA strain | 2000 | Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11 | Bicyclic nucleoside inhibitors of Varicella-Zoster Virus (VZV): the effect of a terminal halogen substitution in the side-chain. |
| AID580313 | Antiviral activity against HSV1 infected in african green monkey Vero cells assessed as reduction of UL54 expression at 1 uM after up to 24 hrs by RT-PCR analysis | 2011 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6 | Synthesis and in vitro anti-HSV-1 activity of a novel Hsp90 inhibitor BJ-B11. |
| AID84951 | Evaluated for the antiviral activity against Herpes simplex virus type 2 (HSV-2) strain G by the plaque reduction assay | 1990 | Journal of medicinal chemistry, Apr, Volume: 33, Issue:4 | Acyclic purine phosphonate analogues as antiviral agents. Synthesis and structure-activity relationships. |
| AID425259 | Total Tmax in horse at 20 mg/kg, po administered as single dose | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID133990 | Protective dose against Herpes simplex virus type type -2 infection in mice at 200 mg/kg | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID429099 | Antiviral activity against HSV1 infected in african green monkey Vero cells assessed as reduction in virus plaque formation at 10 ug per 10'5 cells by plaque infectivity assay | 2009 | European journal of medicinal chemistry, Aug, Volume: 44, Issue:8 | Synthesis and anti-HSV-1 evaluation of some pyrazoles and fused pyrazolopyrimidines. |
| AID84947 | Tested for antiviral activity against HSV-2 (G) | 2001 | Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12 | The cyclohexene ring as bioisostere of a furanose ring: synthesis and antiviral activity of cyclohexenyl nucleosides. |
| AID1079931 | Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source] | |||
| AID63758 | The minimum inhibitory concentration was measured against Herpes simplex virus type 1 (KOS strain) on E6SM cells | 1994 | Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19 | Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity. |
| AID472795 | Antiviral activity against Vaccinia virus Elstree-Lister infected in african green monkey Vero cells after 3 days by plaque reduction assay | 2010 | Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8 | Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives. |
| AID342113 | Antiviral activity against acyclovir-resistant HSV2 ACR in african green monkey Vero cells assessed as inhibition of virus plaque formation | 2008 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 18, Issue:15 | Successful kinase bypass with new acyclovir phosphoramidate prodrugs. |
| AID400435 | Cytotoxicity against HSV2 infected human Hep2 cells after 3 days | 1998 | Journal of natural products, May, Volume: 61, Issue:5 | Antiviral phenylpropanoid glycosides from the medicinal plant Markhamia lutea. |
| AID90595 | In vitro antiviral activity against Human cytomegalovirus (HCMV) was determined; ND= Not determined | 2002 | Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3 | 5-Bromo (or chloro)-6-azido-5,6-dihydro-2' -deoxyuridine and -thymidine derivatives with potent antiviral activity. |
| AID63763 | The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 2 (Lyons strain) | 1994 | Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19 | Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity. |
| AID106172 | Compound was tested for inhibition against human cytomegalovirus (HCMV) in MRC-5 cells | 2000 | Bioorganic & medicinal chemistry letters, Apr-03, Volume: 10, Issue:7 | Synthesis and antiviral activity of acyclovir-5'-(phenyl methoxy alaninyl) phosphate as a possible membrane-soluble nucleotide prodrug. |
| AID687663 | Antiviral activity against acyclovir-resistant thymidine kinase deficient HSV1 KOS infected in HEL assessed as inhibition of virus-induced cytopathicity after 3 days | 2012 | European journal of medicinal chemistry, Nov, Volume: 57 | Synthesis and antiviral evaluation of bis(POM) prodrugs of (E)-[4'-phosphono-but-2'-en-1'-yl]purine nucleosides. |
| AID87770 | Minimal cytotoxic concentration, required to alter microscopically detectable cell morphology | 2004 | Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10 | Bicyclic anti-VZV nucleosides: thieno analogues bearing an alkylphenyl side chain have reduced antiviral activity. |
| AID246712 | Effective concentration to reduce plaque formation of thymidine kinase deficient Varicella zoster virus TK- VZV 07/1 strain in human embryonic lung cell cultures | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | The novel L- and D-amino acid derivatives of hydroxyurea and hydantoins: synthesis, X-ray crystal structure study, and cytostatic and antiviral activity evaluations. |
| AID634838 | Antiviral activity against Human immunodeficiency virus 1 infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID1854965 | Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as reduction in virus-induced cytopathic effect by microscopic analysis | 2022 | European journal of medicinal chemistry, Nov-05, Volume: 241 | Synthesis and antiviral properties of biomimetic iminosugar-based nucleosides. |
| AID498590 | Antiviral activity against Macacine herpesvirus 1 isolate MR7 infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds. |
| AID70227 | In vitro antiviral activity against Epstein Barr virus (EBV) was determined | 2002 | Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3 | 5-Bromo (or chloro)-6-azido-5,6-dihydro-2' -deoxyuridine and -thymidine derivatives with potent antiviral activity. |
| AID1402824 | Antiviral activity against TK-positive VZV Oka infected in HEL cells assessed as reduction in plaque formation after 5 days | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Emimycin and its nucleoside derivatives: Synthesis and antiviral activity. |
| AID429202 | Cytotoxicity against human HEL cells assessed as reduction in cell growth after 3 days | 2009 | European journal of medicinal chemistry, Aug, Volume: 44, Issue:8 | Synthesis and anti-VZV activity of 6-heteroaryl derivatives of tricyclic acyclovir and 9-{[cis-1',2'-bis(hydroxymethyl)cycloprop-1'-yl]methyl}guanine analogues. |
| AID139416 | Day of death in lethal test against herpes simplex virus type-2 at 50 mg/kg/day (mean day of death +/-SD) | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID540216 | Clearance in dog after iv administration | 2005 | Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7 | Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. |
| AID718734 | Antiviral activity against thymidine kinase deficient and acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect | 2012 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 | Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities. |
| AID66021 | Compound was evaluated for the minimum inhibition concentration required to reduce virus-induced cytopathogenicity by 50%, determined against Varicella-Zoster virus (YS) | 1998 | Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22 | 5-Substituted pyrimidines with a 1,5-anhydro-2, 3-dideoxy-D-arabino-hexitol moiety at N-1: synthesis, antiviral activity, conformational analysis, and interaction with viral thymidine kinase. |
| AID766703 | Antiviral activity against thymidine kinase negative Varicella-zoster virus 07-1 infected in human HEL cells assessed as reduction in the virus plaque formation | 2013 | European journal of medicinal chemistry, Sep, Volume: 67 | Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity. |
| AID1422439 | Antiviral activity against Human herpesvirus 2 strain G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method | 2018 | Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21 | Synthesis, biological evaluation and molecular modeling of a novel series of fused 1,2,3-triazoles as potential anti-coronavirus agents. |
| AID156861 | In vitro minimum inhibitory concentration to inhibit protein synthesis (incorporation of [methyl-3H]dThd) in PRK cells by 50% | 1988 | Journal of medicinal chemistry, Jul, Volume: 31, Issue:7 | Synthesis and antiviral activity of novel N-substituted derivatives of acyclovir. |
| AID257886 | Antiviral activity against HEL cells | 2006 | Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2 | Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators. |
| AID91282 | Antiviral activity against Varicella-Zoster virus (VV) in human foreskin cell cultures in virus plaque reduction assay at 100 uM | 1987 | Journal of medicinal chemistry, Nov, Volume: 30, Issue:11 | Synthesis and antiviral activity of carbocyclic analogues of xylofuranosides of 2-amino-6-substituted-purines and 2-amino-6-substituted-8-azapurines. |
| AID1427855 | Cytotoxicity against African green monkey Vero cells assessed as growth inhibition after 48 hrs | |||
| AID1422441 | Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method | 2018 | Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21 | Synthesis, biological evaluation and molecular modeling of a novel series of fused 1,2,3-triazoles as potential anti-coronavirus agents. |
| AID167138 | Minimum inhibitory concentration required to reduce virus induced cytopathogenicity in primary rabbit kidney cell cultures by 50% against HSV-2 (Lycons) | 1983 | Journal of medicinal chemistry, Apr, Volume: 26, Issue:4 | Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl]guanine]. |
| AID84591 | Minimal inhibitory concentration to reduce virus-induced cytopathicity against McIntyre strain of human Herpes Simplex Virus-1 | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Fluorescent tricyclic analogues of acyclovir and ganciclovir. A structure-antiviral activity study. |
| AID1251996 | Antiviral activity against thymidine kinase-positive Varicella zoster virus 07-1 infected in HEL cells assessed as reduction in viral plaque formation | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Toward the discovery of dual HCMV-VZV inhibitors: Synthesis, structure activity relationship analysis, and cytotoxicity studies of long chained 2-uracil-3-yl-N-(4-phenoxyphenyl)acetamides. |
| AID282654 | Cytotoxicity against Daudi cells | 2004 | Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27 | (Z)- and (E)-[2-Fluoro-2-(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines, a new class of methylenecyclopropane analogues of nucleosides: synthesis and antiviral activity. |
| AID588964 | Substrates of transporters of clinical importance in the absorption and disposition of drugs, OAT1 | 2010 | Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3 | Membrane transporters in drug development. |
| AID87031 | Minimum inhibitory concentration against Herpes simplex Virus-2(G) | 2002 | Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23 | Synthesis and biological activity of strongly fluorescent tricyclic analogues of acyclovir and ganciclovir. |
| AID81360 | concentration required to reduce virus HHuman Cytomegalovirus (Davis)plaque formation by 50%; ND=No Data | 2000 | Journal of medicinal chemistry, Aug-24, Volume: 43, Issue:17 | Nonnucleoside human cytomegalovirus inhibitors: synthesis and antiviral evaluation of (chlorophenylmethyl)benzothiadiazine dioxide derivatives. |
| AID1079936 | Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source] | |||
| AID1139394 | Cytotoxicity against HEL cells assessed as reduction in cell growth after 3 to 5 days by Coulter counting analysis | 2014 | Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9 | ProTides of N-(3-(5-(2'-deoxyuridine))prop-2-ynyl)octanamide as potential anti-tubercular and anti-viral agents. |
| AID83893 | Minimum inhibitory concentration against HSV-1. | 1985 | Journal of medicinal chemistry, Nov, Volume: 28, Issue:11 | 5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue. |
| AID510174 | Antiviral activity against HSV1 infected in MDCK cells assessed as reduction of virus-induced cytopathic effect | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities. |
| AID85374 | Inhibitory concentration against HSV type 1 strain Mc Intyre in human embryonic skin muscle (ESM) fibroblast cell culture | 1993 | Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14 | Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides. |
| AID65705 | Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology | 2001 | Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16 | Design, synthesis, DNA binding, and biological evaluation of water-soluble hybrid molecules containing two pyrazole analogues of the alkylating cyclopropylpyrroloindole (CPI) subunit of the antitumor agent CC-1065 and polypyrrole minor groove binders. |
| AID106173 | Compound was tested for inhibition against varicella zoster virus(VZV) infected MRC5 cells | 2000 | Bioorganic & medicinal chemistry letters, Apr-03, Volume: 10, Issue:7 | Synthesis and antiviral activity of acyclovir-5'-(phenyl methoxy alaninyl) phosphate as a possible membrane-soluble nucleotide prodrug. |
| AID472792 | Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay | 2010 | Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8 | Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives. |
| AID663911 | Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay | 2012 | European journal of medicinal chemistry, Jul, Volume: 53 | 5-acetyl-2-arylbenzimidazoles as antiviral agents. Part 4. |
| AID425275 | Apparent volume of distribution at steady state in horse at 10 mg/kg, iv | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID224328 | Inhibitory effect on KOS strain of Herper simplex virus-1 yield, in primary rabbit kidney cell culture 0.4 ug/mL concentration after 48 hours. | 1987 | Journal of medicinal chemistry, Jun, Volume: 30, Issue:6 | Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases. |
| AID85562 | In vitro minimum inhibitory concentration to inhibit HSV-1 (McIntyre)-induced cytopathogenicity in PRK cells by 50% | 1988 | Journal of medicinal chemistry, Jul, Volume: 31, Issue:7 | Synthesis and antiviral activity of novel N-substituted derivatives of acyclovir. |
| AID400428 | Selectivity index, ratio of EC50 for HSV2 by cytopathic effect over IC50 for human Hep2 cells | 1998 | Journal of natural products, May, Volume: 61, Issue:5 | Antiviral phenylpropanoid glycosides from the medicinal plant Markhamia lutea. |
| AID1884107 | Antiviral activity against HSV-1 infected in African green monkey Vero cells assessed as inhibition of viral replication by measuring log suppression of virus-induced cytopathic effect at 5 uM incubated for 1 hr followed by washing with PBS and subsequent | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Synthetic derivatives of the antifungal drug ciclopirox are active against herpes simplex virus 2. |
| AID588212 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID1251997 | Cytotoxicity against Varicella zoster virus infected HEL cells assessed as alteration of cell morphology incubated for 3 days by microscopy | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Toward the discovery of dual HCMV-VZV inhibitors: Synthesis, structure activity relationship analysis, and cytotoxicity studies of long chained 2-uracil-3-yl-N-(4-phenoxyphenyl)acetamides. |
| AID1498127 | Antiviral activity against thymidine kinase deficient Varicella-Zoster virus infected in HEL cells assessed as reduction in virus plaque formation | 2018 | Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12 | Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs. |
| AID1071705 | Selectivity index, ratio of CC50 for cytotoxicity to EC50 for HSV1 | 2014 | European journal of medicinal chemistry, Mar-03, Volume: 74 | Synthesis and biological evaluation of 2-oxonicotinonitriles and 2-oxonicotinonitrile based nucleoside analogues. |
| AID578853 | Antiviral activity against 5 MOI Herpes simplex viruses 1 infected in vero cells after 24 hrs by viral plaque number reduction assay | 2011 | Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6 | Synthesis and anti-HSV-1 activity of new 1,2,3-triazole derivatives. |
| AID72035 | Antitumor activity against murine mammary carcinoma FM3A cells | 1988 | Journal of medicinal chemistry, Jul, Volume: 31, Issue:7 | Synthesis and antiviral activity of novel N-substituted derivatives of acyclovir. |
| AID634753 | Antiviral activity against thymidine kinase-positive Varicella Zoster virus Oka infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID87302 | Percentage of monophosphates (MP) formed in the first step of staggered assay compound was incubated with HSV-1 thymidine kinase for 4 hr | 1988 | Journal of medicinal chemistry, Dec, Volume: 31, Issue:12 | Synthesis and antiherpetic activity of (+/-)-9-[[(Z)-2-(hydroxymethyl)cyclopropyl]methyl]guanine and related compounds. |
| AID383517 | Antiviral activity against Vaccinia virus in human HEL cells assessed as reduction of virus-induced cytopathogenicity | 2008 | European journal of medicinal chemistry, Feb, Volume: 43, Issue:2 | Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents. |
| AID304888 | Inhibition of VZV-TK catalyzed dThd phosphorylation | 2007 | Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26 | Synthesis and antiviral activity of the carbocyclic analogue of the highly potent and selective anti-VZV bicyclo furano pyrimidines. |
| AID232886 | Ralative safety was expressed as Selective index (TC50/IC50) at HSV-1 passage 4 in vero cells | 1998 | Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16 | Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. |
| AID1576577 | Effective permeability of compound incubated for 8 hrs by PAMPA | 2019 | MedChemComm, Dec-01, Volume: 10, Issue:12 | Synthesis of new lophine-carbohydrate hybrids as cholinesterase inhibitors: cytotoxicity evaluation and molecular modeling. |
| AID1176316 | Antiviral activity against vesicular stomatitis virus infected in human WISH cells | 2015 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2 | Synthesis and quantitative structure-activity relationship (QSAR) analysis of some novel oxadiazolo[3,4-d]pyrimidine nucleosides derivatives as antiviral agents. |
| AID393992 | Antiviral activity against wild type HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity | 2009 | Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6 | 4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus. |
| AID249179 | Permeability Coefficient in hexadecane membranes model | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | Exploring the role of different drug transport routes in permeability screening. |
| AID574827 | Antiviral activity against Herpes simplex virus 1 isolate 7 harboring N23S, K36E, R89Q, +1C 464-465 = Stop 228 mutations in thymidine kinase and S33G, A330R, P1124H, T1208A, A870G mutations in DNA polymerase infected in african green monkey Vero cells by | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. |
| AID1407617 | Antiviral activity against thymidine kinase-deficient Varicella Zoster virus Oka strain infected in HELF cells assessed as inhibition of virus-induced plaque formation | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Synthesis of a 3'-C-ethynyl-β-d-ribofuranose purine nucleoside library: Discovery of C7-deazapurine analogs as potent antiproliferative nucleosides. |
| AID309812 | Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 5 days | 2007 | Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22 | Influence of 6 or 8-substitution on the antiviral activity of 3-phenethylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (HCMV) and varicella-zoster virus (VZV). |
| AID91307 | Concentration of the drug required to reduce the uptake of neural red stain by uninfected cell monolayers (HFF) | 1993 | Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17 | Synthesis and antiviral activity of novel 5-(1-azido-2-haloethyl) and 5-(1-azido-, amino-, or methoxyethyl) analogs of 2'-deoxyuridine. |
| AID229054 | In vitro antiherpesvirus activity against vero cells infected with HSV-2(G strain)[plaque reduction assay] | 1992 | Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16 | Synthesis and antiviral activity of methyl derivatives of 9-[2-(phosphonomethoxy)ethyl]guanine. |
| AID1402823 | Antiviral activity against HCMV Davis infected in HEL cells assessed as reduction in virus-induced cytopathic effect after 6 to 7 days | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Emimycin and its nucleoside derivatives: Synthesis and antiviral activity. |
| AID634835 | Antiviral activity against Felid herpesvirus 1 infected in CrFK cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID63599 | Minimum inhibitory conc. for 50% inhibition of alteration of morphology in E6SM cells | 1997 | Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9 | Carbocyclic oxetanocins lacking the C-3' methylene. |
| AID87303 | Percentage of monophosphates (MP) in the second step of staggered assay mixture from step 1 was incubated with GMP kinase and crude extract of HSV-1 infected HeLa cells over night | 1988 | Journal of medicinal chemistry, Dec, Volume: 31, Issue:12 | Synthesis and antiherpetic activity of (+/-)-9-[[(Z)-2-(hydroxymethyl)cyclopropyl]methyl]guanine and related compounds. |
| AID167879 | Antiviral Activity against herpes simplex virus-1 TK- VMW 1837 in rabbit kidney cell | 1990 | Journal of medicinal chemistry, Sep, Volume: 33, Issue:9 | Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives. |
| AID68269 | Concentration required to inhibit HSV-1 (KOS) induced cytopathogenicity in ESM cells by 50% | 1991 | Journal of medicinal chemistry, Aug, Volume: 34, Issue:8 | Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir. |
| AID224335 | Inhibitory effect on KOS strain of Herper simplex virus-1 yield, in primary rabbit kidney cell culture at 0.04 ug/mL concentration after 24 hours | 1987 | Journal of medicinal chemistry, Jun, Volume: 30, Issue:6 | Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases. |
| AID569239 | Cytotoxicity against HEL cells after 3 days by coulter counter analysis | 2011 | European journal of medicinal chemistry, Feb, Volume: 46, Issue:2 | Synthesis of new C5-(1-substituted-1,2,3-triazol-4 or 5-yl)-2'-deoxyuridines and their antiviral evaluation. |
| AID1726778 | Antiviral activity against HCMV AD169 infected in human HFF cells assessed as reduction in virus-induced cytopathic effect incubated for 14 days by cell-titer glo assay | 2021 | RSC medicinal chemistry, May-26, Volume: 12, Issue:5 | Introduction of a cyano group at the 2-position of an ( |
| AID257900 | Antiviral activity against Coxsackie virus B4 in HeLa cells | 2006 | Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2 | Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators. |
| AID359195 | Antiviral activity against HSV1 infected in african green monkey Vero cells after 72 hrs by SRB assay | 2001 | Journal of natural products, Mar, Volume: 64, Issue:3 | Potent antiviral potamogetonyde and potamogetonol, new furanoid labdane diterpenes from Potamogeton malaianus. |
| AID434310 | Antiviral activity against sVesicular stomatitis virus infected in HEL cells assessed as protection against virus-induced cytopathogenicity | 2009 | European journal of medicinal chemistry, Sep, Volume: 44, Issue:9 | Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide. |
| AID68266 | Concentration required to cause 50% reduction in cellular DNA synthesis in ESM cells | 1991 | Journal of medicinal chemistry, Aug, Volume: 34, Issue:8 | Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir. |
| AID419667 | Antiviral activity against Varicella zoster virus in HFF by plaque reduction assay | 2009 | Bioorganic & medicinal chemistry, Jun-01, Volume: 17, Issue:11 | Phosphonate analogues of cyclopropavir phosphates and their E-isomers. Synthesis and antiviral activity. |
| AID216156 | Effective concentration against TK- Varicella-Zoster Virus (VZV) YS/R strain | 2003 | Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23 | Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine. |
| AID42121 | Antiviral activity of the compound was evaluated against the Herpes simplex virus type-1 in BSC-1 cells | 1989 | Journal of medicinal chemistry, Feb, Volume: 32, Issue:2 | Synthesis, cytotoxicity, and antiviral activity of some acyclic analogues of the pyrrolo[2,3-d]pyrimidine nucleoside antibiotics tubercidin, toyocamycin, and sangivamycin. |
| AID665385 | Antiviral activity against thymidine kinase-deficient Varicella-zoster virus 07/1 infected in HEL cells assessed as reduction in virus-induced cytopathicity | 2012 | European journal of medicinal chemistry, Jul, Volume: 53 | Synthesis and antiviral evaluation of C5-substituted-(1,3-diyne)-2'-deoxyuridines. |
| AID354678 | Antiviral activity against herpes simplex virus type 2 assessed as effect on virus-induced cytopathic effect | 1996 | Journal of natural products, Aug, Volume: 59, Issue:8 | Two new naphthoquinones with antiviral activity from Rhinacanthus nasutus. |
| AID45815 | The mitochondrial toxicity was measured on human T-lymphoid CEM cells. | 2000 | Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13 | Structure-activity relationships of (E)-5-(2-bromovinyl)uracil and related pyrimidine nucleosides as antiviral agents for herpes viruses. |
| AID217745 | The concentration required to inhibit the growth of viral plaques by 50% of control in plaque reduction assay | 1985 | Journal of medicinal chemistry, Aug, Volume: 28, Issue:8 | Modifications on the heterocyclic base of acyclovir: syntheses and antiviral properties. |
| AID224331 | Inhibitory effect on KOS strain of Herper simplex virus-1 yield, in primary rabbit kidney cell culture 1 ug/mL concentration after 48 hours. | 1987 | Journal of medicinal chemistry, Jun, Volume: 30, Issue:6 | Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases. |
| AID91272 | Cytotoxicity was determined at 100 uM | 1987 | Journal of medicinal chemistry, Nov, Volume: 30, Issue:11 | Synthesis and antiviral activity of carbocyclic analogues of xylofuranosides of 2-amino-6-substituted-purines and 2-amino-6-substituted-8-azapurines. |
| AID87341 | Antiviral activity was determined against Herpes simplex virus type 1 by Plaque-reduction assay | 1989 | Journal of medicinal chemistry, Jul, Volume: 32, Issue:7 | Synthesis, cytotoxicity, and antiviral activity of certain 7-[(2-hydroxyethoxy)methyl]pyrrolo[2,3-d]pyrimidine nucleosides related to toyocamycin and sangivamycin. |
| AID79957 | Tested for antiviral activity against human cytomegalovirus (HCMV) by means of plaque reduction assay. | 1990 | Journal of medicinal chemistry, Jul, Volume: 33, Issue:7 | Synthesis and antiviral activity of some 7-[(2-hydroxyethoxy)methyl]pyrazolo[3,4-d]pyrimidine analogues of sangivamycin and toyocamycin. |
| AID307433 | Cytotoxicity against HFF cells after 3 days | 2007 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12 | 2-Aryl-2-hydroxyethylamine substituted 4-oxo-4,7-dihydrothieno[2,3-b]pyridines as broad-spectrum inhibitors of human herpesvirus polymerases. |
| AID246331 | Effective concentration required to inhibit herpes simplex virus 2 in HFF cells in cytopathic effect (CPE) assay | 2005 | Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1 | Nucleotides and pronucleotides of 2,2-bis(hydroxymethyl)methylenecyclopropane analogues of purine nucleosides: synthesis and antiviral activity. |
| AID1113468 | Antiviral activity against Vaccinia virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay | 2013 | Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4 | Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)- |
| AID275068 | Antiviral activity against HSV2 in HEL cells | 2006 | Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26 | Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine. |
| AID481439 | Absolute bioavailability in human | 2010 | Journal of medicinal chemistry, May-13, Volume: 53, Issue:9 | How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability? |
| AID665384 | Antiviral activity against thymidine kinase-positive Varicella-zoster virus OKA infected in HEL cells assessed as reduction in virus-induced cytopathicity | 2012 | European journal of medicinal chemistry, Jul, Volume: 53 | Synthesis and antiviral evaluation of C5-substituted-(1,3-diyne)-2'-deoxyuridines. |
| AID88668 | Inhibition of HSV-1 DNA synthesis in virus-infected HeLa cells | 1995 | Journal of medicinal chemistry, May-12, Volume: 38, Issue:10 | Inhibition of herpes simplex virus type 1 helicase-primase by (dichloroanilino)purines and -pyrimidines. |
| AID84961 | Minimum inhibitory concentration against HSV-2. | 1985 | Journal of medicinal chemistry, Nov, Volume: 28, Issue:11 | 5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue. |
| AID1176318 | Selectivity index, ratio of toxic concentration for human WISH cells to ED50 for vesicular stomatitis virus infected in human WISH cells | 2015 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2 | Synthesis and quantitative structure-activity relationship (QSAR) analysis of some novel oxadiazolo[3,4-d]pyrimidine nucleosides derivatives as antiviral agents. |
| AID689097 | Cytotoxicity against african green monkey Vero E6 cells after 72 hrs by trypan blue staining | 2012 | Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19 | Phosphoramidate derivatives of acyclovir: synthesis and antiviral activity in HIV-1 and HSV-1 models in vitro. |
| AID611617 | Antiviral activity against Human herpesvirus 2 G infected in HEL cells assessed as protection against virus-induced cytopathicity | 2011 | Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11 | New prodrugs of Adefovir and Cidofovir. |
| AID273050 | Cytotoxicity against Daudi cells | 2006 | Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20 | 9-{[3-fluoro-2-(hydroxymethyl)cyclopropylidene]methyl}adenines and -guanines. Synthesis and antiviral activity of all stereoisomers1. |
| AID63607 | Tested for antiviral activity against thymidine kinase-deficient (TK-HSV-2G) virus in E6SM cell line(human embryonic skin-muscle fibroblasts) | 2002 | Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5 | New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation. |
| AID393988 | Antiviral activity against cidofovir HCMV AD169 clone 5 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity | 2009 | Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6 | 4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus. |
| AID1450217 | Selectivity index, ratio of MCC for African green monkey Vero E6 cells to IC50 for acyclovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells | 2017 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11 | New modified 2-aminobenzimidazole nucleosides: Synthesis and evaluation of their activity against herpes simplex virus type 1. |
| AID216472 | Antiviral activity was tested against TK- Varicella-Zoster virus 07/1 which reduces virus plaque formation by 50% | 2002 | Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19 | Synthesis and antiviral/antiproliferative activity of some N-sulphonylbenzimidazoles. |
| AID481587 | Antiviral activity against VZV Webster infected in HFF cells assessed as reduction in plaque formation | 2010 | Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10 | Modifications of C-2 on the pyrroloquinoline template aimed at the development of potent herpesvirus antivirals with improved aqueous solubility. |
| AID85114 | Minimum inhibitory concentration was determined against HSV-2 (Lyons) in E6SM cell culture | 2000 | Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4 | The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine. |
| AID553342 | Antiviral activity against VZV OKA expressing thymidine kinase infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 5 days | 2011 | Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1 | Novel antiviral C5-substituted pyrimidine acyclic nucleoside phosphonates selected as human thymidylate kinase substrates. |
| AID1209456 | Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1 | In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. |
| AID216461 | Effective concentration required for reduction of plaque formation of Varicella-Zoster Virus (OKA strain) | 2001 | Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3 | Bicyclic nucleoside inhibitors of Varicella-Zoster Virus (VZV): the effect of terminal unsaturation in the side chain. |
| AID167133 | Minimum inhibitory concentration required to reduce virus induced cytopathogenicity in primary rabbit kidney cell cultures by 50% against HSV-1 ((KOS) | 1983 | Journal of medicinal chemistry, Apr, Volume: 26, Issue:4 | Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl]guanine]. |
| AID1661189 | Antiviral activity against thymidine kinase positive Varicella zoster virus OKA infected in human HEL cells assessed as reduction in plaque formation measured after 5 days | 2020 | ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7 | Amidate Prodrugs of |
| AID498603 | Antiviral activity against Macacine herpesvirus 1 isolate MC1 infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds. |
| AID137474 | Number of survivors against Herpes simplex virus type-2 infection in mice at 12.5 mg/kg/day | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID85557 | Concentration required to inhibit HSV-1 strain KOS cytopathic effect by 50% was measured by plaque reduction assay | 1991 | Journal of medicinal chemistry, Mar, Volume: 34, Issue:3 | Fluorocarbocyclic nucleosides: synthesis and antiviral activity of 2'- and 6'-fluorocarbocyclic 2'-deoxy guanosines. |
| AID634752 | Antiviral activity against Human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID611615 | Antiviral activity against Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity | 2011 | Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11 | New prodrugs of Adefovir and Cidofovir. |
| AID79938 | Antiviral activity of the compound was evaluated against the Human cytomegalo virus (HCMV) | 1989 | Journal of medicinal chemistry, Feb, Volume: 32, Issue:2 | Synthesis, cytotoxicity, and antiviral activity of some acyclic analogues of the pyrrolo[2,3-d]pyrimidine nucleoside antibiotics tubercidin, toyocamycin, and sangivamycin. |
| AID1667298 | Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTT assay | 2020 | Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7 | DNA sequence-specific ligands. XVIII. Synthesis, physico-chemical properties; genetic, virological, and biochemical studies of fluorescent dimeric bisbenzimidazoles DBPA(n). |
| AID675218 | Antiviral activity against HCMV Davis infected in HEL cells by viral CPE assay | 2012 | European journal of medicinal chemistry, Sep, Volume: 55 | Synthesis and antiviral activities of hexadecyloxypropyl prodrugs of acyclic nucleoside phosphonates containing guanine or hypoxanthine and a (S)-HPMP or PEE acyclic moiety. |
| AID431631 | Cytotoxicity against HEL cells assessed as inhibition of cell proliferation | 2009 | Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17 | The application of phosphoramidate protide technology to acyclovir confers anti-HIV inhibition. |
| AID244773 | Minimum cytotoxic concentration required to cause a microscopically visible alteration of HEL fibroblast cell morphology | 2005 | Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7 | From 1-acyl-beta-lactam human cytomegalovirus protease inhibitors to 1-benzyloxycarbonylazetidines with improved antiviral activity. A straightforward approach to convert covalent to noncovalent inhibitors. |
| AID84431 | Inhibitory effects on HSV-1 induced mortality in NMRI mice upon (ip) administration at a dose of 100 mk/kg/day | 2001 | Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22 | Design, synthesis, and biological evaluation of novel nucleoside and nucleotide analogues as agents against DNA viruses and/or retroviruses. |
| AID1385755 | Antiviral activity against Herpes simplex virus 1 KOS infected in African green monkey Vero cells assessed as inhibition of plaque formation at 5 ug treated 1 hr prior to viral infection followed by compound washout and subsequent compound addition measur | 2018 | ACS medicinal chemistry letters, Aug-09, Volume: 9, Issue:8 | Inhibition of Herpes Simplex Virus-1 Entry into Human Cells by Nonsaccharide Glycosaminoglycan Mimetics. |
| AID106184 | Compound was tested for antiviral activity against Herpes Simplex virus Type-1(18189) in human lung fibroblasts (MRC-5) | 1987 | Journal of medicinal chemistry, Sep, Volume: 30, Issue:9 | Synthesis and antiviral activity of 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]purines. |
| AID1211770 | Tmax in PepT1 knockout mouse treated with 25 nmol/g, po of valacyclovir | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3 | Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice. |
| AID229024 | Inhibitory activity against vaccinia virus (VV) replication in E6SM cell cultures of human embryonic skin-muscle | 2002 | Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25 | A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity. |
| AID1055689 | Antiviral activity against thymidine kinase-deficient ACV-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity | 2013 | European journal of medicinal chemistry, , Volume: 70 | Novel water-soluble prodrugs of acyclovir cleavable by the dipeptidyl-peptidase IV (DPP IV/CD26) enzyme. |
| AID429100 | Antiviral activity against HSV1 infected in african green monkey Vero cells assessed as reduction in virus plaque formation at 20 ug per 10'5 cells by plaque infectivity assay | 2009 | European journal of medicinal chemistry, Aug, Volume: 44, Issue:8 | Synthesis and anti-HSV-1 evaluation of some pyrazoles and fused pyrazolopyrimidines. |
| AID303929 | Permeability across artificial membrane by PAMPA model | 2007 | Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24 | Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability. |
| AID165784 | Inhibitory activity against Raji cell line | 1990 | Journal of medicinal chemistry, Sep, Volume: 33, Issue:9 | Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives. |
| AID81019 | Tested for Antiherpetic activity against VZV from clinical isolates of HEL cell lines.(average of 11 isolates) | 2000 | Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2 | Synthesis and antiviral activity of novel anti-VZV 5-substituted uracil nucleosides with a cyclopropane sugar moiety. |
| AID84233 | Compound was evaluated for anti-herpesvirus activity against Herpes simplex virus-1 (SC16) strain. | 1993 | Journal of medicinal chemistry, May-14, Volume: 36, Issue:10 | Novel acyclonucleotides: synthesis and antiviral activity of alkenylphosphonic acid derivatives of purines and a pyrimidine. |
| AID304887 | Cytotoxicity against HEL cells | 2007 | Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26 | Synthesis and antiviral activity of the carbocyclic analogue of the highly potent and selective anti-VZV bicyclo furano pyrimidines. |
| AID246487 | Effective concentration required to reduce Varicella-Zoster virus 07/1(TK-) plaque formation after 5 days in HEL fibroblast cell line | 2005 | Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7 | From 1-acyl-beta-lactam human cytomegalovirus protease inhibitors to 1-benzyloxycarbonylazetidines with improved antiviral activity. A straightforward approach to convert covalent to noncovalent inhibitors. |
| AID307432 | Antiviral activity against VZV Webster in HFF cells by plaque reduction assay | 2007 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12 | 2-Aryl-2-hydroxyethylamine substituted 4-oxo-4,7-dihydrothieno[2,3-b]pyridines as broad-spectrum inhibitors of human herpesvirus polymerases. |
| AID288920 | Antiviral activity against thymidine kinase deficient HSV1 VMW1837 in E6SM cells assessed as reduction of virus-induced cytopathogenicity | 2007 | Journal of medicinal chemistry, Jun-14, Volume: 50, Issue:12 | 5-alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells. |
| AID675212 | Antiviral activity against thymidine kinase negative VZV 07/01 infected in HEL cells by plaque formation assay | 2012 | European journal of medicinal chemistry, Sep, Volume: 55 | Synthesis and antiviral activities of hexadecyloxypropyl prodrugs of acyclic nucleoside phosphonates containing guanine or hypoxanthine and a (S)-HPMP or PEE acyclic moiety. |
| AID1727353 | Antiviral activity against thymidine kinase deficient Varicella zoster virus 07-1 infected in human HEL cells assessed as reduction in virus-induced cytopathogenic effect measured after 3 days coulter counter method | 2021 | European journal of medicinal chemistry, Jan-01, Volume: 209 | Extension of furopyrimidine nucleosides with 5-alkynyl substituent: Synthesis, high fluorescence, and antiviral effect in the absence of free ribose hydroxyl groups. |
| AID218519 | Antiviral activity against HSV-2 (Herpes simplex virus) in vero cells | 1994 | Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1 | S-glucosylated hydantoins as new antiviral agents. |
| AID665383 | Antiviral activity against thymidine kinase-positive Varicella-zoster virus YS infected in HEL cells assessed as reduction in virus-induced cytopathicity | 2012 | European journal of medicinal chemistry, Jul, Volume: 53 | Synthesis and antiviral evaluation of C5-substituted-(1,3-diyne)-2'-deoxyuridines. |
| AID35826 | Compound was tested for the inhibition of HeLa DNA polymerase | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Enzymatic phosphorylation of the antiherpetic agent 9-[(2,3-dihydroxy-1-propoxy)methyl]guanine. |
| AID113236 | Efficacy expressed as number of surviving mice infected with herpetic encephalitis at dose of 75 mg/kg; Not determined | 1986 | Journal of medicinal chemistry, Feb, Volume: 29, Issue:2 | Systematic synthesis and biological evaluation of alpha- and beta-D-xylofuranosyl nucleosides of the five naturally occurring bases in nucleic acids and related analogues. |
| AID210868 | Maximum velocity constant of the rate of phosphorylation was determined against Vero cell thymidine kinase | 2001 | Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22 | Design, synthesis, and biological evaluation of novel nucleoside and nucleotide analogues as agents against DNA viruses and/or retroviruses. |
| AID521954 | Ratio of Cmax in human CSF to Cmax in human plasma with normal renal function at 2000 mg, po every 6 hrs measured after fifth dose by radioimmunoassay | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. |
| AID246170 | Effective concentration required to inhibit herpes simplex virus 1 in BSC-1 cells in ELISA | 2005 | Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1 | Nucleotides and pronucleotides of 2,2-bis(hydroxymethyl)methylenecyclopropane analogues of purine nucleosides: synthesis and antiviral activity. |
| AID296672 | Antiviral activity against TK+ VZV YS in HEL cells assessed as reduction of virus plaque formation after 5 days | 2007 | Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16 | Synthesis and antiviral evaluation of 6-(alkyl-heteroaryl)furo[2,3-d]pyrimidin-2(3H)-one nucleosides and analogues with ethynyl, ethenyl, and ethyl spacers at C6 of the furopyrimidine core. |
| AID63946 | Minimum cytotoxic concentration (MCC) required to cause a microscopically detectable alteration of normal cell morphology against E6SM cells | 1992 | Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8 | Synthesis and antiviral activity of acyclic nucleosides with a 3(S),5-dihydroxypentyl or 4(R)-methoxy-3(S),5-dihydroxypentyl side chain. |
| AID280941 | Cytotoxicity against mouse L1210/0 cells after 48 hrs | 2007 | Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7 | Probing the anticancer activity of nucleoside analogues: a QSAR model approach using an internally consistent training set. |
| AID85560 | In vitro minimum inhibitory concentration to inhibit HSV-1 (F)-induced cytopathogenicity in primary rabbit kidney cells by 50% | 1988 | Journal of medicinal chemistry, Jul, Volume: 31, Issue:7 | Synthesis and antiviral activity of novel N-substituted derivatives of acyclovir. |
| AID63601 | Minimum inhibitory conc. for 50% inhibition of vesicular stomatitis virus induced cytopathicity in E6SM cells | 1997 | Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9 | Carbocyclic oxetanocins lacking the C-3' methylene. |
| AID42134 | The compound was tested for cytotoxicity against BSC1 cell | 1988 | Journal of medicinal chemistry, Aug, Volume: 31, Issue:8 | Synthesis and antiviral activity of certain 4-substituted and 2,4-disubstituted 7-[(2-hydroxyethoxy)methyl]pyrrolo[2,3-d]pyrimidines. |
| AID291032 | Cytotoxicity against HEL cells assessed as cell growth after 7 days | 2007 | Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13 | Novel C-6 fluorinated acyclic side chain pyrimidine derivatives: synthesis, (1)H and (13)C NMR conformational studies, and antiviral and cytostatic evaluations. |
| AID68272 | Concentration required to inhibit HSV-2(G) induced cytopathogenicity in ESM cells by 50% | 1991 | Journal of medicinal chemistry, Aug, Volume: 34, Issue:8 | Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir. |
| AID1407611 | Antiviral activity against Human herpesvirus 1 KOS strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Synthesis of a 3'-C-ethynyl-β-d-ribofuranose purine nucleoside library: Discovery of C7-deazapurine analogs as potent antiproliferative nucleosides. |
| AID1237437 | Cytotoxicity against mock-infected African green monkey Vero cells assessed as inhibition of cell survival after 3 days by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 | Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity. |
| AID365176 | Antiviral activity against HCMV 530 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity | 2008 | Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18 | 4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action. |
| AID217649 | Minimum inhibitory concentration was determined against VZV (TK-07/1) in HEL cells | 2000 | Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4 | The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine. |
| AID260768 | Antiviral activity against HSV1 at 10 uM | 2006 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4 | Synthesis and anti-HSV-1 activity of quinolonic acyclovir analogues. |
| AID54953 | Effective concentration required against HCMV AD169 for antiviral activity | 2001 | Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12 | The cyclohexene ring as bioisostere of a furanose ring: synthesis and antiviral activity of cyclohexenyl nucleosides. |
| AID257890 | Antiviral activity against Herpes simplex virus 2 G strain in HEL cells | 2006 | Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2 | Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators. |
| AID445445 | Permeability at pH 6.5 by PAMPA method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. |
| AID521955 | Ratio of Cmax in human CSF to Cmax in human plasma with chronic kidney disease at 1500 mg, po every 12 hrs measured after fifth dose by radioimmunoassay | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. |
| AID84251 | Antiviral activity is expressed as virus rating (VR) against the HSV-1 HF strain | 1987 | Journal of medicinal chemistry, Jun, Volume: 30, Issue:6 | Synthesis and antiviral evaluation of carbocyclic analogues of 2-amino-6-substituted-purine 3'-deoxyribofuranosides. |
| AID309814 | Cytotoxicity against HEL cells assessed as alteration in cell morphology after 3 days | 2007 | Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22 | Influence of 6 or 8-substitution on the antiviral activity of 3-phenethylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (HCMV) and varicella-zoster virus (VZV). |
| AID1504158 | Antiviral activity against HSV1/F infected in African green monkey Vero cells assessed as inhibition of plaque formation after 24 hrs by crystal violet staining-based assay | 2017 | Journal of natural products, 11-22, Volume: 80, Issue:11 | Houttuynoid M, an Anti-HSV Active Houttuynoid from Houttuynia cordata Featuring a Bis-houttuynin Chain Tethered to a Flavonoid Core. |
| AID563784 | Antiviral activity against HSV2 harboring frameshift mutation in TK infected in HFF after 3 days by plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides. |
| AID588211 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID232892 | Ralative safety was expressed as Selective index (TC50/IC50) at HSV-2 passage 1 in vero cells | 1998 | Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16 | Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. |
| AID82116 | Antiviral activity against HIV-1 was determined; No inhibition | 1990 | Journal of medicinal chemistry, Sep, Volume: 33, Issue:9 | Synthesis of new (+-)-3,5-dihydroxypentyl nucleoside analogues from 1-amino-5-(benzyloxy)pentan-3-ol and their antiviral evaluation. |
| AID45841 | Compound concentration required to reduce viability of CEM cells | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24 | Synthesis and antiviral evaluation of 3-hydroxy-2-methylpyridin-4-one dideoxynucleoside derivatives. |
| AID1504159 | Cytotoxicity against African green monkey Vero cells assessed as decrease in cell viability after 24 hrs by CellTiter-Glo luminescent assay | 2017 | Journal of natural products, 11-22, Volume: 80, Issue:11 | Houttuynoid M, an Anti-HSV Active Houttuynoid from Houttuynia cordata Featuring a Bis-houttuynin Chain Tethered to a Flavonoid Core. |
| AID1593186 | Therapeutic index, ratio of CC50 of rhesus monkey FRhK cells to IC50 of antiviral activity against Hepatitis A virus infected in rhesus monkey FRhK4 cells | 2019 | European journal of medicinal chemistry, Apr-15, Volume: 168 | New 4-phenylcoumarin derivatives as potent 3C protease inhibitors: Design, synthesis, anti-HAV effect and molecular modeling. |
| AID224326 | Inhibitory effect on KOS strain of Herper simplex virus-1 yield, in primary rabbit kidney cell culture 0.04 ug/mL concentration after 48 hours. | 1987 | Journal of medicinal chemistry, Jun, Volume: 30, Issue:6 | Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases. |
| AID307441 | Antiviral activity against EBV in GG68 cells after 72 hrs | 2007 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12 | 2-Aryl-2-hydroxyethylamine substituted 4-oxo-4,7-dihydrothieno[2,3-b]pyridines as broad-spectrum inhibitors of human herpesvirus polymerases. |
| AID332490 | Antiviral activity against HSV1 H29S in african green monkey Vero cells assessed as log reduction in viral titers after 0.001 multiple round of replication at 12.5 ug/ml after 72 hrs | 1994 | Journal of natural products, May, Volume: 57, Issue:5 | Comparison of the anti-herpes simplex virus activities of propolis and 3-methyl-but-2-enyl caffeate. |
| AID90939 | In vitro antiviral and anticellular activity was evaluated against human cytomegalovirus (HCMV AD 169) in (HCMV AD 169) cells. | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis and antiherpes simplex virus activity of 9-[(1,3-dihydroxy-2-propylthio)methyl]guanine. |
| AID1113466 | Antiviral activity against acyclovir-resistant thymidine kinase negative Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay | 2013 | Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4 | Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)- |
| AID1219944 | Transport efficiency, ratio of maximal rate of transport to Km for drug transport in human OAT2 expressed in HEK Flp-In cells measured per mg of protein | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3 | Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs. |
| AID85120 | Inhibitory activity against HSV-2 (G) replication in E6SM cell cultures of human embryonic skin-muscle | 2002 | Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25 | A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity. |
| AID1410507 | Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07-1 assessed as inhibition of plaque formation measured after 5 days post-infection | 2018 | ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4 | Amidate Prodrugs of Cyclic 9-( |
| AID63768 | The minimum inhibitory concentration was measured on E6SM cells for morphological alteration | 1994 | Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19 | Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity. |
| AID1283355 | Antiviral activity against HSV1 KOS ATCC VR1493 infected in human iPSC cells assessed as reduction in expression of ICP4 gene at 50 uM measured 24 hrs post infection by RT-qPCR analysis | 2016 | ACS medicinal chemistry letters, Jan-14, Volume: 7, Issue:1 | iPSC Neuronal Assay Identifies Amaryllidaceae Pharmacophore with Multiple Effects against Herpesvirus Infections. |
| AID303213 | Antiviral activity against VZV OKA in HEL cells assessed as reduction of virus-induced cytopathogenicity | 2007 | Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23 | Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity. |
| AID250857 | Effect on HSV-1 encephalitis in mice following intraperitoneal dosage at 50 mg/kg; expressed as number of survivors/10 | 2005 | Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11 | Inhibition of herpes simplex virus thymidine kinases by 2-phenylamino-6-oxopurines and related compounds: structure-activity relationships and antiherpetic activity in vivo. |
| AID404023 | Antiviral activity against herpes simplex virus 1 infected in MDCK cells | 2005 | Journal of natural products, Dec, Volume: 68, Issue:12 | Antiviral Terpenoid Constituents of Ganoderma pfeifferi. |
| AID1055688 | Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity | 2013 | European journal of medicinal chemistry, , Volume: 70 | Novel water-soluble prodrugs of acyclovir cleavable by the dipeptidyl-peptidase IV (DPP IV/CD26) enzyme. |
| AID85559 | Concentration required to reduce the number of viral plaques in vivo cell monolayers of herpes simplex virus type 1. | 1989 | Journal of medicinal chemistry, Feb, Volume: 32, Issue:2 | Synthesis and antiviral activity of phosphonoacetic and phosphonoformic acid esters of 5-bromo-2'-deoxyuridine and related pyrimidine nucleosides and acyclonucleosides. |
| AID412420 | Antiviral activity against ganciclovir-sensitive HCMV1 isolate replication in HFF cells by plaque reduction assay | 2009 | Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1 | Synthesis and in vitro activities of a new antiviral duplex drug linking Zidovudine (AZT) and Foscarnet (PFA) via an octadecylglycerol residue. |
| AID1256245 | Antiviral activity against Varicella-zoster virus Ellen VR-1367 infected in African green monkey Vero cells after 3 days by MTT assay | 2015 | Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21 | Selenoacyclovir and Selenoganciclovir: Discovery of a New Template for Antiviral Agents. |
| AID118654 | Compound was evaluated in nu/nu mice infected with TK- HSV-1 (VMW-1837) to increase the mean survival time when administered intraperitoneally at 100 mg/kg per day after 39 days | 1990 | Journal of medicinal chemistry, Sep, Volume: 33, Issue:9 | Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives. |
| AID472783 | Cytotoxicity against human MT4 cells after 96 hrs by MTT assay | 2010 | Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8 | Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives. |
| AID83716 | Ability to reduce plaque formation of herpes simplex virus type 1 (HSV-1) by 50% in human embryonic lung fibroblast (HELF) cell cultures | 1988 | Journal of medicinal chemistry, Feb, Volume: 31, Issue:2 | Synthesis and biological activities of 4-O-(difluoromethyl)-5-substituted-uracil nucleoside analogues. |
| AID682754 | Antiviral activity against HSV-2G ATCC 734 infected in african green monkey Vero cells after 2 to 3 days by plaque reduction assay | 2012 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19 | Structure based molecular design, synthesis and biological evaluation of α-pyrone analogs as anti-HSV agent. |
| AID1186327 | Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay | 2014 | Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17 | Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents. |
| AID1139390 | Antiviral activity against thymidine kinase-deficient Varicella zoster virus 07-1 infected in HEL cells assessed as reduction in viral plaque formation after 5 days | 2014 | Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9 | ProTides of N-(3-(5-(2'-deoxyuridine))prop-2-ynyl)octanamide as potential anti-tubercular and anti-viral agents. |
| AID81024 | The compound was tested for anti CMV (Cytomegalovirus- virus) activity against AD-169 strain in HEL cells;d ='not determined' | 1998 | Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25 | Synthesis of imidazo[1,2-a]pyridines as antiviral agents. |
| AID687665 | Antiviral activity against thymidine kinase-deficient VZV 07/1 infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days | 2012 | European journal of medicinal chemistry, Nov, Volume: 57 | Synthesis and antiviral evaluation of bis(POM) prodrugs of (E)-[4'-phosphono-but-2'-en-1'-yl]purine nucleosides. |
| AID218050 | Minimum inhibitory concentration required to reduce cytopathogenicity of Herpes Virus-2 (HSV-2) in vero cells by 50%. | 1991 | Journal of medicinal chemistry, Sep, Volume: 34, Issue:9 | The synthesis and antiviral activity of some 4'-thio-2'-deoxy nucleoside analogues. |
| AID90766 | Antiviral activity against human cytomegalovirus by plaque reduction assay | 1996 | Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18 | Synthesis of non-nucleoside analogs of toyocamycin, sangivamycin, and thiosangivamycin: the effect of certain 4- and 4,6-substituents on the antiviral activity of pyrrolo[2,3-d]pyrimidines. |
| AID1592936 | Selectivity index, ratio of Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by SRB assay to Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in African green monke | |||
| AID27595 | Partition coefficient (logP) | 2002 | Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23 | CycloSal-BVDUMP pronucleotides: how to convert an antiviral-inactive nucleoside analogue into a bioactive compound against EBV. |
| AID1219943 | Drug transport in human OAT2 expressed in HEK Flp-In cells | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3 | Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs. |
| AID563768 | Antiviral activity against HSV1 DM2.1 harboring frameshift mutation in TK infected in HFF after 3 days by plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides. |
| AID259179 | Antiviral activity against HSV2 G in HEL cells | 2006 | Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1 | Synthesis and antiviral evaluation of cyclic and acyclic 2-methyl-3-hydroxy-4-pyridinone nucleoside derivatives. |
| AID575025 | Antiviral activity against Herpes simplex virus 1 isolate 10 harboring N23S, K36E, R89Q, A265T C336Y mutations in thymidine kinase and S33G, A330R, V905M mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. |
| AID1274006 | Antiviral activity against HHV-2 VR-734-G infected in African green monkey Vero cells assessed as reduction in plaque formation administered simultaneously with virus for 1 hr measured after 72 hrs by crystal violet staining technique | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Anti-herpetic and anti-dengue activity of abietane ferruginol analogues synthesized from (+)-dehydroabietylamine. |
| AID82684 | Compound was tested for anti-viral activity against HSV-1(G) in HEL cells | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24 | Synthesis and antiviral evaluation of 3-hydroxy-2-methylpyridin-4-one dideoxynucleoside derivatives. |
| AID68253 | Minimum inhibitory concentration required for antiviral activity to reduce HSV-2 (G) induced cytopathicity in human embryonic skin-muscle cells (ESM) | 1994 | Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9 | Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues. |
| AID658755 | Antiviral activity against VSV OKA expressing thymidine kinase infected in HEL cells assessed as reduction of virus plaque formation after 4 days | 2012 | European journal of medicinal chemistry, Jun, Volume: 52 | 2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies. |
| AID82404 | Cytotoxicity was evaluated against the Human diploid cells (HFF) | 1989 | Journal of medicinal chemistry, Feb, Volume: 32, Issue:2 | Synthesis, cytotoxicity, and antiviral activity of some acyclic analogues of the pyrrolo[2,3-d]pyrimidine nucleoside antibiotics tubercidin, toyocamycin, and sangivamycin. |
| AID609575 | Antiviral activity against Herpes simplex virus 2 strain G assessed as reduction of virus induced cytopathicity by cell based assay | 2011 | Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15 | Acyclic nucleoside phosphonates with a branched 2-(2-phosphonoethoxy)ethyl chain: efficient synthesis and antiviral activity. |
| AID82890 | Tested for inhibitory effect on DNA virus TK-VZV (YS/R) in HEL cell line | 1993 | Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23 | Synthesis and antiviral activity of 5'-deoxypyrazofurin. |
| AID425273 | AUC in horse at 10 mg/kg, iv | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID257895 | Antiviral activity against Reovirus 1 in vero cells | 2006 | Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2 | Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators. |
| AID1256248 | Solubility of compound in double-deionized water after 3 days by LC-MS/MS analysis | 2015 | Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21 | Selenoacyclovir and Selenoganciclovir: Discovery of a New Template for Antiviral Agents. |
| AID1410508 | Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 6 to 7 days post-infection | 2018 | ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4 | Amidate Prodrugs of Cyclic 9-( |
| AID766711 | Cytotoxicity against human HEL cells assessed as morphological changes | 2013 | European journal of medicinal chemistry, Sep, Volume: 67 | Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity. |
| AID250859 | Effect on HSV-2 encephalitis in mice following intraperitoneal dosage at 50 mg/kg; expressed as number of survivors/10 | 2005 | Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11 | Inhibition of herpes simplex virus thymidine kinases by 2-phenylamino-6-oxopurines and related compounds: structure-activity relationships and antiherpetic activity in vivo. |
| AID82244 | Concentration for HSV-1 plaque reduction (VPR) by 50% in HFF cells | 2003 | Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23 | Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine. |
| AID1462031 | Antiviral activity against wild type Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect | 2017 | Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17 | New prodrugs of two pyrimidine acyclic nucleoside phosphonates: Synthesis and antiviral activity. |
| AID216040 | Inhibitory activity against herpes simplex virus type 2 (HSV 2) strain 186 in Vero cells. | 1996 | Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3 | Synthesis and anti-herpes virus activity of 2'-deoxy-4'-thiopyrimidine nucleosides. |
| AID120296 | In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through intraperitoneal at a dose 1 mg/kg per day | 1985 | Journal of medicinal chemistry, Nov, Volume: 28, Issue:11 | 5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue. |
| AID217751 | Antiviral activity determined by plaque reduction assay of HSV-1 (BWS) in vero cells | 1991 | Journal of medicinal chemistry, Jul, Volume: 34, Issue:7 | A new class of acyclic phosphonate nucleotide analogues: phosphonate isosteres of acyclovir and ganciclovir monophosphates as antiviral agents. |
| AID575026 | Antiviral activity against Herpes simplex virus 1 isolate 11 harboring N23S, K36E, G251C, A265T, P268T, R176W mutations in thymidine kinase and S33G, A330R, P1124H, T1208A, S724N, V117L, L267M mutations in DNA polymerase infected in african green monkey V | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. |
| AID85380 | Inhibitory concentration against HSV type 2 strain Lyons in human embryonic skin muscle (ESM) fibroblast cell culture | 1993 | Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14 | Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides. |
| AID167746 | Antiviral Activity against herpes simplex virus-1 (KOS) in rabbit kidney cell | 1990 | Journal of medicinal chemistry, Sep, Volume: 33, Issue:9 | Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives. |
| AID634756 | Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID81048 | Concentration required to cause 50% reduction in HEL cell growth. | 1991 | Journal of medicinal chemistry, Aug, Volume: 34, Issue:8 | Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir. |
| AID682749 | Antiviral activity against HSV-1F ATCC 733 infected in african green monkey Vero cells assessed as inhibition of virus yield at 20 ug/ml after 3 days by MTT assay | 2012 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19 | Structure based molecular design, synthesis and biological evaluation of α-pyrone analogs as anti-HSV agent. |
| AID393987 | Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity | 2009 | Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6 | 4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus. |
| AID1464791 | Anti-viral activity against Herpes simplex virus-1 harboring EGFP infected in iPSC-derived neurons assessed as late apoptotic cells at 10 mM treated 2 hrs post infection measured after 72 hrs by Alexa fluor 488 staining based flow cytometric analysis (Rvb | 2017 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 27, Issue:20 | Discovery of potent antiviral (HSV-1) quinazolinones and initial structure-activity relationship studies. |
| AID88291 | Therapeutic index (vero CC50/ED50) against HSV-2 | 2003 | Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23 | Anti-herpes simplex virus activity of substituted 1-hydroxyacridones. |
| AID68257 | Minimum inhibitory concentration to reduce cytopathicity by 50% in morphology of human embryonic skin-muscle cells (ESM) | 1994 | Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9 | Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues. |
| AID561621 | Half life in immunocompromized children at 10.5 mg/kg, iv | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. |
| AID85128 | Minimum inhibitory concentration was determined against HSV-1 (TK-KOS ACV) in E6SM cell culture | 2000 | Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4 | The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine. |
| AID472785 | Cytotoxicity against BHK cells after 48 to 96 hrs by MTT assay | 2010 | Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8 | Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives. |
| AID1186336 | Antiviral activity against Poliovirus type 1 Sabin strain infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay | 2014 | Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17 | Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents. |
| AID28925 | Highest effective permeability across hexadecane membrane (pH 4-8) | 2001 | Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6 | High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. |
| AID216324 | The concentration required to reduce virus plaque formation by 50% was measured on YS strain of VZV expressing viral thymidine kinase(TK+) | 1999 | Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7 | Novel potential agents for human cytomegalovirus infection: synthesis and antiviral activity evaluation of benzothiadiazine dioxide acyclonucleosides. |
| AID1854968 | Antiviral activity against Vaccinia virus infected in HEL cells assessed as reduction in virus-induced cytopathic effect by microscopic analysis | 2022 | European journal of medicinal chemistry, Nov-05, Volume: 241 | Synthesis and antiviral properties of biomimetic iminosugar-based nucleosides. |
| AID288919 | Antiviral activity against thymidine kinase-deficient HSV1 B2006 in E6SM cells assessed as reduction of virus-induced cytopathogenicity | 2007 | Journal of medicinal chemistry, Jun-14, Volume: 50, Issue:12 | 5-alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells. |
| AID85397 | Antiviral activity against DNA polymerase mutant resistant to PFA 1a (PFA) was determined at a conc of 50 uM | 1987 | Journal of medicinal chemistry, Nov, Volume: 30, Issue:11 | Acetylenic nucleosides. 4. 1-beta-D-arabinofuranosyl-5-ethynylcytosine. Improved synthesis and evaluation of biochemical and antiviral properties. |
| AID472790 | Antiviral activity against Yellow fever virus 17D infected in BHK cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method | 2010 | Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8 | Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives. |
| AID209539 | Inhibitory concentration against TK-VZV strain YS-R in human embryonic lung (HEL) cell culture | 1993 | Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14 | Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides. |
| AID396937 | Antiviral activity against HSV1 assessed as reduction in plaque formation at 100 ug | |||
| AID1651493 | Antiviral activity against ACV-resistant Herpes simplex virus 1 AR-29 infected in female Balb/c mouse assessed as reduction in skin lesion at 50 mg/g applied topically as cream formulation 5 times a day at 3 hrs interval for 10 days | |||
| AID1256246 | Antiviral activity against Human cytomegalovirus Davis VR-807 infected in African green monkey Vero cells after 3 days by MTT assay | 2015 | Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21 | Selenoacyclovir and Selenoganciclovir: Discovery of a New Template for Antiviral Agents. |
| AID561615 | Renal clearance in patient with Epstein-Barr virus infection assessed per m'2 at 500 mg/kg, po administered every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. |
| AID232888 | Ralative safety was expressed as Selective index (TC50/IC50) at HSV-1 passage 6 in vero cells | 1998 | Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16 | Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. |
| AID1869621 | Selectivity index, ratio of CC50 for cytotoxicity against human HFF cells infected with VZV Ellen virus assessed as reduction in cell viability by cell titer-glo assay to EC50 for antiviral activity against VZV Ellen infected in HFF cells assessed as inhi | 2022 | Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13 | Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound. |
| AID396936 | Antiviral activity against HSV1 assessed as reduction in plaque formation at 10 ug | |||
| AID1256243 | Antiviral activity against Herpes simplex virus 1 strain F VR-733 infected in African green monkey Vero cells after 3 days by MTT assay | 2015 | Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21 | Selenoacyclovir and Selenoganciclovir: Discovery of a New Template for Antiviral Agents. |
| AID217507 | In vitro antiviral activity against Varicella zoster virus | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Synthesis and antiviral activity of novel acyclic nucleoside analogues of 5-(1-azido-2-haloethyl)uracils. |
| AID444051 | Total clearance in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID64102 | Minimum inhibitory concentration (MIC) required to reduce VMW 1837 strain of TK-HSV-1 induced cytopathogenicity by 50% in E6SM cells | 1992 | Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8 | Synthesis and antiviral activity of acyclic nucleosides with a 3(S),5-dihydroxypentyl or 4(R)-methoxy-3(S),5-dihydroxypentyl side chain. |
| AID63609 | Tested for antiviral activity against vaccinia virus in human embryonic skin muscle fibroblast | 2002 | Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5 | New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation. |
| AID106007 | Tested for Antiherpetic activity against HSV-1 from Tomioka strain in MRC-5 cell lines. | 2000 | Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2 | Synthesis and antiviral activity of novel anti-VZV 5-substituted uracil nucleosides with a cyclopropane sugar moiety. |
| AID151172 | Minimum cytotoxic concentration that causes alterations of VZV infected Osteosarcoma cell morphology | 2003 | Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23 | Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine. |
| AID516967 | Antiviral activity against acyclovir-resistant HSV2 strain G infected in HEL assessed as reduction in virus-induce cytopathicity | 2010 | Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19 | Synthesis of ester prodrugs of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) as anti-poxvirus agents. |
| AID326129 | Inhibition of Herpes simplex virus 2 recombinant thymidine kinase | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides. |
| AID81055 | Concentration required to inhibit TK-VZV (07-1) induced cytopathogenicity in HEL cells by 50% | 1991 | Journal of medicinal chemistry, Aug, Volume: 34, Issue:8 | Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir. |
| AID540213 | Half life in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID216468 | Antiviral activity against Varicella-Zoster virus (thymidine kinase deficient) TK-(07/1) | 2004 | Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10 | Bicyclic anti-VZV nucleosides: thieno analogues bearing an alkylphenyl side chain have reduced antiviral activity. |
| AID84244 | Antiviral activity against HSV-1 cell line (concentration required to prevent viral cytopathic effect in half of primary rabbit kidney cell cultures) | 1988 | Journal of medicinal chemistry, Dec, Volume: 31, Issue:12 | Synthesis and antiherpetic activity of (+/-)-9-[[(Z)-2-(hydroxymethyl)cyclopropyl]methyl]guanine and related compounds. |
| AID676762 | Antiviral activity against HSV-1 infected in african green monkey Vero cells assessed as inhibition of viral replication at 50 uM treated 2 hrs after post infection by GFP reduction assay | 2012 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16 | Antiviral activity and synthesis of quaternized promazine derivatives against HSV-1. |
| AID1610164 | Antiviral activity against Herpes simplex virus 2 G infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis | 2019 | European journal of medicinal chemistry, Dec-15, Volume: 184 | Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives. |
| AID84242 | Minimum inhibitory concentration was determined against HSV-1 (TK-/TK+VMW1837) in E6SM cell culture | 2000 | Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4 | The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine. |
| AID277834 | Antiviral activity against HSV2 G | 2007 | Journal of natural products, Feb, Volume: 70, Issue:2 | Cinnamacrins A-C, cinnafragrin D, and cytostatic metabolites with alpha-glucosidase inhibitory activity from Cinnamosma macrocarpa. |
| AID634836 | Antiviral activity against Feline coronavirus infected in CrFK cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID217500 | In vitro minimum inhibitory concentration to inhibit VZV (YS)-induced cytopathogenicity in HEL cells by 50% | 1988 | Journal of medicinal chemistry, Jul, Volume: 31, Issue:7 | Synthesis and antiviral activity of novel N-substituted derivatives of acyclovir. |
| AID63604 | Tested for antiviral activity against VSV-virus in human embryonic skin muscle fibroblasts | 2002 | Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5 | New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation. |
| AID516964 | Cytotoxicity against HEL | 2010 | Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19 | Synthesis of ester prodrugs of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) as anti-poxvirus agents. |
| AID91288 | Antiviral activity against Varicella-Zoster virus (VV) in human foreskin cell cultures in virus plaque reduction assay at 32 uM | 1987 | Journal of medicinal chemistry, Nov, Volume: 30, Issue:11 | Synthesis and antiviral activity of carbocyclic analogues of xylofuranosides of 2-amino-6-substituted-purines and 2-amino-6-substituted-8-azapurines. |
| AID719255 | Antiviral activity against Herpes simplex virus type 1 infected in Vero cells at 0.01 ID50/cells assessed as protection against virus-induced cytopathic effect after 3 days by neutral red dye method | 2012 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24 | Synthesis of C3-arylated-3-deazauridine derivatives with potent anti-HSV-1 activities. |
| AID77651 | Mean of severity score obtained from five different individuals at 5% ACV | 1989 | Journal of medicinal chemistry, Jul, Volume: 32, Issue:7 | Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. |
| AID589395 | Antiviral activity against HSV2 by plaque reduction assay | 2011 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7 | Isatin-β-thiosemicarbazones as potent herpes simplex virus inhibitors. |
| AID774683 | Antiviral activity against Cytomegalovirus VR-538 infected in human MRC5 cells assessed as inhibition of virus-induced cytopathogenicity | 2013 | Bioorganic & medicinal chemistry, Sep-15, Volume: 21, Issue:18 | Synthesis and biological evaluation of furopyrimidine N,O-nucleosides. |
| AID224324 | Inhibitory effect on 196 strain of Herper simplex virus-2 yield, in primary rabbit kidney cell culture 4 ug/mL concentration after 24 hours. | 1987 | Journal of medicinal chemistry, Jun, Volume: 30, Issue:6 | Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases. |
| AID88973 | Concentration required to inhibit 50% of host cell replication in human hepatoma (2.2.15) cells used against HBV studies; not determined | 2000 | Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18 | Synthesis and biological evaluation of L- and D-configuration 1,3-dioxolane 5-azacytosine and 6-azathymine nucleosides. |
| AID82889 | Tested for inhibitory effect on DNA virus TK-VZV (07/1) in HEL cell line | 1993 | Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23 | Synthesis and antiviral activity of 5'-deoxypyrazofurin. |
| AID245958 | Cytotoxic concentration to inhibit replication in HFF cells in cytopathic effect inhibition assay | 2005 | Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1 | Nucleotides and pronucleotides of 2,2-bis(hydroxymethyl)methylenecyclopropane analogues of purine nucleosides: synthesis and antiviral activity. |
| AID45814 | Dose that inhibited 50% cell growth of human T-lymphoid CEM cells compared with untreated control | 2000 | Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13 | Structure-activity relationships of (E)-5-(2-bromovinyl)uracil and related pyrimidine nucleosides as antiviral agents for herpes viruses. |
| AID280180 | Antiviral activity against TK- VZV 07-1 in HEL cells assessed as inhibition of plaque formation | 2007 | Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5 | Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds. |
| AID210684 | Kinase activity against purified VZV Thymidine kinase (conversion of the nucleoside analogue to its monophosphate by VZV -TK ) | 1992 | Journal of medicinal chemistry, May-15, Volume: 35, Issue:10 | Synthesis and antiviral activity of 1-cyclobutyl-5-(2-bromovinyl)uracil nucleoside analogues and related compounds. |
| AID1382171 | Antiviral activity against Human simplex virus 1 KOS infected in HEL cells assessed as reduction in viral cytopathic effect | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Highly convergent synthesis and antiviral activity of (E)-but-2-enyl nucleoside phosphonoamidates. |
| AID332246 | Antiviral activity against HSV2 infected in human HeP2 ells | 2002 | Journal of natural products, Feb, Volume: 65, Issue:2 | Cytotoxic effect (on tumor cells) and in vitro antiviral activity against herpes simplex virus of synthetic spongiane diterpenes. |
| AID210686 | Catalytic turnover constant against HSV-1 thymidine kinase | 2003 | Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23 | Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine. |
| AID611625 | Cytotoxicity against human HEL cells assessed as growth inhibition after 3 days by coulter counter | 2011 | Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11 | New prodrugs of Adefovir and Cidofovir. |
| AID224200 | Inhibitory effect on 196 strain of Herper simplex virus-2 yield, in primary rabbit kidney cell culture 1 ug/mL concentration after 24 hours. | 1987 | Journal of medicinal chemistry, Jun, Volume: 30, Issue:6 | Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases. |
| AID106752 | Cytotoxicity indicative of 50% survival concentration in HSV-1-uninfected MT-4 cells. | 2002 | Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17 | Synthesis and biological evaluation of novel D-2'-azido-2',3'-dideoxyarabinofuranosyl-4'-thiopyrimidines and purines. |
| AID258991 | Antiviral activity against Varicella-Zoster virus YS/R strain | 2006 | Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1 | Synthesis and biological evaluation of 6-(alkyn-1-yl)furo[2,3-d]pyrimidin-2(3H)-one base and nucleoside derivatives. |
| AID218195 | Tested in vitro for minimum inhibitory concentration against herpes simplex virus-1 (HSV-1) 1142 strain by plaque-reduction assay in vero cells | 1993 | Journal of medicinal chemistry, May-28, Volume: 36, Issue:11 | 3-Quinolinecarboxamides. A series of novel orally-active antiherpetic agents. |
| AID607914 | Antiviral activity against Varicella-zoster virus OKA expressing thymidine kinase infected in human HEL cells assessed as reduction in the virus plaque formation | 2011 | Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14 | Design, synthesis and biological evaluation of 2'-deoxy-2',2'-difluoro-5-halouridine phosphoramidate ProTides. |
| AID697737 | Cytotoxicity against african green monkey Vero cells assessed as inhibition of cell viability after 48 hrs by MTT assay | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14 | Anti-herpes simplex virus efficacies of 2-aminobenzamide derivatives as novel HSP90 inhibitors. |
| AID665389 | Cytostatic against human HEL cells assessed as reduction in cell growth after 3 days by coulter counter | 2012 | European journal of medicinal chemistry, Jul, Volume: 53 | Synthesis and antiviral evaluation of C5-substituted-(1,3-diyne)-2'-deoxyuridines. |
| AID250785 | Effect on HSV-2 encephalitis in mice following intraperitoneal dosage at 25 mg/kg; expressed as mean day of death | 2005 | Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11 | Inhibition of herpes simplex virus thymidine kinases by 2-phenylamino-6-oxopurines and related compounds: structure-activity relationships and antiherpetic activity in vivo. |
| AID431630 | Cytotoxicity against HEL cells assessed as concentration required to cause alteration in cell alteration by microscopically | 2009 | Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17 | The application of phosphoramidate protide technology to acyclovir confers anti-HIV inhibition. |
| AID321395 | Antiviral activity against HSV1 KOS in african green monkey Vero cells by plaque reduction assay | 2008 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1 | Antiviral activities against herpes simplex virus type 1 by HPH derivatives and their structure-activity relationships. |
| AID561448 | Renal clearance in children and young patient with malignancy assessed per m'2 at 5 mg/kg, iv administered every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. |
| AID87812 | Antiviral activity against Herpes simplex virus type-2 (HSV-2). | 1999 | Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15 | Nucleosides and nucleotides. 185. Synthesis and biological activities of 4'alpha-C-branched-chain sugar pyrimidine nucleosides. |
| AID224191 | Inhibitory effect on 196 strain of Herper simplex virus-2 yield, in primary rabbit kidney cell culture 0.04 ug/mL concentration after 48 hours. | 1987 | Journal of medicinal chemistry, Jun, Volume: 30, Issue:6 | Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases. |
| AID106185 | Compound was tested for antiviral activity against Herpes Simplex virus Type-1(19407) in human lung fibroblasts (MRC-5) | 1987 | Journal of medicinal chemistry, Sep, Volume: 30, Issue:9 | Synthesis and antiviral activity of 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]purines. |
| AID521927 | AUC (0 to 12 hrs) in human CSF with chronic kidney disease at 1500 mg, po every 12 hrs measured after fifth dose by radioimmunoassay | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. |
| AID68271 | Concentration required to inhibit HSV-2(196) induced cytopathogenicity in ESM cells by 50% | 1991 | Journal of medicinal chemistry, Aug, Volume: 34, Issue:8 | Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir. |
| AID120293 | In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through at a dose 25 mg/kg per day | 1985 | Journal of medicinal chemistry, Nov, Volume: 28, Issue:11 | 5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue. |
| AID1610165 | Antiviral activity against Herpes simplex virus 1 TK-KOS-ACV infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis | 2019 | European journal of medicinal chemistry, Dec-15, Volume: 184 | Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives. |
| AID1450213 | Antiviral activity against HSV1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect | 2017 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11 | New modified 2-aminobenzimidazole nucleosides: Synthesis and evaluation of their activity against herpes simplex virus type 1. |
| AID1433150 | Antiviral activity against TK positive Varicella-zoster virus OKA infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis | 2015 | European journal of medicinal chemistry, Aug-28, Volume: 101 | Synthesis, antiplasmodial activity and mechanistic studies of pyrimidine-5-carbonitrile and quinoline hybrids. |
| AID224194 | Inhibitory effect on 196 strain of Herper simplex virus-2 yield, in primary rabbit kidney cell culture 0.4 ug/mL concentration after 24 hours. | 1987 | Journal of medicinal chemistry, Jun, Volume: 30, Issue:6 | Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases. |
| AID90952 | Cytotoxicity of compound was determined visually in human diploid fibroblasts (HFF). | 1992 | Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3 | Synthesis, antiproliferative, and antiviral activity of certain 4-aminopyrrolo[2,3-d]pyridazine nucleosides: an entry into a novel series of adenosine analogues. |
| AID82535 | Compound concentration required to reduce viability of HEL cells | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24 | Synthesis and antiviral evaluation of 3-hydroxy-2-methylpyridin-4-one dideoxynucleoside derivatives. |
| AID30873 | Antiherpes activity was tested as percent of control of plaque-formation against ACG (S1) virus by 5 uM of the compound | 1985 | Journal of medicinal chemistry, Jul, Volume: 28, Issue:7 | Synthesis and biological activities of 2-pyrimidinone nucleosides. 2. 5-Halo-2-pyrimidinone 2'-deoxyribonucleosides. |
| AID216464 | Effective concentration required for reduction of plaque formation of thymidine kinase deficient Varicella-Zoster Virus (YSR strain) | 2001 | Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3 | Bicyclic nucleoside inhibitors of Varicella-Zoster Virus (VZV): the effect of terminal unsaturation in the side chain. |
| AID540211 | Fraction unbound in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID246330 | Effective concentration required to inhibit herpes simplex virus 1 in HFF cells in cytopathic effect (CPE) assay | 2005 | Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1 | Nucleotides and pronucleotides of 2,2-bis(hydroxymethyl)methylenecyclopropane analogues of purine nucleosides: synthesis and antiviral activity. |
| AID444052 | Hepatic clearance in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID681795 | TP_TRANSPORTER: inhibition of PAH uptake (PAH: 2 uM, ACV: 1000 uM) in Xenopus laevis oocytes | 2000 | The Journal of pharmacology and experimental therapeutics, Sep, Volume: 294, Issue:3 | Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs. |
| AID383533 | Cytotoxicity against human HEL cells assessed as reduction of cell growth | 2008 | European journal of medicinal chemistry, Feb, Volume: 43, Issue:2 | Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents. |
| AID1303381 | Antiviral activity against Vaccinia virus Elstree infected in Vero 76 cells after 3 days by crystal violet staining based plaque reduction assay | 2016 | European journal of medicinal chemistry, Jul-19, Volume: 117 | A combined in silico/in vitro approach unveils common molecular requirements for efficient BVDV RdRp binding of linear aromatic N-polycyclic systems. |
| AID609577 | Antiviral activity against Human cytomegalovirus strain AD169 assessed as reduction of virus induced cytopathicity by cell based assay | 2011 | Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15 | Acyclic nucleoside phosphonates with a branched 2-(2-phosphonoethoxy)ethyl chain: efficient synthesis and antiviral activity. |
| AID303797 | Permeability across artificial membrane by PAMPA | 2007 | Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24 | Multiple N-methylation by a designed approach enhances receptor selectivity. |
| AID1431071 | Oral bioavailability in rat at 25 mg/kg by HPLC analysis | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Synthesis and pre-clinical studies of new amino-acid ester thiazolide prodrugs. |
| AID1394852 | Cytotoxicity against HEL cells assessed as alteration in cell morphology after 3 days by microscopic analysis | 2018 | European journal of medicinal chemistry, Apr-25, Volume: 150 | Synthesis and antiviral evaluation of cyclopentyl nucleoside phosphonates. |
| AID296675 | Antiviral activity against thymidine kinase deficient VZV YS/R in HEL cells assessed as reduction of virus plaque formation after 5 days | 2007 | Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16 | Synthesis and antiviral evaluation of 6-(alkyl-heteroaryl)furo[2,3-d]pyrimidin-2(3H)-one nucleosides and analogues with ethynyl, ethenyl, and ethyl spacers at C6 of the furopyrimidine core. |
| AID540212 | Mean residence time in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID383520 | Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human E6SM cells assessed as reduction of virus-induced cytopathogenicity | 2008 | European journal of medicinal chemistry, Feb, Volume: 43, Issue:2 | Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents. |
| AID217436 | Compound was tested for inhibition against herpes simplex virus (HSV-2) infected vero cells | 2000 | Bioorganic & medicinal chemistry letters, Apr-03, Volume: 10, Issue:7 | Synthesis and antiviral activity of acyclovir-5'-(phenyl methoxy alaninyl) phosphate as a possible membrane-soluble nucleotide prodrug. |
| AID697734 | Antiviral activity against HSV2 strain 333 infected in african green monkey Vero cells assessed as inhibition of cytopathic effect after 48 hrs by plaque reduction assay | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14 | Anti-herpes simplex virus efficacies of 2-aminobenzamide derivatives as novel HSP90 inhibitors. |
| AID1113469 | Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay | 2013 | Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4 | Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)- |
| AID625280 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID232894 | Ralative safety was expressed as Selective index (TC50/IC50) at HSV-2 passage 3 in vero cells | 1998 | Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16 | Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. |
| AID85423 | Minimal inhibitory concentration to reduce virus-induced cytopathicity against Lyons strain of human Herpes Simplex Virus-2 | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Fluorescent tricyclic analogues of acyclovir and ganciclovir. A structure-antiviral activity study. |
| AID431632 | Antiviral activity against HIV1 3B/Lai infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days | 2009 | Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17 | The application of phosphoramidate protide technology to acyclovir confers anti-HIV inhibition. |
| AID481442 | Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells | 2010 | Journal of medicinal chemistry, May-13, Volume: 53, Issue:9 | How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability? |
| AID245938 | Cytotoxic concentration required to inhibit herpes simplex virus 1 infected vero cells | 2005 | Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1 | Nucleotides and pronucleotides of 2,2-bis(hydroxymethyl)methylenecyclopropane analogues of purine nucleosides: synthesis and antiviral activity. |
| AID1251998 | Cytotoxicity against Varicella zoster virus infected HEL cells assessed as cell growth inhibition incubated for 3 days by coulter counter method | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Toward the discovery of dual HCMV-VZV inhibitors: Synthesis, structure activity relationship analysis, and cytotoxicity studies of long chained 2-uracil-3-yl-N-(4-phenoxyphenyl)acetamides. |
| AID324738 | Antiviral activity against TK- HSV2 MS in HFF cells after 72 hrs by plaque reduction assay | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase. |
| AID42132 | Cytotoxicity against Monkey kidney cells(BSC-1 cells) | 1989 | Journal of medicinal chemistry, Jul, Volume: 32, Issue:7 | Synthesis, cytotoxicity, and antiviral activity of certain 7-[(2-hydroxyethoxy)methyl]pyrrolo[2,3-d]pyrimidine nucleosides related to toyocamycin and sangivamycin. |
| AID697730 | Antiviral activity against HSV2 strain 333 infected in african green monkey Vero cells assessed as inhibition of cytopathic effect at 3.5 uM after 48 hrs by plaque reduction assay | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14 | Anti-herpes simplex virus efficacies of 2-aminobenzamide derivatives as novel HSP90 inhibitors. |
| AID498609 | Antiviral activity against HSV1 infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds. |
| AID1261825 | Antiviral activity against HSV-1 KOS ATCC VR- 1493 infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay | 2015 | European journal of medicinal chemistry, Nov-13, Volume: 105 | Synthesis, cytotoxicity and antiviral evaluation of new series of imidazo[4,5-g]quinoline and pyrido[2,3-g]quinoxalinone derivatives. |
| AID1410510 | Cytotoxicity against HEL cells assessed as morphological changes after 3 days by microscopic analysis | 2018 | ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4 | Amidate Prodrugs of Cyclic 9-( |
| AID217674 | Inhibitory concentration against VZV strain YS in human embryonic lung (HEL) cell culture | 1993 | Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14 | Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides. |
| AID1854969 | Antiviral activity against Human adenovirus 2 infected in HEL cells assessed as reduction in virus-induced cytopathic effect by microscopic analysis | 2022 | European journal of medicinal chemistry, Nov-05, Volume: 241 | Synthesis and antiviral properties of biomimetic iminosugar-based nucleosides. |
| AID1261308 | Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID67294 | In vitro minimum inhibitory concentration to inhibit EHV-1-induced cytopathogenicity in PRK cells by 50% | 1988 | Journal of medicinal chemistry, Jul, Volume: 31, Issue:7 | Synthesis and antiviral activity of novel N-substituted derivatives of acyclovir. |
| AID83534 | Minimum cytotoxic concentration against HEL cell morphology; ND denotes no data | 2002 | Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19 | Synthesis and antiviral/antiproliferative activity of some N-sulphonylbenzimidazoles. |
| AID1382169 | Selectivity index, ratio of CC50 for HEL cells to EC50 for Varicella zoster virus Oka infected in HEL cells | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Highly convergent synthesis and antiviral activity of (E)-but-2-enyl nucleoside phosphonoamidates. |
| AID1854966 | Antiviral activity against Varicella zoster-virus OKA strain harboring thymidine kinase infected in HEL cells assessed as reduction in plaque formation by microscopic analysis | 2022 | European journal of medicinal chemistry, Nov-05, Volume: 241 | Synthesis and antiviral properties of biomimetic iminosugar-based nucleosides. |
| AID246312 | Effective concentration required to reduce CMV davis strain virus plaque formation by 50% in HEL cell culture | 2004 | Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22 | 6-azapyrimidine-2'-deoxy-4'-thionucleosides: antiviral agents against TK+ and TK- HSV and VZV strains. |
| AID87187 | Inhibition of herpes simplex virus (HSV-1) in yield reduction assay | 1990 | Journal of medicinal chemistry, Jul, Volume: 33, Issue:7 | Synthesis, antiproliferative, and antiviral activity of certain 4-substituted and 4,5-disubstituted 7-[(1,3-dihydroxy-2-propoxy)methyl]pyrrolo[2,3-d]pyrimidines. |
| AID425653 | Renal clearance in human | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15 | Physicochemical determinants of human renal clearance. |
| AID561612 | Half life in children and young patient with malignancy at 5 mg/kg, iv administered every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. |
| AID64098 | Minimum inhibitory concentration (MIC) required to reduce G strain of HSV-2 induced cytopathogenicity by 50% in E6SM cells | 1992 | Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8 | Synthesis and antiviral activity of acyclic nucleosides with a 3(S),5-dihydroxypentyl or 4(R)-methoxy-3(S),5-dihydroxypentyl side chain. |
| AID1261309 | Cytotoxicity against MDBK cells assessed as cell viability after 48 to 96 hrs by MTT assay | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID376984 | Antiviral activity against HSV1 15577 in african green monkey Vero cells assessed as reduction of virus induced cytopathic effect | 2006 | Journal of natural products, May, Volume: 69, Issue:5 | Antiviral flavans from the leaves of Pithecellobium clypearia. |
| AID342116 | Antiviral activity against acyclovir-resistant and thymidine kinase deficient HSV1 KOS in HEL cells assessed as inhibition of virus induced cytopathicity within 48 hrs | 2008 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 18, Issue:15 | Successful kinase bypass with new acyclovir phosphoramidate prodrugs. |
| AID1593188 | Therapeutic index, ratio of CC50 of rhesus monkey FRhK cells to IC50 for antiviral activity against Hepatitis A virus infected in rhesus monkey FRhK4 cells assessed as inhibition in viral replication using cells pre-infected with virus before compound exp | 2019 | European journal of medicinal chemistry, Apr-15, Volume: 168 | New 4-phenylcoumarin derivatives as potent 3C protease inhibitors: Design, synthesis, anti-HAV effect and molecular modeling. |
| AID1886806 | Antiviral activity against ZIKV infected in African green monkey Vero E6 cells assessed as inhibition of plaque formation by measuring reduction in PFU per well incubated for 72 hrs by crystal violet staining based assay | 2022 | Journal of natural products, 08-26, Volume: 85, Issue:8 | Antiviral Profiling of C-18- or C-19-Functionalized Semisynthetic Abietane Diterpenoids. |
| AID1464793 | Anti-viral activity against Herpes simplex virus-1 harboring EGFP infected in iPSC-derived neurons assessed as viable cells at 50 mM treated 2 hrs post infection measured after 72 hrs by Alexa fluor 488 staining based flow cytometric analysis (Rvb = 17.8% | 2017 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 27, Issue:20 | Discovery of potent antiviral (HSV-1) quinazolinones and initial structure-activity relationship studies. |
| AID634748 | Antiviral activity against thymidine kinase-deficient acv-resistant Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID84606 | In vitro minimum inhibitory concentration to inhibit HSV-2 (196)-induced cytopathogenicity in PRK cells by 50% | 1988 | Journal of medicinal chemistry, Jul, Volume: 31, Issue:7 | Synthesis and antiviral activity of novel N-substituted derivatives of acyclovir. |
| AID1079932 | Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source] | |||
| AID425258 | fCmax in horse at 20 mg/kg, po administered as single dose | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID249057 | Cytotoxicity against MT-2 cell lines of human | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | Synthesis and antiviral activity of helioxanthin analogues. |
| AID1427831 | Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity | |||
| AID118721 | Number of mice normal, without lesion after HSV-1 infection observed from day 0 to day 3 | 1987 | Journal of medicinal chemistry, Jun, Volume: 30, Issue:6 | Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases. |
| AID79173 | Effect on the development of Herpetic vesicles in Guinea pigs infected intradermally with Herpes virus Hominis, Type 1,AA strain on day 4 at 5 % concentration | 1984 | Journal of medicinal chemistry, May, Volume: 27, Issue:5 | Synthesis of some phosphonates with antiherpetic activity. |
| AID1697848 | Antiviral activity against recombinant EGFP/RFP expressing Herpes simplex virus 1 KOS infected in iPSC-neurons assessed as decrease in proportion of fluorescent cells compound added 2 hr post infection incubated for 48 hrs by flow cytometry analysis | 2020 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24 | Synthesis of non-nucleoside anti-viral cyclopropylcarboxacyl hydrazones and initial anti-HSV-1 structure-activity relationship studies. |
| AID393979 | Antiviral activity against thymidine kinase expressing Varicella zoster virus Oka infected in human HEL cells assessed reduction in viral plaque formation | 2009 | Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6 | 4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus. |
| AID296678 | Cytotoxicity against HEL cells assessed as alteration in cell morphology after 3 days | 2007 | Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16 | Synthesis and antiviral evaluation of 6-(alkyl-heteroaryl)furo[2,3-d]pyrimidin-2(3H)-one nucleosides and analogues with ethynyl, ethenyl, and ethyl spacers at C6 of the furopyrimidine core. |
| AID87204 | Tested in vitro for antiviral activity against HSV-1 in yield reduction assay. | 1990 | Journal of medicinal chemistry, Dec, Volume: 33, Issue:12 | Arabinofuranosylpyrrolo[2,3-d]pyrimidines as potential agents for human cytomegalovirus infections. |
| AID216160 | Compound was tested for its antiviral activity against VZV(Ellen) using plaque reduction assay. | 1991 | Journal of medicinal chemistry, Jan, Volume: 34, Issue:1 | Synthesis and antiviral activity of 9-alkoxypurines. 2. 9-(2,3-Dihydroxypropoxy)-, 9-(3,4-dihydroxybutoxy)-, and 9-(1,4-dihydroxybut-2-oxy)purines. |
| AID431627 | Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity | 2009 | Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17 | The application of phosphoramidate protide technology to acyclovir confers anti-HIV inhibition. |
| AID111522 | Tested for the appearance of skin lesions or paralysis of the legs after 52 days when applied topically at 10% after 52 days | 1990 | Journal of medicinal chemistry, Sep, Volume: 33, Issue:9 | Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives. |
| AID1261314 | Antiviral activity against Reo-1 virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID250865 | Effect on HSV-1 encephalitis in mice following intraperitoneal dosage at 100 mg/kg; expressed as number of survivors/10 | 2005 | Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11 | Inhibition of herpes simplex virus thymidine kinases by 2-phenylamino-6-oxopurines and related compounds: structure-activity relationships and antiherpetic activity in vivo. |
| AID120302 | In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through oral route at a dose 2.5 mg/kg per day | 1985 | Journal of medicinal chemistry, Nov, Volume: 28, Issue:11 | 5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue. |
| AID675213 | Antiviral activity against thymidine kinase negative VZV YS/R infected in HEL cells by plaque formation assay | 2012 | European journal of medicinal chemistry, Sep, Volume: 55 | Synthesis and antiviral activities of hexadecyloxypropyl prodrugs of acyclic nucleoside phosphonates containing guanine or hypoxanthine and a (S)-HPMP or PEE acyclic moiety. |
| AID521926 | AUC (0 to 12 hrs) in human systemic circulation with chronic kidney disease at 1500 mg, po every 12 hrs measured after fifth dose by radioimmunoassay | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. |
| AID1219941 | Drug transport in human ENT in HEK cells in presence of 100 uM ENT inhibitor benzythioinosine | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3 | Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs. |
| AID303224 | Cytotoxicity against HEL cells assessed as cell growth after 3 days | 2007 | Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23 | Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity. |
| AID1576576 | Effective permeability of compound by PAMPA | 2019 | MedChemComm, Dec-01, Volume: 10, Issue:12 | Synthesis of new lophine-carbohydrate hybrids as cholinesterase inhibitors: cytotoxicity evaluation and molecular modeling. |
| AID304884 | Antiviral activity against TK- VZV 07 in HEL cells after 5 days | 2007 | Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26 | Synthesis and antiviral activity of the carbocyclic analogue of the highly potent and selective anti-VZV bicyclo furano pyrimidines. |
| AID1113467 | Antiviral activity against Vesicular stomatitis virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay | 2013 | Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4 | Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)- |
| AID217409 | Cytotoxic concentration to uninfected vero cells | 1998 | Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8 | Synthesis and antiviral activity of novel acyclic nucleosides: discovery of a cyclopropyl nucleoside with potent inhibitory activity against herpesviruses. |
| AID350210 | Antiviral activity against Hepatitis B virus | 2009 | Journal of medicinal chemistry, May-28, Volume: 52, Issue:10 | (Z)- and (E)-2-(1,2-dihydroxyethyl)methylenecyclopropane analogues of 2'-deoxyadenosine and 2'-deoxyguanosine. Synthesis of all stereoisomers, absolute configuration, and antiviral activity. |
| AID634750 | Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID378981 | Antiviral activity against HSV1 | 2006 | Journal of natural products, Jan, Volume: 69, Issue:1 | 2-substituted furans from the roots of Polyalthia evecta. |
| AID282657 | Inhibition of VZV replication in HFF cells by CPE assay | 2004 | Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27 | (Z)- and (E)-[2-Fluoro-2-(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines, a new class of methylenecyclopropane analogues of nucleosides: synthesis and antiviral activity. |
| AID516969 | Antiviral activity against acyclovir-resistant VZV 07/1 infected in HEL assessed as reduction in virus-induce cytopathicity | 2010 | Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19 | Synthesis of ester prodrugs of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) as anti-poxvirus agents. |
| AID1726782 | Selectivity index, ratio of CC50 of human HFF cells to EC50 of antiviral activity against VZV | 2021 | RSC medicinal chemistry, May-26, Volume: 12, Issue:5 | Introduction of a cyano group at the 2-position of an ( |
| AID1186340 | Antiviral activity against HSV1 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay | 2014 | Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17 | Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents. |
| AID412414 | Antiviral activity against acyclovir-sensitive HSV1 KOS isolate replication in african green monkey Vero cells by plaque reduction assay | 2009 | Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1 | Synthesis and in vitro activities of a new antiviral duplex drug linking Zidovudine (AZT) and Foscarnet (PFA) via an octadecylglycerol residue. |
| AID216163 | Tested for antiviral activity against VZV (YS) | 2001 | Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12 | The cyclohexene ring as bioisostere of a furanose ring: synthesis and antiviral activity of cyclohexenyl nucleosides. |
| AID156075 | PNP activity in human RBC | 1993 | Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8 | Nucleosides. 5. Synthesis of guanine and formycin B derivatives as potential inhibitors of purine nucleoside phosphorylase. |
| AID634760 | Antiviral activity against Vesicular stomatitis virus infected in human Hela cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID1869616 | Antiviral activity against HCMV AD-169 infected in HFF cells assessed as reduction in viral replication measured after 14 days | 2022 | Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13 | Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound. |
| AID55084 | Inhibitory activity against human cytomegalovirus determined by plaque reduction assay | 1988 | Journal of medicinal chemistry, Aug, Volume: 31, Issue:8 | Synthesis and antiviral activity of certain 4-substituted and 2,4-disubstituted 7-[(2-hydroxyethoxy)methyl]pyrrolo[2,3-d]pyrimidines. |
| AID85416 | In vitro antiviral activity against herpesvirus, HSV-2, X-79 strain by plaque reduction assay in human foreskin fibroblasts. | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5 | Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS. |
| AID284533 | Antiviral activity against HSV1 TK- KOS ACV-induced cytopathogenicity in E6SM cells | 2007 | Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2 | The novel C-5 aryl, alkenyl, and alkynyl substituted uracil derivatives of L-ascorbic acid: synthesis, cytostatic, and antiviral activity evaluations. |
| AID634837 | Antiviral activity against Human immunodeficiency virus 2 infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID1427854 | Antiviral activity against Herpes simplex virus-1 F VR 733 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect | |||
| AID82700 | Antiviral activity against human cytomegalovirus (HCMV) AD 169 strain HEL (human erythroleukemia) cells. | 1997 | Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14 | A facile, alternative synthesis of 4'-thioarabinonucleosides and their biological activities. |
| AID1661190 | Antiviral activity against thymidine kinase deficient Varicella zoster virus 07-1 infected in human HEL cells assessed as reduction in plaque formation measured after 5 days | 2020 | ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7 | Amidate Prodrugs of |
| AID284525 | Antiviral activity against HSV1 KOS-induced cytopathogenicity in E6SM cells | 2007 | Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2 | The novel C-5 aryl, alkenyl, and alkynyl substituted uracil derivatives of L-ascorbic acid: synthesis, cytostatic, and antiviral activity evaluations. |
| AID87480 | Compound was tested for antiviral activity against HSV-1 | 2002 | Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17 | Synthesis and biological evaluation of novel D-2'-azido-2',3'-dideoxyarabinofuranosyl-4'-thiopyrimidines and purines. |
| AID125368 | Inhibitory activity against Molt/4F cell line | 1990 | Journal of medicinal chemistry, Sep, Volume: 33, Issue:9 | Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives. |
| AID255994 | Antiviral activity against herpes simplex virus type 1 Patton (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO | 2005 | Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18 | 4-Oxo-4,7-dihydrothieno[2,3-b]pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases. |
| AID425246 | Free redistribution half life in horse at elimination phase at 10 mg/kg, iv after 1 hr by three-compartmental study | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID42115 | Cytotoxic activity against BSC cells | 1990 | Journal of medicinal chemistry, Jul, Volume: 33, Issue:7 | Synthesis, antiproliferative, and antiviral activity of certain 4-substituted and 4,5-disubstituted 7-[(1,3-dihydroxy-2-propoxy)methyl]pyrrolo[2,3-d]pyrimidines. |
| AID611618 | Antiviral activity against VZV OKA infected in HEL cells assessed as protection against virus-induced cytopathicity | 2011 | Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11 | New prodrugs of Adefovir and Cidofovir. |
| AID636696 | Antiviral activity against Vaccinia virus Copenhagen infected in HFF cells incubated for 3 days by plaque reduction assay | 2011 | Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16 | Tyrosine-based 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine and -adenine ((S)-HPMPC and (S)-HPMPA) prodrugs: synthesis, stability, antiviral activity, and in vivo transport studies. |
| AID510176 | Antiviral activity against parainfluenza-3 virus infected in Vero cells assessed as reduction of virus-induced cytopathic effect | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities. |
| AID67101 | Effective concentration for the inhibition of Epstein-Barr virus EBV-DNA synthesis in human lymphoblastoid P3HR-1 cells | 2002 | Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23 | CycloSal-BVDUMP pronucleotides: how to convert an antiviral-inactive nucleoside analogue into a bioactive compound against EBV. |
| AID82558 | Antiviral activity was measured as effective concentration required to reduce thymidine kinase-deficient. Varicella Zoster virus (07/1)-induced plaque formation in human embryonic lung cells | 2001 | Bioorganic & medicinal chemistry letters, Sep-17, Volume: 11, Issue:18 | Bicyclic anti-VZV nucleosides: Thieno analogues retain full antiviral activity. |
| AID431635 | Antiviral activity against HIV1 3B/Lai infected in human MT4 cells assessed as suppression of p24 production after 3 days | 2009 | Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17 | The application of phosphoramidate protide technology to acyclovir confers anti-HIV inhibition. |
| AID1857463 | Elimination half life in human | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Treatment Option for Acyclovir-Resistant Herpes Simplex Virus Infections. |
| AID63766 | The minimum inhibitory concentration was measured on E6SM cells against Vaccinia virus | 1994 | Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19 | Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity. |
| AID87032 | Minimum inhibitory concentration against Herpes simplex Virus-2(Lyons) | 2002 | Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23 | Synthesis and biological activity of strongly fluorescent tricyclic analogues of acyclovir and ganciclovir. |
| AID246328 | Effective concentration to inhibit 50% of hepatitis B virus replication in a cell culture model | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | Synthesis and antiviral activity of helioxanthin analogues. |
| AID1237435 | Cytotoxicity against mock-infected human HuH7 cells assessed as inhibition of cell survival after 2 days by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 | Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity. |
| AID412417 | Antiviral activity against acyclovir-resistant HSV1 K143 isolate replication in african green monkey Vero cells by plaque reduction assay | 2009 | Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1 | Synthesis and in vitro activities of a new antiviral duplex drug linking Zidovudine (AZT) and Foscarnet (PFA) via an octadecylglycerol residue. |
| AID257896 | Antiviral activity against Sindbis virus in vero cells | 2006 | Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2 | Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators. |
| AID288917 | Antiviral activity against HSV2 G in E6SM cells assessed as reduction of virus-induced cytopathogenicity | 2007 | Journal of medicinal chemistry, Jun-14, Volume: 50, Issue:12 | 5-alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells. |
| AID625286 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID106190 | Compound was tested for antiviral activity against Herpes Simplex virus Type-2(MS) in human lung fibroblasts (MRC-5) | 1987 | Journal of medicinal chemistry, Sep, Volume: 30, Issue:9 | Synthesis and antiviral activity of 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]purines. |
| AID1857466 | Oral bioavailability in dog | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Treatment Option for Acyclovir-Resistant Herpes Simplex Virus Infections. |
| AID1211769 | Tmax in wild type mouse treated with 25 nmol/g, po of valacyclovir | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3 | Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice. |
| AID561618 | Clearance in immunocompromized children at 250 mg/kg, po administered every 12 hrs | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. |
| AID1204083 | Antiviral activity against HSV1 infected in African green monkey Vero 76 cells after 3 days by plaque reduction assay | 2015 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11 | N-((1,3-Diphenyl-1H-pyrazol-4-yl)methyl)anilines: A novel class of anti-RSV agents. |
| AID224190 | Inhibitory effect on 196 strain of Herper simplex virus-2 yield, in primary rabbit kidney cell culture 0.04 ug/mL concentration after 24 hours. | 1987 | Journal of medicinal chemistry, Jun, Volume: 30, Issue:6 | Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases. |
| AID697723 | Antiviral activity against HSV1 infected herpes simplex keratitis New zealand rabbit model assessed as reduction in viral DNA level in corneal sample at 0.025% to 0.1% administered twice daily as gel 24 hrs post inoculation measured on day 9 post infectio | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14 | Anti-herpes simplex virus efficacies of 2-aminobenzamide derivatives as novel HSP90 inhibitors. |
| AID1462035 | Antiviral activity against wild type thymidine kinase-deficient Varicella-Zoster virus 07-1 infected in HEL cells assessed as inhibition of virus-induced plaque formation | 2017 | Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17 | New prodrugs of two pyrimidine acyclic nucleoside phosphonates: Synthesis and antiviral activity. |
| AID464100 | Antiviral activity against Varicella zoster virus infected in HFF cells by plaque reduction assay | 2010 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 20, Issue:6 | The design and development of 2-aryl-2-hydroxy ethylamine substituted 1H,7H-pyrido[1,2,3-de]quinoxaline-6-carboxamides as inhibitors of human cytomegalovirus polymerase. |
| AID404022 | Antiviral activity against influenza A virus infected in MDCK cells | 2005 | Journal of natural products, Dec, Volume: 68, Issue:12 | Antiviral Terpenoid Constituents of Ganoderma pfeifferi. |
| AID1391449 | Antiviral activity against Herpes simplex virus-1 strain F infected in African green monkey Vero cells assessed as late protein gb level at 50 ug/ml after 48 hrs by immunostaining based luminescent microscopic method (Rvb = 95.6%) | 2018 | Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9 | DNA sequence-specific ligands. XVII. Synthesis, spectral properties, virological and biochemical studies of fluorescent dimeric bisbenzimidazoles DBA(n). |
| AID85433 | Compound was tested for the inhibition of HSV-1 polymerase | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Enzymatic phosphorylation of the antiherpetic agent 9-[(2,3-dihydroxy-1-propoxy)methyl]guanine. |
| AID1410509 | Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 6 to 7 days post-infection | 2018 | ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4 | Amidate Prodrugs of Cyclic 9-( |
| AID209538 | Inhibitory concentration against TK-VZV strain 07-1 in human embryonic lung (HEL) cell culture | 1993 | Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14 | Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides. |
| AID578852 | Cytotoxicity against african green monkey Vero cells after 72 hrs by XTT assay | 2011 | Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6 | Synthesis and anti-HSV-1 activity of new 1,2,3-triazole derivatives. |
| AID1457769 | Cytotoxic activity against HEL cells assessed as alteration of cell morphology after 3 days by microscopic method | 2017 | Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14 | Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs. |
| AID17091 | Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10 | 1985 | Journal of medicinal chemistry, Jul, Volume: 28, Issue:7 | Synthesis and antiherpetic activity of (S)-, (R)-, and (+/-)-9-[(2,3-dihydroxy-1-propoxy)methyl]guanine, linear isomers of 2'-nor-2'-deoxyguanosine. |
| AID217499 | In vitro minimum inhibitory concentration to inhibit VZV (Oka)-induced cytopathogenicity in HEL cells by 50% | 1988 | Journal of medicinal chemistry, Jul, Volume: 31, Issue:7 | Synthesis and antiviral activity of novel N-substituted derivatives of acyclovir. |
| AID83712 | Tested for anti-viral activity against Herpes simplex virus type-1 using ELISA. | 1994 | Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18 | Benzimidazole ribonucleosides: design, synthesis, and antiviral activity of certain 2-(alkylthio)- and 2-(benzylthio)-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazoles. |
| AID217605 | Comparative Potency (IC50s) at HSV-1 passage 9 in vero cells | 1998 | Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16 | Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. |
| AID393993 | Antiviral activity against wild type HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity | 2009 | Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6 | 4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus. |
| AID83415 | Concentration required to inhibit 50% of HIV-IIIB virus replication; not determined | 2000 | Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18 | Synthesis and biological evaluation of L- and D-configuration 1,3-dioxolane 5-azacytosine and 6-azathymine nucleosides. |
| AID1402828 | Antiviral activity against HSV2 strain G infected in HEL cells assessed as reduction in virus-induced cytopathic effect after 2 to 3 days | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Emimycin and its nucleoside derivatives: Synthesis and antiviral activity. |
| AID1303375 | Antiviral activity against Reovirus type-1 3651 infected in BHK21 cells assessed as inhibition of virus induced cytopathogenicity after 3 to 4 days by MTT assay | 2016 | European journal of medicinal chemistry, Jul-19, Volume: 117 | A combined in silico/in vitro approach unveils common molecular requirements for efficient BVDV RdRp binding of linear aromatic N-polycyclic systems. |
| AID299443 | Antiviral activity against HSV1 in human foreskin fibroblast assessed as inhibition of virus plaque formation | 2007 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14 | 7-Oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamides: synthesis and biological activity of a new class of highly potent inhibitors of human cytomegalovirus DNA polymerase. |
| AID216038 | Inhibitory activity against herpes simplex virus type 1 (HSV-1) strain SC16 in Vero cells. | 1996 | Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3 | Synthesis and anti-herpes virus activity of 2'-deoxy-4'-thiopyrimidine nucleosides. |
| AID217407 | Compound was tested for cytotoxic activity uninfected vero cells | 2000 | Bioorganic & medicinal chemistry letters, Apr-03, Volume: 10, Issue:7 | Synthesis and antiviral activity of acyclovir-5'-(phenyl methoxy alaninyl) phosphate as a possible membrane-soluble nucleotide prodrug. |
| AID232891 | Ralative safety was expressed as Selective index (TC50/IC50) at HSV-1 passage 9 in vero cells | 1998 | Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16 | Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. |
| AID444054 | Oral bioavailability in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID561620 | Volume of distribution in immunocompromized children at 250 mg/kg, po administered every 12 hrs | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. |
| AID1382172 | Antiviral activity against thymidine kinase deficient acyclovir-resistant Human simplex virus 1 KOS infected in HEL cells assessed as reduction in viral cytopathic effect | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Highly convergent synthesis and antiviral activity of (E)-but-2-enyl nucleoside phosphonoamidates. |
| AID41529 | Effective concentration was evaluated against HSV-2 by using serum starved baby hamster kidney cells in a colorimetric viral yield assay. | 1996 | Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21 | Peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase with improved in vivo antiviral activity. |
| AID634749 | Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID1726779 | Cytotoxicity against human HFF cells assessed as reduction in cell viability incubated for 14 days by cell titer glo assay | 2021 | RSC medicinal chemistry, May-26, Volume: 12, Issue:5 | Introduction of a cyano group at the 2-position of an ( |
| AID106225 | Tested for inhibitory effect on RNA virus cell growth in MT-4 cell line | 1993 | Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23 | Synthesis and antiviral activity of 5'-deoxypyrazofurin. |
| AID580303 | Cytotoxicity against african green monkey Vero cells by MTT assay | 2011 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6 | Synthesis and in vitro anti-HSV-1 activity of a novel Hsp90 inhibitor BJ-B11. |
| AID275086 | Antiviral activity against HSV1 KOS in HEL cells | 2006 | Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26 | Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine. |
| AID84085 | Minimum inhibitory concentration was determined against HSV-1 (F) in E6SM cell culture | 2000 | Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4 | The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine. |
| AID1872793 | Antiviral activity against VZV strain Oka bearing wild type thymidine kinase assessed as reduction in virus induced cytopathogenicity | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Recent applications of vinyl sulfone motif in drug design and discovery. |
| AID609581 | Cytotoxicity against human HEL cells after 3 days by coulter counter | 2011 | Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15 | Acyclic nucleoside phosphonates with a branched 2-(2-phosphonoethoxy)ethyl chain: efficient synthesis and antiviral activity. |
| AID1382174 | Antiviral activity against Vaccinia virus infected in HEL cells assessed as reduction in viral cytopathic effect | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Highly convergent synthesis and antiviral activity of (E)-but-2-enyl nucleoside phosphonoamidates. |
| AID286285 | Cytotoxicity against Kaposi's sarcoma-associated herpesvirus infected BC3 cells after 120 hrs by MTT assay | 2007 | Journal of medicinal chemistry, May-03, Volume: 50, Issue:9 | 9-(2-C-Cyano-2-deoxy-beta-D-arabino-pentofuranosyl)guanine, a potential antitumor agent against B-lymphoma infected with Kaposi's sarcoma-associated herpesvirus. |
| AID87029 | Minimum inhibitory concentration against Herpes simplex Virus-2(196) | 2002 | Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23 | Synthesis and biological activity of strongly fluorescent tricyclic analogues of acyclovir and ganciclovir. |
| AID1219946 | Drug transport in human OAT1 expressed in HEK Flp-In cells | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3 | Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs. |
| AID1256247 | Cytotoxicity against human HEL299 cells after 3 days by MTT assay | 2015 | Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21 | Selenoacyclovir and Selenoganciclovir: Discovery of a New Template for Antiviral Agents. |
| AID81042 | Minimum cytotoxic concentration required to alter microscopically detectable HEL cell morphology | 2001 | Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3 | Bicyclic nucleoside inhibitors of Varicella-Zoster Virus (VZV): the effect of terminal unsaturation in the side chain. |
| AID1462037 | Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus-induced cytopathic effect | 2017 | Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17 | New prodrugs of two pyrimidine acyclic nucleoside phosphonates: Synthesis and antiviral activity. |
| AID434311 | Antiviral activity against acyclovir-resistant thymidine kinase-deficient HSV1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity | 2009 | European journal of medicinal chemistry, Sep, Volume: 44, Issue:9 | Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide. |
| AID388919 | Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07/1 in HEL cells assessed as inhibition of viral cytopathicity | 2008 | Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21 | Influence of 6- or 8-substitution on the antiviral activity of 3-arylalkylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (CMV) and varicella-zoster virus (VZV): part II. |
| AID54955 | Effective concentration required against HCMV strain for antiviral activity; Not determined | 2001 | Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12 | The cyclohexene ring as bioisostere of a furanose ring: synthesis and antiviral activity of cyclohexenyl nucleosides. |
| AID1884106 | Antiviral activity against HSV-2 infected in African green monkey Vero cells assessed as inhibition of viral replication by measuring log suppression of virus-induced cytopathic effect at 1 uM incubated for 1 hr followed by washing with PBS and subsequent | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Synthetic derivatives of the antifungal drug ciclopirox are active against herpes simplex virus 2. |
| AID304882 | Antiviral activity against TK+ VZV OKA in HEL cells after 5 days | 2007 | Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26 | Synthesis and antiviral activity of the carbocyclic analogue of the highly potent and selective anti-VZV bicyclo furano pyrimidines. |
| AID84217 | Inhibitory activity against HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle | 2002 | Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25 | A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity. |
| AID625288 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID625287 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1394849 | Antiviral activity against thymidine kinase-deficient ACV-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of plaque formation measured after 2 to 3 days post infection | 2018 | European journal of medicinal chemistry, Apr-25, Volume: 150 | Synthesis and antiviral evaluation of cyclopentyl nucleoside phosphonates. |
| AID83196 | Minimum inhibitory concentration required for antiviral activity to reduce Cytomegalovirus (CMV) (AD-169) induced cytopathicity in human embryonic lung cells (HEL) | 1994 | Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9 | Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues. |
| AID85403 | Antiviral activity against HSV-1 kinase mutant resistant to B3(BVdU) was determined at a conc of 50 uM | 1987 | Journal of medicinal chemistry, Nov, Volume: 30, Issue:11 | Acetylenic nucleosides. 4. 1-beta-D-arabinofuranosyl-5-ethynylcytosine. Improved synthesis and evaluation of biochemical and antiviral properties. |
| AID217645 | Antiviral activity against Varicella zoster virus (Ito strain) | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID91311 | Cytotoxic activity against HFF cells. | 1990 | Journal of medicinal chemistry, Jul, Volume: 33, Issue:7 | Synthesis, antiproliferative, and antiviral activity of certain 4-substituted and 4,5-disubstituted 7-[(1,3-dihydroxy-2-propoxy)methyl]pyrrolo[2,3-d]pyrimidines. |
| AID561611 | Volume of distribution in children and young patient with malignancy at 10 mg/kg, po administered every 12 hrs | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. |
| AID81068 | Cytotoxicity against HIV-1 (human immunodeficiency virus type 1); Not determined | 1999 | Bioorganic & medicinal chemistry letters, Feb-08, Volume: 9, Issue:3 | Nucleosides and nucleotides. 183. Synthesis of 4'alpha-branched thymidines as a new type of antiviral agent. |
| AID324740 | Antiviral activity against Varicella-Zoster virus Ellen in HFF cells after 10 days by plaque reduction assay | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase. |
| AID137471 | Number of survivors against Herpes simplex virus type-1 infection in mice at 25 mg/kg/day | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID1651495 | Antiviral activity against ACV-resistant Herpes simplex virus 1 AR-29 infected in male Balb/c mouse assessed as reduction in ulcerated lesion at 50 mg/g applied topically as cream formulation 5 times a day at 3 hrs interval for 10 days measured on day 5 p | |||
| AID687666 | Cytotoxicity against HEL assessed as minimum compound concentration causes microscopically detectable alteration of cell morphology after 3 days | 2012 | European journal of medicinal chemistry, Nov, Volume: 57 | Synthesis and antiviral evaluation of bis(POM) prodrugs of (E)-[4'-phosphono-but-2'-en-1'-yl]purine nucleosides. |
| AID1261326 | Antiviral activity against DENV-2 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID675216 | Antiviral activity against thymidine kinase negative and ACV resistant HSV1 KOS infected in HEL cells by viral CPE assay | 2012 | European journal of medicinal chemistry, Sep, Volume: 55 | Synthesis and antiviral activities of hexadecyloxypropyl prodrugs of acyclic nucleoside phosphonates containing guanine or hypoxanthine and a (S)-HPMP or PEE acyclic moiety. |
| AID412421 | Antiviral activity against ganciclovir-resistant HCMV3 isolate replication in HFF cells by plaque reduction assay | 2009 | Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1 | Synthesis and in vitro activities of a new antiviral duplex drug linking Zidovudine (AZT) and Foscarnet (PFA) via an octadecylglycerol residue. |
| AID326134 | Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides. |
| AID28234 | % absorbed in human GI-tract | 2001 | Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6 | High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. |
| AID1572735 | Antiviral activity against Human cytomegalovirus AD169 assessed as reduction in virus-induced cytopathogenicity by microscopic analysis | 2019 | Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6 | Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives. |
| AID607912 | Cytotoxicity against cat CRFK cells by colorimetric formazan-based MTS assay | 2011 | Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14 | Design, synthesis and biological evaluation of 2'-deoxy-2',2'-difluoro-5-halouridine phosphoramidate ProTides. |
| AID82698 | Antiviral activity against herpes simplex virus-1 VR-3 strain in HEL (human erythroleukemia) cells. | 1997 | Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14 | A facile, alternative synthesis of 4'-thioarabinonucleosides and their biological activities. |
| AID65708 | Antiviral activity against herpes simplex virus-1 KOS (HSV-1) in E6SM cell cultures | 2001 | Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16 | Design, synthesis, DNA binding, and biological evaluation of water-soluble hybrid molecules containing two pyrazole analogues of the alkylating cyclopropylpyrroloindole (CPI) subunit of the antitumor agent CC-1065 and polypyrrole minor groove binders. |
| AID675220 | Antiviral activity against Vaccinia virus Lederie infected in HEL cells by viral CPE assay | 2012 | European journal of medicinal chemistry, Sep, Volume: 55 | Synthesis and antiviral activities of hexadecyloxypropyl prodrugs of acyclic nucleoside phosphonates containing guanine or hypoxanthine and a (S)-HPMP or PEE acyclic moiety. |
| AID1773424 | Antiviral activity against Human herpesvirus-1 MacIntyre infected in A549 cells assessed as inhibition of viral adsorption at early stage of replication treated for 1 hr during viral infection followed by replacement with fresh medium and measured after 4 | 2021 | European journal of medicinal chemistry, Dec-05, Volume: 225 | Novel betulin dicarboxylic acid ester derivatives as potent antiviral agents: Design, synthesis, biological evaluation, structure-activity relationship and in-silico study. |
| AID1818211 | Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 3 days by MTT assay | |||
| AID1407614 | Antiviral activity against Vaccinia virus Lederle infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Synthesis of a 3'-C-ethynyl-β-d-ribofuranose purine nucleoside library: Discovery of C7-deazapurine analogs as potent antiproliferative nucleosides. |
| AID81188 | Concentration required to inhibit VZV (YS) induced cytopathogenicity in HEL cells by 50% | 1991 | Journal of medicinal chemistry, Aug, Volume: 34, Issue:8 | Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir. |
| AID1684817 | Antiviral activity against thymidine kinase positive Varicella zoster virus OKA infected in human HEL cells assessed as reduction in virus plaque formation measured on day 5 post-viral infection | 2021 | ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1 | Influence of 4'-Substitution on the Activity of Gemcitabine and Its ProTide Against VZV and SARS-CoV-2. |
| AID563744 | Antiviral activity against HSV2 MS infected in HFF after 3 days by plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides. |
| AID84772 | Concentration required to inhibit 50% of HSV-2 replication | 2000 | Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18 | Synthesis and biological evaluation of L- and D-configuration 1,3-dioxolane 5-azacytosine and 6-azathymine nucleosides. |
| AID1636356 | Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA | 2016 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16 | Development of a cell viability assay to assess drug metabolite structure-toxicity relationships. |
| AID425264 | fAUC in horse at 20 mg/kg, po administered as single dose | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID682756 | Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for HSV-2G ATCC 734 by plaque reduction assay | 2012 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19 | Structure based molecular design, synthesis and biological evaluation of α-pyrone analogs as anti-HSV agent. |
| AID1667302 | Selectivity index, ratio of CC50 for cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTT assay to EC50 for antiviral activity against Herpes simplex virus 1 infected in African green mo | 2020 | Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7 | DNA sequence-specific ligands. XVIII. Synthesis, physico-chemical properties; genetic, virological, and biochemical studies of fluorescent dimeric bisbenzimidazoles DBPA(n). |
| AID110458 | Cumulative mortality in percent of HSV-1 infected mice, after intraperitoneal administration of 25 mg/kg | 1988 | Journal of medicinal chemistry, Sep, Volume: 31, Issue:9 | Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity. |
| AID83724 | In Vitro antiviral activity against HSV-1 at 500 ug/mL concentration | 1994 | Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19 | Synthesis of new acyclic pyrimidine nucleoside analogs as potential antiviral drugs. |
| AID1773421 | Selectivity index, ratio of CC50 for cytotoxicity against human A549 cells to EC50 for antiviral activity against Enterovirus E LCR-4 infected in A549 cells | 2021 | European journal of medicinal chemistry, Dec-05, Volume: 225 | Novel betulin dicarboxylic acid ester derivatives as potent antiviral agents: Design, synthesis, biological evaluation, structure-activity relationship and in-silico study. |
| AID749442 | Antiviral activity against Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis | 2013 | European journal of medicinal chemistry, May, Volume: 63 | Ester prodrugs of acyclic nucleoside thiophosphonates compared to phosphonates: synthesis, antiviral activity and decomposition study. |
| AID431634 | Cytotoxicity against human MT4 cells assessed as inhibition of cell proliferation | 2009 | Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17 | The application of phosphoramidate protide technology to acyclovir confers anti-HIV inhibition. |
| AID91284 | Antiviral activity against Varicella-Zoster virus (VV) in human foreskin cell cultures in virus plaque reduction assay at 1000 uM | 1987 | Journal of medicinal chemistry, Nov, Volume: 30, Issue:11 | Synthesis and antiviral activity of carbocyclic analogues of xylofuranosides of 2-amino-6-substituted-purines and 2-amino-6-substituted-8-azapurines. |
| AID383511 | Cytotoxicity against human HEL cells assessed as alteration of cell morphology | 2008 | European journal of medicinal chemistry, Feb, Volume: 43, Issue:2 | Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents. |
| AID1055503 | Antiviral activity against acyclovir-resistant thymidine kinase-deficient Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity | 2013 | European journal of medicinal chemistry, , Volume: 70 | Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides. |
| AID434308 | Antiviral activity against Herpes simplex virus 2 infected in HEL cells assessed as protection against in virus-induced cytopathogenicity | 2009 | European journal of medicinal chemistry, Sep, Volume: 44, Issue:9 | Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide. |
| AID595592 | Selectivity index, ratio of CC50 for human HFF cells infected with Cowpox virus (Brighton Red) to EC50 for Cowpox virus (Brighton Red) | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | Broad-spectrum antiviral activity including human immunodeficiency and hepatitis C viruses mediated by a novel retinoid thiosemicarbazone derivative. |
| AID83040 | Minimal cytotoxic concentration required to alter microscopically detectable cell (of human embryonic lung cells (HEL)) morphology | 2001 | Bioorganic & medicinal chemistry letters, Sep-17, Volume: 11, Issue:18 | Bicyclic anti-VZV nucleosides: Thieno analogues retain full antiviral activity. |
| AID342114 | Antiviral activity against HSV1 KOS in HEL cells assessed as inhibition of virus induced cytopathicity within 48 hrs | 2008 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 18, Issue:15 | Successful kinase bypass with new acyclovir phosphoramidate prodrugs. |
| AID419652 | Cytotoxicity against HFF by neutral red uptake assay | 2009 | Bioorganic & medicinal chemistry, Jun-01, Volume: 17, Issue:11 | Phosphonate analogues of cyclopropavir phosphates and their E-isomers. Synthesis and antiviral activity. |
| AID68274 | Concentration required to inhibit TK-HSV-1 (B2006) induced cytopathogenicity in ESM cells by 50% | 1991 | Journal of medicinal chemistry, Aug, Volume: 34, Issue:8 | Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir. |
| AID1462032 | Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect | 2017 | Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17 | New prodrugs of two pyrimidine acyclic nucleoside phosphonates: Synthesis and antiviral activity. |
| AID1427833 | Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity | |||
| AID167877 | Antiviral Activity against herpes simplex virus-1 TK- B2006 in rabbit kidney cell | 1990 | Journal of medicinal chemistry, Sep, Volume: 33, Issue:9 | Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives. |
| AID1684810 | Selectivity index, ratio of CC50 for human HEL cells to EC50 for antiviral activity against thymidine kinase deficient Varicella zoster virus 07-1 infected in human HEL cells | 2021 | ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1 | Influence of 4'-Substitution on the Activity of Gemcitabine and Its ProTide Against VZV and SARS-CoV-2. |
| AID607919 | Cytotoxicity against human HEL cells by colorimetric formazan-based MTS assay | 2011 | Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14 | Design, synthesis and biological evaluation of 2'-deoxy-2',2'-difluoro-5-halouridine phosphoramidate ProTides. |
| AID1209457 | Unbound Cmax in human plasma | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1 | In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. |
| AID1079943 | Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source] | |||
| AID87348 | In vitro antiviral activity of the compound, determined by plaque-reduction assay against thymidine kinase deficient Herpes simplex virus type 1, Z826 strain in Vero cells | 1989 | Journal of medicinal chemistry, Jul, Volume: 32, Issue:7 | Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. |
| AID540220 | Clearance in human after iv administration | 2005 | Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7 | Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. |
| AID118655 | Compound was evaluated in nu/nu mice infected with TK- HSV-1 (VMW-1837) to increase the mean survival time when applied topically at 10% after 52 days | 1990 | Journal of medicinal chemistry, Sep, Volume: 33, Issue:9 | Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives. |
| AID87188 | In vitro antiviral activity against Herpes simplex virus (HSV-1) was determined | 2002 | Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3 | 5-Bromo (or chloro)-6-azido-5,6-dihydro-2' -deoxyuridine and -thymidine derivatives with potent antiviral activity. |
| AID607909 | Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis | 2011 | Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14 | Design, synthesis and biological evaluation of 2'-deoxy-2',2'-difluoro-5-halouridine phosphoramidate ProTides. |
| AID1055686 | Oral bioavailability in human | 2013 | European journal of medicinal chemistry, , Volume: 70 | Novel water-soluble prodrugs of acyclovir cleavable by the dipeptidyl-peptidase IV (DPP IV/CD26) enzyme. |
| AID216479 | Antiviral activity was tested against TK- Varicella-Zoster virus YS/R which reduces virus plaque formation by 50% | 2002 | Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19 | Synthesis and antiviral/antiproliferative activity of some N-sulphonylbenzimidazoles. |
| AID255995 | Antiviral activity against herpes simplex virus type 1 Patton (BWr) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO | 2005 | Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18 | 4-Oxo-4,7-dihydrothieno[2,3-b]pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases. |
| AID425265 | Total oral bioavailability in horse at 20 mg/kg administered as single dose | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID85563 | In vitro minimum inhibitory concentration to inhibit thymidine deficient HSV-1 (B2006)-induced cytopathogenicity in PRK cells by 50% | 1988 | Journal of medicinal chemistry, Jul, Volume: 31, Issue:7 | Synthesis and antiviral activity of novel N-substituted derivatives of acyclovir. |
| AID299444 | Antiviral activity against VZV in human foreskin fibroblast assessed as inhibition of virus plaque formation | 2007 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14 | 7-Oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamides: synthesis and biological activity of a new class of highly potent inhibitors of human cytomegalovirus DNA polymerase. |
| AID256000 | Antiviral activity against human cytomegalovirus (Davis strain) grown on human foreskin fibroblast cells determined by reduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO | 2005 | Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18 | 4-Oxo-4,7-dihydrothieno[2,3-b]pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases. |
| AID409956 | Inhibition of mouse brain MAOB | 2008 | Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21 | Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. |
| AID83205 | Tested for antiviral activity against thymidine kinase wild type Varicella zoster virus in human embryonic lung fibroblast | 2002 | Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5 | New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation. |
| AID607915 | Antiviral activity against thymidine kinase-deficient Varicella-zoster virus 07-1 infected in human HEL cells assessed as reduction in the virus plaque formation | 2011 | Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14 | Design, synthesis and biological evaluation of 2'-deoxy-2',2'-difluoro-5-halouridine phosphoramidate ProTides. |
| AID340474 | Cytotoxicity against HFF cells after 3 days by neutral red dye uptake assay | 2008 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14 | Synthesis of 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamides with broad-spectrum human herpesvirus polymerase inhibition. |
| AID165906 | Tested for the inhibition of diffuse early antigen production assayed by immunofluorescent monoclonal antibody. | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5 | Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS. |
| AID719257 | Cytotoxicity against african green monkey Vero cells after 3 days by neutral red dye method | 2012 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24 | Synthesis of C3-arylated-3-deazauridine derivatives with potent anti-HSV-1 activities. |
| AID65862 | Antiviral activity in herpes simplex virus-2 (HSV-2) G strain in E6SM cell culture | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20 | Acyclic nucleotide analogs derived from 8-azapurines: synthesis and antiviral activity. |
| AID224340 | Inhibitory effect on KOS strain of Herper simplex virus-1 yield, in primary rabbit kidney cell culture at 1 ug/mL concentration after 24 hours | 1987 | Journal of medicinal chemistry, Jun, Volume: 30, Issue:6 | Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases. |
| AID376987 | Antiviral activity against influenza A virus H1N1 A/NWS/33 in human MDCK cells assessed as reduction of virus induced cytopathic effect | 2006 | Journal of natural products, May, Volume: 69, Issue:5 | Antiviral flavans from the leaves of Pithecellobium clypearia. |
| AID625277 | FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI | 2011 | Drug discovery today, Aug, Volume: 16, Issue:15-16 | FDA-approved drug labeling for the study of drug-induced liver injury. |
| AID498409 | Antiviral activity against Macacine herpesvirus 1 isolate MR4 infected in african green monkey Vero cells by plaque reduction assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds. |
| AID682751 | Cytotoxicity against african green monkey Vero cells after 2 days by MTT assay | 2012 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19 | Structure based molecular design, synthesis and biological evaluation of α-pyrone analogs as anti-HSV agent. |
| AID766699 | Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity | 2013 | European journal of medicinal chemistry, Sep, Volume: 67 | Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity. |
| AID1273993 | Antiviral activity against HHV-2 VR-734-G infected in African green monkey Vero cells assessed as maximal non toxic concentration causing reduction of viral titer after 72 hrs by crystal violet staining assay | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Anti-herpetic and anti-dengue activity of abietane ferruginol analogues synthesized from (+)-dehydroabietylamine. |
| AID105824 | Minimum inhibitory concentration required to reduce cytopathogenicity of Varicella Zoster Virus (VZV) in MRC-5 cells by 50%. | 1991 | Journal of medicinal chemistry, Sep, Volume: 34, Issue:9 | The synthesis and antiviral activity of some 4'-thio-2'-deoxy nucleoside analogues. |
| AID676763 | Antiviral activity against HSV-1 infected in african green monkey Vero cells assessed as inhibition of viral replication at 50 uM treated for 24 hrs measured 24 hrs after drug washout by GFP reduction assay | 2012 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16 | Antiviral activity and synthesis of quaternized promazine derivatives against HSV-1. |
| AID106200 | Antiviral activity determined by plaque reduction assay of HCMV (AD-169) in MRC-5 cells | 1991 | Journal of medicinal chemistry, Jul, Volume: 34, Issue:7 | A new class of acyclic phosphonate nucleotide analogues: phosphonate isosteres of acyclovir and ganciclovir monophosphates as antiviral agents. |
| AID64096 | Minimum inhibitory concentration (MIC) required to reduce B2006 strain of TK-HSV-1 induced cytopathogenicity by 50% in E6SM cells | 1992 | Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8 | Synthesis and antiviral activity of acyclic nucleosides with a 3(S),5-dihydroxypentyl or 4(R)-methoxy-3(S),5-dihydroxypentyl side chain. |
| AID563775 | Antiviral activity against HSV2 11680 harboring TK R223H mutant gene infected in HFF after 3 days by plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides. |
| AID675210 | Antiviral activity against thymidine kinase positive VZV YS infected in HEL cells by plaque formation assay | 2012 | European journal of medicinal chemistry, Sep, Volume: 55 | Synthesis and antiviral activities of hexadecyloxypropyl prodrugs of acyclic nucleoside phosphonates containing guanine or hypoxanthine and a (S)-HPMP or PEE acyclic moiety. |
| AID1407620 | Antiviral activity against Human cytomegalovirus Davis strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Synthesis of a 3'-C-ethynyl-β-d-ribofuranose purine nucleoside library: Discovery of C7-deazapurine analogs as potent antiproliferative nucleosides. |
| AID81359 | concentration required to reduce virus HCMV (AD-169)plaque formation by 50%; ND=No Data | 2000 | Journal of medicinal chemistry, Aug-24, Volume: 43, Issue:17 | Nonnucleoside human cytomegalovirus inhibitors: synthesis and antiviral evaluation of (chlorophenylmethyl)benzothiadiazine dioxide derivatives. |
| AID218423 | Anti viral activity against VZV(Ellen strain) in WI-38 cell monolayers. | 1992 | Journal of medicinal chemistry, May-15, Volume: 35, Issue:10 | Synthesis and antiviral activity of 1-cyclobutyl-5-(2-bromovinyl)uracil nucleoside analogues and related compounds. |
| AID224201 | Inhibitory effect on 196 strain of Herper simplex virus-2 yield, in primary rabbit kidney cell culture 1 ug/mL concentration after 48 hours. | 1987 | Journal of medicinal chemistry, Jun, Volume: 30, Issue:6 | Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases. |
| AID217501 | In vitro minimum inhibitory concentration to inhibit thymidine deficient VZV(7-1)-induced cytopathogenicity in PRK cells by 50% | 1988 | Journal of medicinal chemistry, Jul, Volume: 31, Issue:7 | Synthesis and antiviral activity of novel N-substituted derivatives of acyclovir. |
| AID719259 | Antiviral activity against Herpes simplex virus type 1 infected in Vero cells at 0.001 ID50/cells assessed as protection against virus-induced cytopathic effect after 3 days by neutral red dye method | 2012 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24 | Synthesis of C3-arylated-3-deazauridine derivatives with potent anti-HSV-1 activities. |
| AID83193 | Minimum inhibitory conc. for 50% inhibition of VZV (OKA) virus plaque formation in HEL cells | 1997 | Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9 | Carbocyclic oxetanocins lacking the C-3' methylene. |
| AID87777 | Inhibition of cytopathogenicity of herpes simplex type 2 virus(HSV-12(G) in Hela cell culture | 1995 | Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23 | Design, synthesis, and structure-activity relationship of novel dinucleotide analogs as agents against herpes and human immunodeficiency viruses. |
| AID376982 | Selectivity index, CC50 for human Hep2 cells to IC50 for RSV Long | 2006 | Journal of natural products, May, Volume: 69, Issue:5 | Antiviral flavans from the leaves of Pithecellobium clypearia. |
| AID83535 | Minimum cytotoxic concentration that causes a microscopically detectable alteration of cell morphology in human embryonic lung cells | 1999 | Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14 | Novel pyrimidine and purine derivatives of L-ascorbic acid: synthesis and biological evaluation. |
| AID1407612 | Antiviral activity against Human herpesvirus 2 G strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Synthesis of a 3'-C-ethynyl-β-d-ribofuranose purine nucleoside library: Discovery of C7-deazapurine analogs as potent antiproliferative nucleosides. |
| AID580314 | Antiviral activity against HSV1 infected in african green monkey Vero cells assessed as reduction of UL52 expression at 1 uM after up to 24 hrs by RT-PCR analysis | 2011 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6 | Synthesis and in vitro anti-HSV-1 activity of a novel Hsp90 inhibitor BJ-B11. |
| AID358239 | Antiviral activity against Herpes simplex virus 2 infected in african green monkey Vero cells assessed as ratio of the viral titers in absence to presence of drug after 48 hrs by end-point titration technique | 2001 | Journal of natural products, Oct, Volume: 64, Issue:10 | Structure-activity relationship of in vitro antiviral and cytotoxic activity of semisynthetic analogues of scopadulane diterpenes. |
| AID81026 | The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK+OKA strain | 1999 | Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14 | Novel pyrimidine and purine derivatives of L-ascorbic acid: synthesis and biological evaluation. |
| AID246561 | Effective concentration required to reduce TK+ (thymidine kinase deficient) VZV strain 07/1 virus plaque formation by 50% in HEL cell culture | 2004 | Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22 | 6-azapyrimidine-2'-deoxy-4'-thionucleosides: antiviral agents against TK+ and TK- HSV and VZV strains. |
| AID167744 | Antiviral Activity against herpes simplex virus-1 (F) in rabbit kidney cell | 1990 | Journal of medicinal chemistry, Sep, Volume: 33, Issue:9 | Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives. |
| AID1636357 | Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA | 2016 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16 | Development of a cell viability assay to assess drug metabolite structure-toxicity relationships. |
| AID291030 | Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07/1 assessed as reduction of plaque formation | 2007 | Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13 | Novel C-6 fluorinated acyclic side chain pyrimidine derivatives: synthesis, (1)H and (13)C NMR conformational studies, and antiviral and cytostatic evaluations. |
| AID1303376 | Cytotoxicity against mock-infected african green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay | 2016 | European journal of medicinal chemistry, Jul-19, Volume: 117 | A combined in silico/in vitro approach unveils common molecular requirements for efficient BVDV RdRp binding of linear aromatic N-polycyclic systems. |
| AID718735 | Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect | 2012 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 | Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities. |
| AID718736 | Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect | 2012 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 | Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities. |
| AID115767 | The compound was tested in vivo for the lowest dose(minimum effective dose) at which anti-herpetic activity was observed in terms of survival times of mice after po administration. | 1995 | Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14 | Cyclic variations of 3-quinolinecarboxamides and effects on antiherpetic activity. |
| AID1449628 | Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. |
| AID90597 | In vitro anti viral activity tested against HCMV(AD169) virus on MRC-5 cell monolayers; 20-25 | 1985 | Journal of medicinal chemistry, Jul, Volume: 28, Issue:7 | Synthesis and antiherpetic activity of (S)-, (R)-, and (+/-)-9-[(2,3-dihydroxy-1-propoxy)methyl]guanine, linear isomers of 2'-nor-2'-deoxyguanosine. |
| AID383515 | Antiviral activity against HSV2 G in human HEL cells assessed as reduction of virus-induced cytopathogenicity | 2008 | European journal of medicinal chemistry, Feb, Volume: 43, Issue:2 | Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents. |
| AID563743 | Cytotoxicity against HFF after 3 days by MTS assay | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides. |
| AID63947 | Tested for cytotoxic activity in human embryonic skin muscle fibroblast (E6SM) | 2002 | Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5 | New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation. |
| AID84935 | Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell monolayers of HSV-2 MS Vero cells by 50% | 2001 | Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21 | Synthesis and antiviral activity of novel 5-(1-cyanamido-2-haloethyl) and 5-(1-hydroxy(or methoxy)-2-azidoethyl) analogues of uracil nucleosides. |
| AID303214 | Antiviral activity against VZV 07-1 TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity | 2007 | Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23 | Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity. |
| AID1303377 | Antiviral activity against CVB-2 infected in Vero 76 cells after 3 days by crystal violet staining based plaque reduction assay | 2016 | European journal of medicinal chemistry, Jul-19, Volume: 117 | A combined in silico/in vitro approach unveils common molecular requirements for efficient BVDV RdRp binding of linear aromatic N-polycyclic systems. |
| AID1237439 | Cytotoxicity against mock-infected African green monkey Vero E6 cells assessed as inhibition of cell survival after 3 days by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 | Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity. |
| AID216470 | In vitro anti viral activity tested against VZV(KMcC) virus on MRC-5 cell monolayers; 1-2 | 1985 | Journal of medicinal chemistry, Jul, Volume: 28, Issue:7 | Synthesis and antiherpetic activity of (S)-, (R)-, and (+/-)-9-[(2,3-dihydroxy-1-propoxy)methyl]guanine, linear isomers of 2'-nor-2'-deoxyguanosine. |
| AID687667 | Cytotoxicity against HEL after 3 days | 2012 | European journal of medicinal chemistry, Nov, Volume: 57 | Synthesis and antiviral evaluation of bis(POM) prodrugs of (E)-[4'-phosphono-but-2'-en-1'-yl]purine nucleosides. |
| AID106922 | Concentration required to inhibit 50% of host cell replication in MT-2 cells used against HIV studies; not determined | 2000 | Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18 | Synthesis and biological evaluation of L- and D-configuration 1,3-dioxolane 5-azacytosine and 6-azathymine nucleosides. |
| AID521913 | Drug level in human CSF with chronic kidney disease at 1500 mg, po every 12 hrs measured after fifth dose by radioimmunoassay | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. |
| AID1079933 | Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is | |||
| AID136142 | Percentage survival of mice after intraperitoneal administration of compound at 100 mg/kg per day in experiment 1; survival/ tested =7/10 | 1989 | Journal of medicinal chemistry, Jul, Volume: 32, Issue:7 | Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. |
| AID1782672 | Antiviral activity against thymidine kinase positive Varicella zoster virus | 2021 | European journal of medicinal chemistry, Aug-05, Volume: 220 | Phenoxazine nucleoside derivatives with a multiple activity against RNA and DNA viruses. |
| AID689096 | Selectivity ratio of CC50 for african green monkey Vero cells to EC50 for acyclovir-resistant HSV1 L2 | 2012 | Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19 | Phosphoramidate derivatives of acyclovir: synthesis and antiviral activity in HIV-1 and HSV-1 models in vitro. |
| AID260766 | Cytotoxicity against Vero cells by MTT assay | 2006 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4 | Synthesis and anti-HSV-1 activity of quinolonic acyclovir analogues. |
| AID1337440 | Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation | 2016 | European journal of medicinal chemistry, Nov-29, Volume: 124 | Identification of an indol-based derivative as potent and selective varicella zoster virus (VZV) inhibitor. |
| AID232893 | Ralative safety was expressed as Selective index (TC50/IC50) at HSV-2 passage 2 in vero cells | 1998 | Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16 | Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. |
| AID1572731 | Antiviral activity against thymidine kinase deficient and aciclovir resistant herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity by microscopic analysis | 2019 | Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6 | Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives. |
| AID63720 | Concentration required to reduce the viral DNA in infected cells to 50% of untreated infected controls; ND means Not determined | 2001 | Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22 | Novel 5-vinyl pyrimidine nucleosides with potent anti-hepatitis B virus activity. |
| AID1402825 | Antiviral activity against TK-defecient VZV 07-1 infected in HEL cells assessed as reduction in plaque formation after 5 days | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Emimycin and its nucleoside derivatives: Synthesis and antiviral activity. |
| AID68273 | Concentration required to inhibit HSV-2(lyons) induced cytopathogenicity in ESM cells by 50% | 1991 | Journal of medicinal chemistry, Aug, Volume: 34, Issue:8 | Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir. |
| AID689103 | Antiviral activity against HIV1 pseudovirus infected in Jurkat cells coexpressing GFP assessed as viral growth inhibition up to 100 uM incubated for 2 to 8 hrs prior to infection measured after 48 hrs by flow cytofluorimetric analysis | 2012 | Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19 | Phosphoramidate derivatives of acyclovir: synthesis and antiviral activity in HIV-1 and HSV-1 models in vitro. |
| AID82545 | Cytotoxic concentration required to inhibit growth of human embryonic lung cells (HEL) | 2001 | Bioorganic & medicinal chemistry letters, Sep-17, Volume: 11, Issue:18 | Bicyclic anti-VZV nucleosides: Thieno analogues retain full antiviral activity. |
| AID86827 | Percentage of diphosphates (DP) in the second step of staggered assay mixture from step 1 was incubated with GMP kinase and crude extract of HSV-1 infected HeLa cells over night | 1988 | Journal of medicinal chemistry, Dec, Volume: 31, Issue:12 | Synthesis and antiherpetic activity of (+/-)-9-[[(Z)-2-(hydroxymethyl)cyclopropyl]methyl]guanine and related compounds. |
| AID80086 | Compound was evaluated for the antiviral activity against HCMV; Not determined | 1998 | Bioorganic & medicinal chemistry letters, Apr-07, Volume: 8, Issue:7 | Synthesis and antiviral activity of novel isodideoxy nucleosides with exocyclic methylene. |
| AID210518 | Ability (300 uM) to compete with 150 uM of [14C]ACV for binding sites on viral enzyme, Mac strain (HSV-1 TK) | 1985 | Journal of medicinal chemistry, Aug, Volume: 28, Issue:8 | Modifications on the heterocyclic base of acyclovir: syntheses and antiviral properties. |
| AID72044 | Inhibitory activity against FM3A/0 cell line | 1990 | Journal of medicinal chemistry, Sep, Volume: 33, Issue:9 | Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives. |
| AID642215 | Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by crystal violet staining | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Quinoline tricyclic derivatives. Design, synthesis and evaluation of the antiviral activity of three new classes of RNA-dependent RNA polymerase inhibitors. |
| AID218227 | Cytotoxicity concentration required to microscopically detectable alteration of cell morphology in Vero | 2000 | Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4 | The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine. |
| AID82422 | Tested in vitro for cytotoxicity against the normal human diploid cells (HFF cells). | 1990 | Journal of medicinal chemistry, Dec, Volume: 33, Issue:12 | Arabinofuranosylpyrrolo[2,3-d]pyrimidines as potential agents for human cytomegalovirus infections. |
| AID217652 | Minimum inhibitory concentration was determined against VZV (TK-YS/R) in HEL cells | 2000 | Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4 | The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine. |
| AID426929 | Antiviral activity against HSV1 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days | 2009 | Journal of natural products, Jun, Volume: 72, Issue:6 | 7-O-methylkaempferol and -quercetin glycosides from the whole plant of Nervilia fordii. |
| AID224334 | Inhibitory effect on KOS strain of Herper simplex virus-1 yield, in primary rabbit kidney cell culture 4 ug/mL concentration after 48 hours. | 1987 | Journal of medicinal chemistry, Jun, Volume: 30, Issue:6 | Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases. |
| AID86852 | Concentration required to inhibit 50% of Hepatitis B virus replication; not determined | 2000 | Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18 | Synthesis and biological evaluation of L- and D-configuration 1,3-dioxolane 5-azacytosine and 6-azathymine nucleosides. |
| AID217600 | Comparative Potency (IC50s) at HSV-1 passage 4 in vero cells | 1998 | Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16 | Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. |
| AID1079942 | Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source] | |||
| AID1219942 | Drug transport in human OAT2 expressed in HEK Flp-In cells assessed as maximal rate of transport measured per mg of protein | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3 | Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs. |
| AID1457766 | Antiviral activity against HCMV Davis strain infected in HEL cells assessed as inhibition of virus-induced cytopathic effect | 2017 | Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14 | Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs. |
| AID1422440 | Antiviral activity against acyclovir-resistant TK-defecient Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method | 2018 | Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21 | Synthesis, biological evaluation and molecular modeling of a novel series of fused 1,2,3-triazoles as potential anti-coronavirus agents. |
| AID1434779 | Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay | 2017 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4 | Anti-HSV-1, antioxidant and antifouling phenolic compounds from the deep-sea-derived fungus Aspergillus versicolor SCSIO 41502. |
| AID90616 | Concentration required to decrease the growth rate to 50% of control was evaluated against HCMV by using plaque reduction assay. | 1992 | Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3 | Synthesis, antiproliferative, and antiviral activity of certain 4-aminopyrrolo[2,3-d]pyridazine nucleosides: an entry into a novel series of adenosine analogues. |
| AID1407616 | Cytotoxicity against HELF cells after by Coulter counter method | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Synthesis of a 3'-C-ethynyl-β-d-ribofuranose purine nucleoside library: Discovery of C7-deazapurine analogs as potent antiproliferative nucleosides. |
| AID1462038 | Antiviral activity against Vaccinia virus Lederle infected in HEL cells assessed as inhibition of virus-induced cytopathic effect | 2017 | Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17 | New prodrugs of two pyrimidine acyclic nucleoside phosphonates: Synthesis and antiviral activity. |
| AID425261 | Total elimination half life in horse at 20 mg/kg, po administered as single dose | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. |
| AID235624 | Therapeutic index of compound maesured as ratio of ID50 for WI-38 cell growth inhibition / ID50 anti-VZV (strain Ellen) | 1992 | Journal of medicinal chemistry, May-15, Volume: 35, Issue:10 | Synthesis and antiviral activity of 1-cyclobutyl-5-(2-bromovinyl)uracil nucleoside analogues and related compounds. |
| AID246353 | Effective concentration required to inhibit Coxsackie B3 virus induced cytopathicity in vero cells; not determined | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | Synthesis and antiviral evaluation of cis-substituted cyclohexenyl and cyclohexanyl nucleosides. |
| AID297306 | Antiviral activity against thymidine kinase-positive VZV OKA in human HEL cells after 7 days | 2007 | Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17 | Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives. |
| AID332492 | Antiviral activity against HSV1 H29S in african green monkey Vero cells assessed as log reduction in viral titers after 0.001 multiple round of replication at 50 ug/ml after 72 hrs | 1994 | Journal of natural products, May, Volume: 57, Issue:5 | Comparison of the anti-herpes simplex virus activities of propolis and 3-methyl-but-2-enyl caffeate. |
| AID342118 | Antiviral activity against TK+ VZV OKA infected HEL cells assessed as reduction in virus plaque formation after 5 days | 2008 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 18, Issue:15 | Successful kinase bypass with new acyclovir phosphoramidate prodrugs. |
| AID82245 | Concentration for HSV-2 plaque reduction (VPR) by 50% in HFF cells | 2003 | Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23 | Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine. |
| AID81040 | Minimum cytotoxic concentration against HEL cell morphology. | 2002 | Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19 | Synthesis and antiviral/antiproliferative activity of some N-sulphonylbenzimidazoles. |
| AID86023 | Inhibition of plaque formation in monolayers of HSV-1 KOSSB(TK-) Vero cells by 50% | 2001 | Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21 | Synthesis and antiviral activity of novel 5-(1-cyanamido-2-haloethyl) and 5-(1-hydroxy(or methoxy)-2-azidoethyl) analogues of uracil nucleosides. |
| AID167134 | Minimum inhibitory concentration required to reduce virus induced cytopathogenicity in primary rabbit kidney cell cultures by 50% against HSV-1 (F) | 1983 | Journal of medicinal chemistry, Apr, Volume: 26, Issue:4 | Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl]guanine]. |
| AID229047 | Tested for cytotoxicity in vero cells, activity is expressed as CC50. | 2000 | Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2 | Synthesis and antiviral activity of novel anti-VZV 5-substituted uracil nucleosides with a cyclopropane sugar moiety. |
| AID1186334 | Cytotoxicity against mock-infected african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay | 2014 | Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17 | Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents. |
| AID687664 | Antiviral activity against VZV OKA expressing thymidine kinase infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 3 days | 2012 | European journal of medicinal chemistry, Nov, Volume: 57 | Synthesis and antiviral evaluation of bis(POM) prodrugs of (E)-[4'-phosphono-but-2'-en-1'-yl]purine nucleosides. |
| AID86970 | Ability to inhibit cytopathogenicity of thymidine kinase-deficient (TK-) strain of Varicella zoster virus (YS/R) in HeLa cell culture | 2001 | Journal of medicinal chemistry, May-24, Volume: 44, Issue:11 | Synthesis and biological evaluation of purine-containing butenolides. |
| AID217800 | In vitro antiviral activity against herpesvirus, VZV, Ellen strain by plaque reduction assay in human foreskin fibroblasts. | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5 | Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS. |
| AID1323835 | Displacement of [3H]rosiglitazone from recombinant human C-terminal His-tagged MitoNEET cytosolic domain (32 to 108 residues) expressed in Escherichia coli BL21 by Cheng-Prusoff analysis | 2016 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21 | Identification of small molecules that bind to the mitochondrial protein mitoNEET. |
| AID87180 | In vitro antiviral activity against Herpes simplex virus (HSV-2) was determined | 2002 | Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3 | 5-Bromo (or chloro)-6-azido-5,6-dihydro-2' -deoxyuridine and -thymidine derivatives with potent antiviral activity. |
| AID569234 | Antiviral activity against VZV OKA expressing thymidine kinase infected in HEL cells assessed as inhibition of plaque formation | 2011 | European journal of medicinal chemistry, Feb, Volume: 46, Issue:2 | Synthesis of new C5-(1-substituted-1,2,3-triazol-4 or 5-yl)-2'-deoxyuridines and their antiviral evaluation. |
| AID85421 | Minimal inhibitory concentration to reduce virus-induced cytopathicity against 196 strain of human Herpes Simplex Virus-2 | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Fluorescent tricyclic analogues of acyclovir and ganciclovir. A structure-antiviral activity study. |
| AID81018 | Tested for Antiherpetic activity against VZV from Kawaguchi strain in HEL cell lines. | 2000 | Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2 | Synthesis and antiviral activity of novel anti-VZV 5-substituted uracil nucleosides with a cyclopropane sugar moiety. |
| AID217722 | Compound was tested for antiviral activity against Herpes Simplex virus Type-1(HFEM) in vero cells | 1987 | Journal of medicinal chemistry, Sep, Volume: 30, Issue:9 | Synthesis and antiviral activity of 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]purines. |
| AID218426 | Anti viral activity against VZV(Oka strain) in WI-38 cell monolayers. | 1992 | Journal of medicinal chemistry, May-15, Volume: 35, Issue:10 | Synthesis and antiviral activity of 1-cyclobutyl-5-(2-bromovinyl)uracil nucleoside analogues and related compounds. |
| AID297311 | Cytotoxicity against human HEL cells assessed as reduction of cell growth | 2007 | Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17 | Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives. |
| AID86844 | Ability to inhibit cytopathogenicity of herpes simplex type 1 virus (G) in HeLa cell culture | 2001 | Journal of medicinal chemistry, May-24, Volume: 44, Issue:11 | Synthesis and biological evaluation of purine-containing butenolides. |
| AID255990 | Antiviral activity against herpes simplex virus type 1 KOS (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO | 2005 | Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18 | 4-Oxo-4,7-dihydrothieno[2,3-b]pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases. |
| AID105823 | Minimum inhibitory concentration required to reduce cytopathogenicity of Herpes Virus-1 (HSV-1) in MRC -5 cells by 50%. | 1991 | Journal of medicinal chemistry, Sep, Volume: 34, Issue:9 | The synthesis and antiviral activity of some 4'-thio-2'-deoxy nucleoside analogues. |
| AID1079948 | Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source] | |||
| AID611623 | Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection against virus-induced cytopathicity | 2011 | Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11 | New prodrugs of Adefovir and Cidofovir. |
| AID167881 | Antiviral Activity against herpes simplex virus-2 (196) in rabbit kidney cell | 1990 | Journal of medicinal chemistry, Sep, Volume: 33, Issue:9 | Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives. |
| AID540209 | Volume of distribution at steady state in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID105822 | Minimum inhibitory concentration required to reduce cytopathogenicity of Cytomegalovirus Virus (CMV) in MRC-5 cells by 50%. | 1991 | Journal of medicinal chemistry, Sep, Volume: 34, Issue:9 | The synthesis and antiviral activity of some 4'-thio-2'-deoxy nucleoside analogues. |
| AID749438 | Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis | 2013 | European journal of medicinal chemistry, May, Volume: 63 | Ester prodrugs of acyclic nucleoside thiophosphonates compared to phosphonates: synthesis, antiviral activity and decomposition study. |
| AID218230 | In vitro antiviral and anticellular activity was evaluated against vero cells in tissue culture | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis and antiherpes simplex virus activity of 9-[(1,3-dihydroxy-2-propylthio)methyl]guanine. |
| AID84048 | Number of survivors per number of HSV-1 infected mice treated with 50 mg/kg per day; 0/10 | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5 | Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS. |
| AID82854 | Compound was evaluated for the anti-viral activity against HEL cells | 1999 | Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22 | Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base. |
| AID1498116 | Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathicity | 2018 | Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12 | Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs. |
| AID90794 | Tested in vitro for antiviral activity against human cytomegalovirus (HCMV) in plaque reduction assay. | 1990 | Journal of medicinal chemistry, Dec, Volume: 33, Issue:12 | Arabinofuranosylpyrrolo[2,3-d]pyrimidines as potential agents for human cytomegalovirus infections. |
| AID216462 | Effective concentration required for reduction of plaque formation of Varicella-Zoster Virus, (YS strain) | 2001 | Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3 | Bicyclic nucleoside inhibitors of Varicella-Zoster Virus (VZV): the effect of terminal unsaturation in the side chain. |
| AID1572729 | Antiviral activity against herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity by microscopic analysis | 2019 | Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6 | Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives. |
| AID88286 | Inhibitory activity against HSV-2 in vero cells | 2003 | Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23 | Anti-herpes simplex virus activity of substituted 1-hydroxyacridones. |
| AID165913 | Tested for the inhibition of diffuse early antigen production assayed by immunofluorescent monoclonal antibody. | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5 | Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS. |
| AID85408 | Antiviral activity against HSV-1 kinase mutant resistant to Tr7(ACV) was determined at a conc of 50 uM | 1987 | Journal of medicinal chemistry, Nov, Volume: 30, Issue:11 | Acetylenic nucleosides. 4. 1-beta-D-arabinofuranosyl-5-ethynylcytosine. Improved synthesis and evaluation of biochemical and antiviral properties. |
| AID246491 | Effective concentration to inhibit 50% of cytomegalovirus (CMV) replication in a cell culture model;ND=Not determined | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | Synthesis and antiviral activity of helioxanthin analogues. |
| AID91294 | Cytotoxicity against uninfected human foreskin fibroblast(HFF cells) | 1988 | Journal of medicinal chemistry, Nov, Volume: 31, Issue:11 | Synthesis and antiviral activity of certain 4- and 4,5-disubstituted 7-[(2-hydroxyethoxy)methyl]pyrrolo[2,3-d]pyrimidines. |
| AID71873 | Inhibitory activity against FM3A TK- cell line | 1990 | Journal of medicinal chemistry, Sep, Volume: 33, Issue:9 | Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives. |
| AID81226 | In vitro inhibition of Thymidine Kinase-Varicella Zoster Virus(YS) plaque formation. | 2000 | Journal of medicinal chemistry, Aug-24, Volume: 43, Issue:17 | Nonnucleoside human cytomegalovirus inhibitors: synthesis and antiviral evaluation of (chlorophenylmethyl)benzothiadiazine dioxide derivatives. |
| AID16018 | Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally. | 1985 | Journal of medicinal chemistry, Jul, Volume: 28, Issue:7 | Synthesis and antiherpetic activity of (S)-, (R)-, and (+/-)-9-[(2,3-dihydroxy-1-propoxy)methyl]guanine, linear isomers of 2'-nor-2'-deoxyguanosine. |
| AID297314 | Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity | 2007 | Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17 | Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives. |
| AID455986 | Permeability across human Caco-2 cells | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19 | Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. |
| AID393991 | Antiviral activity against acyclovir-resistant HCMV AD169 clone 1 infected in HEL cells assessed as inhibition of virus-induced cytopathicity | 2009 | Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6 | 4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus. |
| AID521907 | Drug level in human plasma with chronic kidney disease at 1500 mg, po every 12 hrs measured after fifth dose by radioimmunoassay | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. |
| AID139283 | Day of death in lethal test against herpes simplex virus type-2 at 200 mg/kg/day (mean day of death +/-SD) | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID1714438 | Selectivity index, ratio of CC50 for HFF to EC50 for inhibition of HSV2 replication in HFF cells | 2016 | Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23 | Synthesis and Antiviral Evaluation of Octadecyloxyethyl Benzyl 9-[(2-Phosphonomethoxy)ethyl]guanine (ODE-Bn-PMEG), a Potent Inhibitor of Transient HPV DNA Amplification. |
| AID766704 | Antiviral activity against thymidine kinase positive Varicella-zoster virus OKA infected in human HEL cells assessed as reduction in virus plaque formation | 2013 | European journal of medicinal chemistry, Sep, Volume: 67 | Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity. |
| AID81757 | Minimum toxic effect against HEp-2 cells. | 1985 | Journal of medicinal chemistry, Nov, Volume: 28, Issue:11 | 5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue. |
| AID84779 | Compound was evaluated for antiviral activity against HSV-2 reported as virus rating | 1987 | Journal of medicinal chemistry, Jan, Volume: 30, Issue:1 | Synthesis and biological evaluation of acyclic neplanocin analogues. |
| AID1498113 | Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity | 2018 | Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12 | Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs. |
| AID1274004 | Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation after 8 days | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Anti-herpetic and anti-dengue activity of abietane ferruginol analogues synthesized from (+)-dehydroabietylamine. |
| AID217644 | Antiviral activity against Varicella zoster virus (Ellen strain) | 1993 | Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9 | Synthesis and antiviral activity of novel isonucleoside analogs. |
| AID766696 | Antiviral activity against thymidine kinase negative acyclovir positive Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity | 2013 | European journal of medicinal chemistry, Sep, Volume: 67 | Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity. |
| AID218235 | In vitro cytotoxic concentration in vero cells. | 2003 | Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23 | Anti-herpes simplex virus activity of substituted 1-hydroxyacridones. |
| AID246259 | Effective concentration required to reduce vaccinia virus plaque formation by 50% in E6SM Cell Culture | 2004 | Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22 | 6-azapyrimidine-2'-deoxy-4'-thionucleosides: antiviral agents against TK+ and TK- HSV and VZV strains. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347121 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347141 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347122 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347136 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347116 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347114 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347115 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347123 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347128 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347119 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347140 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347137 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for Daoy cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347110 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347135 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347118 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347124 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347138 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D caspase screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347125 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347113 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347109 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347139 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347111 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347117 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347127 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347129 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347126 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347112 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1508628 | Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1508627 | Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1508629 | Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1347050 | Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588378 | qHTS for Inhibitors of ATXN expression: Validation | |||
| AID504836 | Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation | 2002 | The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16 | Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. |
| AID1347045 | Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID1347049 | Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID588349 | qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay | |||
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588460 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588460 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588460 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588461 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588461 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588461 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588459 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588459 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588459 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| AID1347405 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347058 | CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347410 | qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library | 2019 | Cellular signalling, 08, Volume: 60 | A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening. |
| AID1347057 | CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347059 | CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347151 | Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1224864 | HCS microscopy assay (F508del-CFTR) | 2016 | PloS one, , Volume: 11, Issue:10 | Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics. |
| AID1745855 | NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay | 2023 | Disease models & mechanisms, 03-01, Volume: 16, Issue:3 | In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. |
| AID1745854 | NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS | 2023 | Disease models & mechanisms, 03-01, Volume: 16, Issue:3 | In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. |
| AID977610 | Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB | 2003 | Biochemical and biophysical research communications, Aug-29, Volume: 308, Issue:3 | Crystal structure of human purine nucleoside phosphorylase complexed with acyclovir. |
| AID1811 | Experimentally measured binding affinity data derived from PDB | 2003 | Biochemical and biophysical research communications, Aug-29, Volume: 308, Issue:3 | Crystal structure of human purine nucleoside phosphorylase complexed with acyclovir. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11 | 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1942 (21.55) | 18.7374 |
| 1990's | 2187 (24.27) | 18.2507 |
| 2000's | 2285 (25.36) | 29.6817 |
| 2010's | 2063 (22.89) | 24.3611 |
| 2020's | 535 (5.94) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1,007 (10.42%) | 5.53% |
| Reviews | 1,229 (12.71%) | 6.00% |
| Case Studies | 3,051 (31.56%) | 4.05% |
| Observational | 23 (0.24%) | 0.25% |
| Other | 4,358 (45.08%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effectiveness of Oral Acyclovir in the Treatment of Molluscum Contagiosum in Children[NCT04476186] | 35 participants (Anticipated) | Interventional | 2020-06-15 | Recruiting | |||
| A Randomized, Cross-Over Study to Evaluate the Suppressive Effect of High-Dose Acyclovir Versus Once Daily Valacyclovir on Herpes Simplex Virus Type 2 Genital Shedding in Herpes Simplex Virus-2 Seropositive Adults[NCT00362297] | Phase 4 | 31 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| A Randomized, Double-Blind, to Compare Non-inferiority Efficacy and Safety of Penciclovir 10mg/g to Acyclovir 50mg/g in the Treatment of Recurrent Herpes Labialis.[NCT01257074] | Phase 3 | 76 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Airway Intervention Registry (AIR) Extension: Recurrent Respiratory Papillomatosis[NCT03465280] | 400 participants (Anticipated) | Observational [Patient Registry] | 2018-04-01 | Recruiting | |||
| A Randomized Trial of Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis[NCT03626376] | Phase 4 | 0 participants (Actual) | Interventional | 2019-12-10 | Withdrawn(stopped due to Unable to enroll participants) | ||
| Population Pharmacokinetics of Anti-infective Drugs in Children in Anti-infectious Therapies[NCT03113344] | 800 participants (Anticipated) | Observational [Patient Registry] | 2017-06-21 | Recruiting | |||
| Prospective Study of Pharmacokinetics, Clinical and Virologic Response to Acyclovir Episodic Therapy for Genital Herpes Ulcers in HIV Negative African Women[NCT02053142] | 74 participants (Actual) | Interventional | 2009-01-31 | Completed | |||
| A Randomized, Double-blind, Multi-center, Three Arm (Pritelivir, Placebo and Zovirax®) Parallel Group, Comparative Trial to Assess the Efficacy and Safety of Pritelivir 5% w/w Ointment for the Treatment of Recurrent Herpes Labialis in Adults - LipP1[NCT02871492] | Phase 2 | 362 participants (Actual) | Interventional | 2016-11-29 | Completed | ||
| A Phase I/II Study of Carfilzomib in Combination With R-CHOP (CR-CHOP) for Patients With Diffuse Large B-cell Lymphoma[NCT02073097] | Phase 1/Phase 2 | 48 participants (Actual) | Interventional | 2015-01-28 | Active, not recruiting | ||
| Aciclovir for HSV-2 Meningitis: A Double-blind Randomised Controlled Trial (AMEN)[NCT05452928] | Phase 4 | 150 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | ||
| A Randomized, Double-Blind, Placebo-Controlled Trial of Acyclovir Prophylaxis Versus Placebo Among HIV-1/HSV-2 Co-Infected Individuals in Uganda[NCT00405821] | Phase 2 | 440 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| A Placebo-Controlled Phase III Evaluation of Suppressive Therapy With Oral Acyclovir Suspension Following Neonatal Herpes Simplex Virus Infections Involving the Central Nervous System[NCT00031460] | Phase 3 | 46 participants (Actual) | Interventional | 1997-12-31 | Completed | ||
| Single Arm Study To Assess Comprehensive Infusion Guidance For The Management Of The Infusion- Associated Reactions (IARs) In Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated With LEMTRADA[NCT02205489] | Phase 4 | 58 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| Randomized Phase III Study in EBV Positive Locally Advanced Nasopharyngeal Carcinoma Treated With Concurrent Chemo-radiotherapy With or Without Anti-Viral Drug[NCT03656965] | Phase 3 | 50 participants (Anticipated) | Interventional | 2018-05-01 | Active, not recruiting | ||
| A Multi-centered, Randomized Study to Evaluate the Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection Compared to Intravenous Acyclovir in Patients With Herpes Zoster From China[NCT02151240] | Phase 4 | 94 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Single Intravenous and Subcutaneous Doses of GZ402668 in Men and Women With Progressive Multiple Sclerosis[NCT02282826] | Phase 1 | 48 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| Bioequivalence of Two Formulations of Acyclovir[NCT02255734] | Phase 4 | 14 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| A Placebo-Controlled Phase III Evaluation of Suppressive Therapy With Oral Acyclovir Suspension Following Neonatal Herpes Simplex Virus Infections Limited to the Skin, Eye, and Mouth[NCT00031447] | Phase 3 | 29 participants (Actual) | Interventional | 1999-08-31 | Completed | ||
| A Phase II, Randomized, Double-Blind, Parallel Group, Acyclovir-Controlled Study to Evaluate ZEP-3 Ointment for the Treatment of Cold Sores (Herpes Labialis).[NCT02483182] | Phase 2 | 210 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| A Randomized, Open-label, Crossover Trial of the Effect of High-dose Daily HSV-2 Suppressive Therapy on Plasma HIV-1 Levels Among HIV-1/HSV-2 Co-infected Persons[NCT01026454] | Phase 4 | 32 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| Phase III Randomized Placebo-Controlled Trial of HSV-2 Suppression to Prevent HIV Transmission Among HIV-Discordant Couples[NCT00194519] | Phase 3 | 3,408 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Impact of Dosing Weight on Clinical Outcomes in Obese Patients Receiving Acyclovir for HSV Encephalitis (ID-OPRAH)[NCT05127395] | 50 participants (Actual) | Observational | 2021-03-09 | Completed | |||
| A Randomized, Double-Blind, Active-Controlled, Subject Initiated Study Comparing ME-609 to Acyclovir Cream for Treatment of Recurrent Herpes Simplex Labialis in Immunocompromised Patients[NCT00735761] | Phase 3 | 201 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Effect of Acyclovir Therapy on the Outcome of Mechanically Ventilated Patients With Lower Respiratory Tract Infection and Detection of Herpes Simplex Virus in Bronchoalveolar Lavage[NCT06134492] | Phase 3 | 710 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| Individualization of Dosage Regimens in Obese Patients: Application to Acyclovir[NCT05589688] | Phase 1 | 20 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| A Phase I/II Dose Escalation Study of Subcutaneous Campath-1H (NSC #715969, IND #10864) During Intensification Therapy in Adults With Untreated Acute Lymphoblastic Leukemia (ALL)[NCT00061945] | Phase 1/Phase 2 | 302 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| A Randomized, Open-label, Crossover Trial of the Effect of Dosing of Daily HSV-2 Suppressive Therapy on HSV Reactivation and Plasma HIV-1 Levels Among HIV-1/ HSV-2 Co-infected Persons[NCT00527618] | Phase 4 | 28 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| [NCT00000138] | Phase 3 | 0 participants | Interventional | 1989-05-31 | Active, not recruiting | ||
| Prospective Study Evaluating Plasma Exposure of Optimized Antibiotic Therapy According to TDM in Patients With Subarachnoid Haemorrhage (ES) and Cerebral Haemorrhage (EC)[NCT04132115] | 104 participants (Anticipated) | Observational | 2019-10-01 | Recruiting | |||
| A Phase 1, Exploratory, Randomized, Open-label, 2-Arm Study to Characterize the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Alemtuzumab 12mg Administered Subcutaneously or Intravenously in Patients With Progressive Multiple Sclerosis[NCT02583594] | Phase 1 | 24 participants (Actual) | Interventional | 2015-12-06 | Completed | ||
| Effect of Suppressive Therapy on Behavioral Determinants of HSV-2 Transmission[NCT00495716] | Phase 4 | 72 participants (Actual) | Interventional | 2008-01-31 | Terminated(stopped due to Investigator relocated and study funding ended.) | ||
| Intralesional Vitamin D3 Versus Intralesional Acyclovir in Treatment of Plantar Warts[NCT05324904] | 44 participants (Anticipated) | Interventional | 2022-10-31 | Not yet recruiting | |||
| An Open Label Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants[NCT00942084] | Phase 1 | 32 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| Clinical and Dermoscopic Study of Intralesional Injection of Acyclovir Versus Candida Antigen in Treatment of Plantar Warts[NCT05429151] | Phase 4 | 40 participants (Anticipated) | Interventional | 2022-06-13 | Recruiting | ||
| [NCT00006132] | Phase 3 | 132 participants | Interventional | 1997-06-30 | Recruiting | ||
| [NCT00006135] | Phase 3 | 66 participants | Interventional | 1997-06-30 | Completed | ||
| [NCT00000139] | Phase 3 | 0 participants | Interventional | 1992-10-31 | Completed | ||
| A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3[NCT00000712] | Phase 2 | 400 participants | Interventional | Completed | |||
| Impact of Episodic Acyclovir Therapy on Ulcer Duration and HIV Shedding From Genital Ulcers Among Men in South Africa[NCT00164424] | Phase 2/Phase 3 | 613 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| Anti-Herpetic Treatment Associated With Syndromic Management of Genital Ulcer in Africa: Clinical and Biological Evaluation on HIV-1 and HSV-2 Shedding (ANRS 1212)[NCT00158483] | Phase 2 | 449 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| A Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Famciclovir 500 mg Comparing To Aciclovir 400mg in Patients With Herpes Zoster[NCT01327144] | Phase 3 | 177 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Infection in Patients With the Acquired Immunodeficiency Syndrome: A Randomized Multicenter Study of Foscarnet Versus Vidarabine[NCT00000985] | Phase 3 | 26 participants | Interventional | Completed | |||
| A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Paediatric Patients With Relapsing Remitting Multiple Sclerosis (RRMS) With Disease Activity on Prior Disease Modifyi[NCT03368664] | Phase 3 | 16 participants (Actual) | Interventional | 2017-10-24 | Active, not recruiting | ||
| Low Dose Versus Weight-based Intravenous Acyclovir for Herpes Simplex Virus Prophylaxis in the Neutropenic Patient[NCT00855309] | Phase 3 | 112 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| An Exploratory Study to Evaluate Dermal Open Flow Microperfusion's (dOFM) Ability to Assess Bioequivalence and Non-bioequivalence of Topical Acyclovir Formulations in Healthy Volunteers[NCT02711267] | 36 participants (Actual) | Interventional | 2014-01-31 | Completed | |||
| Evaluation of Biopharmaceutics Classification System Class 3 Drugs for Possible Biowaivers[NCT01010698] | Phase 1 | 48 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| A Randomized, Cross-Over Study to Evaluate the Suppressive Effect of Acyclovir on Rapidly Cleared Herpes Simplex Virus Type 2 Genital Reactivation Episodes in Herpes Simplex Virus-2 Seropositive Adults[NCT00723229] | Phase 4 | 48 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| A Multicenter, Placebo Controlled, Randomized, Double Blind, Subject Initiated Study of the Safety and Efficacy of the Electrokinetic Transdermal System (ETS) With Acyclovir Gel for the Episodic Treatment of Herpes Labialis[NCT00469300] | Phase 2 | 810 participants (Anticipated) | Interventional | 2007-04-30 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled Crossover Trial of Acyclovir for Suppression of HSV and HIV Shedding in HIV-1, HSV-2 Coinfected Persons in Cameroon[NCT00209313] | Phase 2/Phase 3 | 40 participants (Anticipated) | Interventional | 2005-03-31 | Completed | ||
| Randomized Trial of Long-Term Oral Acyclovir Usage to Prevent Varicella Zoster Virus Infection After Allogeneic Bone Marrow Transplant[NCT00209352] | Phase 3 | 120 participants | Interventional | 1985-06-30 | Completed | ||
| Half-life and Pattern of Resolution of Herpes Simplex Virus Type 2 (HSV-2) Shedding After Beginning Acyclovir Treatment[NCT00495573] | 36 participants (Actual) | Observational | 2007-06-30 | Completed | |||
| Antimicrobial Pharmacokinetics in High Risk Infants (Urinary Proteomics in Antimicrobial/Antifungal-Treated Newborns - add-on Study)[NCT00491426] | 450 participants (Actual) | Observational | 2006-01-31 | Completed | |||
| Assessment of Acyclovir Efficacy Versus Placebo in Controlling Vertigo Attacks of Patients With Meniere's Disease Visited in Amiralam Hospital[NCT01729767] | Phase 2/Phase 3 | 80 participants (Anticipated) | Interventional | 2011-08-31 | Recruiting | ||
| [NCT00004644] | Phase 1/Phase 2 | 25 participants | Interventional | 1995-02-28 | Completed | ||
| A Phase II, Randomized, Double-blind, Placebo-controlled Trial of Acyclovir for the Suppression of Human Immunodeficiency Virus Type 1 (HIV-1) Viral Load and Mucosal Shedding in HIV-1, Herpes Simplex Virus, Type 2 (HSV-2) Co-Infected Women[NCT00371592] | Phase 2 | 50 participants (Anticipated) | Interventional | 2006-09-30 | Completed | ||
| A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Acyclovir for the Reduction of HIV Acquisition Among High-Risk HSV-2 Seropositive, HIV Seronegative Individuals[NCT00076232] | Phase 3 | 3,682 participants (Anticipated) | Interventional | 2005-04-30 | Completed | ||
| "The Safety, Efficacy and Convenience of Use of the Natural Agent Superlysin Gel as Treatment for Herpes Labialis in Comparison to Acyclovir 5% and Docozanole 10%."[NCT00467662] | Phase 4 | 75 participants (Anticipated) | Interventional | Not yet recruiting | |||
| Effect of Various Treatment Modalities on Dendritic Vial Ulcer[NCT05313828] | 40 participants (Anticipated) | Observational | 2022-03-18 | Recruiting | |||
| A Randomised, Double-Blind, Single Dose, One-Day Early Administration, Multicentre Study Comparing the Efficacy and Safety of Acyclovir Lauriad® 50 mg Muco-adhesive Buccal Tablet to Matching Placebo, in the Treatment of Herpes Labialis in Immunocompetent [NCT00769314] | Phase 3 | 1,727 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| A Randomized, Double-Blind Trial of Valacyclovir Hydrochloride (BW 256U87) Prophylaxis for Opportunistic Cytomegalovirus End-Organ Disease in Patients With Advanced HIV Infection (< 100 CD4+ Lymphocytes)[NCT00001038] | Phase 3 | 1,200 participants | Interventional | Completed | |||
| Effects of Melatonin in the Treatment of Genital Herpes[NCT03831165] | Phase 4 | 90 participants (Actual) | Interventional | 2015-09-02 | Completed | ||
| A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients[NCT00002084] | 0 participants | Interventional | Completed | ||||
| Double-Blind Placebo-Controlled Study Comparing the Combination of 15% SP-303 Gel With Acyclovir Versus Acyclovir Alone for the Treatment of Recurrent Herpes Simplex Virus (HSV) Infections in Subjects With Acquired Immunodeficiency Syndrome (AIDS)[NCT00002186] | 400 participants | Interventional | Completed | ||||
| A Pilot Study to Determine the Effect of Acyclovir Treatment for Herpes Simplex Virus (HSV) Infection on Peripheral Blood HIV Viral Load.[NCT00001115] | 75 participants | Interventional | Completed | ||||
| An Uncontrolled Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of Zidovudine (AZT) and Acyclovir (ACV) Given Concomitantly to Patients With Human Immunodeficiency Virus Infection[NCT00001010] | Phase 1 | 72 participants | Interventional | Completed | |||
| A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants[NCT00045292] | Phase 3 | 0 participants | Interventional | 2002-04-30 | Completed | ||
| Prospective Study of Pharmacokinetics, Clinical and Virologic Response to Acyclovir Episodic Therapy for Genital Herpes Ulcers in HIV Negative African Women[NCT00808405] | 88 participants (Actual) | Interventional | 2009-01-31 | Completed | |||
| A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus (CMV) Disease in Adult Kidney Transplant Recipients[NCT03443869] | Phase 3 | 601 participants (Actual) | Interventional | 2018-05-03 | Completed | ||
| Pharmacokinetic Properties of Acyclovir[NCT04988646] | 56 participants (Actual) | Interventional | 2020-02-21 | Completed | |||
| A Multicenter, Placebo Controlled, Randomized, Double Blind, Subject Initiated Study of the Safety and Efficacy of a Single Topical Iontophoretic Application of Acyclovir 5% Cream With an Open Label Conventional Therapy Treatment Arm, and a Blinded Evalua[NCT00230867] | Phase 2 | 1,800 participants | Interventional | 2005-04-30 | Completed | ||
| An Investigator Initiated Prospective Randomized, Controlled Pilot Study in Order to Evaluate the Place of Valganciclovir in Prevention of Cytomegalovirus Reactivation Following Allogeneic Stem Cell Transplantation[NCT00330018] | Phase 3 | 40 participants (Anticipated) | Interventional | 2006-02-28 | Completed | ||
| Anti-viral Prophylaxis for Prevention of Cytomegalovirus (CMV) Reactivation in Immunocompetent Patients in Critical Care[NCT01503918] | Phase 2 | 124 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| A Prospective, Randomized Trial of Antiviral Prophylaxis in a Population of Burn Patients[NCT02349828] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2015-09-30 | Withdrawn(stopped due to PI decided to stop due to divisional reorganization. No pts enrolled.) | ||
| Efficacy of a Preemptive Treatment by Ganciclovir or by Aciclovir in ICU Patients Requiring Prolonged Mechanical Ventilation and Presenting a Viral Replication (CMV and/or HSV) - Prospective, Randomized, Double-blinded Multicenter Trial[NCT02152358] | Phase 4 | 317 participants (Actual) | Interventional | 2014-02-05 | Completed | ||
| A Randomized, Double-Blind, Active Controlled, Vehicle-Controlled, Subject Initiated Study Comparing Efficacy and Safety of ME-609 Versus Acyclovir Cream for Treatment of Recurrent Herpes Simplex Labialis[NCT00361881] | Phase 3 | 1,443 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Suppression of Cytomegalovirus Retinitis Utilizing High Dose Intravenous Acyclovir and Oral Zidovudine in Patients With AIDS[NCT00000693] | 25 participants | Interventional | Completed | ||||
| Prospective Study of the Etiology, Pathogenesis, Clinical Picture and Outcome of Aseptic Meningitis in Slovenia[NCT02328469] | 800 participants (Anticipated) | Observational | 2014-06-30 | Recruiting | |||
| A Randomized, Double-blind, Placebo-controlled Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Dose of GZ402668 in Men and Women With Progressive Multiple Sclerosis[NCT02977533] | Phase 1 | 20 participants (Actual) | Interventional | 2016-12-01 | Completed | ||
| Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)[NCT00002026] | 0 participants | Interventional | Completed | ||||
| A Multi-Center, Double-Blind Trial to Evaluate the Safety and Efficacy of Concurrent Retrovir (Zidovudine) and Zovirax (Acyclovir) Therapy in Patients With Early Symptomatic Human Immunodeficiency Virus (HIV) Infection[NCT00002290] | 0 participants | Interventional | Completed | ||||
| A Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Famciclovir 125 mg Comparing to Aciclovir 200 mg in Patients With Active Recurrent Genital Herpes[NCT01281007] | Phase 3 | 150 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| The Use of Campath-1H, Tacrolimus, and Sirolimus Followed by Sirolimus Withdrawal in Renal Transplant Patients[NCT00078559] | Phase 1/Phase 2 | 10 participants (Actual) | Interventional | 2003-11-30 | Completed | ||
| A Randomized Controlled Crossover Trial of Acylcovir Among HIV and HSV-2 Co-Infected Women, Chiang Rai, Thailand[NCT00362596] | Phase 4 | 67 participants | Interventional | 2005-01-31 | Completed | ||
| A Phase 2 Trial of Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D[NCT01833143] | Phase 2 | 17 participants (Actual) | Interventional | 2013-04-11 | Completed | ||
| A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected Patients[NCT00002000] | 0 participants | Interventional | Completed | ||||
| A Double-Blind, Multicenter Study Comparing Oral 882C87 With Oral Acyclovir for Treatment of Localized Herpes Zoster in Immunocompromised Patients[NCT00002315] | Phase 3 | 400 participants | Interventional | Completed | |||
| A Randomized, Multi-Center, Double Blinded, Self-Initiated, Single Treatment Study Comparing Sitavig® (Acyclovir) 50 mg Muco-adhesive Buccal Tablet to Placebo in the Treatment of Herpes Labialis in Immunocompetent Adults[NCT05098938] | Phase 3 | 1,820 participants (Anticipated) | Interventional | 2021-11-23 | Active, not recruiting | ||
| [NCT02265913] | Phase 3 | 4,076 participants (Actual) | Interventional | 2014-10-06 | Completed | ||
| Phase I Study of Neoadjuvant GMCI Plus Immune Checkpoint Inhibitor Combined With Standard of Care for Newly Diagnosed High-Grade Gliomas[NCT03576612] | Phase 1 | 36 participants (Anticipated) | Interventional | 2018-02-27 | Active, not recruiting | ||
| A Mono-centric, No-profit, Case-control Study With Daily Oral Supplementation of Zinc Sulphate After Autologous Stem Cell Transplantation in Patients Affected by Multiple Myeloma[NCT03159845] | Phase 2 | 20 participants (Anticipated) | Interventional | 2014-01-01 | Completed | ||
| Evaluation of Brovavir ( BV-ara-U; SQ 32,756 ) Versus Acyclovir in the Treatment of Localized Herpes Zoster in HIV-Infected Patients[NCT00000953] | Phase 2 | 180 participants | Interventional | Completed | |||
| Antiviral Treatment in Facial Palsy. Randomized Control Trial[NCT02328079] | 50 participants (Actual) | Interventional | 2013-04-30 | Completed | |||
| An Open Label Multi Center Phase III Subject/Caregiver Initiated Safety Study of Xerese(Acyclovir and Hydrocortisone)Cream 5%/1% in the Treatment of Recurrent Herpes Labialis in Children[NCT01574612] | Phase 3 | 54 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| An Exploratory Study to Investigate the Inflammatory Response During a Cold Sore Episode[NCT01653509] | Phase 1 | 60 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| [NCT00004757] | Phase 3 | 0 participants | Interventional | 1992-08-31 | Completed | ||
| A Clinical Trial of Oral Acyclovir in Viral Uveitis[NCT03389191] | 30 participants (Anticipated) | Interventional | 2017-01-31 | Recruiting | |||
| A Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Chemotherapy and Androgen Pathway Inhibitors[NCT02047253] | Phase 2 | 28 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||